{"8e89329ba5682ffd98598d5b5c6ccd2067abdd12": [["IntroductionNucleic acid amplification tests (NAATs) have become indispensable tools in biology and medicine.", [["IntroductionNucleic acid", "CHEMICAL", 0, 24], ["IntroductionNucleic acid", "SIMPLE_CHEMICAL", 0, 24], ["IntroductionNucleic acid amplification tests", "TEST", 0, 44]]], ["For example, for infectious diseases diagnostics, NAATs are generally faster, more sensitive, and more specific than the current gold standard of culture-based techniques.", [["infectious diseases", "DISEASE", 17, 36], ["NAATs", "SIMPLE_CHEMICAL", 50, 55], ["infectious diseases diagnostics", "TEST", 17, 48], ["culture", "TEST", 146, 153], ["infectious", "OBSERVATION_MODIFIER", 17, 27]]], ["In fact, a number of DNA-and RNA-based diagnostics are now recommended by the US Food and Drug Administration (FDA) for infectious diseases such as human immunodeficiency virus (HIV) [1, 2] .", [["infectious diseases", "DISEASE", 120, 139], ["human immunodeficiency virus (HIV)", "DISEASE", 148, 182], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["human immunodeficiency virus", "ORGANISM", 148, 176], ["human immunodeficiency virus", "SPECIES", 148, 176], ["human immunodeficiency virus", "SPECIES", 148, 176], ["HIV", "SPECIES", 178, 181], ["DNA", "TEST", 21, 24], ["RNA", "TEST", 29, 32], ["infectious diseases", "PROBLEM", 120, 139], ["human immunodeficiency virus", "PROBLEM", 148, 176]]], ["Unfortunately, many NAATs require access to expensive, specialized equipment and a degree of expertise that is highly unlikely to be found in decentralized laboratories.", [["specialized equipment", "TREATMENT", 55, 76], ["highly unlikely", "UNCERTAINTY", 111, 126]]], ["As an additional challenge, these tests typically require an extraction step to isolate DNA or RNA from blood, urine or sputum, and a purification step to eliminate contaminants from the sample matrix that can confound the actual detection procedure (Figure 1 ).", [["blood", "ANATOMY", 104, 109], ["urine", "ANATOMY", 111, 116], ["sputum", "ANATOMY", 120, 126], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["urine", "ORGANISM_SUBSTANCE", 111, 116], ["sputum", "ORGANISM_SUBSTANCE", 120, 126], ["matrix", "CELLULAR_COMPONENT", 194, 200], ["these tests", "TEST", 28, 39], ["an extraction step", "TREATMENT", 58, 76], ["isolate DNA", "PROBLEM", 80, 91], ["RNA from blood, urine or sputum", "PROBLEM", 95, 126], ["a purification step", "TEST", 132, 151], ["contaminants from the sample matrix", "PROBLEM", 165, 200], ["the actual detection procedure", "TREATMENT", 219, 249]]], ["These procedures necessitate expensive instrumentation and can add up to several hours to sample-to-answer results, which further restricts the use of NAATs within centralized laboratories.", [["These procedures", "TREATMENT", 0, 16], ["expensive instrumentation", "TREATMENT", 29, 54]]], ["Direct nucleic acid testing is much more convenient and streamlined than the three-step method with preparatory techniques.", [["nucleic acid", "CHEMICAL", 7, 19], ["Direct nucleic acid testing", "TEST", 0, 27], ["preparatory techniques", "TREATMENT", 100, 122]]], ["In a typical extraction experiment, buffer with lytic agents is added to dilute the sample and homogenized with a mixer.", [["sample", "ANATOMY", 84, 90], ["a typical extraction experiment", "TREATMENT", 3, 34], ["lytic agents", "TREATMENT", 48, 60], ["a mixer", "TREATMENT", 112, 119]]], ["Sonication creates pressure waves that burst the cells in mechanical lysis.", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["pressure waves", "PROBLEM", 19, 33], ["burst the cells", "PROBLEM", 39, 54], ["mechanical lysis", "TREATMENT", 58, 74], ["pressure", "OBSERVATION_MODIFIER", 19, 27], ["waves", "OBSERVATION_MODIFIER", 28, 33], ["burst", "OBSERVATION_MODIFIER", 39, 44], ["cells", "OBSERVATION", 49, 54], ["mechanical lysis", "OBSERVATION", 58, 74]]], ["Lysozyme enzymatically destroys cells, and is removed from the reaction with vortexing and centrifugation in a phenol/chloroform phase separation.", [["cells", "ANATOMY", 32, 37], ["phenol/chloroform", "CHEMICAL", 111, 128], ["phenol", "CHEMICAL", 111, 117], ["chloroform", "CHEMICAL", 118, 128], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["cells", "CELL", 32, 37], ["phenol", "SIMPLE_CHEMICAL", 111, 117], ["chloroform", "SIMPLE_CHEMICAL", 118, 128], ["Lysozyme", "PROTEIN", 0, 8], ["Lysozyme enzymatically destroys cells", "PROBLEM", 0, 37], ["the reaction", "PROBLEM", 59, 71], ["vortexing", "TREATMENT", 77, 86], ["centrifugation", "TREATMENT", 91, 105], ["a phenol/chloroform phase separation", "TREATMENT", 109, 145], ["destroys cells", "OBSERVATION", 23, 37], ["chloroform phase", "OBSERVATION_MODIFIER", 118, 134]]], ["The DNA is precipitated in fresh ethanol and the resulting mixture is washed to remove excess contaminants.", [["ethanol", "CHEMICAL", 33, 40], ["ethanol", "CHEMICAL", 33, 40], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["ethanol", "SIMPLE_CHEMICAL", 33, 40], ["The DNA", "PROBLEM", 0, 7], ["fresh ethanol", "TREATMENT", 27, 40], ["excess contaminants", "PROBLEM", 87, 106], ["DNA", "OBSERVATION", 4, 7]]], ["Excess liquid is removed so that the DNA can be resuspended in an appropriate buffer.IntroductionMany groups have attempted to develop portable, integrated, microfluidics-based platforms to increase the functionality of diagnostic sensing and analysis [3] [4] [5] , and some of these have even been commercialized (e.g., bioMerieux's NucliSENS easyQ tests, TwistDx's TwistAmp kits, and Enigma Diagnostic's MiniLab).", [["DNA", "CELLULAR_COMPONENT", 37, 40], ["Excess liquid", "PROBLEM", 0, 13], ["the DNA", "TREATMENT", 33, 40], ["diagnostic sensing", "TEST", 220, 238], ["analysis", "TEST", 243, 251], ["bioMerieux", "TEST", 321, 331], ["liquid", "OBSERVATION", 7, 13]]], ["While it remains to be seen whether these systems are simple and error-free enough for developed and developing settings, they demonstrate the feasibility of implementing existing nucleic acid amplification methods for POC use [6] [7] [8] [9] .IntroductionAn alternative approach to time-consuming and cumbersome sample preparation is performing NAATs directly from complex samples ( Figure 1 ).", [["samples", "ANATOMY", 374, 381], ["nucleic acid", "CHEMICAL", 180, 192], ["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 227, 242], ["NAATs", "SIMPLE_CHEMICAL", 346, 351], ["NAATs", "PROTEIN", 346, 351], ["nucleic acid amplification methods", "TREATMENT", 180, 214], ["IntroductionAn alternative approach", "TREATMENT", 244, 279], ["cumbersome sample preparation", "TREATMENT", 302, 331]]], ["The advantage of traditional amplification technologies, such as PCR with real-time spectroscopic or mass spectrometry detection, is that the results are highly specific and quantitative.", [["traditional amplification technologies", "TEST", 17, 55], ["PCR", "TEST", 65, 68], ["mass spectrometry detection", "TEST", 101, 128]]], ["However, these sensing platforms are expensive and require prior extraction of genetic material from the sample.IntroductionDirect NAATs are advantageous when complicated, costly laboratory apparatuses are not available.", [["prior extraction", "TREATMENT", 59, 75], ["genetic material", "PROBLEM", 79, 95]]], ["They not only reduce the time, labor, and technical constraints of molecular testing, but also bring the additional benefit of standardizing results [10] .", [["labor", "PROBLEM", 31, 36], ["molecular testing", "TEST", 67, 84]]], ["Indeed, a growing number of groups are developing such \"direct\" NAATs.", [["NAATs", "CANCER", 64, 69], ["growing", "OBSERVATION_MODIFIER", 10, 17], ["number", "OBSERVATION_MODIFIER", 18, 24]]], ["Most notably, the Alere i Influenza A&B assay became the first FDA Clinical Laboratory Improvement Amendments (CLIA)-waived nucleic acid-based test [11] in January 2015.", [["nucleic acid", "CHEMICAL", 124, 136], ["the Alere i Influenza A&B assay", "TEST", 14, 45], ["nucleic acid", "TEST", 124, 136]]], ["As the Alere i system requires no front-end nucleic acid extraction, and can be used outside of traditional laboratory sites [12] [13] [14] [15] [16] , its development and CLIA-waived status provide strong support for further development of direct assays that can minimize or even bypass sample preparation.IntroductionThus motivated, we present the current state of direct assays and platforms that achieve nucleic acids detection and analysis from clinically-relevant, complex samples but with either minimal or Biosensors 2019, 9, 117 3 of 29 even no sample preparation procedures.", [["sample", "ANATOMY", 288, 294], ["samples", "ANATOMY", 479, 486], ["nucleic acid", "CHEMICAL", 44, 56], ["nucleic acids", "CHEMICAL", 408, 421], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 125, 149], ["nucleic acid extraction", "TREATMENT", 44, 67], ["CLIA", "TEST", 172, 176], ["strong support", "TREATMENT", 199, 213], ["direct assays", "TEST", 241, 254], ["bypass sample preparation", "TREATMENT", 281, 306], ["direct assays", "TEST", 367, 380], ["nucleic acids detection", "TEST", 408, 431], ["analysis", "TEST", 436, 444], ["Biosensors", "TEST", 514, 524], ["sample preparation procedures", "TREATMENT", 554, 583], ["minimal", "OBSERVATION_MODIFIER", 503, 510]]], ["We surveyed the literature from 1989-2017 and came across a significant number of works that reported NAATs from bodily samples (e.g., blood-based liquids, oral samples, swabs) without the complex steps generally involved in sample preparation.", [["samples", "ANATOMY", 120, 127], ["blood", "ANATOMY", 135, 140], ["oral samples", "ANATOMY", 156, 168], ["swabs", "ANATOMY", 170, 175], ["sample", "ANATOMY", 225, 231], ["NAATs", "SIMPLE_CHEMICAL", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["oral samples", "MULTI-TISSUE_STRUCTURE", 156, 168], ["bodily samples", "TEST", 113, 127], ["blood-based liquids", "TREATMENT", 135, 154], ["oral samples", "TREATMENT", 156, 168], ["swabs", "TEST", 170, 175]]], ["This meant discarding the works that depended on sophisticated instruments and operations that are labor-, time-, and cost-intensive, such as enzymatic (proteinases), chemical (acids, detergents), or physical (temperature shock, mechanical disruptions) treatments.", [["shock", "DISEASE", 222, 227], ["proteinases", "PROTEIN", 153, 164], ["operations", "TREATMENT", 79, 89], ["enzymatic (proteinases", "TREATMENT", 142, 164], ["chemical (acids, detergents", "TREATMENT", 167, 194], ["physical (temperature shock", "TREATMENT", 200, 227], ["mechanical disruptions) treatments", "TREATMENT", 229, 263]]], ["Then, we describe examples whereby data visualization can be used to reveal the connections between the robustness, sensitivity, and efficacy of technologies developed for direct DNA-and RNA-based tests.", [["DNA", "CELLULAR_COMPONENT", 179, 182], ["data visualization", "TEST", 35, 53], ["technologies", "TEST", 145, 157], ["direct DNA", "TEST", 172, 182], ["RNA-based tests", "TEST", 187, 202]]], ["It is our hope that in reviewing technologies such as these, and presenting these promising early findings in an information-rich and accessible fashion, we can help to accelerate the development of approaches that make POC nucleic acid testing rapid, accurate, simple, and affordable.MethodsIn order to find relevant articles with data on NAAT parameters, we performed literature searches from December 2014 to February 2018.Literature SearchWe searched Google Scholar with a combination of search terms.", [["nucleic acid", "CHEMICAL", 224, 236], ["POC nucleic acid testing", "TEST", 220, 244], ["NAAT parameters", "TEST", 340, 355]]], ["These followed a formula of combining a descriptor (e.g., \"point-of-care\"), an amplification technology (e.g., \"LAMP\" OR \"loop-mediated isothermal amplification\") and a sample matrix (e.g., \"blood\").", [["sample matrix", "ANATOMY", 169, 182], ["blood", "ANATOMY", 191, 196], ["matrix", "CELLULAR_COMPONENT", 176, 182], ["blood", "ORGANISM_SUBSTANCE", 191, 196], ["a sample matrix", "TEST", 167, 182]]], ["References of previously published reviews, as well as those included in original studies, were checked for possible candidate articles.Record ScreeningArticles were initially screened on the title, and secondly on the abstract.", [["original studies", "TEST", 73, 89]]], ["Any articles that relied on microfluidic platforms or commercialized extraction devices were excluded.", [["microfluidic platforms", "TREATMENT", 28, 50], ["commercialized extraction devices", "TREATMENT", 54, 87]]], ["Publications that required complex pre-processing with enzymatic treatment or chemical purification were not selected.", [["enzymatic treatment", "TREATMENT", 55, 74], ["chemical purification", "TREATMENT", 78, 99]]], ["Studies were included if they involved direct amplification and detection of genetic material from one of six representative sample types: blood, dried blood spot, serum and plasma, saliva and sputum, swabs, urine, and stool.", [["sample", "ANATOMY", 125, 131], ["blood", "ANATOMY", 139, 144], ["blood spot", "ANATOMY", 152, 162], ["serum", "ANATOMY", 164, 169], ["plasma", "ANATOMY", 174, 180], ["saliva", "ANATOMY", 182, 188], ["sputum", "ANATOMY", 193, 199], ["swabs", "ANATOMY", 201, 206], ["urine", "ANATOMY", 208, 213], ["stool", "ANATOMY", 219, 224], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["blood", "ORGANISM_SUBSTANCE", 152, 157], ["spot", "ORGANISM_SUBSTANCE", 158, 162], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["plasma", "ORGANISM_SUBSTANCE", 174, 180], ["saliva", "ORGANISM_SUBSTANCE", 182, 188], ["sputum", "ORGANISM_SUBSTANCE", 193, 199], ["swabs", "ORGANISM_SUBSTANCE", 201, 206], ["urine", "ORGANISM_SUBSTANCE", 208, 213], ["stool", "ORGANISM_SUBSTANCE", 219, 224], ["direct amplification", "TEST", 39, 59], ["genetic material", "PROBLEM", 77, 93], ["blood", "TEST", 139, 144], ["dried blood spot", "TEST", 146, 162], ["serum and plasma, saliva and sputum, swabs, urine", "TEST", 164, 213], ["stool", "ANATOMY", 219, 224]]], ["The full text of appropriate articles was read to extract the necessary information.Data AbstractionFrom each of the 174 published works surveyed, we extracted and recorded data that corresponded to test performance.", [["test performance", "TEST", 199, 215]]], ["As such, we provide an extensive examination of nucleic acid template specificity (including single or multiplexed reactions), amplification methodologies (enzymes, operating temperatures, and amplification technology), and user-friendliness (storage considerations, pretreatment requirements, and physical involvement) in Supplementary Table S1 .Data AbstractionIn addition, we have classified assays that can feasibly be completed without extensive training or high-end instrumentation as \"direct,\" whereas those with greater labor or equipment demands (e.g., freezers, high-speed centrifugation, or incubation for multiple hours) are deemed \"semi-direct.\"", [["nucleic acid", "CHEMICAL", 48, 60], ["an extensive examination", "TEST", 20, 44], ["nucleic acid template specificity", "PROBLEM", 48, 81], ["single or multiplexed reactions", "PROBLEM", 93, 124], ["pretreatment requirements", "TREATMENT", 267, 292], ["extensive training", "TREATMENT", 441, 459], ["high-end instrumentation", "TREATMENT", 463, 487]]], ["Methods categorized as \"semi-direct\" face some hurdles to implementation as an on-site service for patient care.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["Methods", "TREATMENT", 0, 7]]], ["What these tests do offer is a way to deliver actionable results that can link diagnosis to treatment.", [["treatment", "TREATMENT", 92, 101]]], ["With appropriate conversion from requirements for highly trained staff and sophisticated tools to easy-to-use methods, \"semi-direct\" procedures will meet the requirements for POC diagnostic devices.Visualization ProcessWe found certain parameters could be distilled into numerical data, yielding particularly useful insights when examining different tests.", [["methods", "TREATMENT", 110, 117], ["POC diagnostic devices", "TREATMENT", 175, 197], ["Visualization ProcessWe", "TEST", 198, 221], ["different tests", "TEST", 340, 355]]], ["We have devised three major criteria that are indicative of each platform's robustness, sensitivity, and clinical efficacy:Visualization ProcessTolerance to the sample of interest-ideally, the assay should be able to detect its target against a high concentration of background contaminants.", [["each platform's robustness", "TEST", 60, 86], ["the assay", "TEST", 189, 198], ["a high concentration of background contaminants", "PROBLEM", 243, 290], ["indicative of", "UNCERTAINTY", 46, 59]]], ["We note that, although sample dilution sometimes provides a convenient way of permitting amplification, doing so inevitably reduces the limit of detection (LOD).", [["sample dilution", "TEST", 23, 38], ["permitting amplification", "TREATMENT", 78, 102]]], ["Most NAATs analyze only a fraction of the sample volume.", [["sample", "ANATOMY", 42, 48], ["NAATs", "PROTEIN", 5, 10]]], ["Sample dilution therefore increases the likelihood of false negative results, especially when the samples already have low target concentrations.", [["samples", "ANATOMY", 98, 105], ["Sample dilution", "TEST", 0, 15], ["the samples", "TEST", 94, 105], ["low target concentrations", "PROBLEM", 119, 144]]], ["2.Visualization ProcessLOD-by foregoing sample preparation, one generally sacrifices the opportunity to concentrate bulk samples, reducing the limit of detection and making sensitivity an important consideration.3.Clinical evaluation-recognizing assays that have been validated with clinical samples.3.Finally, we sought to devise a visual strategy that would clearly and quickly communicate the importance of our criteria, compare the wide range of assays, discover trends in the data, and reveal patterns in a single glance.", [["samples", "ANATOMY", 121, 128], ["Visualization ProcessLOD", "TEST", 2, 26], ["foregoing sample preparation", "TREATMENT", 30, 58], ["bulk samples", "TEST", 116, 128], ["Clinical evaluation", "TEST", 214, 233], ["recognizing assays", "TEST", 234, 252], ["clinical samples", "TEST", 283, 299], ["assays", "TEST", 450, 456], ["the data", "TEST", 477, 485]]], ["Relevant values are standardized and communicated in terms of visual attributes of position, size, shape, and color.3.We have found it particularly useful to visualize the data as \"bubble plots.\"", [["size", "OBSERVATION_MODIFIER", 93, 97], ["shape", "OBSERVATION_MODIFIER", 99, 104]]], ["In a bubble plot, numerical values from three parameters are simultaneously visualized via the two axes and the size of the circular marker.", [["a bubble plot", "TEST", 3, 16], ["numerical values", "TEST", 18, 34], ["bubble plot", "OBSERVATION", 5, 16], ["size", "OBSERVATION_MODIFIER", 112, 116], ["circular marker", "OBSERVATION", 124, 139]]], ["In our case, we can readily display the essential information (e.g., sample tolerance, LOD, and instances of clinical testing) of related procedures to discern those that enhance test performance.Brief Overview of Isothermal Amplification TechniquesIn our survey, we came across eight DNA-and RNA-based testing techniques.", [["DNA", "CELLULAR_COMPONENT", 285, 288], ["clinical testing", "TEST", 109, 125], ["related procedures", "TREATMENT", 130, 148], ["Isothermal Amplification Techniques", "TREATMENT", 214, 249], ["eight DNA", "TEST", 279, 288], ["RNA", "TEST", 293, 296], ["testing techniques", "TEST", 303, 321]]], ["As expected, PCR (and reverse transcription PCR, or RT-PCR) has been the predominant technique.", [["PCR", "TEST", 13, 16], ["reverse transcription PCR", "TEST", 22, 47], ["RT-PCR", "TEST", 52, 58]]], ["Notably, a number of isothermal amplification techniques have also been used to develop direct NAATs.", [["NAATs", "PROTEIN", 95, 100], ["isothermal amplification techniques", "TREATMENT", 21, 56]]], ["Herein, we provide brief overviews of these lesser known isothermal amplification techniques.LAMPWhile PCR is the most commonly reported method of amplification, there is an increasing number of isothermal amplification technologies that can be truly used at the POC.", [["these lesser known isothermal amplification techniques", "TREATMENT", 38, 92], ["LAMPWhile PCR", "TEST", 93, 106], ["isothermal amplification technologies", "TREATMENT", 195, 232], ["increasing", "OBSERVATION_MODIFIER", 174, 184]]], ["The single reaction temperature enables the use of less costly, complicated instruments than for thermal cycling tests.", [["The single reaction temperature", "PROBLEM", 0, 31], ["thermal cycling tests", "TEST", 97, 118]]], ["Loop-mediated isothermal amplification (LAMP) is one such widely researched, developed, and characterized method [17] .", [["Loop-mediated isothermal amplification", "TREATMENT", 0, 38]]], ["Amplification employs a strand-displacing polymerase and two or three pairs of primers: one that is sacrificed to linearize the template, and one or two others that prime the DNA synthesis to produce concatenated, cauliflower-like products [18] .", [["DNA", "CELLULAR_COMPONENT", 175, 178], ["strand-displacing polymerase", "PROTEIN", 24, 52], ["a strand-displacing polymerase", "TREATMENT", 22, 52], ["the DNA synthesis", "PROBLEM", 171, 188]]], ["As with PCR, LAMP has been modified to target RNA as reverse-transcription (RT)-LAMP [19] .LAMPLAMP has been compared to PCR in other ways as well, including applications with bacterial, viral, fungal, and parasitic assays.", [["LAMP", "PROTEIN", 13, 17], ["reverse-transcription (RT)-LAMP [19] .LAMPLAMP", "DNA", 53, 99], ["PCR", "TEST", 8, 11], ["LAMP", "TREATMENT", 13, 17], [".LAMPLAMP", "TREATMENT", 90, 99], ["PCR", "TEST", 121, 124], ["bacterial, viral, fungal, and parasitic assays", "PROBLEM", 176, 222], ["fungal", "OBSERVATION", 194, 200], ["parasitic assays", "OBSERVATION", 206, 222]]], ["Not only has the specificity and sensitivity been equivalent to that of PCR, the robustness of LAMP to certain preparations of serum, swabs, and blood has shown it to be more tolerant to inhibitors than PCR [8] .NASBAThe nucleic acid sequence-based amplification (NASBA) method is unique in its ability to amplify single-stranded RNA directly [20] .", [["serum", "ANATOMY", 127, 132], ["swabs", "ANATOMY", 134, 139], ["blood", "ANATOMY", 145, 150], ["nucleic acid", "CHEMICAL", 221, 233], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["swabs", "ORGANISM_SUBSTANCE", 134, 139], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["PCR", "TEST", 72, 75], ["LAMP", "TREATMENT", 95, 99], ["serum, swabs", "TEST", 127, 139], ["blood", "TEST", 145, 150], ["PCR", "TEST", 203, 206], ["NASBAThe nucleic acid sequence", "TREATMENT", 212, 242], ["based amplification (NASBA) method", "TREATMENT", 243, 277]]], ["This is most desirable for targeting RNA viruses and for transcriptome analysis [8] .", [["targeting RNA viruses", "PROBLEM", 27, 48], ["transcriptome analysis", "TEST", 57, 79]]], ["The continuous, homogeneous, isothermal process relies on RNA polymerase, RNase, and reverse transcriptase.", [["RNase", "GENE_OR_GENE_PRODUCT", 74, 79], ["RNA polymerase", "PROTEIN", 58, 72], ["RNase", "PROTEIN", 74, 79], ["reverse transcriptase", "PROTEIN", 85, 106], ["RNA polymerase", "TEST", 58, 72], ["RNase", "TREATMENT", 74, 79], ["reverse transcriptase", "TREATMENT", 85, 106], ["homogeneous", "OBSERVATION_MODIFIER", 16, 27]]], ["First, the reverse transcriptase creates a double stranded RNA:DNA hybrid from the RNA template; next, the original RNA is destroyed; a DNA duplex is synthesized; then, the polymerase can transcribe RNA from the DNA.", [["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["DNA", "CELLULAR_COMPONENT", 212, 215], ["reverse transcriptase", "PROTEIN", 11, 32], ["double stranded RNA", "RNA", 43, 62], ["RNA template", "RNA", 83, 95], ["DNA duplex", "DNA", 136, 146], ["the reverse transcriptase", "TREATMENT", 7, 32], ["a double stranded RNA", "PROBLEM", 41, 62], ["DNA hybrid", "PROBLEM", 63, 73], ["the RNA template", "TREATMENT", 79, 95], ["a DNA duplex", "TEST", 134, 146], ["the polymerase", "PROBLEM", 169, 183]]], ["Each new RNA molecule can repeat the cycle for exponential amplification.NASBANASBA has been applied to a wide-ranging set of research problems, including HIV diagnosis during the AIDS epidemic of the 1990s and automated, real-time, clinical tests in blood with the modern NucliSENS (bioMerieux, Inc., Durham, NC, USA) or in urine with the APTIMA assay (Hologic, San Diego, CA, USA).", [["blood", "ANATOMY", 251, 256], ["urine", "ANATOMY", 325, 330], ["NASBANASBA", "CHEMICAL", 73, 83], ["AIDS", "DISEASE", 180, 184], ["blood", "ORGANISM_SUBSTANCE", 251, 256], ["urine", "ORGANISM_SUBSTANCE", 325, 330], ["HIV", "SPECIES", 155, 158], ["HIV", "SPECIES", 155, 158], ["Each new RNA molecule", "PROBLEM", 0, 21], ["exponential amplification", "TREATMENT", 47, 72], ["NASBANASBA", "TREATMENT", 73, 83], ["research problems", "PROBLEM", 126, 143], ["clinical tests", "TEST", 233, 247], ["the APTIMA assay", "TEST", 336, 352], ["RNA molecule", "OBSERVATION", 9, 21]]], ["NASBA is also used outside of the commercial sector with systems to monitor viruses in serum [21] .SDAThe strand displacement amplification (SDA) technique is based upon the abilities of a restriction enzyme and a DNA polymerase.", [["serum", "ANATOMY", 87, 92], ["NASBA", "CHEMICAL", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["restriction enzyme", "PROTEIN", 189, 207], ["DNA polymerase", "PROTEIN", 214, 228], ["NASBA", "TREATMENT", 0, 5], ["viruses in serum", "TEST", 76, 92], ["SDAThe strand displacement amplification (SDA) technique", "TREATMENT", 99, 155], ["a restriction enzyme", "TEST", 187, 207], ["a DNA polymerase", "TEST", 212, 228], ["strand displacement", "OBSERVATION", 106, 125]]], ["A primer containing a recognition sequence for the restriction enzyme binds to its complementary, single stranded DNA target.", [["DNA", "CELLULAR_COMPONENT", 114, 117], ["restriction enzyme", "PROTEIN", 51, 69], ["complementary, single stranded DNA target", "DNA", 83, 124], ["A primer", "TREATMENT", 0, 8], ["the restriction enzyme binds", "PROBLEM", 47, 75], ["single stranded DNA target", "PROBLEM", 98, 124]]], ["After extension by the polymerase, the restriction enzyme nicks the unmodified strand of the double-stranded hemiphosphorothioate recognition site.", [["hemiphosphorothioate", "CHEMICAL", 109, 129], ["restriction enzyme", "PROTEIN", 39, 57], ["double-stranded hemiphosphorothioate recognition site", "DNA", 93, 146], ["the polymerase", "TEST", 19, 33], ["the restriction enzyme nicks", "TREATMENT", 35, 63], ["the double-stranded hemiphosphorothioate recognition site", "TREATMENT", 89, 146], ["unmodified strand", "OBSERVATION", 68, 85], ["double", "OBSERVATION_MODIFIER", 93, 99]]], ["DNA polymerase then extends the 3 end of the nick, displacing the downstream strand.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["strand", "CELLULAR_COMPONENT", 77, 83], ["DNA polymerase", "PROTEIN", 0, 14], ["downstream strand", "DNA", 66, 83], ["DNA polymerase", "PROBLEM", 0, 14], ["downstream strand", "OBSERVATION", 66, 83]]], ["The end result is exponential target amplification from the displaced strands, which serve as targets for new reactions.SDASDA is not complex, but it does suffer from sensitivity issues in the presence of background DNA.", [["SDASDA", "SIMPLE_CHEMICAL", 120, 126], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["SDASDA", "PROTEIN", 120, 126], ["exponential target amplification", "PROBLEM", 18, 50], ["the displaced strands", "PROBLEM", 56, 77], ["new reactions", "PROBLEM", 106, 119], ["sensitivity issues", "PROBLEM", 167, 185], ["background DNA", "PROBLEM", 205, 219], ["exponential", "OBSERVATION_MODIFIER", 18, 29], ["target", "OBSERVATION_MODIFIER", 30, 36], ["displaced", "OBSERVATION_MODIFIER", 60, 69], ["strands", "OBSERVATION", 70, 77], ["not", "UNCERTAINTY", 130, 133], ["complex", "OBSERVATION_MODIFIER", 134, 141], ["DNA", "OBSERVATION", 216, 219]]], ["The best way to overcome off-target amplification, and hence reduce false-positives, is to use simple pretreatment procedures like those that have been developed for detection with the BDProbe-Tec (Becton Dickinson Microbiology Systems, Sparks, MD, USA) and in-house systems for urine [22] .RPARecombinase polymerase amplification (RPA) avoids thermal cycling by using three core proteins that operate optimally between 37-40 \u2022 C [23] .", [["urine", "ANATOMY", 279, 284], ["urine", "ORGANISM_SUBSTANCE", 279, 284], ["RPARecombinase polymerase", "GENE_OR_GENE_PRODUCT", 291, 316], ["Tec", "PROTEIN", 193, 196], ["RPARecombinase polymerase", "PROTEIN", 291, 316], ["false-positives", "PROBLEM", 68, 83], ["simple pretreatment procedures", "TREATMENT", 95, 125], ["RPARecombinase polymerase amplification", "TREATMENT", 291, 330], ["thermal cycling", "TREATMENT", 344, 359]]], ["The first protein, recombinase, binds to primers that recombine with a duplex target for strand displacement.", [["recombinase", "PROTEIN", 19, 30], ["a duplex target", "TEST", 69, 84], ["strand displacement", "PROBLEM", 89, 108], ["strand displacement", "OBSERVATION", 89, 108]]], ["The second, a single-stranded DNA binding protein, attaches to the displaced strand before a strand-displacing polymerase copies the DNA from the primer onwards for exponential amplification.RPAOne of the requirements for RPA technology is sequence-specific detection.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["RPA", "GENE_OR_GENE_PRODUCT", 222, 225], ["single-stranded DNA binding protein", "PROTEIN", 14, 49], ["strand-displacing polymerase", "PROTEIN", 93, 121], ["RPA", "PROTEIN", 222, 225], ["a single-stranded DNA binding protein", "PROBLEM", 12, 49], ["the displaced strand", "PROBLEM", 63, 83], ["a strand-displacing polymerase", "TREATMENT", 91, 121], ["exponential amplification", "TREATMENT", 165, 190], ["RPA technology", "TEST", 222, 236], ["displaced", "OBSERVATION_MODIFIER", 67, 76], ["strand", "OBSERVATION", 77, 83]]], ["This avoids the problem of primer artifacts that add to background fluorescence with nonspecific, intercalating dyes.", [["primer artifacts", "PROBLEM", 27, 43], ["background fluorescence", "PROBLEM", 56, 79], ["nonspecific, intercalating dyes", "PROBLEM", 85, 116], ["primer artifacts", "OBSERVATION", 27, 43], ["nonspecific", "OBSERVATION_MODIFIER", 85, 96], ["intercalating dyes", "OBSERVATION", 98, 116]]], ["With its specific readout and rapidity (<20 min to results) as two main features, RPA provides an alternative to the time-consuming processes of culturing and bacterial genotyping when testing for pathogens [7] .SIBAStrand invasion based amplification (SIBA) is another amplification process that relies on recombinase activity.", [["RPA", "GENE_OR_GENE_PRODUCT", 82, 85], ["recombinase", "GENE_OR_GENE_PRODUCT", 307, 318], ["RPA", "PROTEIN", 82, 85], ["culturing", "TEST", 145, 154], ["bacterial genotyping", "TEST", 159, 179], ["pathogens", "PROBLEM", 197, 206], ["SIBAStrand invasion", "PROBLEM", 212, 231], ["another amplification process", "PROBLEM", 262, 291], ["invasion", "OBSERVATION", 223, 231]]], ["In SIBA, there is a separate recombinase substrate that is inserted between two primer-binding sites.", [["SIBA", "GENE_OR_GENE_PRODUCT", 3, 7], ["SIBA", "PROTEIN", 3, 7], ["recombinase substrate", "PROTEIN", 29, 50], ["primer-binding sites", "DNA", 80, 100], ["a separate recombinase substrate", "TREATMENT", 18, 50], ["recombinase substrate", "OBSERVATION", 29, 50], ["binding sites", "OBSERVATION", 87, 100]]], ["The duplex peripheral to this insertion site is separated, enabling the primers to bind.", [["insertion site", "DNA", 30, 44], ["The duplex peripheral to this insertion site", "TREATMENT", 0, 44], ["peripheral", "ANATOMY_MODIFIER", 11, 21], ["separated", "OBSERVATION", 48, 57]]], ["DNA polymerase can then extend the template from the bound primers.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA polymerase", "PROTEIN", 0, 14], ["DNA polymerase", "PROBLEM", 0, 14], ["the bound primers", "PROBLEM", 49, 66], ["bound primers", "OBSERVATION", 53, 66]]], ["This use of an invading substrate, one that is neither consumed nor included in the extension of DNA, is advantageous because it abolishes primer artifacts.", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["an invading substrate", "TREATMENT", 12, 33], ["primer artifacts", "PROBLEM", 139, 155]]], ["SIBA can therefore be used to reliably detect low copy numbers of pathogens-other isothermal methods generate non-specific amplification products in the absence of target DNA [24] .", [["SIBA", "CHEMICAL", 0, 4], ["SIBA", "SIMPLE_CHEMICAL", 0, 4], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["low copy numbers of pathogens", "PROBLEM", 46, 75], ["other isothermal methods", "TREATMENT", 76, 100], ["non-specific amplification products", "TREATMENT", 110, 145]]], ["Going further, the specificity of SIBA enables multiplexing for the detection of templates that differ by as little as two bases [25] .MDAMultiple displacement amplification (MDA) is a technique that exploits the strand displacement, proofreading, and polymerase activity of the \u03c629 bacteriophage DNA polymerase [26] .", [["SIBA", "SIMPLE_CHEMICAL", 34, 38], ["MDA", "SIMPLE_CHEMICAL", 175, 178], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["SIBA", "PROTEIN", 34, 38], ["\u03c629 bacteriophage DNA polymerase", "PROTEIN", 279, 311], ["the detection", "TEST", 64, 77], ["MDAMultiple displacement amplification", "PROBLEM", 135, 173], ["a technique", "TREATMENT", 183, 194], ["the strand displacement", "PROBLEM", 209, 232], ["polymerase activity", "TEST", 252, 271], ["bacteriophage DNA polymerase", "TEST", 283, 311], ["displacement", "OBSERVATION_MODIFIER", 147, 159], ["strand displacement", "OBSERVATION", 213, 232]]], ["The highly processive polymerase uses random primers to amplify an entire genome.", [["highly processive polymerase", "PROTEIN", 4, 32], ["The highly processive polymerase", "PROBLEM", 0, 32], ["random primers", "TREATMENT", 38, 52], ["highly", "OBSERVATION_MODIFIER", 4, 10], ["processive", "OBSERVATION_MODIFIER", 11, 21], ["polymerase", "OBSERVATION", 22, 32]]], ["MDA is therefore well-suited for whole genome amplification from crude biological samples, which can be followed by single nucleotide polymorphism (SNP) testing and genotyping [8] .HCRThe concept of hybridization chain reaction (HCR) [27] -an enzyme-free, room-temperature method-relies on a DNA trigger to initiate amplification.", [["samples", "ANATOMY", 82, 89], ["MDA", "CHEMICAL", 0, 3], ["SNP", "CHEMICAL", 148, 151], ["MDA", "CHEMICAL", 0, 3], ["MDA", "SIMPLE_CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 292, 295], ["whole genome amplification", "TREATMENT", 33, 59], ["single nucleotide polymorphism (SNP) testing", "TREATMENT", 116, 160], ["hybridization chain reaction", "TEST", 199, 227], ["an enzyme", "TEST", 240, 249], ["a DNA trigger", "TREATMENT", 290, 303]]], ["The initiator interacts with two stable DNA hairpins to create nicked double helices.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA hairpins", "DNA", 40, 52], ["nicked double helices", "PROTEIN", 63, 84], ["two stable DNA hairpins", "TREATMENT", 29, 52], ["nicked double helices", "TREATMENT", 63, 84]]], ["HCR is a useful assay for detecting short DNAs, such as human immunodeficiency virus type 1 (HIV-1) in serum [28] .Growing Prevalence of Direct NAATsTime-series plots offer an effective means for showing the growing prevalence of direct NAATs.", [["serum", "ANATOMY", 103, 108], ["human immunodeficiency virus", "DISEASE", 56, 84], ["human immunodeficiency virus type 1", "ORGANISM", 56, 91], ["HIV-1", "ORGANISM", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["NAATs", "GENE_OR_GENE_PRODUCT", 237, 242], ["HCR", "PROTEIN", 0, 3], ["short DNAs", "DNA", 36, 46], ["human immunodeficiency virus type 1", "SPECIES", 56, 91], ["HIV-1", "SPECIES", 93, 98], ["human immunodeficiency virus type 1", "SPECIES", 56, 91], ["HIV-1", "SPECIES", 93, 98], ["HCR", "TEST", 0, 3], ["short DNAs", "PROBLEM", 36, 46], ["human immunodeficiency virus type", "PROBLEM", 56, 89], ["HIV", "TEST", 93, 96], ["Direct NAATsTime-series plots", "TREATMENT", 137, 166]]], ["Specifically, within each sample type, we plotted the number of clinical samples that have been analyzed by direct NAATs from 1989 to 2017 ( Figure 2 ).", [["samples", "CANCER", 73, 80], ["clinical samples", "TEST", 64, 80]]], ["Here, we also divided the data into two cohorts based on whether samples were subjected to PCR (Figure 2 , black) or isothermal amplification techniques ( Figure 2 , red).", [["samples", "ANATOMY", 65, 72], ["PCR", "TEST", 91, 94], ["isothermal amplification techniques", "TEST", 117, 152]]], ["As expected, we saw an overall rise in the number of clinical samples analyzed via NAATs with minimal or no sample preparation over the analyzed period.", [["samples", "ANATOMY", 62, 69], ["clinical samples", "TEST", 53, 69], ["sample preparation", "TREATMENT", 108, 126], ["overall", "OBSERVATION_MODIFIER", 23, 30], ["rise", "OBSERVATION_MODIFIER", 31, 35]]], ["Across all six sample types, we observed sharp spikes, which indicate studies of high numbers of clinical samples.", [["samples", "ANATOMY", 106, 113], ["samples", "CANCER", 106, 113], ["sharp spikes", "PROBLEM", 41, 53], ["high numbers of clinical samples", "PROBLEM", 81, 113]]], ["Based on the sample type, swab samples had been most analyzed, while urine and stool samples had been least analyzed.", [["swab samples", "ANATOMY", 26, 38], ["urine", "ANATOMY", 69, 74], ["stool samples", "ANATOMY", 79, 92], ["swab samples", "ORGANISM_SUBSTANCE", 26, 38], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["stool samples", "ORGANISM_SUBSTANCE", 79, 92], ["swab samples", "TEST", 26, 38], ["urine and stool samples", "TEST", 69, 92]]], ["Within each sample type, after an initial lag, we saw a notable rise in the use of isothermal amplification techniques.", [["isothermal amplification techniques", "TREATMENT", 83, 118]]], ["PCR-based systems emerged within five years of the technique's inception in 1986 [29] , and PCR largely continues to dominate the realm of nucleic acid testing.", [["nucleic acid", "CHEMICAL", 139, 151], ["nucleic acid", "SIMPLE_CHEMICAL", 139, 151], ["PCR", "TEST", 0, 3], ["the technique", "TEST", 47, 60], ["PCR", "TEST", 92, 95], ["nucleic acid testing", "TEST", 139, 159]]], ["The one notable exception is seen in our time-course of blood testing, where isothermal techniques have surpassed PCR and RT-PCR in terms of the number of assays performed on whole blood samples.HCRThe concept of hybridization chain reaction (HCR) [27] -an enzyme-free, room-temperature method-relies on a DNA trigger to initiate amplification.", [["blood", "ANATOMY", 56, 61], ["whole blood samples", "ANATOMY", 175, 194], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["blood samples", "ORGANISM_SUBSTANCE", 181, 194], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["blood testing", "TEST", 56, 69], ["isothermal techniques", "TEST", 77, 98], ["PCR", "TEST", 114, 117], ["RT-PCR", "TEST", 122, 128], ["assays", "TEST", 155, 161], ["whole blood samples", "TEST", 175, 194], ["hybridization chain reaction", "TEST", 213, 241], ["an enzyme", "TEST", 254, 263], ["a DNA trigger", "TREATMENT", 304, 317], ["one", "OBSERVATION_MODIFIER", 4, 7], ["notable", "OBSERVATION_MODIFIER", 8, 15]]], ["The initiator interacts with two stable DNA hairpins to create nicked double helices.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA hairpins", "DNA", 40, 52], ["nicked double helices", "PROTEIN", 63, 84], ["two stable DNA hairpins", "TREATMENT", 29, 52], ["nicked double helices", "TREATMENT", 63, 84]]], ["HCR is a useful assay for detecting short DNAs, such as human immunodeficiency virus type 1 (HIV-1) in serum [28] .Growing Prevalence of Direct NAATsTime-series plots offer an effective means for showing the growing prevalence of direct NAATs.", [["serum", "ANATOMY", 103, 108], ["human immunodeficiency virus", "DISEASE", 56, 84], ["human immunodeficiency virus type 1", "ORGANISM", 56, 91], ["HIV-1", "ORGANISM", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["NAATs", "GENE_OR_GENE_PRODUCT", 237, 242], ["HCR", "PROTEIN", 0, 3], ["short DNAs", "DNA", 36, 46], ["human immunodeficiency virus type 1", "SPECIES", 56, 91], ["HIV-1", "SPECIES", 93, 98], ["human immunodeficiency virus type 1", "SPECIES", 56, 91], ["HIV-1", "SPECIES", 93, 98], ["HCR", "TEST", 0, 3], ["short DNAs", "PROBLEM", 36, 46], ["human immunodeficiency virus type", "PROBLEM", 56, 89], ["HIV", "TEST", 93, 96], ["Direct NAATsTime-series plots", "TREATMENT", 137, 166]]], ["Specifically, within each sample type, we plotted the number of clinical samples that have been analyzed by direct NAATs from 1989 to 2017 ( Figure 2 ).", [["samples", "CANCER", 73, 80], ["clinical samples", "TEST", 64, 80]]], ["Here, we also divided the data into two cohorts based on whether samples were subjected to PCR (Figure 2 , black) or isothermal amplification techniques (Figure 2 , red).", [["samples", "ANATOMY", 65, 72], ["PCR", "TEST", 91, 94], ["isothermal amplification techniques", "TEST", 117, 152]]], ["As expected, we saw an overall rise in the number of clinical samples analyzed via NAATs with minimal or no sample preparation over the analyzed period.", [["samples", "ANATOMY", 62, 69], ["clinical samples", "TEST", 53, 69], ["sample preparation", "TREATMENT", 108, 126], ["overall", "OBSERVATION_MODIFIER", 23, 30], ["rise", "OBSERVATION_MODIFIER", 31, 35]]], ["Across all six sample types, we observed sharp spikes, which indicate studies of high numbers of clinical samples.", [["samples", "ANATOMY", 106, 113], ["samples", "CANCER", 106, 113], ["sharp spikes", "PROBLEM", 41, 53], ["high numbers of clinical samples", "PROBLEM", 81, 113]]], ["Based on the sample type, swab samples had been most analyzed, while urine and stool samples had been least analyzed.", [["swab samples", "ANATOMY", 26, 38], ["urine", "ANATOMY", 69, 74], ["stool samples", "ANATOMY", 79, 92], ["swab samples", "ORGANISM_SUBSTANCE", 26, 38], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["stool samples", "ORGANISM_SUBSTANCE", 79, 92], ["swab samples", "TEST", 26, 38], ["urine and stool samples", "TEST", 69, 92]]], ["Within each sample type, after an initial lag, we saw a notable rise in the use of isothermal amplification techniques.", [["isothermal amplification techniques", "TREATMENT", 83, 118]]], ["PCR-based systems emerged within five years of the technique's inception in 1986 [29] , and PCR largely continues to dominate the realm of nucleic acid testing.", [["nucleic acid", "CHEMICAL", 139, 151], ["nucleic acid", "SIMPLE_CHEMICAL", 139, 151], ["PCR", "TEST", 0, 3], ["the technique", "TEST", 47, 60], ["PCR", "TEST", 92, 95], ["nucleic acid testing", "TEST", 139, 159]]], ["The one notable exception is seen in our time-course of blood testing, where isothermal techniques have surpassed PCR and RT-PCR in terms of the number of assays performed on whole blood samples.Direct NAATs for Whole BloodBecause blood contains circulating nucleic acids, cells, and over 20,000 different proteins, it offers an abundance of biomarkers for disease detection.", [["blood", "ANATOMY", 56, 61], ["whole blood samples", "ANATOMY", 175, 194], ["blood", "ANATOMY", 231, 236], ["cells", "ANATOMY", 273, 278], ["nucleic acids", "CHEMICAL", 258, 271], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["blood samples", "ORGANISM_SUBSTANCE", 181, 194], ["NAATs", "SIMPLE_CHEMICAL", 202, 207], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["cells", "CELL", 273, 278], ["blood testing", "TEST", 56, 69], ["isothermal techniques", "TEST", 77, 98], ["PCR", "TEST", 114, 117], ["RT-PCR", "TEST", 122, 128], ["assays", "TEST", 155, 161], ["whole blood samples", "TEST", 175, 194], ["Direct NAATs", "TEST", 195, 207], ["Whole BloodBecause blood", "TEST", 212, 236], ["circulating nucleic acids", "TEST", 246, 271], ["cells", "TEST", 273, 278], ["disease detection", "PROBLEM", 357, 374], ["one", "OBSERVATION_MODIFIER", 4, 7], ["notable", "OBSERVATION_MODIFIER", 8, 15], ["nucleic acids", "OBSERVATION", 258, 271]]], ["Molecular diagnostics in blood are useful for detecting specific DNA or RNA sequences from a range of bacterial, toxic, and viral infectious agents.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["Molecular diagnostics in blood", "TEST", 0, 30], ["specific DNA", "PROBLEM", 56, 68], ["RNA sequences", "PROBLEM", 72, 85], ["bacterial", "PROBLEM", 102, 111], ["toxic", "PROBLEM", 113, 118], ["viral infectious agents", "TREATMENT", 124, 147]]], ["Platforms for hepatitis and human immunodeficiency virus [30] , Staphylococcus aureus [31] , and Plasmodium species are just a few of the most-used systems enabling rapid diagnostics in whole blood.Direct NAATs for Whole BloodBlood-based testing generally demands sophisticated detection instruments or extensive preparation to recover inhibitor-free and high-purity DNA.", [["whole blood", "ANATOMY", 186, 197], ["hepatitis and human immunodeficiency virus", "DISEASE", 14, 56], ["human immunodeficiency virus [30", "ORGANISM", 28, 60], ["Staphylococcus aureus", "ORGANISM", 64, 85], ["Plasmodium", "ORGANISM", 97, 107], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["DNA", "CELLULAR_COMPONENT", 367, 370], ["human immunodeficiency virus", "SPECIES", 28, 56], ["Staphylococcus aureus", "SPECIES", 64, 85], ["human immunodeficiency virus", "SPECIES", 28, 56], ["Staphylococcus aureus", "SPECIES", 64, 85], ["hepatitis", "PROBLEM", 14, 23], ["human immunodeficiency virus", "PROBLEM", 28, 56], ["Staphylococcus aureus", "PROBLEM", 64, 85], ["Plasmodium species", "PROBLEM", 97, 115], ["Whole BloodBlood-based testing", "TEST", 215, 245], ["sophisticated detection instruments", "TREATMENT", 264, 299], ["extensive preparation", "TREATMENT", 303, 324], ["inhibitor", "TEST", 336, 345], ["hepatitis", "OBSERVATION", 14, 23], ["purity DNA", "OBSERVATION", 360, 370]]], ["Not all inhibitory blood components are known [32] , but heme compounds, anticoagulants, and immunoglobulin G (IgG) can all interfere with amplification reactions by inhibiting DNA polymerase activity [33] or chelating necessary cofactors [34, 35] .", [["blood", "ANATOMY", 19, 24], ["heme", "CHEMICAL", 57, 61], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["heme compounds", "SIMPLE_CHEMICAL", 57, 71], ["anticoagulants", "SIMPLE_CHEMICAL", 73, 87], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 93, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["immunoglobulin G", "PROTEIN", 93, 109], ["IgG", "PROTEIN", 111, 114], ["DNA polymerase", "PROTEIN", 177, 191], ["all inhibitory blood components", "PROBLEM", 4, 35], ["heme compounds", "PROBLEM", 57, 71], ["anticoagulants", "TREATMENT", 73, 87], ["immunoglobulin G (IgG)", "TREATMENT", 93, 115], ["amplification reactions", "PROBLEM", 139, 162]]], ["Although a wide range of bloodborne viruses, bacteria, and parasites can in principle be detected with nucleic acid testing, extraction-and purification-free means of detecting these pathogens are not currently commercially available.Direct NAATs for Whole BloodWe have visualized the general trends of direct and semi-direct nucleic acid testing in blood as a function of the LODs ( Figure 3 ).", [["Blood", "ANATOMY", 257, 262], ["blood", "ANATOMY", 350, 355], ["nucleic acid", "CHEMICAL", 103, 115], ["nucleic acid", "CHEMICAL", 326, 338], ["Blood", "ORGANISM_SUBSTANCE", 257, 262], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["bloodborne viruses", "PROBLEM", 25, 43], ["bacteria", "PROBLEM", 45, 53], ["parasites", "PROBLEM", 59, 68], ["nucleic acid testing", "TEST", 103, 123], ["extraction", "TEST", 125, 135], ["purification", "TEST", 140, 152], ["these pathogens", "PROBLEM", 177, 192], ["Whole Blood", "TEST", 251, 262], ["semi-direct nucleic acid testing", "TEST", 314, 346], ["wide", "OBSERVATION_MODIFIER", 11, 15], ["bloodborne viruses", "OBSERVATION", 25, 43], ["pathogens", "OBSERVATION", 183, 192]]], ["The % (v/v) of blood tolerated in a reaction is plotted against the LOD in g of template, with the number of clinical samples encoded as the area of the bubble.", [["blood", "ANATOMY", 15, 20], ["samples", "ANATOMY", 118, 125], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["a reaction", "PROBLEM", 34, 44], ["the LOD in g of template", "TREATMENT", 64, 88], ["bubble", "OBSERVATION", 153, 159]]], ["It is evident that many studies have achieved high sensitivity in detecting their target in a low concentration of blood.", [["blood", "ANATOMY", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["many studies", "TEST", 19, 31], ["high sensitivity", "PROBLEM", 46, 62], ["low concentration", "OBSERVATION_MODIFIER", 94, 111]]], ["This shows that nucleic acid testing has great potential for blood-based tests in POC situations where collection volumes are small (e.g., finger pricks) and parasite loads may be low.", [["blood", "ANATOMY", 61, 66], ["finger", "ANATOMY", 139, 145], ["nucleic acid", "CHEMICAL", 16, 28], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["nucleic acid testing", "TEST", 16, 36], ["blood-based tests", "TEST", 61, 78], ["collection volumes", "TEST", 103, 121], ["finger pricks", "TEST", 139, 152], ["parasite loads", "TEST", 158, 172], ["small", "OBSERVATION_MODIFIER", 126, 131], ["low", "OBSERVATION_MODIFIER", 180, 183]]], ["Those examples from the literature that were not demonstrated on patient samples are considered separately in the plot, and represented by Xs rather than bubble markers.", [["patient", "ORGANISM", 65, 72], ["bubble markers", "PROTEIN", 154, 168], ["patient", "SPECIES", 65, 72], ["patient samples", "TEST", 65, 80], ["bubble markers", "TEST", 154, 168]]], ["Some of these are purported to have very low LODs that reach below the fg level (Table S1 )-it remains to be seen whether such tests will perform with the same extreme sensitivity in a clinical context.Direct NAATs for Whole BloodBecause blood contains circulating nucleic acids, cells, and over 20,000 different proteins, it offers an abundance of biomarkers for disease detection.", [["blood", "ANATOMY", 238, 243], ["cells", "ANATOMY", 280, 285], ["nucleic acids", "CHEMICAL", 265, 278], ["NAATs", "SIMPLE_CHEMICAL", 209, 214], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["cells", "CELL", 280, 285], ["very low LODs", "PROBLEM", 36, 49], ["such tests", "TEST", 122, 132], ["Direct NAATs", "TEST", 202, 214], ["Whole BloodBecause blood", "TEST", 219, 243], ["circulating nucleic acids", "TEST", 253, 278], ["cells", "TEST", 280, 285], ["disease detection", "PROBLEM", 364, 381], ["nucleic acids", "OBSERVATION", 265, 278]]], ["Molecular diagnostics in blood are useful for detecting specific DNA or RNA sequences from a range of bacterial, toxic, and viral infectious agents.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["Molecular diagnostics in blood", "TEST", 0, 30], ["specific DNA", "PROBLEM", 56, 68], ["RNA sequences", "PROBLEM", 72, 85], ["bacterial", "PROBLEM", 102, 111], ["toxic", "PROBLEM", 113, 118], ["viral infectious agents", "TREATMENT", 124, 147]]], ["Platforms for hepatitis and human immunodeficiency virus [30] , Staphylococcus aureus [31] , and Plasmodium species are just a few of the most-used systems enabling rapid diagnostics in whole blood.Direct NAATs for Whole BloodBlood-based testing generally demands sophisticated detection instruments or extensive preparation to recover inhibitor-free and high-purity DNA.", [["whole blood", "ANATOMY", 186, 197], ["hepatitis and human immunodeficiency virus", "DISEASE", 14, 56], ["human immunodeficiency virus [30", "ORGANISM", 28, 60], ["Staphylococcus aureus", "ORGANISM", 64, 85], ["Plasmodium", "ORGANISM", 97, 107], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["DNA", "CELLULAR_COMPONENT", 367, 370], ["human immunodeficiency virus", "SPECIES", 28, 56], ["Staphylococcus aureus", "SPECIES", 64, 85], ["human immunodeficiency virus", "SPECIES", 28, 56], ["Staphylococcus aureus", "SPECIES", 64, 85], ["hepatitis", "PROBLEM", 14, 23], ["human immunodeficiency virus", "PROBLEM", 28, 56], ["Staphylococcus aureus", "PROBLEM", 64, 85], ["Plasmodium species", "PROBLEM", 97, 115], ["Whole BloodBlood-based testing", "TEST", 215, 245], ["sophisticated detection instruments", "TREATMENT", 264, 299], ["extensive preparation", "TREATMENT", 303, 324], ["inhibitor", "TEST", 336, 345], ["hepatitis", "OBSERVATION", 14, 23], ["purity DNA", "OBSERVATION", 360, 370]]], ["Not all inhibitory blood components are known [32] , but heme compounds, anticoagulants, and immunoglobulin G (IgG) can all interfere with amplification reactions by inhibiting DNA polymerase activity [33] or chelating necessary cofactors [34, 35] .", [["blood", "ANATOMY", 19, 24], ["heme", "CHEMICAL", 57, 61], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["heme compounds", "SIMPLE_CHEMICAL", 57, 71], ["anticoagulants", "SIMPLE_CHEMICAL", 73, 87], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 93, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["immunoglobulin G", "PROTEIN", 93, 109], ["IgG", "PROTEIN", 111, 114], ["DNA polymerase", "PROTEIN", 177, 191], ["all inhibitory blood components", "PROBLEM", 4, 35], ["heme compounds", "PROBLEM", 57, 71], ["anticoagulants", "TREATMENT", 73, 87], ["immunoglobulin G (IgG)", "TREATMENT", 93, 115], ["amplification reactions", "PROBLEM", 139, 162]]], ["Although a wide range of bloodborne viruses, bacteria, and parasites can in principle be detected with nucleic acid testing, extraction-and purification-free means of detecting these pathogens are not currently commercially available.Direct NAATs for Whole BloodWe have visualized the general trends of direct and semi-direct nucleic acid testing in blood as a function of the LODs ( Figure 3 ).", [["Blood", "ANATOMY", 257, 262], ["blood", "ANATOMY", 350, 355], ["nucleic acid", "CHEMICAL", 103, 115], ["nucleic acid", "CHEMICAL", 326, 338], ["Blood", "ORGANISM_SUBSTANCE", 257, 262], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["bloodborne viruses", "PROBLEM", 25, 43], ["bacteria", "PROBLEM", 45, 53], ["parasites", "PROBLEM", 59, 68], ["nucleic acid testing", "TEST", 103, 123], ["extraction", "TEST", 125, 135], ["purification", "TEST", 140, 152], ["these pathogens", "PROBLEM", 177, 192], ["Whole Blood", "TEST", 251, 262], ["semi-direct nucleic acid testing", "TEST", 314, 346], ["wide", "OBSERVATION_MODIFIER", 11, 15], ["bloodborne viruses", "OBSERVATION", 25, 43], ["pathogens", "OBSERVATION", 183, 192]]], ["The % (v/v) of blood tolerated in a reaction is plotted against the LOD in g of template, with the number of clinical samples encoded as the area of the bubble.", [["blood", "ANATOMY", 15, 20], ["samples", "ANATOMY", 118, 125], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["a reaction", "PROBLEM", 34, 44], ["the LOD in g of template", "TREATMENT", 64, 88], ["bubble", "OBSERVATION", 153, 159]]], ["It is evident that many studies have achieved high sensitivity in detecting their target in a low concentration of blood.", [["blood", "ANATOMY", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["many studies", "TEST", 19, 31], ["high sensitivity", "PROBLEM", 46, 62], ["low concentration", "OBSERVATION_MODIFIER", 94, 111]]], ["This shows that nucleic acid testing has great potential for blood-based tests in POC situations where collection volumes are small (e.g., finger pricks) and parasite loads may be low.", [["blood", "ANATOMY", 61, 66], ["finger", "ANATOMY", 139, 145], ["nucleic acid", "CHEMICAL", 16, 28], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["nucleic acid testing", "TEST", 16, 36], ["blood-based tests", "TEST", 61, 78], ["collection volumes", "TEST", 103, 121], ["finger pricks", "TEST", 139, 152], ["parasite loads", "TEST", 158, 172], ["small", "OBSERVATION_MODIFIER", 126, 131], ["low", "OBSERVATION_MODIFIER", 180, 183]]], ["Those examples from the literature that were not demonstrated on patient samples are considered separately in the plot, and represented by Xs rather than bubble markers.", [["patient", "ORGANISM", 65, 72], ["bubble markers", "PROTEIN", 154, 168], ["patient", "SPECIES", 65, 72], ["patient samples", "TEST", 65, 80], ["bubble markers", "TEST", 154, 168]]], ["Some of these are purported to have very low LODs that reach below the fg level (Table S1 )-it remains to be seen whether such tests will perform with the same extreme sensitivity in a clinical context.", [["very low LODs", "PROBLEM", 36, 49], ["such tests", "TEST", 122, 132]]], ["Bubble plot of nucleic acid diagnostics performed in whole blood.", [["whole blood", "ANATOMY", 53, 64], ["nucleic acid", "CHEMICAL", 15, 27], ["nucleic acid", "SIMPLE_CHEMICAL", 15, 27], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["Bubble plot", "TEST", 0, 11], ["nucleic acid diagnostics", "TEST", 15, 39]]], ["Percent concentration (v/v) of blood per reaction in a given procedure is displayed as a function of the limit of detection (LOD) in g of template.", [["blood", "ANATOMY", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["Percent concentration", "TEST", 0, 21], ["blood per reaction", "PROBLEM", 31, 49], ["a given procedure", "TREATMENT", 53, 70], ["concentration", "OBSERVATION_MODIFIER", 8, 21], ["blood", "ANATOMY", 31, 36]]], ["The number of patient samples tested is proportional to the log of the marker area, as shown at top, and the testing methodology is indicated by marker color.", [["samples", "ANATOMY", 22, 29], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["patient samples", "TEST", 14, 29], ["the testing methodology", "TEST", 105, 128]]], ["Cases shown with \u00d7 instead of bubble markers illustrate that patient testing was not reported.Direct NAATs for Whole BloodBy assessing the PCR-and isothermal-based data, we could obtain some insight into how to optimize these techniques to better tolerate blood as a sample matrix.", [["blood", "ANATOMY", 256, 261], ["sample matrix", "ANATOMY", 267, 280], ["patient", "ORGANISM", 61, 68], ["blood", "ORGANISM_SUBSTANCE", 256, 261], ["matrix", "CELLULAR_COMPONENT", 274, 280], ["patient", "SPECIES", 61, 68], ["bubble markers", "TEST", 30, 44], ["patient testing", "TEST", 61, 76], ["the PCR", "TEST", 135, 142], ["isothermal-based data", "TEST", 147, 168], ["these techniques", "TREATMENT", 220, 236]]], ["Several of the semi-direct works with PCR have employed over 50% blood in a reaction after heat-cold shock [36] .", [["blood", "ANATOMY", 65, 70], ["shock", "DISEASE", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["PCR", "TEST", 38, 41], ["a reaction", "PROBLEM", 74, 84], ["cold shock", "PROBLEM", 96, 106]]], ["More noteworthy is a truly direct example that relied on the specificity and efficacy of the Phusion polymerase (New England Biolab, Ipswich, MA, USA) to perform PCR in 40% blood [37] .", [["blood", "ANATOMY", 173, 178], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["Phusion polymerase", "PROTEIN", 93, 111], ["the Phusion polymerase", "TEST", 89, 111], ["PCR", "TEST", 162, 165]]], ["PCR typically employs the Taq polymerase from Thermus aquaticus.", [["Taq", "GENE_OR_GENE_PRODUCT", 26, 29], ["Thermus aquaticus", "ORGANISM", 46, 63], ["Taq polymerase", "PROTEIN", 26, 40], ["Thermus aquaticus", "SPECIES", 46, 63], ["Thermus aquaticus", "SPECIES", 46, 63], ["PCR", "TEST", 0, 3], ["the Taq polymerase from Thermus aquaticus", "PROBLEM", 22, 63]]], ["Chemical additives, whether commercially-available cocktails [38, 39] or in-house buffers [39-52], allow the Taq family of polymerases to amplify DNA from whole blood.", [["whole blood", "ANATOMY", 155, 166], ["Taq", "GENE_OR_GENE_PRODUCT", 109, 112], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["Taq family", "PROTEIN", 109, 119], ["polymerases", "TREATMENT", 123, 134], ["whole blood", "TEST", 155, 166]]], ["PCR can likewise be optimized through the use of more unconventional polymerases [53-58] and physical heating steps [53, [59] [60] [61] [62] [63] [64] to reduce the inhibitory effect of blood components.", [["blood", "ANATOMY", 186, 191], ["[59] [60] [61] [62] [63] [64]", "CHEMICAL", 121, 150], ["[59] [60] [61] [62] [63] [64]", "SIMPLE_CHEMICAL", 121, 150], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["PCR", "TEST", 0, 3], ["physical heating steps", "TEST", 93, 115], ["blood components", "PROBLEM", 186, 202]]], ["These referenced works offer expedited methods to obtain amplifiable templates with similar sensitivities to chemical-based extraction kits [59] .", [["amplifiable templates", "TREATMENT", 57, 78]]], ["Though several authors include the use of a centrifuge in the extraction process, these semi-direct methods of template preparation could likely be completed by relying on careful pipette-based transfer of supernatants rather than high-speed centrifugation [59, 63] .Direct NAATs for Whole BloodMost isothermal amplification-based diagnostics in blood make use of LAMP [17] , which offers a highly tolerant means of amplification [8] .Direct NAATs for Whole BloodSimple treatments with heat [59, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] or chemicals [73, [77] [78] [79] [80] [81] can increase the sensitivity of the LAMP or RT-LAMP reaction.", [["supernatants", "ANATOMY", 206, 218], ["Blood", "ANATOMY", 290, 295], ["blood", "ANATOMY", 346, 351], ["[65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75]", "CHEMICAL", 496, 550], ["Blood", "ORGANISM_SUBSTANCE", 290, 295], ["blood", "ORGANISM_SUBSTANCE", 346, 351], ["NAATs", "SIMPLE_CHEMICAL", 442, 447], ["[65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76]", "SIMPLE_CHEMICAL", 496, 555], ["[77] [78] [79] [80] [81]", "SIMPLE_CHEMICAL", 574, 598], ["a centrifuge in the extraction process", "TREATMENT", 42, 80], ["these semi-direct methods of template preparation", "TREATMENT", 82, 131], ["careful pipette", "TEST", 172, 187], ["Whole Blood", "TEST", 284, 295], ["isothermal amplification", "TEST", 300, 324], ["Whole BloodSimple treatments", "TREATMENT", 452, 480], ["the LAMP", "TEST", 631, 639], ["LAMP reaction", "PROBLEM", 646, 659]]], ["Most impressive are the examples of direct amplification of DNA in blood with LAMP-based technologies [82, 83] and other isothermal amplification methods like MDA [84] .", [["blood", "ANATOMY", 67, 72], ["MDA", "CHEMICAL", 159, 162], ["MDA", "CHEMICAL", 159, 162], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["MDA", "SIMPLE_CHEMICAL", 159, 162], ["direct amplification of DNA", "PROBLEM", 36, 63], ["LAMP", "TEST", 78, 82]]], ["Some of these assays employ a post-heating centrifugation step, but since Poon et al. have demonstrated that LAMP can be performed directly on heat-treated blood without a spin-down process, this step could likely be avoided in semi-direct processes [68] .Direct NAATs for Whole BloodEven though these successful examples of simple, direct nucleic acid testing methods highlight the promise of DNA amplification in whole blood, there is an ongoing need for further improvements.", [["blood", "ANATOMY", 156, 161], ["Blood", "ANATOMY", 279, 284], ["whole blood", "ANATOMY", 415, 426], ["nucleic acid", "CHEMICAL", 340, 352], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["Blood", "ORGANISM_SUBSTANCE", 279, 284], ["DNA", "CELLULAR_COMPONENT", 394, 397], ["blood", "ORGANISM_SUBSTANCE", 421, 426], ["these assays", "TEST", 8, 20], ["a post-heating centrifugation step", "TREATMENT", 28, 62], ["Whole Blood", "TEST", 273, 284], ["direct nucleic acid testing methods", "TEST", 333, 368], ["DNA amplification in whole blood", "PROBLEM", 394, 426]]], ["No assay has come close to reaching the capacity of Burckhardt et al.'s PCR amplification with Taq polymerase in nearly 80% whole blood, as demonstrated over 20 years ago in 1994 [36] .", [["whole blood", "ANATOMY", 124, 135], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 95, 109], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["Taq polymerase", "PROTEIN", 95, 109], ["assay", "PROBLEM", 3, 8], ["PCR amplification", "TEST", 72, 89], ["Taq polymerase", "TEST", 95, 109]]], ["The associated treatment method is one of the more technically-involved and time-intensive, demanding 20 cycles of heating and cooling.", [["The associated treatment method", "TREATMENT", 0, 31], ["heating and cooling", "TREATMENT", 115, 134]]], ["It remains to be seen whether an isothermal amplification method could equal this tolerance.", [["an isothermal amplification method", "TREATMENT", 30, 64]]], ["Perhaps these techniques will make up for their decreased level of tolerance in their ease of use, as evidenced by Suzuki et al. achieving 20% incorporation of whole blood in LAMP with only a five-minute heating [76] .Direct NAATs for Dried BloodDried blood spots offer a convenient alternative for screening for genetic disorders, testing for infectious diseases, and profiling drug metabolism in settings with limited laboratory or storage capabilities.", [["whole blood", "ANATOMY", 160, 171], ["blood", "ANATOMY", 252, 257], ["genetic disorders", "DISEASE", 313, 330], ["infectious diseases", "DISEASE", 344, 363], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["Dried BloodDried blood spots", "PROBLEM", 235, 263], ["screening", "TEST", 299, 308], ["genetic disorders", "PROBLEM", 313, 330], ["testing", "TEST", 332, 339], ["infectious diseases", "PROBLEM", 344, 363]]], ["Such samples are typically prepared by spotting whole blood, either from venous blood or a finger prick, onto filter paper [85] .", [["samples", "ANATOMY", 5, 12], ["blood", "ANATOMY", 54, 59], ["venous blood", "ANATOMY", 73, 85], ["finger", "ANATOMY", 91, 97], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["venous blood", "ORGANISM_SUBSTANCE", 73, 85], ["spotting whole blood", "PROBLEM", 39, 59], ["venous blood", "TEST", 73, 85], ["a finger prick", "TEST", 89, 103], ["venous", "ANATOMY", 73, 79], ["finger", "ANATOMY", 91, 97]]], ["Sampling time is quick, temperature-controlled storage is unnecessary, and biohazard risks are minimized for health care workers [86] .", [["Sampling time", "TEST", 0, 13]]], ["The downside of such samples is that the DNA in the dried blood must be eluted from the paper-based cellular components before it can be amplifiable.Direct NAATs for Dried BloodFilter paper has been used as medium to test blood for infectious diseases since the 1940s [87] .", [["samples", "ANATOMY", 21, 28], ["blood", "ANATOMY", 58, 63], ["cellular", "ANATOMY", 100, 108], ["blood", "ANATOMY", 222, 227], ["infectious diseases", "DISEASE", 232, 251], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["cellular", "CELL", 100, 108], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["the DNA in the dried blood", "PROBLEM", 37, 63], ["Direct NAATs", "TREATMENT", 149, 161], ["Dried BloodFilter paper", "TREATMENT", 166, 189], ["infectious diseases", "PROBLEM", 232, 251], ["DNA", "OBSERVATION", 41, 44], ["cellular components", "OBSERVATION", 100, 119]]], ["From syphilis diagnosis during World War II [88] , to infant screening in the 1960s [89] , to HIV detection and monitoring in the modern day [85, 90] , there are important assays with dried blood spots in NAATs.", [["blood", "ANATOMY", 190, 195], ["syphilis", "DISEASE", 5, 13], ["HIV", "ORGANISM", 94, 97], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["HIV", "SPECIES", 94, 97], ["infant screening", "TEST", 54, 70], ["HIV detection", "TEST", 94, 107], ["dried blood spots in NAATs", "PROBLEM", 184, 210], ["syphilis", "OBSERVATION", 5, 13]]], ["Commercial technologies are even becoming widely available to map, monitor, and survey blood spots from patients infected with malaria or other neglected tropical diseases [74, 91] .", [["blood", "ANATOMY", 87, 92], ["malaria", "DISEASE", 127, 134], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["map", "TEST", 62, 65], ["monitor", "TEST", 67, 74], ["survey blood spots", "TEST", 80, 98], ["malaria", "PROBLEM", 127, 134], ["other neglected tropical diseases", "PROBLEM", 138, 171]]], ["In a similar manner, the preparation and processing techniques for dried blood samples presented below could open new avenues for disease control and elimination when combined with well-standardized assays for detecting bloodborne pathogens.Direct NAATs for Dried BloodAs shown in Figure 4 , all of the tests we surveyed have been validated with actual dried blood spots.", [["blood samples", "ANATOMY", 73, 86], ["Blood", "ANATOMY", 264, 269], ["blood", "ANATOMY", 359, 364], ["blood samples", "ORGANISM_SUBSTANCE", 73, 86], ["Blood", "ORGANISM_SUBSTANCE", 264, 269], ["blood", "ORGANISM_SUBSTANCE", 359, 364], ["the preparation", "TREATMENT", 21, 36], ["processing techniques", "TREATMENT", 41, 62], ["dried blood samples", "TEST", 67, 86], ["disease control", "TREATMENT", 130, 145], ["bloodborne pathogens", "PROBLEM", 220, 240], ["Dried Blood", "TEST", 258, 269], ["the tests", "TEST", 299, 308], ["actual dried blood spots", "PROBLEM", 346, 370]]], ["In the most-heavily tested example (720 clinical samples) by Raskin et al., pretreatment with heating-cooling cycles and addition of spermidine to the reaction helped boost the efficiency and yield of the amplification [92] .", [["spermidine", "CHEMICAL", 133, 143], ["spermidine", "CHEMICAL", 133, 143], ["spermidine", "SIMPLE_CHEMICAL", 133, 143], ["clinical samples", "TEST", 40, 56], ["heating-cooling cycles", "TREATMENT", 94, 116], ["spermidine", "TREATMENT", 133, 143], ["the reaction", "PROBLEM", 147, 159], ["the amplification", "TEST", 201, 218]]], ["Blood spot-containing filter paper can typically be directly added into a mixture of reagents, though it necessitates overcoming the high background interference of the filter paper and detecting small amounts of dried blood.Direct NAATs for Dried BloodBiosensors 2019, 9, x FOR PEER REVIEW 9 of 28Direct NAATs for Dried BloodAs shown in Figure 4 , all of the tests we surveyed have been validated with actual dried blood spots.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 219, 224], ["Blood", "ANATOMY", 321, 326], ["blood", "ANATOMY", 416, 421], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["Blood", "ORGANISM_SUBSTANCE", 321, 326], ["blood", "ORGANISM_SUBSTANCE", 416, 421], ["Blood spot", "TEST", 0, 10], ["a mixture of reagents", "TREATMENT", 72, 93], ["the filter paper", "TREATMENT", 165, 181], ["small amounts of dried blood", "PROBLEM", 196, 224], ["Dried Blood", "TEST", 315, 326], ["the tests", "TEST", 356, 365], ["actual dried blood spots", "PROBLEM", 403, 427], ["filter", "OBSERVATION", 22, 28], ["filter", "OBSERVATION", 169, 175], ["small", "OBSERVATION_MODIFIER", 196, 201], ["amounts", "OBSERVATION_MODIFIER", 202, 209], ["dried blood", "OBSERVATION", 213, 224]]], ["In the most-heavily tested example (720 clinical samples) by Raskin et al., pretreatment with heating-cooling cycles and addition of spermidine to the reaction helped boost the efficiency and yield of the amplification [92] .", [["spermidine", "CHEMICAL", 133, 143], ["spermidine", "CHEMICAL", 133, 143], ["spermidine", "SIMPLE_CHEMICAL", 133, 143], ["clinical samples", "TEST", 40, 56], ["heating-cooling cycles", "TREATMENT", 94, 116], ["spermidine", "TREATMENT", 133, 143], ["the reaction", "PROBLEM", 147, 159], ["the amplification", "TEST", 201, 218]]], ["Blood spot-containing filter paper can typically be directly added into a mixture of reagents, though it necessitates overcoming the high background interference of the filter paper and detecting small amounts of dried blood.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 219, 224], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["Blood spot", "TEST", 0, 10], ["a mixture of reagents", "TREATMENT", 72, 93], ["the filter paper", "TREATMENT", 165, 181], ["small amounts of dried blood", "PROBLEM", 196, 224], ["filter", "OBSERVATION", 22, 28], ["filter", "OBSERVATION", 169, 175], ["small", "OBSERVATION_MODIFIER", 196, 201], ["amounts", "OBSERVATION_MODIFIER", 202, 209], ["dried blood", "OBSERVATION", 213, 224]]], ["To overcome the background interference from filter paper in directly amplifying dried blood spots via PCR, researchers have bolstered the enzyme's resistance to inhibitors and included various buffer components [47, 93] .", [["blood", "ANATOMY", 87, 92], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["filter paper", "TREATMENT", 45, 57], ["dried blood spots via PCR", "PROBLEM", 81, 106], ["inhibitors", "TREATMENT", 162, 172], ["various buffer components", "TREATMENT", 186, 211]]], ["Even if the procedures are reported as being too lengthy for POC, there are appropriate ways to scale down the waiting period: for instance, an overnight drying period with methanol while under vacuum [98] can be streamlined into a five-minute methanol fix [100] .", [["methanol", "CHEMICAL", 173, 181], ["methanol", "CHEMICAL", 173, 181], ["methanol", "CHEMICAL", 244, 252], ["methanol", "SIMPLE_CHEMICAL", 173, 181], ["methanol", "TREATMENT", 173, 181], ["a five-minute methanol fix", "TREATMENT", 230, 256]]], ["Most of the approaches to amplify DNA directly in blood spots use eluants-either from commercial kits [51, 101] , in-house buffers [44,59,102-105], or water [106, 107] -to overcome the various difficulties that impede PCR reactions with paper matrices.", [["blood spots", "ANATOMY", 50, 61], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["the various difficulties", "PROBLEM", 181, 205], ["PCR reactions", "PROBLEM", 218, 231]]], ["Buffer-based eluants, in addition to being cost-effective, can achieve even higher sensitivities than standard extraction protocols [105] .", [["Buffer", "TREATMENT", 0, 6], ["standard extraction protocols", "TREATMENT", 102, 131]]], ["Similar preparatory approaches are used for LAMP, wherein heating in water [72, 108] , phosphate buffered saline (PBS) [59] , or sodium dodecyl sulfate (SDS) buffer [74] enables a fast and easy nucleic acid elution with amplification results that are comparable to the conventional gold standard of microscopy [72, 74, 108] .Direct NAATs for Dried BloodOne of the difficulties in making blood spots suitable for LAMP and PCR is the need to resuspend the spots in liquid, then filter out the species of interest.", [["blood", "ANATOMY", 387, 392], ["phosphate", "CHEMICAL", 87, 96], ["sodium dodecyl sulfate", "CHEMICAL", 129, 151], ["phosphate", "CHEMICAL", 87, 96], ["sodium dodecyl sulfate", "CHEMICAL", 129, 151], ["SDS", "CHEMICAL", 153, 156], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 87, 112], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 129, 151], ["blood", "ORGANISM_SUBSTANCE", 387, 392], ["LAMP, wherein heating in water", "TREATMENT", 44, 74], ["phosphate buffered saline (PBS)", "TREATMENT", 87, 118], ["sodium dodecyl sulfate", "TREATMENT", 129, 151], ["a fast and easy nucleic acid elution", "TREATMENT", 178, 214], ["microscopy", "TEST", 299, 309], ["Direct NAATs", "TREATMENT", 325, 337], ["the difficulties", "PROBLEM", 360, 376], ["blood spots", "PROBLEM", 387, 398], ["LAMP and PCR", "TEST", 412, 424], ["the spots in liquid", "TREATMENT", 450, 469]]], ["This makes Taylor et al.'s amplification of Plasmodium spp.", [["Plasmodium spp", "DISEASE", 44, 58], ["Plasmodium spp", "ORGANISM", 44, 58], ["Plasmodium spp", "PROBLEM", 44, 58]]], ["DNA directly from clinical filter paper samples such a remarkable achievement for low-resource settings.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["low-resource settings", "TREATMENT", 82, 103]]], ["The combination of an inhibitor-resistant Taq mutant and an enhancer cocktail resulted in a specificity and sensitivity of 100% for 48 patient To overcome the background interference from filter paper in directly amplifying dried blood spots via PCR, researchers have bolstered the enzyme's resistance to inhibitors and included various buffer components [47, 93] .", [["blood", "ANATOMY", 230, 235], ["Taq", "GENE_OR_GENE_PRODUCT", 42, 45], ["patient", "ORGANISM", 135, 142], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["Taq mutant", "PROTEIN", 42, 52], ["patient", "SPECIES", 135, 142], ["an inhibitor-resistant Taq mutant", "TREATMENT", 19, 52], ["an enhancer cocktail", "TREATMENT", 57, 77], ["sensitivity", "TEST", 108, 119], ["filter paper", "TREATMENT", 188, 200], ["dried blood spots via PCR", "PROBLEM", 224, 249], ["inhibitors", "TREATMENT", 305, 315], ["various buffer components", "TREATMENT", 329, 354]]], ["Even if the procedures are reported as being too lengthy for POC, there are appropriate ways to scale down the waiting period: for instance, an overnight drying period with methanol while under vacuum [98] can be streamlined into a five-minute methanol fix [100] .", [["methanol", "CHEMICAL", 173, 181], ["methanol", "CHEMICAL", 173, 181], ["methanol", "CHEMICAL", 244, 252], ["methanol", "SIMPLE_CHEMICAL", 173, 181], ["methanol", "TREATMENT", 173, 181], ["a five-minute methanol fix", "TREATMENT", 230, 256]]], ["Most of the approaches to amplify DNA directly in blood spots use eluants-either from commercial kits [51, 101] , in-house buffers [44,59,102-105], or water [106, 107] -to overcome the various difficulties that impede PCR reactions with paper matrices.", [["blood spots", "ANATOMY", 50, 61], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["the various difficulties", "PROBLEM", 181, 205], ["PCR reactions", "PROBLEM", 218, 231]]], ["Buffer-based eluants, in addition to being cost-effective, can achieve even higher sensitivities than standard extraction protocols [105] .", [["Buffer", "TREATMENT", 0, 6], ["standard extraction protocols", "TREATMENT", 102, 131]]], ["Similar preparatory approaches are used for LAMP, wherein heating in water [72, 108] , phosphate buffered saline (PBS) [59] , or sodium dodecyl sulfate (SDS) buffer [74] enables a fast and easy nucleic acid elution with amplification results that are comparable to the conventional gold standard of microscopy [72, 74, 108] .Direct NAATs for Dried BloodOne of the difficulties in making blood spots suitable for LAMP and PCR is the need to re-suspend the spots in liquid, then filter out the species of interest.", [["blood", "ANATOMY", 387, 392], ["phosphate", "CHEMICAL", 87, 96], ["sodium dodecyl sulfate", "CHEMICAL", 129, 151], ["phosphate", "CHEMICAL", 87, 96], ["sodium dodecyl sulfate", "CHEMICAL", 129, 151], ["SDS", "CHEMICAL", 153, 156], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 87, 112], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 129, 151], ["blood", "ORGANISM_SUBSTANCE", 387, 392], ["LAMP, wherein heating in water", "TREATMENT", 44, 74], ["phosphate buffered saline (PBS)", "TREATMENT", 87, 118], ["sodium dodecyl sulfate", "TREATMENT", 129, 151], ["a fast and easy nucleic acid elution", "TREATMENT", 178, 214], ["microscopy", "TEST", 299, 309], ["Direct NAATs", "TREATMENT", 325, 337], ["the difficulties", "PROBLEM", 360, 376], ["blood spots", "PROBLEM", 387, 398], ["LAMP and PCR", "TEST", 412, 424], ["the spots in liquid", "TREATMENT", 451, 470]]], ["This makes Taylor et al.'s amplification of Plasmodium spp.", [["Plasmodium spp", "DISEASE", 44, 58], ["Plasmodium spp", "ORGANISM", 44, 58], ["Plasmodium spp", "PROBLEM", 44, 58]]], ["DNA directly from clinical filter paper samples such a remarkable achievement for low-resource settings.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["low-resource settings", "TREATMENT", 82, 103]]], ["The combination of an inhibitor-resistant Taq mutant and an enhancer cocktail resulted in a specificity and sensitivity of 100% for 48 patient samples [47] .", [["samples", "ANATOMY", 143, 150], ["Taq", "GENE_OR_GENE_PRODUCT", 42, 45], ["patient", "ORGANISM", 135, 142], ["Taq mutant", "PROTEIN", 42, 52], ["patient", "SPECIES", 135, 142], ["an inhibitor-resistant Taq mutant", "PROBLEM", 19, 52], ["an enhancer cocktail", "TREATMENT", 57, 77], ["sensitivity", "TEST", 108, 119]]], ["All the approaches have interesting characteristics that make them special, but none achieve the ease in use of this assay for malaria.Direct NAATs for Plasma and SerumBlood plasma and serum are widely used for quantitative molecular diagnostics in the areas of clinical decision-making and therapeutic management [109] .", [["SerumBlood plasma", "ANATOMY", 163, 180], ["serum", "ANATOMY", 185, 190], ["malaria", "DISEASE", 127, 134], ["NAATs", "GENE_OR_GENE_PRODUCT", 142, 147], ["Plasma", "ORGANISM_SUBSTANCE", 152, 158], ["SerumBlood", "ORGANISM_SUBSTANCE", 163, 173], ["plasma", "ORGANISM_SUBSTANCE", 174, 180], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["NAATs", "PROTEIN", 142, 147], ["this assay", "TREATMENT", 112, 122], ["malaria", "PROBLEM", 127, 134], ["Direct NAATs", "TEST", 135, 147], ["Plasma and SerumBlood plasma and serum", "TEST", 152, 190], ["quantitative molecular diagnostics", "TEST", 211, 245], ["therapeutic management", "TREATMENT", 291, 313]]], ["Plasma is the pale yellowish fluid that normally holds the blood cells of whole blood in suspension, whereas serum is the remnants of blood plasma after the removal of clotting factors [110] .", [["yellowish fluid", "ANATOMY", 19, 34], ["blood cells", "ANATOMY", 59, 70], ["blood", "ANATOMY", 80, 85], ["serum", "ANATOMY", 109, 114], ["blood plasma", "ANATOMY", 134, 146], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["fluid", "ORGANISM_SUBSTANCE", 29, 34], ["blood cells", "CELL", 59, 70], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["blood cells", "CELL_TYPE", 59, 70], ["clotting factors", "PROTEIN", 168, 184], ["the pale yellowish fluid", "PROBLEM", 10, 34], ["whole blood in suspension", "TREATMENT", 74, 99], ["blood plasma", "TEST", 134, 146], ["the removal of clotting factors", "TREATMENT", 153, 184], ["pale", "OBSERVATION_MODIFIER", 14, 18], ["yellowish", "OBSERVATION_MODIFIER", 19, 28], ["fluid", "OBSERVATION", 29, 34]]], ["Circulating DNA in serum and plasma is a biomarker for a diverse array of systemic, infectious, and genetic diseases.", [["serum", "ANATOMY", 19, 24], ["plasma", "ANATOMY", 29, 35], ["systemic, infectious, and genetic diseases", "DISEASE", 74, 116], ["Circulating", "ORGANISM_SUBSTANCE", 0, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["Circulating DNA in serum", "TEST", 0, 24], ["a biomarker", "TEST", 39, 50], ["systemic, infectious", "PROBLEM", 74, 94], ["genetic diseases", "PROBLEM", 100, 116], ["DNA", "OBSERVATION", 12, 15], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["infectious", "OBSERVATION", 84, 94]]], ["These include particular disorders such as diabetes [109] and hepatitis B virus [111] .Direct NAATs for Plasma and SerumRefining blood into serum or plasma historically requires expensive equipment for centrifugation or sedimentation.", [["blood", "ANATOMY", 129, 134], ["serum", "ANATOMY", 140, 145], ["plasma", "ANATOMY", 149, 155], ["diabetes", "DISEASE", 43, 51], ["hepatitis B", "DISEASE", 62, 73], ["hepatitis B virus", "ORGANISM", 62, 79], ["NAATs", "SIMPLE_CHEMICAL", 94, 99], ["Plasma", "ORGANISM_SUBSTANCE", 104, 110], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["plasma", "ORGANISM_SUBSTANCE", 149, 155], ["hepatitis B virus", "SPECIES", 62, 79], ["hepatitis B virus", "SPECIES", 62, 79], ["particular disorders", "PROBLEM", 14, 34], ["diabetes", "PROBLEM", 43, 51], ["hepatitis B virus", "PROBLEM", 62, 79], ["Plasma", "TEST", 104, 110], ["SerumRefining blood into serum", "PROBLEM", 115, 145], ["expensive equipment", "TREATMENT", 178, 197], ["centrifugation", "TREATMENT", 202, 216], ["sedimentation", "PROBLEM", 220, 233]]], ["Recovering DNA or RNA from blood-based proteins, nutrients, electrolytes, antibodies (particularly IgG), antigens, hormones, and exogenous substances becomes even more challenging when considering the low relative levels of cell-free or cell-bound nucleic acids [112] [113] [114] .", [["blood", "ANATOMY", 27, 32], ["cell", "ANATOMY", 224, 228], ["cell", "ANATOMY", 237, 241], ["nucleic acids", "CHEMICAL", 248, 261], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["electrolytes", "SIMPLE_CHEMICAL", 60, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 99, 102], ["cell", "CELL", 224, 228], ["cell", "CELL", 237, 241], ["nucleic acids", "SIMPLE_CHEMICAL", 248, 261], ["antibodies", "PROTEIN", 74, 84], ["IgG", "PROTEIN", 99, 102], ["antigens", "PROTEIN", 105, 113], ["Recovering DNA", "PROBLEM", 0, 14], ["RNA from blood-based proteins", "PROBLEM", 18, 47], ["electrolytes, antibodies", "TEST", 60, 84], ["IgG", "TEST", 99, 102], ["cell-bound nucleic acids", "TEST", 237, 261]]], ["More recently, however, paper-or card-based devices [115, 116] , membrane-based sedimentation [117] , and microscale devices for cell differentiation and filtration [118] have made blood separation a single step process at the POC.", [["membrane", "ANATOMY", 65, 73], ["cell", "ANATOMY", 129, 133], ["blood", "ANATOMY", 181, 186], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["cell", "CELL", 129, 133], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["membrane-based sedimentation", "TEST", 65, 93], ["microscale devices", "TREATMENT", 106, 124], ["cell differentiation", "TEST", 129, 149], ["filtration", "TEST", 154, 164], ["blood separation", "TREATMENT", 181, 197], ["cell differentiation", "OBSERVATION", 129, 149]]], ["As such, we include these sample types here.Direct NAATs for Plasma and SerumIn assessing nucleic acid testing with plasma or serum, we see that most reactions are performed at sample concentrations in the 20% range ( Figure 5 ).", [["plasma", "ANATOMY", 116, 122], ["serum", "ANATOMY", 126, 131], ["nucleic acid", "CHEMICAL", 90, 102], ["NAATs", "SIMPLE_CHEMICAL", 51, 56], ["Plasma", "ORGANISM_SUBSTANCE", 61, 67], ["SerumIn", "SIMPLE_CHEMICAL", 72, 79], ["nucleic acid", "SIMPLE_CHEMICAL", 90, 102], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["Plasma", "TEST", 61, 67], ["nucleic acid testing", "TEST", 90, 110], ["plasma or serum", "TEST", 116, 131], ["sample concentrations", "TEST", 177, 198]]], ["However, it is important to note that the sensitivity does not necessarily suffer in much more concentrated samples-in Liu et al.'s highly robust two-step amplification process with direct hairpin assembly and HCR-based detection of SNP DNA sequences in 50% (v/v) serum, they achieved a very low LOD of 100 pg [119] .", [["samples", "ANATOMY", 108, 115], ["serum", "ANATOMY", 264, 269], ["SNP", "CHEMICAL", 233, 236], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["serum", "ORGANISM_SUBSTANCE", 264, 269], ["HCR", "PROTEIN", 210, 213], ["SNP DNA sequences", "DNA", 233, 250], ["direct hairpin assembly", "TREATMENT", 182, 205], ["HCR", "TEST", 210, 213], ["SNP DNA sequences", "TEST", 233, 250], ["v/v) serum", "TEST", 259, 269]]], ["These plasma/serum-based tests are especially promising for use in real-world contexts, because their clinical relevance is well-documented-18 out of the 24 cases examined here included testing with patient samples.Direct NAATs for Plasma and Serumsamples [47] .", [["plasma", "ANATOMY", 6, 12], ["serum", "ANATOMY", 13, 18], ["plasma", "ORGANISM_SUBSTANCE", 6, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["patient", "ORGANISM", 199, 206], ["Plasma", "ORGANISM_SUBSTANCE", 232, 238], ["patient", "SPECIES", 199, 206], ["These plasma/serum-based tests", "TEST", 0, 30], ["testing", "TEST", 186, 193], ["patient samples", "TEST", 199, 214], ["Plasma", "TEST", 232, 238], ["Serumsamples", "TEST", 243, 255]]], ["All the approaches have interesting characteristics that make them special, but none achieve the ease in use of this assay for malaria.Direct NAATs for Plasma and SerumBlood plasma and serum are widely used for quantitative molecular diagnostics in the areas of clinical decision-making and therapeutic management [109] .", [["SerumBlood plasma", "ANATOMY", 163, 180], ["serum", "ANATOMY", 185, 190], ["malaria", "DISEASE", 127, 134], ["NAATs", "GENE_OR_GENE_PRODUCT", 142, 147], ["Plasma", "ORGANISM_SUBSTANCE", 152, 158], ["SerumBlood", "ORGANISM_SUBSTANCE", 163, 173], ["plasma", "ORGANISM_SUBSTANCE", 174, 180], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["NAATs", "PROTEIN", 142, 147], ["this assay", "TREATMENT", 112, 122], ["malaria", "PROBLEM", 127, 134], ["Direct NAATs", "TEST", 135, 147], ["Plasma and SerumBlood plasma and serum", "TEST", 152, 190], ["quantitative molecular diagnostics", "TEST", 211, 245], ["therapeutic management", "TREATMENT", 291, 313]]], ["Plasma is the pale yellowish fluid that normally holds the blood cells of whole blood in suspension, whereas serum is the remnants of blood plasma after the removal of clotting factors [110] .", [["yellowish fluid", "ANATOMY", 19, 34], ["blood cells", "ANATOMY", 59, 70], ["blood", "ANATOMY", 80, 85], ["serum", "ANATOMY", 109, 114], ["blood plasma", "ANATOMY", 134, 146], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["fluid", "ORGANISM_SUBSTANCE", 29, 34], ["blood cells", "CELL", 59, 70], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["blood cells", "CELL_TYPE", 59, 70], ["clotting factors", "PROTEIN", 168, 184], ["the pale yellowish fluid", "PROBLEM", 10, 34], ["whole blood in suspension", "TREATMENT", 74, 99], ["blood plasma", "TEST", 134, 146], ["the removal of clotting factors", "TREATMENT", 153, 184], ["pale", "OBSERVATION_MODIFIER", 14, 18], ["yellowish", "OBSERVATION_MODIFIER", 19, 28], ["fluid", "OBSERVATION", 29, 34]]], ["Circulating DNA in serum and plasma is a biomarker for a diverse array of systemic, infectious, and genetic diseases.", [["serum", "ANATOMY", 19, 24], ["plasma", "ANATOMY", 29, 35], ["systemic, infectious, and genetic diseases", "DISEASE", 74, 116], ["Circulating", "ORGANISM_SUBSTANCE", 0, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["plasma", "ORGANISM_SUBSTANCE", 29, 35], ["Circulating DNA in serum", "TEST", 0, 24], ["a biomarker", "TEST", 39, 50], ["systemic, infectious", "PROBLEM", 74, 94], ["genetic diseases", "PROBLEM", 100, 116], ["DNA", "OBSERVATION", 12, 15], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["infectious", "OBSERVATION", 84, 94]]], ["These include particular disorders such as diabetes [109] and hepatitis B virus [111] .Direct NAATs for Plasma and SerumRefining blood into serum or plasma historically requires expensive equipment for centrifugation or sedimentation.", [["blood", "ANATOMY", 129, 134], ["serum", "ANATOMY", 140, 145], ["plasma", "ANATOMY", 149, 155], ["diabetes", "DISEASE", 43, 51], ["hepatitis B", "DISEASE", 62, 73], ["hepatitis B virus", "ORGANISM", 62, 79], ["NAATs", "SIMPLE_CHEMICAL", 94, 99], ["Plasma", "ORGANISM_SUBSTANCE", 104, 110], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["plasma", "ORGANISM_SUBSTANCE", 149, 155], ["hepatitis B virus", "SPECIES", 62, 79], ["hepatitis B virus", "SPECIES", 62, 79], ["particular disorders", "PROBLEM", 14, 34], ["diabetes", "PROBLEM", 43, 51], ["hepatitis B virus", "PROBLEM", 62, 79], ["Plasma", "TEST", 104, 110], ["SerumRefining blood into serum", "PROBLEM", 115, 145], ["expensive equipment", "TREATMENT", 178, 197], ["centrifugation", "TREATMENT", 202, 216], ["sedimentation", "PROBLEM", 220, 233]]], ["Recovering DNA or RNA from blood-based proteins, nutrients, electrolytes, antibodies (particularly IgG), antigens, hormones, and exogenous substances becomes even more challenging when considering the low relative levels of cell-free or cell-bound nucleic acids [112] [113] [114] .", [["blood", "ANATOMY", 27, 32], ["cell", "ANATOMY", 224, 228], ["cell", "ANATOMY", 237, 241], ["nucleic acids", "CHEMICAL", 248, 261], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["electrolytes", "SIMPLE_CHEMICAL", 60, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 99, 102], ["cell", "CELL", 224, 228], ["cell", "CELL", 237, 241], ["nucleic acids", "SIMPLE_CHEMICAL", 248, 261], ["antibodies", "PROTEIN", 74, 84], ["IgG", "PROTEIN", 99, 102], ["antigens", "PROTEIN", 105, 113], ["Recovering DNA", "PROBLEM", 0, 14], ["RNA from blood-based proteins", "PROBLEM", 18, 47], ["electrolytes, antibodies", "TEST", 60, 84], ["IgG", "TEST", 99, 102], ["cell-bound nucleic acids", "TEST", 237, 261]]], ["More recently, however, paper-or card-based devices [115, 116] , membrane-based sedimentation [117] , and microscale devices for cell differentiation and filtration [118] have made blood separation a single step process at the POC.", [["membrane", "ANATOMY", 65, 73], ["cell", "ANATOMY", 129, 133], ["blood", "ANATOMY", 181, 186], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["cell", "CELL", 129, 133], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["membrane-based sedimentation", "TEST", 65, 93], ["microscale devices", "TREATMENT", 106, 124], ["cell differentiation", "TEST", 129, 149], ["filtration", "TEST", 154, 164], ["blood separation", "TREATMENT", 181, 197], ["cell differentiation", "OBSERVATION", 129, 149]]], ["As such, we include these sample types here.Direct NAATs for Plasma and SerumIn assessing nucleic acid testing with plasma or serum, we see that most reactions are performed at sample concentrations in the 20% range ( Figure 5 ).", [["plasma", "ANATOMY", 116, 122], ["serum", "ANATOMY", 126, 131], ["nucleic acid", "CHEMICAL", 90, 102], ["NAATs", "SIMPLE_CHEMICAL", 51, 56], ["Plasma", "ORGANISM_SUBSTANCE", 61, 67], ["SerumIn", "SIMPLE_CHEMICAL", 72, 79], ["nucleic acid", "SIMPLE_CHEMICAL", 90, 102], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["Plasma", "TEST", 61, 67], ["nucleic acid testing", "TEST", 90, 110], ["plasma or serum", "TEST", 116, 131], ["sample concentrations", "TEST", 177, 198]]], ["However, it is important to note that the sensitivity does not necessarily suffer in much more concentrated samples-in Liu et al.'s highly robust two-step amplification process with direct hairpin assembly and HCR-based detection of SNP DNA sequences in 50% (v/v) serum, they achieved a very low LOD of 100 pg [119] .", [["samples", "ANATOMY", 108, 115], ["serum", "ANATOMY", 264, 269], ["SNP", "CHEMICAL", 233, 236], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["serum", "ORGANISM_SUBSTANCE", 264, 269], ["HCR", "PROTEIN", 210, 213], ["SNP DNA sequences", "DNA", 233, 250], ["direct hairpin assembly", "TREATMENT", 182, 205], ["HCR", "TEST", 210, 213], ["SNP DNA sequences", "TEST", 233, 250], ["v/v) serum", "TEST", 259, 269]]], ["These plasma/serum-based tests are especially promising for use in real-world contexts, because their clinical relevance is well-documented-18 out of the 24 cases examined here included testing with patient samples.", [["plasma", "ANATOMY", 6, 12], ["serum", "ANATOMY", 13, 18], ["plasma", "ORGANISM_SUBSTANCE", 6, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["These plasma/serum-based tests", "TEST", 0, 30], ["testing", "TEST", 186, 193], ["patient samples", "TEST", 199, 214]]], ["Researchers have developed convenient PCR assays for both direct and semi-direct testing in blood-based fluids.", [["blood", "ANATOMY", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["convenient PCR assays", "TEST", 27, 48], ["semi-direct testing", "TEST", 69, 88]]], ["By using enhanced enzymes, DNA [49,50,67,120] and RNA [121, 122] targets have been successfully amplified in plasma and serum.", [["plasma", "ANATOMY", 109, 115], ["serum", "ANATOMY", 120, 125], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["plasma", "ORGANISM_SUBSTANCE", 109, 115], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["enhanced enzymes", "TEST", 9, 25], ["DNA", "TEST", 27, 30], ["RNA", "TEST", 50, 53], ["plasma and serum", "TEST", 109, 125]]], ["Additionally, heat-based pretreatment can be used to release nucleic acids prior to carrying out amplification [36, 60, [123] [124] [125] [126] .Direct NAATs for Plasma and SerumThe effect of preheating can be seen in LAMP as well.", [["Serum", "ANATOMY", 173, 178], ["nucleic acids", "CHEMICAL", 61, 74], ["nucleic acids", "SIMPLE_CHEMICAL", 61, 74], ["NAATs", "GENE_OR_GENE_PRODUCT", 152, 157], ["Plasma", "ORGANISM_SUBSTANCE", 162, 168], ["Serum", "ORGANISM_SUBSTANCE", 173, 178], ["heat-based pretreatment", "TREATMENT", 14, 37], ["nucleic acids", "TEST", 61, 74], ["Plasma", "TEST", 162, 168], ["preheating", "TREATMENT", 192, 202]]], ["LAMP is generally tolerant to the serum or plasma environment [120, 127] , but preheating the input sample has been found to have a favorable effect [128] [129] [130] [131] that produces up to a 100-fold improvement in sensitivity [132] .", [["serum", "ANATOMY", 34, 39], ["plasma", "ANATOMY", 43, 49], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["plasma", "ORGANISM_SUBSTANCE", 43, 49], ["the serum", "TEST", 30, 39], ["sensitivity", "TEST", 219, 230]]], ["This heating also enabled Pardee et al. to detect Zika virus RNA in serum with high sensitivity using NASBA [21] .", [["serum", "ANATOMY", 68, 73], ["Zika virus", "ORGANISM", 50, 60], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["Zika virus RNA", "RNA", 50, 64], ["Zika virus", "SPECIES", 50, 60], ["Zika virus RNA", "PROBLEM", 50, 64], ["serum", "TEST", 68, 73], ["NASBA", "TEST", 102, 107]]], ["HCR performs especially well in serum without any pretreatment [28, 119, [133] [134] [135] , presumably because the reaction relies on cascaded hybridization events instead of polymerases.Direct NAATs for Plasma and SerumBecause plasma and serum contain very low-abundance analytes, nucleic acid tests need to operate with high sensitivity.", [["serum", "ANATOMY", 32, 37], ["SerumBecause plasma", "ANATOMY", 216, 235], ["serum", "ANATOMY", 240, 245], ["nucleic acid", "CHEMICAL", 283, 295], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["NAATs", "SIMPLE_CHEMICAL", 195, 200], ["Plasma", "ORGANISM_SUBSTANCE", 205, 211], ["SerumBecause", "ORGANISM_SUBSTANCE", 216, 228], ["plasma", "ORGANISM_SUBSTANCE", 229, 235], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["nucleic acid", "SIMPLE_CHEMICAL", 283, 295], ["HCR", "PROTEIN", 0, 3], ["polymerases", "PROTEIN", 176, 187], ["HCR", "TEST", 0, 3], ["serum", "TEST", 32, 37], ["the reaction", "PROBLEM", 112, 124], ["cascaded hybridization events", "PROBLEM", 135, 164], ["polymerases", "PROBLEM", 176, 187], ["Direct NAATs", "TEST", 188, 200], ["Plasma", "TEST", 205, 211], ["SerumBecause plasma", "TEST", 216, 235], ["serum", "TEST", 240, 245], ["very low-abundance analytes", "PROBLEM", 254, 281], ["nucleic acid tests", "TEST", 283, 301], ["high sensitivity", "PROBLEM", 323, 339]]], ["Fortunately, LAMP-based applications are achieving increasingly low limits of detection.", [["LAMP-based applications", "TREATMENT", 13, 36], ["low limits", "OBSERVATION_MODIFIER", 64, 74]]], ["Nijru et al., for instance, demonstrated that their LOD of 1 Trypanozoan parasite/L serum in HAT diagnosis was 100-fold more sensitive than PCR testing.", [["serum", "ANATOMY", 84, 89], ["L", "ORGANISM", 82, 83], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["HAT", "CANCER", 93, 96], ["their LOD", "TEST", 46, 55], ["Trypanozoan parasite/L serum in HAT diagnosis", "TEST", 61, 106], ["PCR testing", "TEST", 140, 151]]], ["Such methods could still benefit from user-friendly techniques for large-scale processing.", [["large-scale processing", "TREATMENT", 67, 89]]], ["Some semi-direct examples presented above include a centrifugation step to collect condensate formed after heating, but could just as easily rely on pipette collection to obviate the need for a high-speed centrifuge.", [["a centrifugation step", "TREATMENT", 50, 71], ["pipette collection", "TEST", 149, 167], ["a high-speed centrifuge", "TREATMENT", 192, 215]]], ["Others might benefit from certain stand-alone modules for plasma and serum separation that could be integrated into a POC workflow [117, 136] .Direct NAATs for Saliva and SputumSaliva and sputum are abundant and easy to obtain, and are thus attractive samples for diagnostics.", [["plasma", "ANATOMY", 58, 64], ["serum", "ANATOMY", 69, 74], ["sputum", "ANATOMY", 188, 194], ["samples", "ANATOMY", 252, 259], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["NAATs", "GENE_OR_GENE_PRODUCT", 150, 155], ["Saliva", "ORGANISM_SUBSTANCE", 160, 166], ["SputumSaliva", "SIMPLE_CHEMICAL", 171, 183], ["sputum", "ORGANISM_SUBSTANCE", 188, 194], ["samples", "CANCER", 252, 259], ["plasma and serum separation", "TREATMENT", 58, 85], ["Saliva and SputumSaliva and sputum", "TEST", 160, 194], ["diagnostics", "TEST", 264, 275]]], ["Saliva flows into the oral cavities through salivary glands, where blood vessels secrete the same protein and nucleic acid biomarkers as in peripheral blood.", [["oral cavities", "ANATOMY", 22, 35], ["salivary glands", "ANATOMY", 44, 59], ["blood vessels", "ANATOMY", 67, 80], ["peripheral blood", "ANATOMY", 140, 156], ["nucleic acid", "CHEMICAL", 110, 122], ["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["oral cavities", "MULTI-TISSUE_STRUCTURE", 22, 35], ["salivary glands", "ORGAN", 44, 59], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 67, 80], ["peripheral blood", "ORGANISM_SUBSTANCE", 140, 156], ["Saliva flows", "TEST", 0, 12], ["nucleic acid biomarkers", "TEST", 110, 133], ["peripheral blood", "TEST", 140, 156], ["oral cavities", "ANATOMY", 22, 35], ["salivary glands", "ANATOMY", 44, 59], ["peripheral", "ANATOMY_MODIFIER", 140, 150], ["blood", "ANATOMY", 151, 156]]], ["In contrast with blood-based samples, saliva sampling does not require trained technicians, presents fewer antigen-associated risks, and can be more easily purified (saliva is 95% water) [137] .", [["blood", "ANATOMY", 17, 22], ["samples", "ANATOMY", 29, 36], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["saliva", "ORGANISM_SUBSTANCE", 38, 44], ["saliva", "ORGANISM_SUBSTANCE", 166, 172], ["saliva sampling", "TEST", 38, 53]]], ["Sputum, a necessary sample for respiratory infections, is mucus from the lower airways.", [["Sputum", "ANATOMY", 0, 6], ["sample", "ANATOMY", 20, 26], ["respiratory", "ANATOMY", 31, 42], ["mucus", "ANATOMY", 58, 63], ["lower airways", "ANATOMY", 73, 86], ["respiratory infections", "DISEASE", 31, 53], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["mucus", "ORGANISM_SUBSTANCE", 58, 63], ["lower airways", "MULTI-TISSUE_STRUCTURE", 73, 86], ["Sputum", "TEST", 0, 6], ["respiratory infections", "PROBLEM", 31, 53], ["mucus from the lower airways", "PROBLEM", 58, 86], ["infections", "OBSERVATION", 43, 53], ["mucus", "OBSERVATION", 58, 63], ["lower", "ANATOMY_MODIFIER", 73, 78], ["airways", "ANATOMY", 79, 86]]], ["Unfortunately, saliva and sputum are very heterogeneous with respect to the distribution of organisms, chemical composition, and the presence of outside contaminants such as toothpaste, cigarette smoke, coffee, or mouthwash.", [["saliva", "ANATOMY", 15, 21], ["sputum", "ANATOMY", 26, 32], ["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["sputum", "ORGANISM_SUBSTANCE", 26, 32], ["toothpaste", "SIMPLE_CHEMICAL", 174, 184], ["saliva and sputum", "TEST", 15, 32], ["very heterogeneous", "PROBLEM", 37, 55], ["organisms", "PROBLEM", 92, 101], ["mouthwash", "TREATMENT", 214, 223], ["sputum", "OBSERVATION", 26, 32], ["very", "OBSERVATION_MODIFIER", 37, 41], ["heterogeneous", "OBSERVATION", 42, 55], ["organisms", "OBSERVATION", 92, 101], ["chemical composition", "OBSERVATION", 103, 123]]], ["Technical extraction kits such as RNaqueous and MagMAX (Life Technologies, Grand Island, NY, USA) are often used to eliminate inhibitors and nucleases from oral samples.", [["oral samples", "ANATOMY", 156, 168], ["oral samples", "CANCER", 156, 168], ["nucleases", "PROTEIN", 141, 150], ["Technical extraction kits", "TREATMENT", 0, 25], ["inhibitors", "TREATMENT", 126, 136], ["oral samples", "TEST", 156, 168]]], ["The viscosity of sputum requires particularly cumbersome protocols for sample preparation: full processing begins with mucolytic agents such as N-acetyl-L-cysteine (NALC) and dithiothreitol (DTT), disruption of mycobacteria by detergents and proteolytic enzymes, then isolation of target DNA by organic solvents or capture reagents [138, 139] .Direct NAATs for Saliva and SputumThe human salivary microbiome has importance as a diagnostic indicator of oral cancer, oral diseases such as periodontitis, and systemic diseases such as pneumonia [140] .", [["sputum", "ANATOMY", 17, 23], ["sample", "ANATOMY", 71, 77], ["salivary microbiome", "ANATOMY", 388, 407], ["oral cancer", "ANATOMY", 452, 463], ["oral", "ANATOMY", 465, 469], ["N-acetyl-L-cysteine", "CHEMICAL", 144, 163], ["NALC", "CHEMICAL", 165, 169], ["dithiothreitol", "CHEMICAL", 175, 189], ["DTT", "CHEMICAL", 191, 194], ["oral cancer", "DISEASE", 452, 463], ["oral diseases", "DISEASE", 465, 478], ["periodontitis", "DISEASE", 487, 500], ["systemic diseases", "DISEASE", 506, 523], ["pneumonia", "DISEASE", 532, 541], ["N-acetyl-L-cysteine", "CHEMICAL", 144, 163], ["NALC", "CHEMICAL", 165, 169], ["dithiothreitol", "CHEMICAL", 175, 189], ["DTT", "CHEMICAL", 191, 194], ["sputum", "ORGANISM_SUBSTANCE", 17, 23], ["N-acetyl-L-cysteine", "SIMPLE_CHEMICAL", 144, 163], ["NALC", "SIMPLE_CHEMICAL", 165, 169], ["dithiothreitol", "SIMPLE_CHEMICAL", 175, 189], ["DTT", "SIMPLE_CHEMICAL", 191, 194], ["DNA", "CELLULAR_COMPONENT", 288, 291], ["NAATs", "GENE_OR_GENE_PRODUCT", 351, 356], ["Saliva", "ORGANISM_SUBSTANCE", 361, 367], ["Sputum", "ORGANISM_SUBSTANCE", 372, 378], ["human", "ORGANISM", 382, 387], ["salivary microbiome", "MULTI-TISSUE_STRUCTURE", 388, 407], ["oral cancer", "CANCER", 452, 463], ["oral", "ORGANISM_SUBDIVISION", 465, 469], ["proteolytic enzymes", "PROTEIN", 242, 261], ["human", "SPECIES", 382, 387], ["human", "SPECIES", 382, 387], ["particularly cumbersome protocols", "TREATMENT", 33, 66], ["sample preparation", "TREATMENT", 71, 89], ["mucolytic agents", "TREATMENT", 119, 135], ["N-acetyl", "TREATMENT", 144, 152], ["L-cysteine (NALC)", "TREATMENT", 153, 170], ["dithiothreitol (DTT", "TREATMENT", 175, 194], ["mycobacteria", "PROBLEM", 211, 223], ["proteolytic enzymes", "TEST", 242, 261], ["target DNA", "TREATMENT", 281, 291], ["organic solvents", "TREATMENT", 295, 311], ["capture reagents", "TEST", 315, 331], ["Direct NAATs", "TREATMENT", 344, 356], ["Saliva", "TREATMENT", 361, 367], ["oral cancer", "PROBLEM", 452, 463], ["oral diseases", "PROBLEM", 465, 478], ["periodontitis", "PROBLEM", 487, 500], ["systemic diseases", "PROBLEM", 506, 523], ["pneumonia", "PROBLEM", 532, 541], ["sputum", "OBSERVATION", 17, 23], ["mycobacteria", "OBSERVATION", 211, 223], ["cancer", "OBSERVATION", 457, 463], ["periodontitis", "OBSERVATION", 487, 500], ["pneumonia", "OBSERVATION", 532, 541]]], ["As for sputum, it has become the specimen of choice for detecting tuberculosis [141, 142] .", [["sputum", "ANATOMY", 7, 13], ["tuberculosis", "DISEASE", 66, 78], ["sputum", "PROBLEM", 7, 13], ["tuberculosis", "PROBLEM", 66, 78], ["tuberculosis", "OBSERVATION", 66, 78]]], ["NAATs for Mycobacterium tuberculosis have been endorsed by the WHO (World Health Organization) and the FDA for their high accuracy [143, 144] .", [["Mycobacterium tuberculosis", "DISEASE", 10, 36], ["Mycobacterium tuberculosis", "ORGANISM", 10, 36], ["Mycobacterium tuberculosis", "SPECIES", 10, 36], ["Mycobacterium tuberculosis", "SPECIES", 10, 36], ["Mycobacterium tuberculosis", "PROBLEM", 10, 36], ["Mycobacterium tuberculosis", "OBSERVATION", 10, 36]]], ["The systems introduced below extend the practical usage of sputum for POC testing by reducing the requirements for sputum manipulation.Direct NAATs for Saliva and SputumMost reported nucleic acid testing methods for saliva and sputum show fairly high numbers for patient samples tested, with only two of 30 cases that did not examine clinical specimens ( Figure 6 ).", [["sputum", "ANATOMY", 59, 65], ["sputum", "ANATOMY", 115, 121], ["saliva", "ANATOMY", 216, 222], ["sputum", "ANATOMY", 227, 233], ["samples", "ANATOMY", 271, 278], ["specimens", "ANATOMY", 343, 352], ["nucleic acid", "CHEMICAL", 183, 195], ["sputum", "ORGANISM_SUBSTANCE", 59, 65], ["Saliva", "ORGANISM_SUBSTANCE", 152, 158], ["SputumMost", "SIMPLE_CHEMICAL", 163, 173], ["saliva", "ORGANISM_SUBSTANCE", 216, 222], ["sputum", "ORGANISM_SUBSTANCE", 227, 233], ["patient", "ORGANISM", 263, 270], ["patient", "SPECIES", 263, 270], ["POC testing", "TEST", 70, 81], ["sputum manipulation", "TEST", 115, 134], ["Saliva", "TEST", 152, 158], ["nucleic acid testing methods", "TEST", 183, 211], ["saliva and sputum", "TEST", 216, 233], ["patient samples", "TEST", 263, 278], ["clinical specimens", "TEST", 334, 352]]], ["This is critical for avoiding false positives, as the target concentrations in sputum and saliva are small.", [["sputum", "ANATOMY", 79, 85], ["sputum", "ORGANISM_SUBSTANCE", 79, 85], ["saliva", "ORGANISM_SUBSTANCE", 90, 96], ["false positives", "PROBLEM", 30, 45], ["the target concentrations in sputum and saliva", "PROBLEM", 50, 96], ["false positives", "OBSERVATION", 30, 45], ["concentrations", "OBSERVATION_MODIFIER", 61, 75], ["sputum", "OBSERVATION", 79, 85], ["small", "OBSERVATION_MODIFIER", 101, 106]]], ["The lowest LOD achieved-2 fg of Acinetobacter baumannii bacterial gDNA in sputum-required pretreatment with Sputazyme (Kyokuto, Tokyo, Japan) and heat before LAMP analysis [145] .", [["sputum", "ANATOMY", 74, 80], ["Sputazyme", "CHEMICAL", 108, 117], ["Sputazyme", "CHEMICAL", 108, 117], ["Acinetobacter baumannii", "ORGANISM", 32, 55], ["sputum", "ORGANISM_SUBSTANCE", 74, 80], ["Sputazyme", "SIMPLE_CHEMICAL", 108, 117], ["Acinetobacter baumannii", "SPECIES", 32, 55], ["Acinetobacter baumannii", "SPECIES", 32, 55], ["The lowest LOD", "TEST", 0, 14], ["Acinetobacter baumannii bacterial gDNA in sputum", "PROBLEM", 32, 80], ["Sputazyme", "TREATMENT", 108, 117], ["LAMP analysis", "TEST", 158, 171]]], ["In contrast with blood, the high water content of saliva should make it relatively easy to augment the concentration of matrix that can be employed in an amplification reaction.", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["water", "SIMPLE_CHEMICAL", 33, 38], ["saliva", "ORGANISM_SUBSTANCE", 50, 56], ["matrix", "CELLULAR_COMPONENT", 120, 126], ["the high water content of saliva", "TREATMENT", 24, 56], ["the concentration of matrix", "TREATMENT", 99, 126], ["an amplification reaction", "PROBLEM", 151, 176]]], ["There are several examples of amplification directly on dried sputum collected via filter cards, which is an especially promising direction for direct testing at the POC if samples need to be stored, handled by multiple clinicians, or reevaluated at later dates [87, 146, 147] .", [["sputum", "ANATOMY", 62, 68], ["dried sputum", "TEST", 56, 68], ["direct testing", "TEST", 144, 158]]], ["Amongst the collection of approaches for direct PCR amplification on saliva samples, those that begin with dried saliva swabs fully circumvent DNA extraction, purification, and quantification [93] .", [["samples", "ANATOMY", 76, 83], ["saliva samples", "ORGANISM_SUBSTANCE", 69, 83], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["direct PCR amplification", "TEST", 41, 65], ["saliva samples", "TREATMENT", 69, 83], ["dried saliva swabs", "TREATMENT", 107, 125], ["DNA extraction", "TREATMENT", 143, 157]]], ["Hall et al. added punches of saliva stains directly to the reaction mixture in order to perform STR analysis.", [["saliva", "ORGANISM_SUBSTANCE", 29, 35], ["saliva stains", "TREATMENT", 29, 42], ["STR analysis", "TEST", 96, 108]]], ["Genetic testing in saliva or sputum is often performed directly in liquid samples, and dilution into the reagents is typically sufficient to negate the effect of any inhibitors [148] [149] [150] , although heat [151] or additives such as polyethylene glycol (PEG), hydroxides, or dithiothreitol (DTT) may be added to further process samples [42, 43, 56, 145] .", [["saliva", "ANATOMY", 19, 25], ["sputum", "ANATOMY", 29, 35], ["samples", "ANATOMY", 74, 81], ["polyethylene glycol", "CHEMICAL", 238, 257], ["PEG", "CHEMICAL", 259, 262], ["dithiothreitol", "CHEMICAL", 280, 294], ["DTT", "CHEMICAL", 296, 299], ["polyethylene glycol", "CHEMICAL", 238, 257], ["PEG", "CHEMICAL", 259, 262], ["hydroxides", "CHEMICAL", 265, 275], ["dithiothreitol", "CHEMICAL", 280, 294], ["DTT", "CHEMICAL", 296, 299], ["saliva", "ORGANISM_SUBSTANCE", 19, 25], ["sputum", "ORGANISM_SUBSTANCE", 29, 35], ["[148] [149] [150]", "SIMPLE_CHEMICAL", 177, 194], ["polyethylene glycol", "SIMPLE_CHEMICAL", 238, 257], ["PEG", "SIMPLE_CHEMICAL", 259, 262], ["hydroxides", "SIMPLE_CHEMICAL", 265, 275], ["dithiothreitol", "SIMPLE_CHEMICAL", 280, 294], ["DTT", "SIMPLE_CHEMICAL", 296, 299], ["Genetic testing in saliva or sputum", "TEST", 0, 35], ["dilution into the reagents", "TREATMENT", 87, 113], ["any inhibitors", "TREATMENT", 162, 176], ["additives", "TREATMENT", 220, 229], ["polyethylene glycol (PEG)", "TREATMENT", 238, 263], ["hydroxides", "TREATMENT", 265, 275], ["dithiothreitol (DTT", "TREATMENT", 280, 299]]], ["With the broad range of bacterial species present in the mouth (over 600 inventoried), differing in terms of their contributions to health and disease, PCR is very useful for profiling large numbers of bacteria.", [["mouth", "ANATOMY", 57, 62], ["mouth", "ORGANISM_SUBDIVISION", 57, 62], ["bacterial species", "PROBLEM", 24, 41], ["disease", "PROBLEM", 143, 150], ["PCR", "TEST", 152, 155], ["profiling large numbers of bacteria", "PROBLEM", 175, 210], ["broad", "OBSERVATION_MODIFIER", 9, 14], ["bacterial species", "OBSERVATION", 24, 41], ["mouth", "ANATOMY", 57, 62], ["bacteria", "OBSERVATION", 202, 210]]], ["Some species are recalcitrant to lysing, like Streptococcus.", [["Some species", "PROBLEM", 0, 12], ["Streptococcus", "PROBLEM", 46, 59], ["species", "OBSERVATION", 5, 12], ["recalcitrant", "OBSERVATION_MODIFIER", 17, 29], ["Streptococcus", "OBSERVATION_MODIFIER", 46, 59]]], ["So, instead of relying on bead-beating, phenol treatments, or other steps, Aas et al. applied proteinase K lysates directly to PCR reagents [140] .", [["phenol", "CHEMICAL", 40, 46], ["K", "CHEMICAL", 105, 106], ["phenol", "CHEMICAL", 40, 46], ["phenol", "SIMPLE_CHEMICAL", 40, 46], ["proteinase K", "GENE_OR_GENE_PRODUCT", 94, 106], ["proteinase K", "PROTEIN", 94, 106], ["bead-beating", "TREATMENT", 26, 38], ["phenol treatments", "TREATMENT", 40, 57], ["proteinase K lysates", "TREATMENT", 94, 114], ["PCR reagents", "TEST", 127, 139]]], ["Several other groups have followed suit in detecting bacterial taxa in healthy [152, 153] and diseased saliva samples [154] .", [["samples", "ANATOMY", 110, 117], ["saliva samples", "ORGANISM_SUBSTANCE", 103, 117], ["bacterial taxa", "TEST", 53, 67], ["diseased saliva samples", "PROBLEM", 94, 117]]], ["Direct amplification is also possible in the field of LAMP-based diagnostics, as evidenced in testing for Zika [82] and malaria [65] .", [["malaria", "DISEASE", 120, 127], ["Direct amplification", "TEST", 0, 20], ["Zika", "PROBLEM", 106, 110], ["malaria", "PROBLEM", 120, 127]]], ["Du et al. went further than simplifying the sample treatment, a ten-minute heating of Zaire Ebolavirus DNA in saliva, by actually providing a LAMP-to-glucose transduction that can be read out on a handheld glucometer [155] .Direct NAATs for Saliva and SputumDesigning direct tests for sputum is inherently difficult because many nucleic acid-based methods process samples analogously to culture-based protocols.", [["sputum", "ANATOMY", 285, 291], ["samples", "ANATOMY", 364, 371], ["glucose", "CHEMICAL", 150, 157], ["nucleic acid", "CHEMICAL", 329, 341], ["glucose", "CHEMICAL", 150, 157], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["glucose", "SIMPLE_CHEMICAL", 150, 157], ["Saliva", "ORGANISM_SUBSTANCE", 241, 247], ["nucleic acid", "SIMPLE_CHEMICAL", 329, 341], ["Zaire Ebolavirus", "SPECIES", 86, 102], ["the sample treatment", "TREATMENT", 40, 60], ["Zaire Ebolavirus DNA", "TREATMENT", 86, 106], ["a LAMP-to-glucose transduction", "TREATMENT", 140, 170], ["Saliva and SputumDesigning direct tests", "TEST", 241, 280], ["sputum", "PROBLEM", 285, 291], ["nucleic acid", "TEST", 329, 341], ["culture", "TEST", 387, 394]]], ["In this N-acetyl-L-cysteine (NALC)-NaOH method [156] , the viscous sputum matrix is liquefied through several buffer exchanges and high-speed centrifugation into a more manipulative sample for testing.", [["sputum matrix", "ANATOMY", 67, 80], ["sample", "ANATOMY", 182, 188], ["N-acetyl-L-cysteine", "CHEMICAL", 8, 27], ["NALC", "CHEMICAL", 29, 33], ["N-acetyl-L-cysteine", "CHEMICAL", 8, 27], ["NALC", "CHEMICAL", 29, 33], ["NaOH", "CHEMICAL", 35, 39], ["N-acetyl-L-cysteine", "SIMPLE_CHEMICAL", 8, 27], ["NALC", "SIMPLE_CHEMICAL", 29, 33], ["this N-acetyl", "TEST", 3, 16], ["the viscous sputum matrix", "TREATMENT", 55, 80], ["several buffer exchanges", "TREATMENT", 102, 126], ["high-speed centrifugation", "TREATMENT", 131, 156], ["testing", "TEST", 193, 200]]], ["An additional concern is decontamination.", [["decontamination", "PROBLEM", 25, 40], ["decontamination", "OBSERVATION", 25, 40]]], ["This is necessary for culture, but also useful to protect the operator from biosafety hazards in molecular testing [157] .", [["culture", "TEST", 22, 29], ["molecular testing", "TEST", 97, 114]]], ["Several semi-direct examples based on LAMP [158] [159] [160] , recombinase polymerase amplification (RPA) [23, 161] , or PCR [162] [163] [164] [165] [166] have adopted this practice.Direct NAATs for Saliva and SputumHowever, side-by-side comparisons of nucleic acid testing on sputum samples with or without NaOH-NALC treatment have indicated that NaOH-NALC processing could be removed to enable truly direct protocols for sputum.", [["sputum samples", "ANATOMY", 277, 291], ["sputum", "ANATOMY", 423, 429], ["nucleic acid", "CHEMICAL", 253, 265], ["NaOH-NALC", "CHEMICAL", 308, 317], ["NaOH", "CHEMICAL", 348, 352], ["NaOH", "CHEMICAL", 308, 312], ["NaOH", "CHEMICAL", 348, 352], ["Saliva", "ORGANISM_SUBSTANCE", 199, 205], ["nucleic acid", "SIMPLE_CHEMICAL", 253, 265], ["NaOH-NALC", "SIMPLE_CHEMICAL", 308, 317], ["NaOH-NALC", "SIMPLE_CHEMICAL", 348, 357], ["recombinase polymerase", "PROTEIN", 63, 85], ["LAMP", "TEST", 38, 42], ["recombinase polymerase amplification", "TEST", 63, 99], ["RPA", "TEST", 101, 104], ["PCR", "TEST", 121, 124], ["Saliva and SputumHowever", "TEST", 199, 223], ["nucleic acid testing", "TEST", 253, 273], ["sputum samples", "TEST", 277, 291], ["NaOH", "TREATMENT", 308, 312], ["NALC treatment", "TREATMENT", 313, 327], ["NaOH-NALC processing", "TREATMENT", 348, 368], ["sputum", "PROBLEM", 423, 429]]], ["Mitarai et al. reported that the addition of NALC to a sputum specimen prior to extraction had no effect on testing for TB [167] .", [["sputum specimen", "ANATOMY", 55, 70], ["NALC", "CHEMICAL", 45, 49], ["TB", "DISEASE", 120, 122], ["NALC", "SIMPLE_CHEMICAL", 45, 49], ["NALC", "TREATMENT", 45, 49], ["a sputum specimen", "TEST", 53, 70], ["extraction", "TREATMENT", 80, 90], ["testing", "TEST", 108, 115], ["TB", "PROBLEM", 120, 122]]], ["Furthermore, Tarhan et al. showed Amongst the collection of approaches for direct PCR amplification on saliva samples, those that begin with dried saliva swabs fully circumvent DNA extraction, purification, and quantification [93] .", [["samples", "ANATOMY", 110, 117], ["saliva samples", "ORGANISM_SUBSTANCE", 103, 117], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["direct PCR amplification", "TREATMENT", 75, 99], ["saliva samples", "TREATMENT", 103, 117], ["dried saliva swabs", "TREATMENT", 141, 159], ["DNA extraction", "TREATMENT", 177, 191]]], ["Hall et al. added punches of saliva stains directly to the reaction mixture in order to perform STR analysis.", [["saliva", "ORGANISM_SUBSTANCE", 29, 35], ["saliva stains", "TREATMENT", 29, 42], ["STR analysis", "TEST", 96, 108]]], ["Genetic testing in saliva or sputum is often performed directly in liquid samples, and dilution into the reagents is typically sufficient to negate the effect of any inhibitors [148] [149] [150] , although heat [151] or additives such as polyethylene glycol (PEG), hydroxides, or dithiothreitol (DTT) may be added to further process samples [42, 43, 56, 145] .", [["saliva", "ANATOMY", 19, 25], ["sputum", "ANATOMY", 29, 35], ["samples", "ANATOMY", 74, 81], ["polyethylene glycol", "CHEMICAL", 238, 257], ["PEG", "CHEMICAL", 259, 262], ["dithiothreitol", "CHEMICAL", 280, 294], ["DTT", "CHEMICAL", 296, 299], ["polyethylene glycol", "CHEMICAL", 238, 257], ["PEG", "CHEMICAL", 259, 262], ["hydroxides", "CHEMICAL", 265, 275], ["dithiothreitol", "CHEMICAL", 280, 294], ["DTT", "CHEMICAL", 296, 299], ["saliva", "ORGANISM_SUBSTANCE", 19, 25], ["sputum", "ORGANISM_SUBSTANCE", 29, 35], ["[148] [149] [150]", "SIMPLE_CHEMICAL", 177, 194], ["polyethylene glycol", "SIMPLE_CHEMICAL", 238, 257], ["PEG", "SIMPLE_CHEMICAL", 259, 262], ["hydroxides", "SIMPLE_CHEMICAL", 265, 275], ["dithiothreitol", "SIMPLE_CHEMICAL", 280, 294], ["DTT", "SIMPLE_CHEMICAL", 296, 299], ["Genetic testing in saliva or sputum", "TEST", 0, 35], ["dilution into the reagents", "TREATMENT", 87, 113], ["any inhibitors", "TREATMENT", 162, 176], ["additives", "TREATMENT", 220, 229], ["polyethylene glycol (PEG)", "TREATMENT", 238, 263], ["hydroxides", "TREATMENT", 265, 275], ["dithiothreitol (DTT", "TREATMENT", 280, 299]]], ["With the broad range of bacterial species present in the mouth (over 600 inventoried), differing in terms of their contributions to health and disease, PCR is very useful for profiling large numbers of bacteria.", [["mouth", "ANATOMY", 57, 62], ["mouth", "ORGANISM_SUBDIVISION", 57, 62], ["bacterial species", "PROBLEM", 24, 41], ["disease", "PROBLEM", 143, 150], ["PCR", "TEST", 152, 155], ["profiling large numbers of bacteria", "PROBLEM", 175, 210], ["broad", "OBSERVATION_MODIFIER", 9, 14], ["bacterial species", "OBSERVATION", 24, 41], ["mouth", "ANATOMY", 57, 62], ["bacteria", "OBSERVATION", 202, 210]]], ["Some species are recalcitrant to lysing, like Streptococcus.", [["Some species", "PROBLEM", 0, 12], ["Streptococcus", "PROBLEM", 46, 59], ["species", "OBSERVATION", 5, 12], ["recalcitrant", "OBSERVATION_MODIFIER", 17, 29], ["Streptococcus", "OBSERVATION_MODIFIER", 46, 59]]], ["So, instead of relying on bead-beating, phenol treatments, or other steps, Aas et al. applied proteinase K lysates directly to PCR reagents [140] .", [["phenol", "CHEMICAL", 40, 46], ["K", "CHEMICAL", 105, 106], ["phenol", "CHEMICAL", 40, 46], ["phenol", "SIMPLE_CHEMICAL", 40, 46], ["proteinase K", "GENE_OR_GENE_PRODUCT", 94, 106], ["proteinase K", "PROTEIN", 94, 106], ["bead-beating", "TREATMENT", 26, 38], ["phenol treatments", "TREATMENT", 40, 57], ["proteinase K lysates", "TREATMENT", 94, 114], ["PCR reagents", "TEST", 127, 139]]], ["Several other groups have followed suit in detecting bacterial taxa in healthy [152, 153] and diseased saliva samples [154] .", [["samples", "ANATOMY", 110, 117], ["saliva samples", "ORGANISM_SUBSTANCE", 103, 117], ["bacterial taxa", "TEST", 53, 67], ["diseased saliva samples", "PROBLEM", 94, 117]]], ["Direct amplification is also possible in the field of LAMP-based diagnostics, as evidenced in testing for Zika [82] and malaria [65] .", [["malaria", "DISEASE", 120, 127], ["Direct amplification", "TEST", 0, 20], ["Zika", "PROBLEM", 106, 110], ["malaria", "PROBLEM", 120, 127]]], ["Du et al. went further than simplifying the sample treatment, a ten-minute heating of Zaire Ebolavirus DNA in saliva, by actually providing a LAMP-to-glucose transduction that can be read out on a handheld glucometer [155] .Direct NAATs for Saliva and SputumDesigning direct tests for sputum is inherently difficult because many nucleic acid-based methods process samples analogously to culture-based protocols.", [["sputum", "ANATOMY", 285, 291], ["samples", "ANATOMY", 364, 371], ["glucose", "CHEMICAL", 150, 157], ["nucleic acid", "CHEMICAL", 329, 341], ["glucose", "CHEMICAL", 150, 157], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["glucose", "SIMPLE_CHEMICAL", 150, 157], ["Saliva", "ORGANISM_SUBSTANCE", 241, 247], ["nucleic acid", "SIMPLE_CHEMICAL", 329, 341], ["Zaire Ebolavirus", "SPECIES", 86, 102], ["the sample treatment", "TREATMENT", 40, 60], ["Zaire Ebolavirus DNA", "TREATMENT", 86, 106], ["a LAMP-to-glucose transduction", "TREATMENT", 140, 170], ["Saliva and SputumDesigning direct tests", "TEST", 241, 280], ["sputum", "PROBLEM", 285, 291], ["nucleic acid", "TEST", 329, 341], ["culture", "TEST", 387, 394]]], ["In this N-acetyl-L-cysteine (NALC)-NaOH method [156] , the viscous sputum matrix is liquefied through several buffer exchanges and high-speed centrifugation into a more manipulative sample for testing.", [["sputum matrix", "ANATOMY", 67, 80], ["sample", "ANATOMY", 182, 188], ["N-acetyl-L-cysteine", "CHEMICAL", 8, 27], ["NALC", "CHEMICAL", 29, 33], ["N-acetyl-L-cysteine", "CHEMICAL", 8, 27], ["NALC", "CHEMICAL", 29, 33], ["NaOH", "CHEMICAL", 35, 39], ["N-acetyl-L-cysteine", "SIMPLE_CHEMICAL", 8, 27], ["NALC", "SIMPLE_CHEMICAL", 29, 33], ["this N-acetyl", "TEST", 3, 16], ["the viscous sputum matrix", "TREATMENT", 55, 80], ["several buffer exchanges", "TREATMENT", 102, 126], ["high-speed centrifugation", "TREATMENT", 131, 156], ["testing", "TEST", 193, 200]]], ["An additional concern is decontamination.", [["decontamination", "PROBLEM", 25, 40], ["decontamination", "OBSERVATION", 25, 40]]], ["This is necessary for culture, but also useful to protect the operator from biosafety hazards in molecular testing [157] .", [["culture", "TEST", 22, 29], ["molecular testing", "TEST", 97, 114]]], ["Several semi-direct examples based on LAMP [158] [159] [160] , recombinase polymerase amplification (RPA) [23, 161] , or PCR [162] [163] [164] [165] [166] have adopted this practice.Direct NAATs for Saliva and SputumHowever, side-by-side comparisons of nucleic acid testing on sputum samples with or without NaOH-NALC treatment have indicated that NaOH-NALC processing could be removed to enable truly direct protocols for sputum.", [["sputum samples", "ANATOMY", 277, 291], ["sputum", "ANATOMY", 423, 429], ["nucleic acid", "CHEMICAL", 253, 265], ["NaOH-NALC", "CHEMICAL", 308, 317], ["NaOH", "CHEMICAL", 348, 352], ["NaOH", "CHEMICAL", 308, 312], ["NaOH", "CHEMICAL", 348, 352], ["Saliva", "ORGANISM_SUBSTANCE", 199, 205], ["nucleic acid", "SIMPLE_CHEMICAL", 253, 265], ["NaOH-NALC", "SIMPLE_CHEMICAL", 308, 317], ["NaOH-NALC", "SIMPLE_CHEMICAL", 348, 357], ["recombinase polymerase", "PROTEIN", 63, 85], ["LAMP", "TEST", 38, 42], ["recombinase polymerase amplification", "TEST", 63, 99], ["RPA", "TEST", 101, 104], ["PCR", "TEST", 121, 124], ["Saliva and SputumHowever", "TEST", 199, 223], ["nucleic acid testing", "TEST", 253, 273], ["sputum samples", "TEST", 277, 291], ["NaOH", "TREATMENT", 308, 312], ["NALC treatment", "TREATMENT", 313, 327], ["NaOH-NALC processing", "TREATMENT", 348, 368], ["sputum", "PROBLEM", 423, 429]]], ["Mitarai et al. reported that the addition of NALC to a sputum specimen prior to extraction had no effect on testing for TB [167] .", [["sputum specimen", "ANATOMY", 55, 70], ["NALC", "CHEMICAL", 45, 49], ["TB", "DISEASE", 120, 122], ["NALC", "SIMPLE_CHEMICAL", 45, 49], ["NALC", "TREATMENT", 45, 49], ["a sputum specimen", "TEST", 53, 70], ["extraction", "TREATMENT", 80, 90], ["testing", "TEST", 108, 115], ["TB", "PROBLEM", 120, 122]]], ["Furthermore, Tarhan et al. showed that the sensitivity in TB testing was better for sputum samples that were measured directly, rather than after extraction with NaOH-NALC [168] .", [["sputum samples", "ANATOMY", 84, 98], ["NaOH-NALC", "CHEMICAL", 162, 171], ["NaOH-NALC", "CHEMICAL", 162, 171], ["NaOH", "SIMPLE_CHEMICAL", 162, 166], ["the sensitivity in TB testing", "TEST", 39, 68], ["sputum samples", "TEST", 84, 98]]], ["In pursuing alternatives to the lengthy NaOH-NALC method, sputum has been used in PCR after adding mucolytic agents [56, 169] , diluting in buffer [148] , or bead-beating [157] to reduce viscosity.", [["sputum", "ANATOMY", 58, 64], ["NaOH", "CHEMICAL", 40, 44], ["NaOH", "CHEMICAL", 40, 44], ["NaOH", "SIMPLE_CHEMICAL", 40, 44], ["sputum", "ORGANISM_SUBSTANCE", 58, 64], ["the lengthy NaOH-NALC method", "TREATMENT", 28, 56], ["sputum", "TEST", 58, 64], ["mucolytic agents", "TREATMENT", 99, 115]]], ["A more aggressive pretreatment, relying on chemical, thermal, and mechanical means of disruption, used heating and centrifugation to detect TB in 548 sputum samples with comparable performance to more expensive molecular-based systems [170] .", [["sputum samples", "ANATOMY", 150, 164], ["TB", "DISEASE", 140, 142], ["A more aggressive pretreatment", "TREATMENT", 0, 30], ["disruption", "PROBLEM", 86, 96], ["heating and centrifugation", "TREATMENT", 103, 129], ["TB", "PROBLEM", 140, 142], ["sputum samples", "TEST", 150, 164], ["aggressive", "OBSERVATION_MODIFIER", 7, 17]]], ["One particularly noteworthy example of direct testing used LAMP to diagnose tuberculosis at three peripheral laboratories [147] .", [["tuberculosis", "DISEASE", 76, 88], ["direct testing", "TEST", 39, 53]]], ["In the study, LAMP had a sensitivity of 97.9%, detecting 173 out of 177 smear-negative, culture-positive sputum samples.", [["sputum samples", "ANATOMY", 105, 119], ["the study", "TEST", 3, 12], ["LAMP", "TEST", 14, 18], ["a sensitivity", "TEST", 23, 36], ["smear", "TEST", 72, 77], ["culture", "TEST", 88, 95], ["positive sputum samples", "PROBLEM", 96, 119]]], ["The authors canvassed the laboratory personnel after they implemented the heating, washing, and filter-tip capture steps before direct amplification to verify that the assay had significant potential to be adopted for routine use.Direct NAATs for Saliva and SputumSeveral early examples of PCR on sputum samples with Mycobacterium spp. reported sensitivities in the single-digit copy number range.", [["sputum samples", "ANATOMY", 297, 311], ["Saliva", "ORGANISM_SUBSTANCE", 247, 253], ["Mycobacterium spp", "ORGANISM", 317, 334], ["the heating", "TREATMENT", 70, 81], ["washing", "TREATMENT", 83, 90], ["filter-tip capture steps", "TREATMENT", 96, 120], ["direct amplification", "TREATMENT", 128, 148], ["the assay", "TEST", 164, 173], ["Saliva", "TREATMENT", 247, 253], ["PCR", "TEST", 290, 293], ["sputum samples", "TEST", 297, 311], ["Mycobacterium spp", "PROBLEM", 317, 334], ["sensitivities", "TEST", 345, 358]]], ["However, the pretreatment methods were quite divergent.", [["the pretreatment methods", "TEST", 9, 33]]], ["Sjobring et al. used long centrifugation and sonication steps, in addition to boiling, to detect down to eight organisms [171] .", [["long centrifugation and sonication steps", "TREATMENT", 21, 61]]], ["Sritharan et al. was able to cut down the steps to a 30 min boiling period, with a resulting LOD of 1 organism [172] .", [["a resulting LOD of 1 organism", "PROBLEM", 81, 110]]], ["Since these examples in the 1990s, only one technique with a pre-amplification wash and an RPA reaction has been able to match this performance in detecting a single mycobacterium [161] .", [["a pre-amplification wash", "TREATMENT", 59, 83], ["an RPA reaction", "PROBLEM", 88, 103], ["a single mycobacterium", "TEST", 157, 179]]], ["As far as combining specificity and sensitivity without adding technical difficulty, Priye et al.'s recent multiplexed RT-LAMP detection system for Zika, dengue, and chikungunya achieved LODs of 44 copies/reaction with no need for lysis or extraction [82] .", [["dengue", "DISEASE", 154, 160], ["chikungunya", "DISEASE", 166, 177], ["dengue", "SPECIES", 154, 160], ["technical difficulty", "PROBLEM", 63, 83], ["LAMP detection system", "TEST", 122, 143], ["Zika", "PROBLEM", 148, 152], ["dengue", "PROBLEM", 154, 160], ["chikungunya", "PROBLEM", 166, 177], ["lysis", "TREATMENT", 231, 236], ["extraction", "TREATMENT", 240, 250]]], ["These impressive outcomes from isothermal technologies like RPA and LAMP illustrate that fancy hardware is not necessary for testing modalities to achieve high specificity directly in human samples.Direct NAATs for Oral, Dermal, and Conjunctival SwabsSwabs have become a mainstay in testing for viral pathogens.", [["samples", "ANATOMY", 190, 197], ["Dermal", "ANATOMY", 221, 227], ["Conjunctival", "ANATOMY", 233, 245], ["RPA", "GENE_OR_GENE_PRODUCT", 60, 63], ["human", "ORGANISM", 184, 189], ["samples", "CANCER", 190, 197], ["Dermal", "TISSUE", 221, 227], ["RPA", "PROTEIN", 60, 63], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["isothermal technologies", "TEST", 31, 54], ["fancy hardware", "TREATMENT", 89, 103], ["testing modalities", "TEST", 125, 143], ["Direct NAATs", "TREATMENT", 198, 210], ["Oral, Dermal", "TREATMENT", 215, 227], ["Conjunctival SwabsSwabs", "TEST", 233, 256], ["viral pathogens", "PROBLEM", 295, 310], ["Conjunctival", "ANATOMY", 233, 245]]], ["Molecular systems that identify respiratory tract infections in nasal swabs [13] or STIs (sexually transmitted infections) in dermal, genital, and conjunctival swabs [173] are used for rapid, accurate patient diagnosis.", [["respiratory tract", "ANATOMY", 32, 49], ["nasal swabs", "ANATOMY", 64, 75], ["dermal", "ANATOMY", 126, 132], ["genital", "ANATOMY", 134, 141], ["conjunctival swabs", "ANATOMY", 147, 165], ["respiratory tract infections", "DISEASE", 32, 60], ["STIs", "DISEASE", 84, 88], ["sexually transmitted infections", "DISEASE", 90, 121], ["respiratory tract", "ORGANISM_SUBDIVISION", 32, 49], ["dermal", "TISSUE", 126, 132], ["genital", "ORGANISM_SUBDIVISION", 134, 141], ["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["Molecular systems", "PROBLEM", 0, 17], ["respiratory tract infections", "PROBLEM", 32, 60], ["nasal swabs", "PROBLEM", 64, 75], ["STIs (sexually transmitted infections", "PROBLEM", 84, 121], ["conjunctival swabs", "TEST", 147, 165], ["respiratory tract", "ANATOMY", 32, 49], ["nasal", "ANATOMY", 64, 69], ["dermal", "ANATOMY", 126, 132], ["genital", "ANATOMY", 134, 141], ["conjunctival", "ANATOMY", 147, 159]]], ["DNA collection from swabs is attractive because it is simple, minimally invasive, and even enables self-sampling.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA collection from swabs", "PROBLEM", 0, 25], ["minimally invasive", "PROBLEM", 62, 80], ["collection", "OBSERVATION", 4, 14], ["simple", "OBSERVATION_MODIFIER", 54, 60], ["minimally", "OBSERVATION_MODIFIER", 62, 71], ["invasive", "OBSERVATION", 72, 80]]], ["However, swab-collected specimens are likely to contain polymerase inhibitors such as secreted minerals, electrolytes, hormones, enzymes, immunoglobulins, and cytokines, as well as topical medications [137, [174] [175] [176] [177] .", [["specimens", "ANATOMY", 24, 33], ["specimens", "CELL", 24, 33], ["electrolytes", "SIMPLE_CHEMICAL", 105, 117], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 138, 153], ["enzymes", "PROTEIN", 129, 136], ["immunoglobulins", "PROTEIN", 138, 153], ["cytokines", "PROTEIN", 159, 168], ["swab-collected specimens", "TEST", 9, 33], ["polymerase inhibitors", "TREATMENT", 56, 77], ["secreted minerals", "TEST", 86, 103], ["electrolytes", "TEST", 105, 117], ["enzymes", "TEST", 129, 136], ["immunoglobulins", "TREATMENT", 138, 153], ["cytokines", "TREATMENT", 159, 168], ["topical medications", "TREATMENT", 181, 200]]], ["As a result, many swab tests now on the market remove these inhibitors via extraction methods that are too involved and complex to be suitable for the POC [178] .Direct NAATs for Oral, Dermal, and Conjunctival SwabsAll of the swab sample studies we examined employed at least one patient sample, and most achieved high sensitivity at a reasonable level of dilution in the buffer used for DNA elution from the solid swab (Figure 7) .", [["Dermal", "ANATOMY", 185, 191], ["Conjunctival", "ANATOMY", 197, 209], ["swab sample", "ANATOMY", 226, 237], ["Dermal", "TISSUE", 185, 191], ["patient", "ORGANISM", 280, 287], ["DNA", "CELLULAR_COMPONENT", 388, 391], ["patient", "SPECIES", 280, 287], ["many swab tests", "TEST", 13, 28], ["these inhibitors", "TREATMENT", 54, 70], ["extraction methods", "TREATMENT", 75, 93], ["the swab sample studies", "TEST", 222, 245], ["high sensitivity", "PROBLEM", 314, 330], ["the buffer", "TREATMENT", 368, 378], ["DNA elution", "PROBLEM", 388, 399], ["the solid swab", "TEST", 405, 419], ["Conjunctival", "ANATOMY", 197, 209]]], ["One remarkable study examined 4518 patient swabs in direct PCR for STR (short tandem repeat) analysis [179] -unfortunately, the authors did not report the yields of DNA obtained or the lowest amounts detected.", [["patient", "ORGANISM", 35, 42], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["STR (short tandem repeat", "DNA", 67, 91], ["patient", "SPECIES", 35, 42], ["One remarkable study", "TEST", 0, 20], ["patient swabs", "TEST", 35, 48], ["direct PCR", "TEST", 52, 62], ["STR (short tandem repeat) analysis", "TEST", 67, 101], ["DNA", "PROBLEM", 165, 168]]], ["This is a particularly common problem amongst these references-when the LODs are not reported, it is especially difficult to replicate these procedures or compare the manipulations used in sample storage, DNA replication, and detection [180, 181] .", [["DNA", "CELLULAR_COMPONENT", 205, 208], ["these procedures", "TREATMENT", 135, 151], ["the manipulations", "TEST", 163, 180], ["sample storage", "TEST", 189, 203], ["DNA replication", "TEST", 205, 220]]], ["Special attention should therefore be paid to reproducibility in future efforts at direct amplification of swab samples.", [["swab samples", "ANATOMY", 107, 119], ["swab samples", "CANCER", 107, 119], ["swab samples", "TEST", 107, 119]]], ["Typically, elution either at room temperature [51, 176, [182] [183] [184] [185] [186] or with heating [43,44, [187] [188] [189] [190] [191] is sufficient to generate PCR-amplifiable template from swabs in solution.", [["swabs", "ANATOMY", 196, 201], ["[187] [188] [189] [190", "SIMPLE_CHEMICAL", 110, 132], ["heating", "TEST", 94, 101], ["PCR", "TEST", 166, 169]]], ["These methods of dilution or heating can save over thirty minutes of processing time, as with Nihonyanagi et al.'s heating protocol to release MRSA in CellEaseII (Biocosm Inc., Hyogo, Japan) diluents [169] .", [["MRSA", "CHEMICAL", 143, 147], ["CellEaseII", "CHEMICAL", 151, 161], ["MRSA", "SPECIES", 143, 147], ["dilution", "TREATMENT", 17, 25], ["Nihonyanagi et al.'s heating protocol", "TREATMENT", 94, 131], ["MRSA", "PROBLEM", 143, 147], ["MRSA", "OBSERVATION", 143, 147]]], ["LAMP-based testing of swab samples can also be performed at room-temperature [192] [193] [194] [195] [196] or while heated [145, [197] [198] [199] [200] [201] [202] , as can MDA [84] .", [["swab samples", "ANATOMY", 22, 34], ["MDA", "CHEMICAL", 174, 177], ["MDA", "CHEMICAL", 174, 177], ["[197] [198] [199] [200] [201] [202]", "SIMPLE_CHEMICAL", 129, 164], ["MDA", "SIMPLE_CHEMICAL", 174, 177], ["LAMP-based testing of swab samples", "TEST", 0, 34], ["MDA", "TEST", 174, 177]]], ["In particular, Mahony et al.'s LAMP-based test for influenza A and B achieved an analytical sensitivity of one genome equivalent, operating via a novel swab preparation procedure of vortexing and heating [198] .Direct NAATs for Oral, Dermal, and Conjunctival SwabsMoving towards instrument-free molecular diagnostics systems, a lateral-flow stranddisplacement amplification (SDA) [203] assay could directly detect MRSA from nasal swabs with a sensitivity of 600 copies/reaction [204] .", [["Dermal", "ANATOMY", 234, 240], ["Conjunctival", "ANATOMY", 246, 258], ["nasal swabs", "ANATOMY", 424, 435], ["Dermal", "TISSUE", 234, 240], ["nasal swabs", "ORGANISM_SUBDIVISION", 424, 435], ["MRSA", "SPECIES", 414, 418], ["MRSA", "SPECIES", 414, 418], ["'s LAMP", "TEST", 28, 35], ["influenza", "PROBLEM", 51, 60], ["a novel swab preparation procedure", "TREATMENT", 144, 178], ["Oral, Dermal, and Conjunctival Swabs", "TEST", 228, 264], ["a lateral-flow stranddisplacement amplification", "TREATMENT", 326, 373], ["MRSA", "PROBLEM", 414, 418], ["nasal swabs", "TEST", 424, 435], ["a sensitivity", "TEST", 441, 454], ["Dermal", "ANATOMY", 234, 240], ["Conjunctival", "ANATOMY", 246, 258]]], ["Lateral flow eliminates the need for expensive detectors.", [["Lateral flow", "TEST", 0, 12], ["expensive detectors", "TEST", 37, 56], ["flow", "OBSERVATION", 8, 12]]], ["Rogdriguez et al. went one step further by combining paper-based extraction and in situ amplification with lateral flow to develop an RT-LAMP assay for H1N1 in patient nasopharyngeal specimens.", [["nasopharyngeal specimens", "ANATOMY", 168, 192], ["H1N1", "DISEASE", 152, 156], ["patient", "ORGANISM", 160, 167], ["nasopharyngeal specimens", "CANCER", 168, 192], ["patient", "SPECIES", 160, 167], ["based extraction", "TREATMENT", 59, 75], ["lateral flow", "TEST", 107, 119], ["an RT-LAMP assay", "TEST", 131, 147], ["H1N1", "PROBLEM", 152, 156], ["patient nasopharyngeal specimens", "TEST", 160, 192], ["nasopharyngeal", "ANATOMY", 168, 182]]], ["Their sensitivity of 500 copies/reaction was well below the mean viral load for H1N1 patients [205] .", [["H1N1", "DISEASE", 80, 84], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Their sensitivity", "TEST", 0, 17], ["500 copies/reaction", "PROBLEM", 21, 40], ["H1N1", "PROBLEM", 80, 84]]], ["Pushing to even lower limits of detection, an HDA-based assay with a vertical-flow DNA strip readout [206] could directly test clinical genital swabs in transport medium for HSV types 1 and 2 [207] .", [["genital swabs", "ANATOMY", 136, 149], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["genital", "ORGANISM", 136, 143], ["swabs", "ORGANISM_SUBSTANCE", 144, 149], ["HSV", "ORGANISM", 174, 177], ["HSV", "SPECIES", 174, 177], ["an HDA", "TEST", 43, 49], ["clinical genital swabs", "TEST", 127, 149], ["HSV types", "TEST", 174, 183]]], ["The nucleic acid assays had LODs of 5.5 and 34.1 copies/reaction for HSV-1 and HSV-2, respectively, and were able to detect low-viral loads below the sensitivity of culture tests.Direct NAATs for Oral, Dermal, and Conjunctival SwabsThe most sensitive tests on swabs rely on LAMP reactions: for example, fewer than 10 copies/reaction of viral targets were seen after brief heating steps in Hank's buffer (Whittaker Bioproducts, Boston, MA, USA) [197] , M-Swab diluent (Copan Diagnostics Inc., Murrieta, CA) [198] , or water [202] .", [["Dermal", "ANATOMY", 202, 208], ["Conjunctival", "ANATOMY", 214, 226], ["swabs", "ANATOMY", 260, 265], ["nucleic acid", "CHEMICAL", 4, 16], ["HSV-1", "ORGANISM", 69, 74], ["HSV-2", "ORGANISM", 79, 84], ["Dermal", "TISSUE", 202, 208], ["HSV-1", "SPECIES", 69, 74], ["HSV-1", "SPECIES", 69, 74], ["HSV-2", "SPECIES", 79, 84], ["The nucleic acid assays", "TEST", 0, 23], ["LODs", "TEST", 28, 32], ["copies/reaction", "TEST", 49, 64], ["HSV", "TEST", 69, 72], ["HSV", "TEST", 79, 82], ["low-viral loads", "PROBLEM", 124, 139], ["culture tests", "TEST", 165, 178], ["Oral, Dermal, and Conjunctival Swabs", "TEST", 196, 232], ["swabs", "TEST", 260, 265], ["LAMP reactions", "TEST", 274, 288], ["viral targets", "PROBLEM", 336, 349], ["brief heating steps", "TREATMENT", 366, 385], ["Conjunctival", "ANATOMY", 214, 226]]], ["It is noteworthy is that entire swab samples can be used in amplification reactions, eliminating the loss of starting material that accompanies liquid and hardware transfers.", [["swab samples", "ANATOMY", 32, 44], ["entire swab samples", "TEST", 25, 44], ["amplification reactions", "PROBLEM", 60, 83], ["the loss of starting material", "PROBLEM", 97, 126], ["liquid and hardware transfers", "TREATMENT", 144, 173], ["hardware", "OBSERVATION", 155, 163]]], ["This approach has also been successful in several instances of STR testing [43, 179] .", [["STR", "CHEMICAL", 63, 66], ["STR testing", "TEST", 63, 74], ["successful", "OBSERVATION_MODIFIER", 28, 38]]], ["Rodriguez et al. used a similar approach in detecting clinical levels of H1N1 by passing an in-house elution buffer with the sample of interest through a filter paper-based setup, then amplifying on the filter membrane [205] .", [["H1N1", "DISEASE", 73, 77], ["a similar approach", "TREATMENT", 22, 40], ["H1N1", "PROBLEM", 73, 77], ["a filter paper-based setup", "TREATMENT", 152, 178], ["the filter membrane", "TREATMENT", 199, 218]]], ["Future developments could focus on direct reactions with swabs that integrate extraction, Figure 7 .", [["direct reactions", "PROBLEM", 35, 51], ["swabs", "TREATMENT", 57, 62]]], ["Swab-based procedures for nucleic acid testing, with data presented as in Figure 3 .Direct NAATs for Oral, Dermal, and Conjunctival SwabsTypically, elution either at room temperature [51, 176, [182] [183] [184] [185] [186] or with heating [43, 44, [187] [188] [189] [190] [191] is sufficient to generate PCR-amplifiable template from swabs in solution.", [["Dermal", "ANATOMY", 107, 113], ["Conjunctival", "ANATOMY", 119, 131], ["swabs", "ANATOMY", 334, 339], ["nucleic acid", "CHEMICAL", 26, 38], ["Dermal", "TISSUE", 107, 113], ["Swab", "TEST", 0, 4], ["nucleic acid testing", "TEST", 26, 46], ["heating", "TEST", 231, 238], ["PCR", "TEST", 304, 307], ["Dermal", "ANATOMY", 107, 113], ["Conjunctival", "ANATOMY", 119, 131]]], ["These methods of dilution or heating can save over thirty minutes of processing time, as with Nihonyanagi et al.'s heating protocol to release MRSA in CellEaseII (Biocosm Inc., Hyogo, Japan) diluents [169] .", [["MRSA", "CHEMICAL", 143, 147], ["CellEaseII", "CHEMICAL", 151, 161], ["MRSA", "SPECIES", 143, 147], ["dilution", "TREATMENT", 17, 25], ["Nihonyanagi et al.'s heating protocol", "TREATMENT", 94, 131], ["MRSA", "PROBLEM", 143, 147], ["MRSA", "OBSERVATION", 143, 147]]], ["LAMP-based testing of swab samples can also be performed at room-temperature [192] [193] [194] [195] [196] or while heated [145, [197] [198] [199] [200] [201] [202] , as can MDA [84] .", [["swab samples", "ANATOMY", 22, 34], ["MDA", "CHEMICAL", 174, 177], ["MDA", "CHEMICAL", 174, 177], ["[197] [198] [199] [200] [201] [202]", "SIMPLE_CHEMICAL", 129, 164], ["MDA", "SIMPLE_CHEMICAL", 174, 177], ["LAMP-based testing of swab samples", "TEST", 0, 34], ["MDA", "TEST", 174, 177]]], ["In particular, Mahony et al.'s LAMP-based test for influenza A and B achieved an analytical sensitivity of one genome equivalent, operating via a novel swab preparation procedure of vortexing and heating [198] .Direct NAATs for Oral, Dermal, and Conjunctival SwabsMoving towards instrument-free molecular diagnostics systems, a lateral-flow strand-displacement amplification (SDA) [203] assay could directly detect MRSA from nasal swabs with a sensitivity of 600 copies/reaction [204] .", [["Dermal", "ANATOMY", 234, 240], ["Conjunctival", "ANATOMY", 246, 258], ["nasal swabs", "ANATOMY", 425, 436], ["Dermal", "TISSUE", 234, 240], ["nasal swabs", "ORGANISM_SUBDIVISION", 425, 436], ["MRSA", "SPECIES", 415, 419], ["MRSA", "SPECIES", 415, 419], ["'s LAMP", "TEST", 28, 35], ["influenza", "PROBLEM", 51, 60], ["a novel swab preparation procedure", "TREATMENT", 144, 178], ["Oral, Dermal, and Conjunctival Swabs", "TEST", 228, 264], ["instrument", "TEST", 279, 289], ["a lateral-flow strand-displacement amplification", "TREATMENT", 326, 374], ["MRSA", "PROBLEM", 415, 419], ["nasal swabs", "TEST", 425, 436], ["a sensitivity", "TEST", 442, 455], ["Dermal", "ANATOMY", 234, 240], ["Conjunctival", "ANATOMY", 246, 258]]], ["Lateral flow eliminates the need for expensive detectors.", [["Lateral flow", "TEST", 0, 12], ["expensive detectors", "TEST", 37, 56], ["flow", "OBSERVATION", 8, 12]]], ["Rogdriguez et al. went one step further by combining paper-based extraction and in situ amplification with lateral flow to develop an RT-LAMP assay for H1N1 in patient nasopharyngeal specimens.", [["nasopharyngeal specimens", "ANATOMY", 168, 192], ["H1N1", "DISEASE", 152, 156], ["patient", "ORGANISM", 160, 167], ["nasopharyngeal specimens", "CANCER", 168, 192], ["patient", "SPECIES", 160, 167], ["based extraction", "TREATMENT", 59, 75], ["lateral flow", "TEST", 107, 119], ["an RT-LAMP assay", "TEST", 131, 147], ["H1N1", "PROBLEM", 152, 156], ["patient nasopharyngeal specimens", "TEST", 160, 192], ["nasopharyngeal", "ANATOMY", 168, 182]]], ["Their sensitivity of 500 copies/reaction was well below the mean viral load for H1N1 patients [205] .", [["H1N1", "DISEASE", 80, 84], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Their sensitivity", "TEST", 0, 17], ["500 copies/reaction", "PROBLEM", 21, 40], ["H1N1", "PROBLEM", 80, 84]]], ["Pushing to even lower limits of detection, an HDA-based assay with a vertical-flow DNA strip readout [206] could directly test clinical genital swabs in transport medium for HSV types 1 and 2 [207] .", [["genital swabs", "ANATOMY", 136, 149], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["genital", "ORGANISM", 136, 143], ["swabs", "ORGANISM_SUBSTANCE", 144, 149], ["HSV", "ORGANISM", 174, 177], ["HSV", "SPECIES", 174, 177], ["an HDA", "TEST", 43, 49], ["clinical genital swabs", "TEST", 127, 149], ["HSV types", "TEST", 174, 183]]], ["The nucleic acid assays had LODs of 5.5 and 34.1 copies/reaction for HSV-1 and HSV-2, respectively, and were able to detect low-viral loads below the sensitivity of culture tests.Direct NAATs for Oral, Dermal, and Conjunctival SwabsThe most sensitive tests on swabs rely on LAMP reactions: for example, fewer than 10 copies/reaction of viral targets were seen after brief heating steps in Hank's buffer (Whittaker Bioproducts, Boston, MA, USA) [197] , M-Swab diluent (Copan Diagnostics Inc., Murrieta, CA, USA) [198] , or water [202] .", [["Dermal", "ANATOMY", 202, 208], ["Conjunctival", "ANATOMY", 214, 226], ["swabs", "ANATOMY", 260, 265], ["nucleic acid", "CHEMICAL", 4, 16], ["HSV-1", "ORGANISM", 69, 74], ["HSV-2", "ORGANISM", 79, 84], ["Dermal", "TISSUE", 202, 208], ["HSV-1", "SPECIES", 69, 74], ["HSV-1", "SPECIES", 69, 74], ["HSV-2", "SPECIES", 79, 84], ["The nucleic acid assays", "TEST", 0, 23], ["LODs", "TEST", 28, 32], ["copies/reaction", "TEST", 49, 64], ["HSV", "TEST", 69, 72], ["HSV", "TEST", 79, 82], ["low-viral loads", "PROBLEM", 124, 139], ["culture tests", "TEST", 165, 178], ["Oral, Dermal, and Conjunctival Swabs", "TEST", 196, 232], ["swabs", "TEST", 260, 265], ["LAMP reactions", "TEST", 274, 288], ["viral targets", "PROBLEM", 336, 349], ["brief heating steps", "TREATMENT", 366, 385], ["Conjunctival", "ANATOMY", 214, 226]]], ["It is noteworthy is that entire swab samples can be used in amplification reactions, eliminating the loss of starting material that accompanies liquid and hardware transfers.", [["swab samples", "ANATOMY", 32, 44], ["entire swab samples", "TEST", 25, 44], ["amplification reactions", "PROBLEM", 60, 83], ["the loss of starting material", "PROBLEM", 97, 126], ["liquid and hardware transfers", "TREATMENT", 144, 173], ["hardware", "OBSERVATION", 155, 163]]], ["This approach has also been successful in several instances of STR testing [43, 179] .", [["STR", "CHEMICAL", 63, 66], ["STR testing", "TEST", 63, 74], ["successful", "OBSERVATION_MODIFIER", 28, 38]]], ["Rodriguez et al. used a similar approach in detecting clinical levels of H1N1 by passing an in-house elution buffer with the sample of interest through a filter paper-based setup, then amplifying on the filter membrane [205] .Direct NAATs for Oral, Dermal, and Conjunctival SwabsFuture developments could focus on direct reactions with swabs that integrate extraction, amplification, and detection in a single tube for POC usage.", [["Dermal", "ANATOMY", 249, 255], ["Conjunctival", "ANATOMY", 261, 273], ["H1N1", "DISEASE", 73, 77], ["Dermal", "TISSUE", 249, 255], ["tube", "TISSUE", 410, 414], ["a similar approach", "TREATMENT", 22, 40], ["H1N1", "PROBLEM", 73, 77], ["a filter paper-based setup", "TREATMENT", 152, 178], ["the filter membrane", "TREATMENT", 199, 218], ["Conjunctival SwabsFuture developments", "TREATMENT", 261, 298], ["direct reactions", "PROBLEM", 314, 330], ["swabs", "TREATMENT", 336, 341], ["integrate extraction", "TREATMENT", 347, 367], ["a single tube", "TREATMENT", 401, 414], ["POC usage", "TREATMENT", 419, 428], ["Conjunctival", "ANATOMY", 261, 273]]], ["This would give low-resource settings alternatives to instrument-dependent assays like the Alere i platform for detecting influenza A & B from nasal swabs.Direct NAATs for Urine and StoolDiseases of the kidney or genitourinary tract can often be detected from stool or urine.", [["nasal swabs", "ANATOMY", 143, 154], ["kidney", "ANATOMY", 203, 209], ["genitourinary tract", "ANATOMY", 213, 232], ["stool", "ANATOMY", 260, 265], ["urine", "ANATOMY", 269, 274], ["A & B", "GENE_OR_GENE_PRODUCT", 132, 137], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 143, 154], ["NAATs", "GENE_OR_GENE_PRODUCT", 162, 167], ["Urine", "ORGANISM_SUBSTANCE", 172, 177], ["kidney", "ORGAN", 203, 209], ["genitourinary tract", "ORGAN", 213, 232], ["stool", "ORGANISM_SUBSTANCE", 260, 265], ["urine", "ORGANISM_SUBSTANCE", 269, 274], ["instrument-dependent assays", "PROBLEM", 54, 81], ["influenza", "PROBLEM", 122, 131], ["nasal swabs", "TREATMENT", 143, 154], ["Direct NAATs", "TEST", 155, 167], ["Urine", "TEST", 172, 177], ["StoolDiseases of the kidney", "PROBLEM", 182, 209], ["genitourinary tract", "PROBLEM", 213, 232], ["stool or urine", "TEST", 260, 274], ["nasal", "ANATOMY", 143, 148], ["kidney", "ANATOMY", 203, 209], ["genitourinary tract", "ANATOMY", 213, 232], ["stool", "OBSERVATION", 260, 265]]], ["Urea destabilizes interactions between primers, template and polymerase, and since urea is typically present in adult urine at concentrations six-fold greater than can be tolerated in PCR reactions, ultracentrifugation, or related procedures are typically used to prepare such samples for nucleic acid testing [208] [209] [210] .", [["urine", "ANATOMY", 118, 123], ["Urea", "CHEMICAL", 0, 4], ["urea", "CHEMICAL", 83, 87], ["nucleic acid", "CHEMICAL", 289, 301], ["Urea", "CHEMICAL", 0, 4], ["urea", "CHEMICAL", 83, 87], ["Urea", "SIMPLE_CHEMICAL", 0, 4], ["urea", "SIMPLE_CHEMICAL", 83, 87], ["urine", "ORGANISM_SUBSTANCE", 118, 123], ["nucleic acid", "SIMPLE_CHEMICAL", 289, 301], ["Urea destabilizes interactions between primers, template and polymerase", "PROBLEM", 0, 71], ["PCR reactions", "PROBLEM", 184, 197], ["ultracentrifugation", "TREATMENT", 199, 218], ["nucleic acid testing", "TEST", 289, 309]]], ["Molecular tests for the identification of pathogens in stool rely on extraction methods to remove the proteinases, bile salts, polyphenols, and acids that directly inhibit the activity of DNA polymerases [211, 212] .", [["stool", "ANATOMY", 55, 60], ["bile salts", "CHEMICAL", 115, 125], ["bile salts", "CHEMICAL", 115, 125], ["polyphenols", "CHEMICAL", 127, 138], ["stool", "ORGANISM_SUBSTANCE", 55, 60], ["bile salts", "SIMPLE_CHEMICAL", 115, 125], ["polyphenols", "SIMPLE_CHEMICAL", 127, 138], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["proteinases", "PROTEIN", 102, 113], ["DNA polymerases", "PROTEIN", 188, 203], ["Molecular tests", "TEST", 0, 15], ["pathogens in stool", "PROBLEM", 42, 60], ["extraction methods", "TREATMENT", 69, 87], ["the proteinases", "PROBLEM", 98, 113], ["bile salts", "TREATMENT", 115, 125], ["polyphenols", "TREATMENT", 127, 138], ["acids", "TREATMENT", 144, 149], ["DNA polymerases", "TEST", 188, 203], ["stool", "OBSERVATION", 55, 60], ["bile", "ANATOMY", 115, 119]]], ["Methods for testing external specimens have been integrated into diagnostic screens for pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, and Clostridium difficile with high sensitivity and specificity [213] [214] [215] [216] [217] .Direct NAATs for Urine and StoolIn surveying direct nucleic acid testing methods (Figure 8 ), we noted that the LODs are generally lower for urine-based tests than for feces-based.", [["specimens", "ANATOMY", 29, 38], ["urine", "ANATOMY", 388, 393], ["Chlamydia trachomatis", "DISEASE", 106, 127], ["Neisseria gonorrhoeae", "DISEASE", 129, 150], ["Clostridium difficile", "DISEASE", 156, 177], ["nucleic acid", "CHEMICAL", 299, 311], ["Chlamydia trachomatis", "ORGANISM", 106, 127], ["Neisseria gonorrhoeae", "ORGANISM", 129, 150], ["Clostridium difficile", "ORGANISM", 156, 177], ["Urine", "ORGANISM_SUBSTANCE", 264, 269], ["StoolIn", "SIMPLE_CHEMICAL", 274, 281], ["urine", "ORGANISM_SUBSTANCE", 388, 393], ["feces", "ORGANISM_SUBDIVISION", 415, 420], ["Chlamydia trachomatis", "SPECIES", 106, 127], ["Neisseria gonorrhoeae", "SPECIES", 129, 150], ["Clostridium difficile", "SPECIES", 156, 177], ["Chlamydia trachomatis", "SPECIES", 106, 127], ["Neisseria gonorrhoeae", "SPECIES", 129, 150], ["Clostridium difficile", "SPECIES", 156, 177], ["Methods for testing external specimens", "TEST", 0, 38], ["diagnostic screens", "TEST", 65, 83], ["pathogens", "PROBLEM", 88, 97], ["Chlamydia trachomatis", "PROBLEM", 106, 127], ["Neisseria gonorrhoeae", "PROBLEM", 129, 150], ["Clostridium difficile", "PROBLEM", 156, 177], ["specificity", "TEST", 204, 215], ["Urine", "TEST", 264, 269], ["StoolIn", "TREATMENT", 274, 281], ["direct nucleic acid testing methods", "TEST", 292, 327], ["the LODs", "TEST", 355, 363], ["urine-based tests", "TEST", 388, 405]]], ["However, there is one example of direct PCR in stool samples, taking advantage of buffer additives and enhanced Phire polymerase (New England Biolabs, Ipswich, MA, USA), which achieved a LOD of 0.002 pg of bacterial DNA.", [["stool samples", "ANATOMY", 47, 60], ["stool samples", "ORGANISM_SUBSTANCE", 47, 60], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["Phire polymerase", "PROTEIN", 112, 128], ["direct PCR in stool samples", "TEST", 33, 60], ["advantage of buffer additives", "TREATMENT", 69, 98], ["enhanced Phire polymerase", "TEST", 103, 128], ["bacterial DNA", "PROBLEM", 206, 219], ["bacterial DNA", "OBSERVATION", 206, 219]]], ["However, there is a clear need for increased testing with patient samples, as nearly half of the referenced works do not include any clinical validation.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["increased testing", "TEST", 35, 52], ["clear", "OBSERVATION", 20, 25]]], ["This issue is especially notable with fecal testing, where patient testing is only reported in one study.Direct NAATs for Urine and StoolDiseases of the kidney or genitourinary tract can often be detected from stool or urine.", [["kidney", "ANATOMY", 153, 159], ["genitourinary tract", "ANATOMY", 163, 182], ["stool", "ANATOMY", 210, 215], ["urine", "ANATOMY", 219, 224], ["fecal", "ORGANISM_SUBSTANCE", 38, 43], ["patient", "ORGANISM", 59, 66], ["NAATs", "GENE_OR_GENE_PRODUCT", 112, 117], ["Urine", "ORGANISM_SUBSTANCE", 122, 127], ["kidney", "ORGAN", 153, 159], ["genitourinary tract", "ORGAN", 163, 182], ["stool", "ORGANISM_SUBSTANCE", 210, 215], ["urine", "ORGANISM_SUBSTANCE", 219, 224], ["patient", "SPECIES", 59, 66], ["fecal testing", "TEST", 38, 51], ["patient testing", "TEST", 59, 74], ["one study", "TEST", 95, 104], ["Direct NAATs", "TEST", 105, 117], ["Urine", "TEST", 122, 127], ["StoolDiseases of the kidney", "PROBLEM", 132, 159], ["genitourinary tract", "PROBLEM", 163, 182], ["stool or urine", "TEST", 210, 224], ["kidney", "ANATOMY", 153, 159], ["genitourinary tract", "ANATOMY", 163, 182], ["stool", "OBSERVATION", 210, 215]]], ["Urea destabilizes interactions between primers, template and polymerase, and since urea is typically present in adult urine at concentrations six-fold greater than can be tolerated in PCR reactions, ultracentrifugation, or related procedures are typically used to prepare such samples for nucleic acid testing [208] [209] [210] .", [["urine", "ANATOMY", 118, 123], ["Urea", "CHEMICAL", 0, 4], ["urea", "CHEMICAL", 83, 87], ["nucleic acid", "CHEMICAL", 289, 301], ["Urea", "CHEMICAL", 0, 4], ["urea", "CHEMICAL", 83, 87], ["Urea", "SIMPLE_CHEMICAL", 0, 4], ["urea", "SIMPLE_CHEMICAL", 83, 87], ["urine", "ORGANISM_SUBSTANCE", 118, 123], ["nucleic acid", "SIMPLE_CHEMICAL", 289, 301], ["Urea destabilizes interactions between primers, template and polymerase", "PROBLEM", 0, 71], ["PCR reactions", "PROBLEM", 184, 197], ["ultracentrifugation", "TREATMENT", 199, 218], ["nucleic acid testing", "TEST", 289, 309]]], ["Molecular tests for the identification of pathogens in stool rely on extraction methods to remove the proteinases, bile salts, polyphenols, and acids that directly inhibit the activity of DNA polymerases [211, 212] .", [["stool", "ANATOMY", 55, 60], ["bile salts", "CHEMICAL", 115, 125], ["bile salts", "CHEMICAL", 115, 125], ["polyphenols", "CHEMICAL", 127, 138], ["stool", "ORGANISM_SUBSTANCE", 55, 60], ["bile salts", "SIMPLE_CHEMICAL", 115, 125], ["polyphenols", "SIMPLE_CHEMICAL", 127, 138], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["proteinases", "PROTEIN", 102, 113], ["DNA polymerases", "PROTEIN", 188, 203], ["Molecular tests", "TEST", 0, 15], ["pathogens in stool", "PROBLEM", 42, 60], ["extraction methods", "TREATMENT", 69, 87], ["the proteinases", "PROBLEM", 98, 113], ["bile salts", "TREATMENT", 115, 125], ["polyphenols", "TREATMENT", 127, 138], ["acids", "TREATMENT", 144, 149], ["DNA polymerases", "TEST", 188, 203], ["stool", "OBSERVATION", 55, 60], ["bile", "ANATOMY", 115, 119]]], ["Methods for testing external specimens have been integrated into diagnostic screens for pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, and Clostridium difficile with high sensitivity and specificity [213] [214] [215] [216] [217] .Direct NAATs for Urine and StoolIn surveying direct nucleic acid testing methods (Figure 8 ), we noted that the LODs are generally lower for urine-based tests than for feces-based.", [["specimens", "ANATOMY", 29, 38], ["urine", "ANATOMY", 388, 393], ["Chlamydia trachomatis", "DISEASE", 106, 127], ["Neisseria gonorrhoeae", "DISEASE", 129, 150], ["Clostridium difficile", "DISEASE", 156, 177], ["nucleic acid", "CHEMICAL", 299, 311], ["Chlamydia trachomatis", "ORGANISM", 106, 127], ["Neisseria gonorrhoeae", "ORGANISM", 129, 150], ["Clostridium difficile", "ORGANISM", 156, 177], ["Urine", "ORGANISM_SUBSTANCE", 264, 269], ["StoolIn", "SIMPLE_CHEMICAL", 274, 281], ["urine", "ORGANISM_SUBSTANCE", 388, 393], ["feces", "ORGANISM_SUBDIVISION", 415, 420], ["Chlamydia trachomatis", "SPECIES", 106, 127], ["Neisseria gonorrhoeae", "SPECIES", 129, 150], ["Clostridium difficile", "SPECIES", 156, 177], ["Chlamydia trachomatis", "SPECIES", 106, 127], ["Neisseria gonorrhoeae", "SPECIES", 129, 150], ["Clostridium difficile", "SPECIES", 156, 177], ["Methods for testing external specimens", "TEST", 0, 38], ["diagnostic screens", "TEST", 65, 83], ["pathogens", "PROBLEM", 88, 97], ["Chlamydia trachomatis", "PROBLEM", 106, 127], ["Neisseria gonorrhoeae", "PROBLEM", 129, 150], ["Clostridium difficile", "PROBLEM", 156, 177], ["specificity", "TEST", 204, 215], ["Urine", "TEST", 264, 269], ["StoolIn", "TREATMENT", 274, 281], ["direct nucleic acid testing methods", "TEST", 292, 327], ["the LODs", "TEST", 355, 363], ["urine-based tests", "TEST", 388, 405]]], ["However, there is one example of direct PCR in stool samples, taking advantage of buffer additives and enhanced Phire polymerase (New England Biolabs, Ipswich, MA, USA), which achieved a LOD of 0.002 pg of bacterial DNA.", [["stool samples", "ANATOMY", 47, 60], ["stool samples", "ORGANISM_SUBSTANCE", 47, 60], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["Phire polymerase", "PROTEIN", 112, 128], ["direct PCR in stool samples", "TEST", 33, 60], ["advantage of buffer additives", "TREATMENT", 69, 98], ["enhanced Phire polymerase", "TEST", 103, 128], ["bacterial DNA", "PROBLEM", 206, 219], ["bacterial DNA", "OBSERVATION", 206, 219]]], ["However, there is a clear need for increased testing with patient samples, as nearly half of the referenced works do not include any clinical validation.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["increased testing", "TEST", 35, 52], ["clear", "OBSERVATION", 20, 25]]], ["This issue is especially notable with fecal testing, where patient testing is only reported in one study.", [["fecal", "ORGANISM_SUBSTANCE", 38, 43], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["fecal testing", "TEST", 38, 51], ["patient testing", "TEST", 59, 74], ["one study", "TEST", 95, 104]]], ["Though complex extraction methods are recommended prior to PCR in order to remove inhibitory components of urine and feces, changes to the reaction chemistry could effectively relieve the negative effects of the sample matrix.", [["urine", "ANATOMY", 107, 112], ["feces", "ANATOMY", 117, 122], ["sample matrix", "ANATOMY", 212, 225], ["urine", "ORGANISM_SUBSTANCE", 107, 112], ["feces", "ORGANISM_SUBSTANCE", 117, 122], ["matrix", "CELLULAR_COMPONENT", 219, 225], ["complex extraction methods", "TREATMENT", 7, 33], ["PCR", "TEST", 59, 62], ["inhibitory components of urine and feces", "PROBLEM", 82, 122], ["the reaction chemistry", "TEST", 135, 157], ["the sample matrix", "TREATMENT", 208, 225], ["negative", "OBSERVATION", 188, 196]]], ["With urine, this alteration takes the form of a hydrogelencased reaction [183] .", [["urine", "ANATOMY", 5, 10], ["urine", "ORGANISM_SUBSTANCE", 5, 10], ["this alteration", "PROBLEM", 12, 27], ["a hydrogelencased reaction", "PROBLEM", 46, 72], ["urine", "OBSERVATION", 5, 10]]], ["The authors developed a pre-assembled, desiccated, gel-based cassette that is rehydrated by the liquid in raw urine samples.", [["urine samples", "ANATOMY", 110, 123], ["urine samples", "ORGANISM_SUBSTANCE", 110, 123], ["gel-based cassette", "TREATMENT", 51, 69], ["urine samples", "TEST", 110, 123]]], ["The polyacrylamide gel matrix effectively filters Though complex extraction methods are recommended prior to PCR in order to remove inhibitory components of urine and feces, changes to the reaction chemistry could effectively relieve the negative effects of the sample matrix.", [["urine", "ANATOMY", 157, 162], ["feces", "ANATOMY", 167, 172], ["sample matrix", "ANATOMY", 262, 275], ["polyacrylamide", "CHEMICAL", 4, 18], ["matrix", "CELLULAR_COMPONENT", 23, 29], ["urine", "ORGANISM_SUBSTANCE", 157, 162], ["feces", "ORGANISM_SUBSTANCE", 167, 172], ["matrix", "CELLULAR_COMPONENT", 269, 275], ["The polyacrylamide gel matrix", "TREATMENT", 0, 29], ["complex extraction methods", "TREATMENT", 57, 83], ["PCR", "TEST", 109, 112], ["inhibitory components of urine and feces", "PROBLEM", 132, 172], ["the reaction chemistry", "TEST", 185, 207], ["the sample matrix", "TREATMENT", 258, 275], ["negative", "OBSERVATION", 238, 246]]], ["With urine, this alteration takes the form of a hydrogel-encased reaction [183] .", [["urine", "ANATOMY", 5, 10], ["urine", "ORGANISM_SUBSTANCE", 5, 10], ["this alteration", "PROBLEM", 12, 27], ["a hydrogel-encased reaction", "TREATMENT", 46, 73], ["urine", "OBSERVATION", 5, 10]]], ["The authors developed a pre-assembled, desiccated, gel-based cassette that is rehydrated Biosensors 2019, 9, 117 16 of 29 by the liquid in raw urine samples.", [["urine samples", "ANATOMY", 143, 156], ["urine samples", "ORGANISM_SUBSTANCE", 143, 156], ["Biosensors", "TEST", 89, 99], ["urine samples", "TEST", 143, 156]]], ["The polyacrylamide gel matrix effectively filters biological inhibitors out of the amplification reaction, enabling detection of Mycoplasma homonis and Ureaplasma urealyticum.", [["Mycoplasma homonis", "DISEASE", 129, 147], ["Ureaplasma urealyticum", "DISEASE", 152, 174], ["polyacrylamide", "CHEMICAL", 4, 18], ["matrix", "CELLULAR_COMPONENT", 23, 29], ["Mycoplasma homonis", "ORGANISM", 129, 147], ["Ureaplasma urealyticum", "ORGANISM", 152, 174], ["Mycoplasma homonis", "SPECIES", 129, 147], ["Ureaplasma urealyticum", "SPECIES", 152, 174], ["Mycoplasma homonis", "SPECIES", 129, 147], ["Ureaplasma urealyticum", "SPECIES", 152, 174], ["The polyacrylamide gel matrix", "TREATMENT", 0, 29], ["filters biological inhibitors", "TREATMENT", 42, 71], ["the amplification reaction", "PROBLEM", 79, 105], ["Mycoplasma homonis", "PROBLEM", 129, 147], ["Ureaplasma urealyticum", "PROBLEM", 152, 174], ["Mycoplasma homonis", "OBSERVATION", 129, 147], ["Ureaplasma urealyticum", "OBSERVATION", 152, 174]]], ["For feces, the options are to employ inhibitor-resistant polymerases [57] and buffer additives [212] .", [["feces", "ANATOMY", 4, 9], ["feces", "ORGANISM_SUBSTANCE", 4, 9], ["feces", "PROBLEM", 4, 9], ["employ inhibitor", "TREATMENT", 30, 46], ["resistant polymerases", "PROBLEM", 47, 68]]], ["In the case of one large-scale characterization by Hall et al., the combination of both Phire polymerase (New England Biolabs, Ipswich, MA, USA) and Ampdirect (Biomatrica, San Diego, CA) gave an LOD of nearly one copy/reaction in PCR for Francisella tularensis in 0.5% stool [56] .", [["Francisella tularensis", "ORGANISM", 238, 260], ["Phire polymerase", "PROTEIN", 88, 104], ["Francisella tularensis", "SPECIES", 238, 260], ["Francisella tularensis", "SPECIES", 238, 260], ["both Phire polymerase", "PROBLEM", 83, 104], ["PCR", "TEST", 230, 233], ["Francisella tularensis", "PROBLEM", 238, 260]]], ["One can also lyse bacteria in urine [218] or stool [219, 220] through heating to release an amplifiable amount of target DNA with minimal levels of inhibitors.", [["urine", "ANATOMY", 30, 35], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["stool", "ORGANISM_SUBSTANCE", 45, 50], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["lyse bacteria in urine", "TEST", 13, 35], ["stool", "TEST", 45, 50], ["target DNA", "PROBLEM", 114, 124], ["minimal levels of inhibitors", "PROBLEM", 130, 158]]], ["Moore et al. managed to detect Human norovirus repeatedly in 11 out of 12 outbreak stool samples after boiling the diluted feces in PBS [221] .", [["samples", "ANATOMY", 89, 96], ["feces", "ANATOMY", 123, 128], ["Human", "ORGANISM", 31, 36], ["feces", "ORGANISM_SUBSTANCE", 123, 128], ["Human", "SPECIES", 31, 36], ["Human norovirus", "SPECIES", 31, 46], ["Human norovirus", "PROBLEM", 31, 46], ["the diluted feces in PBS", "TEST", 111, 135]]], ["Although centrifugation is employed in some semi-direct methods to create a supernatant from the collected stool, we believe a dilution step could accomplish the same feat by allowing solids to settle at the base of a highly aqueous, non-viscous sample.Direct NAATs for Urine and StoolIsothermal amplification techniques like LAMP and RPA generally demonstrate a higher tolerance than PCR for urine, as they can be carried out directly.", [["supernatant", "ANATOMY", 76, 87], ["sample", "ANATOMY", 246, 252], ["urine", "ANATOMY", 393, 398], ["stool", "ORGANISM_SUBSTANCE", 107, 112], ["Urine", "ORGANISM_SUBSTANCE", 270, 275], ["RPA", "GENE_OR_GENE_PRODUCT", 335, 338], ["urine", "ORGANISM_SUBSTANCE", 393, 398], ["RPA", "PROTEIN", 335, 338], ["centrifugation", "TREATMENT", 9, 23], ["a dilution step", "TREATMENT", 125, 140], ["Direct NAATs", "TEST", 253, 265], ["Urine", "TEST", 270, 275], ["StoolIsothermal amplification techniques", "TREATMENT", 280, 320], ["LAMP and RPA", "TEST", 326, 338], ["PCR for urine", "TEST", 385, 398], ["centrifugation", "OBSERVATION", 9, 23], ["base", "ANATOMY_MODIFIER", 208, 212], ["highly", "OBSERVATION_MODIFIER", 218, 224], ["aqueous", "OBSERVATION", 225, 232]]], ["As such, LAMP-based assays without any pre-processing steps or chemical enhancements have detected the causative agents of viral infections [82, 127, 131] or STIs [222, 223] , and pathogenic bacteria such as Escherichia coli [224] .", [["viral infections", "DISEASE", 123, 139], ["Escherichia coli", "ORGANISM", 208, 224], ["Escherichia coli", "SPECIES", 208, 224], ["Escherichia coli", "SPECIES", 208, 224], ["LAMP-based assays", "TEST", 9, 26], ["viral infections", "PROBLEM", 123, 139], ["STIs", "TEST", 158, 162], ["pathogenic bacteria", "PROBLEM", 180, 199], ["Escherichia coli", "PROBLEM", 208, 224], ["Escherichia coli", "OBSERVATION", 208, 224]]], ["The developers of the recently established isothermal method SIBA showed the utility of this amplification technique by detecting Chlamydia trachomatis and Neisseria gonorrhoeae in a low-copy urine sample [25] .DiscussionThe landscape of molecular diagnostics is constantly advancing, as is the current paradigm of healthcare.", [["urine sample", "ANATOMY", 192, 204], ["Chlamydia trachomatis", "DISEASE", 130, 151], ["Neisseria gonorrhoeae", "DISEASE", 156, 177], ["Chlamydia trachomatis", "ORGANISM", 130, 151], ["Neisseria gonorrhoeae", "ORGANISM", 156, 177], ["urine", "ORGANISM_SUBSTANCE", 192, 197], ["Chlamydia trachomatis", "SPECIES", 130, 151], ["Neisseria gonorrhoeae", "SPECIES", 156, 177], ["Chlamydia trachomatis", "SPECIES", 130, 151], ["Neisseria gonorrhoeae", "SPECIES", 156, 177], ["this amplification technique", "TEST", 88, 116], ["Chlamydia trachomatis", "PROBLEM", 130, 151], ["Neisseria gonorrhoeae", "PROBLEM", 156, 177]]], ["The advent of mobile health and telemedicine has decentralized patient care.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["decentralized patient care", "TREATMENT", 49, 75]]], ["It has also put a new emphasis on usability and non-invasiveness in disease testing.", [["disease testing", "TEST", 68, 83], ["new", "OBSERVATION_MODIFIER", 18, 21]]], ["Nucleic acid diagnostics that reduce the difficulties and expenditures of standard multi-step procedures by direct amplification can expedite patient testing in POC, hospital, and laboratory situations [225] .", [["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["Nucleic acid diagnostics", "TEST", 0, 24], ["the difficulties", "PROBLEM", 37, 53], ["standard multi-step procedures", "TREATMENT", 74, 104], ["patient testing", "TEST", 142, 157]]], ["In this review, we are thus motivated to discuss the current state of the art for direct NAATs: assays and platforms that require minimal or no sample preparation procedures.", [["sample", "ANATOMY", 144, 150], ["NAATs", "SIMPLE_CHEMICAL", 89, 94], ["sample preparation procedures", "TREATMENT", 144, 173]]], ["We first categorize these works based on the type of complex samples.", [["samples", "ANATOMY", 61, 68], ["samples", "CANCER", 61, 68]]], ["We subsequently employ bubble plots to facilitate the comparison of the amplification method, robustness in complex media, sensitivity to target, and clinical usage.", [["bubble plots", "TEST", 23, 35], ["the amplification method", "TEST", 68, 92]]], ["Our findings indicate that the majority of direct NAATs exhibit a tolerance of less than 17% for their sample of interest, and fewer than 30 patient-based evaluations.", [["NAATs", "GENE_OR_GENE_PRODUCT", 50, 55], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["based evaluations", "TEST", 149, 166]]], ["Still, there are diagnostic procedures that far surpass these averages.", [["diagnostic procedures", "TEST", 17, 38]]], ["Sim et al.'s study of direct PCR on 4518 buccal swabs [179] , for instance, is robust and carried out directly on the entire sample for maximal ease.", [["buccal swabs", "ANATOMY", 41, 53], ["direct PCR", "TEST", 22, 32], ["buccal swabs", "TEST", 41, 53]]], ["Improvements must continue to be made for all sample types in terms of facilitating this level of evaluation with clinical samples.DiscussionDespite significant developments to date, there remain several challenges for realizing direct NAATs with user-friendliness, consistency, and generalizability.", [["evaluation", "TEST", 98, 108], ["clinical samples", "TEST", 114, 130]]], ["In furthering the development of direct testing, it is important to take a holistic approach and consider the type of sample to be analyzed, the method of sample acquisition, the throughput and volume, and any chemical or mechanical requirements, and the amplification technique.", [["direct testing", "TEST", 33, 47], ["a holistic approach", "TREATMENT", 73, 92], ["sample acquisition", "TEST", 155, 173], ["volume", "TEST", 194, 200], ["mechanical requirements", "TREATMENT", 222, 245], ["the amplification technique", "TEST", 251, 278]]], ["An improved understanding of the mechanisms behind emerging nucleic acid amplification reactions and mutant polymerases will enable the rationalization of how inhibitory compounds can make or break an amplification system.", [["nucleic acid", "CHEMICAL", 60, 72], ["mutant polymerases", "PROTEIN", 101, 119], ["emerging nucleic acid amplification reactions", "TREATMENT", 51, 96], ["mutant polymerases", "PROBLEM", 101, 119], ["improved", "OBSERVATION_MODIFIER", 3, 11]]], ["Furthermore, molecular assays have much to learn from diagnostics that are continuously being developed in the commercial pipeline.", [["molecular assays", "TEST", 13, 29]]], ["Proprietary technology will always hold knowledge at a cost to the user, but the implementation of new ideas can lead researchers towards better and more successful ways in which to modernize the ever-changing field of disease testing.ConclusionsAs we enter the age of electronic, mobile, and personalized medicine, there remains much room for creativity and innovation in the design of NAATs and POC diagnostics.", [["disease testing", "TEST", 219, 234], ["POC diagnostics", "TEST", 397, 412]]], ["Molecular diagnostics, as the highest-growing segment of all in vitro diagnostic products [226] , truly have great potential for both developed and low-resource areas.", [["Molecular diagnostics", "TEST", 0, 21], ["low", "OBSERVATION_MODIFIER", 148, 151]]], ["The diagnostic community continues to strive for tests that are reliable against variable electrical resources, water quality, trained staff, or harsh environmental conditions [227, 228] .", [["tests", "TEST", 49, 54]]], ["Through this review, it is our hope to stimulate the discussion on direct NAATs and their potential as POC diagnostics.", [["NAATs", "SIMPLE_CHEMICAL", 74, 79], ["POC diagnostics", "TEST", 103, 118]]], ["Ultimately, we seek to help accelerate the development of POC diagnostics that can be CLIA waived and/or meet the WHO ASSURED criteria, thereby ushering in the next revolution in healthcare.Supplementary Materials:The following are available online at http://www.mdpi.com/2079-6374/9/4/117/s1, Table S1 : Detailed Properties of Amplification Assays.", [["POC diagnostics", "TEST", 58, 73], ["Amplification Assays", "TEST", 328, 348]]]], "4b021cba20d59a74bc0d952cc2c94e9d09f158f1": [["From December 2019, several pneumonia cases of unknown etiology were reported in Wuhan city, Hubei Province, China, and were epidemiologically linked to the Huanan Seafood Wholesale Market where live animals were also sold [1].", [["pneumonia", "DISEASE", 28, 37], ["animals", "ORGANISM", 200, 207], ["several pneumonia cases", "PROBLEM", 20, 43], ["pneumonia", "OBSERVATION", 28, 37]]], ["Subsequently, the International Committee on Taxonomy renamed as SARS-CoV-2 the virus responsible for the coronavirus disease 19 (COVID-19), because it was found closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) [3, 4] .", [["coronavirus disease", "DISEASE", 106, 125], ["acute respiratory syndrome coronavirus", "DISEASE", 188, 226], ["SARS", "DISEASE", 228, 232], ["SARS-CoV-2", "ORGANISM", 65, 75], ["coronavirus", "ORGANISM", 106, 117], ["SARS-CoV", "SPECIES", 65, 73], ["severe acute respiratory syndrome coronavirus", "SPECIES", 181, 226], ["SARS-CoV", "SPECIES", 228, 236], ["SARS", "TEST", 65, 69], ["CoV", "TEST", 70, 73], ["the virus", "PROBLEM", 76, 85], ["the coronavirus disease", "PROBLEM", 102, 125], ["COVID", "TEST", 130, 135], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 181, 226], ["coronavirus disease", "OBSERVATION", 106, 125], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["respiratory syndrome coronavirus", "OBSERVATION", 194, 226]]], ["The SARS-CoV-2 sequence shared in the GISAID platform, allowed the development of several molecular diagnostic tests through specific primers and probes design for the rapid detection by reverse transcription (rt) Realtime PCR [5, 6] .", [["SARS-CoV-2 sequence", "DNA", 4, 23], ["The SARS", "TEST", 0, 8], ["CoV-2 sequence", "TEST", 9, 23], ["several molecular diagnostic tests", "TEST", 82, 116], ["the rapid detection", "TEST", 164, 183], ["reverse transcription", "TREATMENT", 187, 208], ["Realtime PCR", "TEST", 214, 226]]], ["In the course of infection, SARS-CoV-2 is usually detectable in upper and lower respiratory specimens and nasopharyngeal secretions collected using swabs are the clinical samples of choice for diagnostic testing [7, 8] .", [["lower respiratory specimens", "ANATOMY", 74, 101], ["nasopharyngeal secretions", "ANATOMY", 106, 131], ["swabs", "ANATOMY", 148, 153], ["infection", "DISEASE", 17, 26], ["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "ORGANISM", 28, 38], ["upper", "ORGANISM_SUBDIVISION", 64, 69], ["nasopharyngeal secretions", "ORGANISM_SUBSTANCE", 106, 131], ["SARS-CoV", "SPECIES", 28, 36], ["infection", "PROBLEM", 17, 26], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["nasopharyngeal secretions", "PROBLEM", 106, 131], ["swabs", "TREATMENT", 148, 153], ["diagnostic testing", "TEST", 193, 211], ["infection", "OBSERVATION", 17, 26], ["upper", "ANATOMY_MODIFIER", 64, 69], ["lower", "ANATOMY_MODIFIER", 74, 79], ["respiratory", "ANATOMY", 80, 91], ["nasopharyngeal", "ANATOMY", 106, 120], ["secretions", "OBSERVATION", 121, 131]]], ["Emergency response to the COVID-19 pandemic has highlighted the critical need of making reliable diagnostic ascertainment widely available, in order to favour the rapid detection and isolation of cases and investigation, monitoring and quarantine of their close contacts.", [["the rapid detection", "TEST", 159, 178], ["investigation", "TEST", 206, 219], ["monitoring", "TEST", 221, 231]]]], "PMC7366851": [["DiscussionAmong 164 symptomatic COVID-19 patients, nearly all experienced fever, cough, or shortness of breath, and all but four would have met the CSTE clinical case definition.", [["fever", "DISEASE", 74, 79], ["cough", "DISEASE", 81, 86], ["shortness of breath", "DISEASE", 91, 110], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["fever", "PROBLEM", 74, 79], ["cough", "PROBLEM", 81, 86], ["shortness of breath", "PROBLEM", 91, 110], ["cough", "OBSERVATION", 81, 86]]], ["However, a wide variety of other symptoms were also reported; chills, myalgia, headache, fatigue, and the presence of at least one GI symptom (most commonly diarrhea) were each reported by >50% of patients.", [["chills", "DISEASE", 62, 68], ["myalgia", "DISEASE", 70, 77], ["headache", "DISEASE", 79, 87], ["fatigue", "DISEASE", 89, 96], ["diarrhea", "DISEASE", 157, 165], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["a wide variety of other symptoms", "PROBLEM", 9, 41], ["chills", "PROBLEM", 62, 68], ["myalgia", "PROBLEM", 70, 77], ["headache", "PROBLEM", 79, 87], ["fatigue", "PROBLEM", 89, 96], ["one GI symptom", "PROBLEM", 127, 141], ["diarrhea", "PROBLEM", 157, 165], ["wide", "OBSERVATION_MODIFIER", 11, 15]]], ["The occurrence of these symptoms in patients with COVID-19 has also been reported elsewhere (5\u20137).", [["COVID-19", "CHEMICAL", 50, 58], ["COVID-19", "CHEMICAL", 50, 58], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["these symptoms", "PROBLEM", 18, 32], ["COVID", "TEST", 50, 55], ["symptoms", "OBSERVATION", 24, 32]]], ["Symptoms other than fever, cough, and shortness of breath were reported more commonly after testing guidelines were expanded.", [["fever", "DISEASE", 20, 25], ["cough", "DISEASE", 27, 32], ["shortness of breath", "DISEASE", 38, 57], ["Symptoms", "PROBLEM", 0, 8], ["fever", "PROBLEM", 20, 25], ["cough", "PROBLEM", 27, 32], ["shortness of breath", "PROBLEM", 38, 57], ["cough", "OBSERVATION", 27, 32]]], ["This change might reflect an expansion of the types of patients eligible for testing and an increased awareness of other COVID-19 symptoms over time, such as changes in smell or taste.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["testing", "TEST", 77, 84], ["other COVID-19 symptoms", "PROBLEM", 115, 138], ["changes in smell or taste", "PROBLEM", 158, 183], ["expansion", "OBSERVATION_MODIFIER", 29, 38], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["Few differences in symptom profile were notable by age or sex, especially when stratifying by hospitalization status; however, hospitalized patients (many of whom were older) more frequently reported experiencing fever, cough, and shortness of breath.", [["fever", "DISEASE", 213, 218], ["cough", "DISEASE", 220, 225], ["shortness of breath", "DISEASE", 231, 250], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["Few differences in symptom profile", "PROBLEM", 0, 34], ["fever", "PROBLEM", 213, 218], ["cough", "PROBLEM", 220, 225], ["shortness of breath", "PROBLEM", 231, 250], ["cough", "OBSERVATION", 220, 225]]], ["As reported by others, changes in smell or taste were more commonly reported by women than by men (6,8).DiscussionThe findings in this report are subject to at least five limitations.", [["women", "ORGANISM", 80, 85], ["men", "ORGANISM", 94, 97], ["women", "SPECIES", 80, 85], ["men", "SPECIES", 94, 97], ["changes in smell or taste", "PROBLEM", 23, 48]]], ["First, these cases represent a convenience sample of predominantly symptomatic COVID-19 patients reported by 16 states during a timeframe that included a period when testing was restricted to certain patients.", [["COVID", "DISEASE", 79, 84], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 200, 208], ["testing", "TEST", 166, 173], ["predominantly", "OBSERVATION_MODIFIER", 53, 66], ["symptomatic", "OBSERVATION_MODIFIER", 67, 78]]], ["For instance, hospitalized patients are likely overrepresented as a result of the guidance to sample cases with a \u201crange of severities\u201d and because early in the outbreak, testing was limited to more severe cases.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["testing", "TEST", 171, 178]]], ["This sampling strategy also precludes estimation of the prevalence of asymptomatic infection because only symptomatic patients are systematically detected as part of standard public health activities.", [["infection", "DISEASE", 83, 92], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["This sampling strategy", "TREATMENT", 0, 22], ["asymptomatic infection", "PROBLEM", 70, 92], ["asymptomatic", "OBSERVATION_MODIFIER", 70, 82], ["infection", "OBSERVATION", 83, 92], ["symptomatic", "OBSERVATION_MODIFIER", 106, 117]]], ["Second, because case investigation forms were occasionally completed by proxy or several weeks after illness onset, some symptoms were unknown or might have been forgotten.", [["illness", "DISEASE", 101, 108], ["illness onset", "PROBLEM", 101, 114], ["some symptoms", "PROBLEM", 116, 129]]], ["Third, case investigation forms completed soon after illness onset might not have captured symptoms that developed later.", [["illness", "DISEASE", 53, 60], ["captured symptoms", "PROBLEM", 82, 99]]], ["Fourth, the prevalence of unsolicited (\u201cwrite-in\u201d) symptoms might be underestimated; this might have been most likely in the early phases of the U.S. outbreak, when less was known about the possible spectrum of symptoms.", [["symptoms", "PROBLEM", 51, 59], ["symptoms", "PROBLEM", 211, 219], ["most likely", "UNCERTAINTY", 106, 117]]], ["Conversely, the prevalence of fever, cough, and shortness of breath might have been overestimated, even after expansion of testing guidelines, because widespread awareness of these symptoms might have affected testing practices.", [["fever", "DISEASE", 30, 35], ["cough", "DISEASE", 37, 42], ["shortness of breath", "DISEASE", 48, 67], ["fever", "PROBLEM", 30, 35], ["cough", "PROBLEM", 37, 42], ["shortness of breath", "PROBLEM", 48, 67], ["testing guidelines", "TEST", 123, 141], ["these symptoms", "PROBLEM", 175, 189], ["fever", "OBSERVATION", 30, 35]]], ["Finally, sample sizes were small, particularly for children, limiting the ability to draw conclusions about differences by age group.DiscussionClinicians and public health professionals should be aware that COVID-19 can manifest a range of symptoms.", [["sample", "ANATOMY", 9, 15], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["sample sizes", "TEST", 9, 21], ["COVID", "TEST", 207, 212], ["symptoms", "PROBLEM", 240, 248], ["sizes", "OBSERVATION_MODIFIER", 16, 21], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["Because prompt identification of COVID-19 patients is important to slow the spread of disease, testing should be considered for patients experiencing 1) fever, cough, or shortness of breath; 2) symptoms included in the CSTE case definition, including chills, myalgia, or headache; 3) other symptoms, including diarrhea or fatigue, especially if reported along with fever, cough, or shortness of breath; and 4) for asymptomatic persons, based on clinical or public health judgment (9).", [["fever", "DISEASE", 153, 158], ["cough", "DISEASE", 160, 165], ["shortness of breath", "DISEASE", 170, 189], ["chills", "DISEASE", 251, 257], ["myalgia", "DISEASE", 259, 266], ["headache", "DISEASE", 271, 279], ["diarrhea", "DISEASE", 310, 318], ["fatigue", "DISEASE", 322, 329], ["fever", "DISEASE", 365, 370], ["cough", "DISEASE", 372, 377], ["shortness of breath", "DISEASE", 382, 401], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 128, 136], ["persons", "ORGANISM", 427, 434], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 128, 136], ["persons", "SPECIES", 427, 434], ["COVID", "TEST", 33, 38], ["disease", "PROBLEM", 86, 93], ["testing", "TEST", 95, 102], ["fever", "PROBLEM", 153, 158], ["cough", "PROBLEM", 160, 165], ["shortness of breath", "PROBLEM", 170, 189], ["symptoms", "PROBLEM", 194, 202], ["chills", "PROBLEM", 251, 257], ["myalgia", "PROBLEM", 259, 266], ["headache", "PROBLEM", 271, 279], ["other symptoms", "PROBLEM", 284, 298], ["diarrhea", "PROBLEM", 310, 318], ["fatigue", "PROBLEM", 322, 329], ["fever", "PROBLEM", 365, 370], ["cough", "PROBLEM", 372, 377], ["shortness of breath", "PROBLEM", 382, 401], ["asymptomatic persons", "PROBLEM", 414, 434]]], ["Representative symptom data from U.S. patients across the spectrum of COVID-19 illness severity, including data on the timing of symptom development, are needed to inform clinical case definitions and guidance for symptom screening or testing criteria.", [["illness", "DISEASE", 79, 86], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["COVID", "TEST", 70, 75], ["illness severity", "PROBLEM", 79, 95], ["symptom", "PROBLEM", 129, 136], ["symptom screening", "TEST", 214, 231], ["testing criteria", "TEST", 235, 251]]]], "d0cd535962322457ab99af525bb76af8f5cbe3e1": [["cell line) or YAC (H-2a, a natural killer cell-susceptible thymoma line) target cells at various ratios in round-bottomed 96-well plates (Petra Plastik ; Inotech, Wohlen, Switzerland) for 5 h at 37\u00b0C in air supplemented with 5% C02 .", [["cell line", "ANATOMY", 0, 9], ["natural killer cell", "ANATOMY", 27, 46], ["thymoma line", "ANATOMY", 59, 71], ["cells", "ANATOMY", 80, 85], ["thymoma", "DISEASE", 59, 66], ["C02", "CHEMICAL", 228, 231], ["cell line", "CELL", 0, 9], ["YAC", "CELL", 14, 17], ["H-2a", "CELL", 19, 23], ["natural killer cell", "CELL", 27, 46], ["thymoma line", "CELL", 59, 71], ["cells", "CELL", 80, 85], ["cell line", "CELL_LINE", 0, 9], ["YAC (H-2a", "CELL_LINE", 14, 23], ["natural killer cell-susceptible thymoma line", "CELL_LINE", 27, 71], ["target cells", "CELL_TYPE", 73, 85], ["cell line", "TREATMENT", 0, 9], ["YAC", "TEST", 14, 17], ["a natural killer cell", "TREATMENT", 25, 46], ["susceptible thymoma line", "TREATMENT", 47, 71], ["target cells", "PROBLEM", 73, 85], ["various ratios", "TEST", 89, 103], ["5% C02", "TREATMENT", 225, 231], ["thymoma line", "OBSERVATION", 59, 71], ["round", "OBSERVATION_MODIFIER", 107, 112]]], ["Specific 5`C r-release from target cells was calculated by correcting for spontaneous \"Cr-release ; maximal lysis was determined in wells containing targets treated with 1 N HCl but no effector cells .", [["cells", "ANATOMY", 35, 40], ["cells", "ANATOMY", 194, 199], ["N HCl", "CHEMICAL", 172, 177], ["HCl", "CHEMICAL", 174, 177], ["cells", "CELL", 35, 40], ["1 N HCl", "SIMPLE_CHEMICAL", 170, 177], ["cells", "CELL", 194, 199], ["5`C", "PROTEIN", 9, 12], ["target cells", "CELL_TYPE", 28, 40], ["effector cells", "CELL_TYPE", 185, 199], ["Specific 5`C r-release", "TREATMENT", 0, 22], ["target cells", "PROBLEM", 28, 40], ["spontaneous \"Cr-release", "PROBLEM", 74, 97], ["maximal lysis", "TREATMENT", 100, 113], ["1 N HCl", "TREATMENT", 170, 177], ["effector cells", "PROBLEM", 185, 199], ["no", "UNCERTAINTY", 182, 184], ["effector cells", "OBSERVATION", 185, 199]]], ["Lytic units (LU), a measure of relative cytolytic activity, were determined according to established methods (20, 21) to be the number of lymphocytes necessary to lyse one-third of the standard number of target cells (104 cells/well) during the standard test duration.", [["lymphocytes", "ANATOMY", 138, 149], ["cells", "ANATOMY", 211, 216], ["cells", "ANATOMY", 222, 227], ["LU", "CELL", 13, 15], ["lymphocytes", "CELL", 138, 149], ["cells", "CELL", 211, 216], ["cells", "CELL", 222, 227], ["lymphocytes", "CELL_TYPE", 138, 149], ["target cells", "CELL_TYPE", 204, 216], ["relative cytolytic activity", "PROBLEM", 31, 58], ["the standard test duration", "TEST", 241, 267], ["cytolytic activity", "OBSERVATION", 40, 58]]], ["LU per spleen or liver were computed by dividing the total number of lymphocytes per organ by LU (20, 21) .", [["spleen", "ANATOMY", 7, 13], ["liver", "ANATOMY", 17, 22], ["lymphocytes", "ANATOMY", 69, 80], ["organ", "ANATOMY", 85, 90], ["spleen", "ORGAN", 7, 13], ["liver", "ORGAN", 17, 22], ["lymphocytes", "CELL", 69, 80], ["organ", "ORGAN", 85, 90], ["lymphocytes", "CELL_TYPE", 69, 80], ["spleen", "ANATOMY", 7, 13], ["liver", "ANATOMY", 17, 22], ["total", "OBSERVATION_MODIFIER", 53, 58], ["lymphocytes", "OBSERVATION", 69, 80], ["organ", "ANATOMY", 85, 90]]]], "PMC7166468": [["INTRODUCTIONAcute lower respiratory tract infections (ALRTI) are one of the most common childhood diseases and is a leading cause of morbidity and mortality in children aged <5 years worldwide [Rudan et al., 2008; Walker et al., 2013].", [["lower respiratory tract", "ANATOMY", 18, 41], ["lower respiratory tract infections", "DISEASE", 18, 52], ["ALRTI", "DISEASE", 54, 59], ["children", "ORGANISM", 160, 168], ["children", "SPECIES", 160, 168], ["INTRODUCTIONAcute lower respiratory tract infections", "PROBLEM", 0, 52], ["morbidity", "PROBLEM", 133, 142], ["lower", "ANATOMY_MODIFIER", 18, 23], ["respiratory tract", "ANATOMY", 24, 41], ["infections", "OBSERVATION", 42, 52], ["most common", "OBSERVATION_MODIFIER", 76, 87]]], ["There are 120 million new cases occur per year; 14 million develop into severe disease [Walker et al., 2013].", [["severe disease", "PROBLEM", 72, 86], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["disease", "OBSERVATION", 79, 86]]], ["The World Health Organization (WHO) estimated that globally in 2010, approximately 7.6 million children died and pneumonia caused 1.4 million deaths in children aged <5 years worldwide [Liu et al., 2012].INTRODUCTIONA number of pathogens are capable of causing ALRTI including bacteria, viruses, and fungi.", [["pneumonia", "DISEASE", 113, 122], ["deaths", "DISEASE", 142, 148], ["children", "ORGANISM", 95, 103], ["children", "ORGANISM", 152, 160], ["ALRTI", "GENE_OR_GENE_PRODUCT", 261, 266], ["children", "SPECIES", 95, 103], ["children", "SPECIES", 152, 160], ["pneumonia", "PROBLEM", 113, 122], ["pathogens", "PROBLEM", 228, 237], ["bacteria", "PROBLEM", 277, 285], ["viruses", "PROBLEM", 287, 294], ["fungi", "PROBLEM", 300, 305], ["pneumonia", "OBSERVATION", 113, 122], ["pathogens", "OBSERVATION", 228, 237], ["viruses", "OBSERVATION", 287, 294]]], ["Viruses are the most frequent cause of respiratory infection [Williams et al., 2002].", [["respiratory", "ANATOMY", 39, 50], ["respiratory infection", "DISEASE", 39, 60], ["Viruses", "PROBLEM", 0, 7], ["respiratory infection", "PROBLEM", 39, 60], ["respiratory", "ANATOMY", 39, 50], ["infection", "OBSERVATION", 51, 60]]], ["Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are two common causes of ALRTI; these two viruses are negative sense single\u2010stranded RNA viruses belonging to the pneumovirinae subfamily of the family Paramyxoviridae.", [["Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)", "DISEASE", 0, 66], ["ALRTI", "DISEASE", 92, 97], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["human metapneumovirus", "ORGANISM", 38, 59], ["HMPV", "ORGANISM", 61, 65], ["ALRTI", "GENE_OR_GENE_PRODUCT", 92, 97], ["pneumovirinae", "GENE_OR_GENE_PRODUCT", 181, 194], ["pneumovirinae subfamily", "PROTEIN", 181, 204], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["human", "SPECIES", 38, 43], ["metapneumovirus", "SPECIES", 44, 59], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["human metapneumovirus", "SPECIES", 38, 59], ["HMPV", "SPECIES", 61, 65], ["Respiratory syncytial virus (RSV)", "PROBLEM", 0, 33], ["human metapneumovirus (HMPV", "PROBLEM", 38, 65], ["these two viruses", "PROBLEM", 99, 116], ["syncytial virus", "OBSERVATION", 12, 27], ["metapneumovirus", "OBSERVATION", 44, 59]]], ["RSV belongs to genus pneumovirus and is the leading cause of ALRTI [Rudan et al., 2013]; it is estimated that 68.8% of children aged <1 year and 82.6% of children aged <2 years are infected with RSV [Glezen et al., 1986].", [["RSV belongs to genus pneumovirus", "DISEASE", 0, 32], ["ALRTI", "DISEASE", 61, 66], ["RSV", "DISEASE", 195, 198], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 119, 127], ["children", "ORGANISM", 154, 162], ["RSV", "ORGANISM", 195, 198], ["children", "SPECIES", 119, 127], ["children", "SPECIES", 154, 162], ["RSV", "SPECIES", 0, 3], ["RSV", "SPECIES", 195, 198], ["RSV", "PROBLEM", 0, 3], ["RSV", "PROBLEM", 195, 198], ["genus pneumovirus", "OBSERVATION", 15, 32]]], ["Globally, RSV results in 33.8 million new episodes ALRTI in children aged <5 years and results in at least 3.4 million cases of severe disease [Nair et al., 2010].", [["RSV", "DISEASE", 10, 13], ["ALRTI", "DISEASE", 51, 56], ["RSV", "ORGANISM", 10, 13], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["RSV", "SPECIES", 10, 13], ["severe disease", "PROBLEM", 128, 142], ["RSV", "OBSERVATION", 10, 13], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["disease", "OBSERVATION", 135, 142]]], ["HMPV belongs to the genus metapneumovirus and was first found in 2001, retrospective serological studies have found that HMPV antibodies in humans have existed more than 50 years [van den Hoogen et al., 2001].", [["HMPV belongs to the genus metapneumovirus", "DISEASE", 0, 41], ["HMPV", "ORGANISM", 0, 4], ["metapneumovirus", "ORGANISM", 26, 41], ["HMPV", "ORGANISM", 121, 125], ["humans", "ORGANISM", 140, 146], ["HMPV antibodies", "PROTEIN", 121, 136], ["humans", "SPECIES", 140, 146], ["HMPV", "SPECIES", 0, 4], ["HMPV", "SPECIES", 121, 125], ["humans", "SPECIES", 140, 146], ["HMPV", "PROBLEM", 0, 4], ["the genus metapneumovirus", "PROBLEM", 16, 41], ["retrospective serological studies", "TEST", 71, 104], ["HMPV antibodies in humans", "PROBLEM", 121, 146], ["genus metapneumovirus", "ANATOMY", 20, 41], ["HMPV", "OBSERVATION", 121, 125]]], ["In children aged <5 years, the hospitalization rate associated with HMPV is one per 1,000 children [Edwards et al., 2013].INTRODUCTIONMost previous studies have focused on epidemiological characteristics and the viral genetics of RSV and HMPV.", [["HMPV", "DISEASE", 68, 72], ["children", "ORGANISM", 3, 11], ["children", "ORGANISM", 90, 98], ["RSV", "ORGANISM", 230, 233], ["HMPV", "ORGANISM", 238, 242], ["children", "SPECIES", 3, 11], ["children", "SPECIES", 90, 98], ["HMPV", "SPECIES", 68, 72], ["RSV", "SPECIES", 230, 233], ["HMPV", "SPECIES", 238, 242], ["previous studies", "TEST", 139, 155], ["RSV", "PROBLEM", 230, 233], ["HMPV", "PROBLEM", 238, 242], ["HMPV", "OBSERVATION", 238, 242]]], ["With the development of real\u2010time PCR, it is now possible to clarify the correlation between viral load and clinical characteristics resulting from these viral pathogens.", [["real\u2010time PCR", "TEST", 24, 37], ["viral load", "TEST", 93, 103], ["these viral pathogens", "PROBLEM", 148, 169], ["viral pathogens", "OBSERVATION", 154, 169]]], ["In this study, the correlation between clinical features and viral load of RSV and HMPV in 387 children hospitalized for ALRTI in Lanzhou, China was explored.Study Design and Subjects ::: METHODSFrom December 2011 to November 2012, 387 children hospitalized for ALRTI in the Department of Pediatrics at The First Hospital of Lanzhou University were enrolled.", [["HMPV", "DISEASE", 83, 87], ["ALRTI", "DISEASE", 121, 126], ["ALRTI", "DISEASE", 262, 267], ["RSV", "ORGANISM", 75, 78], ["HMPV", "ORGANISM", 83, 87], ["children", "ORGANISM", 95, 103], ["children", "ORGANISM", 236, 244], ["children", "SPECIES", 95, 103], ["children", "SPECIES", 236, 244], ["RSV", "SPECIES", 75, 78], ["HMPV", "SPECIES", 83, 87], ["this study", "TEST", 3, 13], ["RSV", "PROBLEM", 75, 78], ["HMPV", "PROBLEM", 83, 87], ["viral load", "OBSERVATION", 61, 71]]], ["Children were diagnosed in three groups: bronchitis, pneumonia, and bronchiolitis.", [["bronchitis", "DISEASE", 41, 51], ["pneumonia", "DISEASE", 53, 62], ["bronchiolitis", "DISEASE", 68, 81], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["bronchitis", "PROBLEM", 41, 51], ["pneumonia", "PROBLEM", 53, 62], ["bronchiolitis", "PROBLEM", 68, 81], ["bronchitis", "OBSERVATION", 41, 51], ["pneumonia", "OBSERVATION", 53, 62], ["bronchiolitis", "OBSERVATION", 68, 81]]], ["The diagnostic criteria of pneumonia was based on Defining pneumonia in critically ill infants and children [Langley and Bradley, 2005], and the diagnostic criteria of bronchiolitis was based on diagnosis and management of bronchiolitis [American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis, 2006].", [["pneumonia", "DISEASE", 27, 36], ["pneumonia", "DISEASE", 59, 68], ["critically ill", "DISEASE", 72, 86], ["bronchiolitis", "DISEASE", 168, 181], ["bronchiolitis", "DISEASE", 223, 236], ["Bronchiolitis", "DISEASE", 313, 326], ["infants", "ORGANISM", 87, 94], ["children", "ORGANISM", 99, 107], ["infants", "SPECIES", 87, 94], ["children", "SPECIES", 99, 107], ["pneumonia", "PROBLEM", 27, 36], ["pneumonia", "PROBLEM", 59, 68], ["bronchiolitis", "PROBLEM", 168, 181], ["bronchiolitis", "PROBLEM", 223, 236], ["Bronchiolitis", "PROBLEM", 313, 326], ["pneumonia", "OBSERVATION", 27, 36], ["pneumonia", "OBSERVATION", 59, 68], ["bronchiolitis", "OBSERVATION", 168, 181], ["bronchiolitis", "OBSERVATION", 223, 236], ["Bronchiolitis", "OBSERVATION", 313, 326]]], ["There has no definite and strict diagnostic criteria for bronchitis, the main signs are cough, expectoration.", [["bronchitis", "DISEASE", 57, 67], ["cough", "DISEASE", 88, 93], ["expectoration", "DISEASE", 95, 108], ["bronchitis", "PROBLEM", 57, 67], ["cough", "PROBLEM", 88, 93], ["expectoration", "PROBLEM", 95, 108], ["no definite", "UNCERTAINTY", 10, 21], ["bronchitis", "OBSERVATION", 57, 67], ["main", "OBSERVATION_MODIFIER", 73, 77], ["cough", "OBSERVATION", 88, 93]]], ["Bronchitis is not associated with constitutional symptoms and other signs such as tachypnea, hypoxemia, and so on.", [["Bronchitis", "DISEASE", 0, 10], ["tachypnea", "DISEASE", 82, 91], ["hypoxemia", "DISEASE", 93, 102], ["Bronchitis", "PROBLEM", 0, 10], ["constitutional symptoms", "PROBLEM", 34, 57], ["other signs", "PROBLEM", 62, 73], ["tachypnea", "PROBLEM", 82, 91], ["hypoxemia", "PROBLEM", 93, 102], ["not associated with", "UNCERTAINTY", 14, 33], ["hypoxemia", "OBSERVATION", 93, 102]]], ["Auscultatory findings of bronchitis consist of coarse crackles, medium crackles, and slight wheezes.", [["bronchitis", "DISEASE", 25, 35], ["wheezes", "DISEASE", 92, 99], ["Auscultatory findings", "TEST", 0, 21], ["bronchitis", "PROBLEM", 25, 35], ["coarse crackles", "PROBLEM", 47, 62], ["medium crackles", "PROBLEM", 64, 79], ["slight wheezes", "PROBLEM", 85, 99], ["bronchitis", "OBSERVATION", 25, 35], ["coarse", "OBSERVATION_MODIFIER", 47, 53], ["crackles", "OBSERVATION", 54, 62], ["medium", "OBSERVATION_MODIFIER", 64, 70], ["crackles", "OBSERVATION", 71, 79], ["slight", "OBSERVATION_MODIFIER", 85, 91], ["wheezes", "OBSERVATION", 92, 99]]], ["The definition of disease severity was based on strategy to enhance influenza surveillance worldwide [Ortiz et al., 2009].", [["influenza", "DISEASE", 68, 77], ["disease severity", "PROBLEM", 18, 34], ["disease", "OBSERVATION", 18, 25]]], ["For children >5 years old, all of the following four items must be required: (i) Sudden onset of fever >38\u00b0C, (ii) Cough or sore throat, (iii) Shortness of breath (breathing faster than 25 breaths/min) or difficult breathing, (iv) Requires hospitalization.", [["fever", "DISEASE", 97, 102], ["Cough", "DISEASE", 115, 120], ["sore throat", "DISEASE", 124, 135], ["Shortness of breath", "DISEASE", 143, 162], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["fever", "PROBLEM", 97, 102], ["Cough", "PROBLEM", 115, 120], ["sore throat", "PROBLEM", 124, 135], ["Shortness of breath", "PROBLEM", 143, 162], ["difficult breathing", "PROBLEM", 205, 224], ["sore throat", "ANATOMY", 124, 135]]], ["For children \u22645 years old, with cough or difficult breathing and at least one sign or symptom of follows: (i) Shortness of breath: breathing faster than 60 breaths/min (infants <2 months), breathing faster than 50 breaths/min (2\u201312 months), breathing faster than 40 breaths/min (1\u20135 years), (ii) Unable to drink or breastfeed, (iii) Vomits everything, (iv) Convulsions, (v) Lethargic or unconscious, (vi) Chest indrawing or stridor in a calm child.Study Design and Subjects ::: METHODSNPAs were collected from each patient within 3 days of admission to hospital.", [["cough", "DISEASE", 32, 37], ["Shortness of breath", "DISEASE", 110, 129], ["stridor", "DISEASE", 424, 431], ["children", "ORGANISM", 4, 12], ["patient", "ORGANISM", 515, 522], ["children", "SPECIES", 4, 12], ["infants", "SPECIES", 169, 176], ["patient", "SPECIES", 515, 522], ["cough", "PROBLEM", 32, 37], ["difficult breathing", "PROBLEM", 41, 60], ["Shortness of breath", "PROBLEM", 110, 129], ["Convulsions", "PROBLEM", 357, 368], ["Lethargic", "PROBLEM", 374, 383], ["unconscious", "PROBLEM", 387, 398], ["Chest indrawing", "PROBLEM", 405, 420], ["stridor", "PROBLEM", 424, 431], ["Chest", "ANATOMY", 405, 410], ["stridor", "OBSERVATION", 424, 431]]], ["Two milliliter virus preservation solution (200 U/ml penicillin, 200 U/ml streptomycin, 200 U/ml amphotericin B, and 0.25% BSA) was added to each NPA immediately after collection.", [["penicillin", "CHEMICAL", 53, 63], ["streptomycin", "CHEMICAL", 74, 86], ["amphotericin B", "CHEMICAL", 97, 111], ["BSA", "CHEMICAL", 123, 126], ["penicillin", "CHEMICAL", 53, 63], ["streptomycin", "CHEMICAL", 74, 86], ["amphotericin B", "CHEMICAL", 97, 111], ["NPA", "CHEMICAL", 146, 149], ["penicillin", "SIMPLE_CHEMICAL", 53, 63], ["streptomycin", "SIMPLE_CHEMICAL", 74, 86], ["amphotericin B", "SIMPLE_CHEMICAL", 97, 111], ["BSA", "SIMPLE_CHEMICAL", 123, 126], ["Two milliliter virus preservation solution", "TREATMENT", 0, 42], ["penicillin", "TREATMENT", 53, 63], ["streptomycin", "TREATMENT", 74, 86], ["amphotericin B", "TREATMENT", 97, 111]]], ["All specimens were transported on dry ice to the National Institute for Viral Disease Control and Prevention, China CDC and stored at \u221280\u00b0C. The demographic characteristics and medical history of each child was obtained from their parents or hospital record.", [["specimens", "ANATOMY", 4, 13], ["Viral Disease", "DISEASE", 72, 85], ["Viral Disease Control", "TREATMENT", 72, 93], ["Viral Disease", "OBSERVATION", 72, 85]]], ["The process obtained families informed consent and the study protocol was approved by the hospital ethics committee.Real\u2010time PCR for RSV and HMPV ::: Extraction of Viral Nucleic Acid ::: METHODSReal\u2010time PCR assays targeted the M gene of RSV (84 bp) and the F gene of HMPV (80 bp) [Weinberg et al., 2013].", [["RSV", "ORGANISM", 134, 137], ["HMPV", "ORGANISM", 142, 146], ["RSV", "ORGANISM", 239, 242], ["HMPV", "ORGANISM", 269, 273], ["M gene", "DNA", 229, 235], ["F gene", "DNA", 259, 265], ["RSV", "SPECIES", 134, 137], ["HMPV", "SPECIES", 142, 146], ["RSV", "SPECIES", 239, 242], ["HMPV", "SPECIES", 269, 273], ["the study protocol", "TEST", 51, 69], ["Real\u2010time PCR", "TEST", 116, 129], ["RSV", "PROBLEM", 134, 137], ["Viral Nucleic Acid", "TEST", 165, 183], ["METHODSReal\u2010time PCR assays", "TEST", 188, 215], ["RSV", "TEST", 239, 242], ["bp", "TEST", 247, 249], ["HMPV", "TEST", 269, 273], ["bp", "TEST", 278, 280], ["Viral Nucleic Acid", "OBSERVATION", 165, 183]]], ["The primers and probes used were as follows (all primers and probes are written from 5\u2032 \u2192 3\u2032);, RSV\u2010F: GGC AAA TAT GGA AAC ATA CGT GAA; RSV\u2010R: TCT TTT TCT AGG ACA TTG TAY TGA ACA G; RSV\u2010Pb: FAM\u2010CTG TGT ATG TGG AGC CTT CGT GAA GCT\u2010BHQ.", [["Pb", "CHEMICAL", 186, 188], ["FAM", "CHEMICAL", 190, 193], ["Pb", "CHEMICAL", 186, 188], ["RSV", "ORGANISM", 96, 99], ["RSV", "ORGANISM", 182, 185], ["FAM", "SIMPLE_CHEMICAL", 190, 193], ["RSV\u2010F", "DNA", 96, 101], ["GGC AAA TAT", "DNA", 103, 114], ["FAM\u2010CTG TGT ATG TGG AGC CTT CGT GAA GCT\u2010BHQ", "DNA", 190, 233], ["RSV", "SPECIES", 96, 99], ["RSV", "SPECIES", 136, 139], ["RSV", "SPECIES", 182, 185], ["The primers", "TREATMENT", 0, 11], ["RSV", "TEST", 96, 99], ["GGC", "TEST", 103, 106], ["AAA TAT", "TEST", 107, 114], ["AAC", "TEST", 119, 122], ["RSV", "PROBLEM", 136, 139], ["TCT TTT TCT", "TEST", 143, 154], ["AGG", "TEST", 155, 158], ["ACA", "TEST", 159, 162], ["TTG", "TEST", 163, 166], ["CTG", "TEST", 194, 197], ["TGT", "TEST", 198, 201], ["TGG", "TEST", 206, 209], ["AGC CTT CGT GAA GCT", "TEST", 210, 229], ["BHQ", "TEST", 230, 233]]], ["HMPV\u2010F: CAA GTG TGA CAT TGC TGA YCT RAA; HMPV\u2010R: ACT GCC GCA CAA CAT TTA GRA A; HMPV\u2010Pb: FAM\u2010TGG CYG TYA GCT TCA GTC AAT TCA ACA GA\u2010BHQ.", [["Pb", "CHEMICAL", 85, 87], ["FAM", "CHEMICAL", 89, 92], ["BHQ", "CHEMICAL", 132, 135], ["Pb", "CHEMICAL", 85, 87], ["Pb", "SIMPLE_CHEMICAL", 85, 87], ["FAM", "SIMPLE_CHEMICAL", 89, 92], ["CAT", "PROTEIN", 20, 23], ["CAA GTG", "TEST", 8, 15], ["TGA", "TEST", 16, 19], ["TGC", "TEST", 24, 27], ["TGA", "TEST", 28, 31], ["YCT", "TEST", 32, 35], ["RAA", "TEST", 36, 39], ["HMPV", "TEST", 41, 45], ["\u2010R", "TEST", 45, 47], ["GCC", "TEST", 53, 56], ["FAM", "TEST", 89, 92], ["TGG", "TEST", 93, 96], ["CYG", "TEST", 97, 100], ["TYA", "TEST", 101, 104], ["GCT", "TEST", 105, 108], ["TCA", "TEST", 109, 112], ["GTC", "TEST", 113, 116], ["TCA", "TEST", 121, 124], ["BHQ", "TEST", 132, 135]]], ["A one Step RT\u2010PCT Kit (Applied Biosystems) was used to amplify viral RNA.", [["viral RNA", "RNA", 63, 72], ["A one Step RT\u2010PCT Kit (Applied Biosystems)", "TREATMENT", 0, 42], ["viral RNA", "PROBLEM", 63, 72], ["viral RNA", "OBSERVATION", 63, 72]]], ["Each 20 \u03bcl reaction mixture contained 2 \u00d7 RT\u2010PCR Buffer, 10 \u03bcl; each forward and reverse premier(20 \u03bcM), 0.4 \u03bcl; probe (10 \u03bcM), 0.4\u03bcl; 25 \u00d7 RT\u2010PCR enzyme, 0.8 \u03bcl; template RNA, 4 \u03bcl; ddH2O, 4 \u03bcl.", [["template RNA", "RNA", 163, 175], ["Each 20 \u03bcl reaction mixture", "TREATMENT", 0, 27], ["RT\u2010PCR Buffer", "TREATMENT", 42, 55], ["enzyme", "TEST", 147, 153], ["\u03bcl", "TEST", 159, 161], ["template RNA", "TEST", 163, 175], ["ddH2O", "TEST", 183, 188]]], ["Real\u2010time PCR conditions were 50\u00b0C for 30 min, 95\u00b0C for 10 min, 40 cycles of 95\u00b0C for 15 sec, and 60\u00b0C for 30 sec.", [["Real\u2010time PCR conditions", "TEST", 0, 24]]], ["In order to standardize the quantification of RSV and HMPV, known numbers of RNA transcripts containing the primer targets were used in 10\u2010fold serial dilutions (100 to 107 copies/\u03bcl).", [["RSV", "ORGANISM", 46, 49], ["HMPV", "ORGANISM", 54, 58], ["RNA transcripts", "RNA", 77, 92], ["primer targets", "DNA", 108, 122], ["RSV", "SPECIES", 46, 49], ["HMPV", "SPECIES", 54, 58], ["RSV", "PROBLEM", 46, 49], ["HMPV", "PROBLEM", 54, 58], ["RNA transcripts", "TREATMENT", 77, 92], ["the primer targets", "TREATMENT", 104, 122], ["serial dilutions", "TEST", 144, 160], ["RSV", "OBSERVATION", 46, 49], ["RNA transcripts", "OBSERVATION", 77, 92]]], ["Any amplification detected before cycle 40 cycle was considered to be a positive amplification.", [["Any amplification", "PROBLEM", 0, 17], ["a positive amplification", "PROBLEM", 70, 94]]], ["Quantification of >100 copies/\u03bcl (103 copies/ml) was considered as a positive result.Detection of Other Viruses ::: METHODSThe presence of 12 additional viruses were also tested by real\u2010time PCR; these included human rhinovirus (HRV), enterovirus (EV), adenovirus (ADV), human bocavirus (HBoV), influenza virus A and B (IFVA, IFVB), parainfluenza virus 1\u20134 (PIV1\u20104), and coronaviruses HKU1 and NL63 [Esposito et al., 2006; Kantola et al., 2010; Jansen et al., 2011; McLeish et al., 2012; Weinberg et al., 2013].", [["human rhinovirus (HRV), enterovirus (EV), adenovirus", "DISEASE", 211, 263], ["human", "ORGANISM", 211, 216], ["rhinovirus", "ORGANISM", 217, 227], ["HRV", "ORGANISM", 229, 232], ["enterovirus (EV)", "ORGANISM", 235, 251], ["adenovirus", "ORGANISM", 253, 263], ["ADV", "ORGANISM", 265, 268], ["human bocavirus (HBoV", "ORGANISM", 271, 292], ["influenza virus A", "ORGANISM", 295, 312], ["B", "GENE_OR_GENE_PRODUCT", 317, 318], ["IFVA, IFVB", "ORGANISM", 320, 330], ["parainfluenza virus 1\u20134", "ORGANISM", 333, 356], ["PIV1\u20104", "ORGANISM", 358, 364], ["coronaviruses", "ORGANISM", 371, 384], ["HKU1", "GENE_OR_GENE_PRODUCT", 385, 389], ["human", "SPECIES", 211, 216], ["rhinovirus", "SPECIES", 217, 227], ["human", "SPECIES", 271, 276], ["influenza virus", "SPECIES", 295, 310], ["parainfluenza virus 1\u20134", "SPECIES", 333, 356], ["coronaviruses", "SPECIES", 371, 384], ["human rhinovirus", "SPECIES", 211, 227], ["HRV", "SPECIES", 229, 232], ["EV", "SPECIES", 248, 250], ["adenovirus", "SPECIES", 253, 263], ["ADV", "SPECIES", 265, 268], ["human bocavirus", "SPECIES", 271, 286], ["HBoV", "SPECIES", 288, 292], ["influenza virus A", "SPECIES", 295, 312], ["IFVA", "SPECIES", 320, 324], ["parainfluenza virus 1\u20134", "SPECIES", 333, 356], ["Quantification", "TEST", 0, 14], ["12 additional viruses", "PROBLEM", 139, 160], ["real\u2010time PCR", "TEST", 181, 194], ["human rhinovirus (HRV)", "PROBLEM", 211, 233], ["enterovirus", "PROBLEM", 235, 246], ["adenovirus (ADV)", "TREATMENT", 253, 269], ["human bocavirus (HBoV", "PROBLEM", 271, 292], ["influenza virus A and B (IFVA, IFVB", "TREATMENT", 295, 330], ["parainfluenza virus", "PROBLEM", 333, 352], ["Viruses", "OBSERVATION", 104, 111]]], ["Real\u2010time PCR reagent concentrationss and conditions for the detection of all RNA viruses were the same as for RSV and HMPV.", [["RSV", "ORGANISM", 111, 114], ["HMPV", "ORGANISM", 119, 123], ["RSV", "SPECIES", 111, 114], ["HMPV", "SPECIES", 119, 123], ["Real\u2010time PCR reagent concentrationss", "TEST", 0, 37], ["the detection", "TEST", 57, 70], ["all RNA viruses", "PROBLEM", 74, 89], ["RSV", "PROBLEM", 111, 114], ["HMPV", "PROBLEM", 119, 123], ["HMPV", "OBSERVATION", 119, 123]]], ["Taqman Universal Master Mix II with UNG (Applied Biosystems) were used to detect ADV and HBoV; real\u2010time PCR conditions were 50\u00b0C for 2 min, 95\u00b0C for 10 min, 40 cycles of 95\u00b0C for 15 sec and 60\u00b0C for 30 sec.", [["HBoV", "ORGANISM", 89, 93], ["Taqman Universal Master Mix II", "DNA", 0, 30], ["UNG", "PROTEIN", 36, 39], ["ADV", "SPECIES", 81, 84], ["HBoV", "SPECIES", 89, 93], ["UNG (Applied Biosystems", "TREATMENT", 36, 59], ["ADV", "TEST", 81, 84], ["HBoV", "PROBLEM", 89, 93], ["PCR conditions", "TEST", 105, 119]]], ["The criteria for a positive result were the same as RSV and HMPV.Statistical Analysis ::: METHODSViral load was expressed as the initial copy number per real\u2010time PCR reaction, all quantitative results were transformed as the log10 of viral copy number/ml.", [["RSV", "ORGANISM", 52, 55], ["HMPV", "ORGANISM", 60, 64], ["RSV", "SPECIES", 52, 55], ["HMPV", "SPECIES", 60, 64], ["a positive result", "PROBLEM", 17, 34], ["RSV", "PROBLEM", 52, 55], ["HMPV", "PROBLEM", 60, 64], ["HMPV", "OBSERVATION", 60, 64]]], ["Continuous variables were given as mean values \u00b1 standard deviation (SD) and compared using the Independent\u2010Samples t\u2010test, One\u2010Way ANOVA or Binary logistic.", [["Samples", "ANATOMY", 108, 115], ["mean values", "TEST", 35, 46], ["standard deviation (SD)", "PROBLEM", 49, 72], ["Samples t\u2010test", "TEST", 108, 122]]], ["Categorical variables were described using frequency or percentage, comparisons were made using the chi\u2010squared or Fisher's exact test.", [["Fisher's exact test", "TEST", 115, 134]]], ["Statistical analysis were performed using SPSS17.0 software (Chinese version).", [["Statistical analysis", "TEST", 0, 20], ["SPSS", "TEST", 42, 46]]], ["P < 0.05 was considered to be statistically significant.Patient Characteristics ::: RESULTSDuring the study period, 387 children diagnosed with ALRTI were enrolled.", [["ALRTI", "DISEASE", 144, 149], ["children", "ORGANISM", 120, 128], ["ALRTI", "CANCER", 144, 149], ["Patient", "SPECIES", 56, 63], ["children", "SPECIES", 120, 128], ["the study", "TEST", 98, 107], ["significant", "OBSERVATION", 44, 55]]], ["The majority of children (86.30%) were aged less than 3 years, the median age was 12 months.", [["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The oldest patient was aged 15 years and the youngest was just 8 days.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["The majority (67.7%) of patients were males.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Pneumonia was diagnosed in 189 cases (48.84%), followed by bronchiolitis in 160 cases (41.34%), and bronchitis in 38 cases (9.82%).", [["Pneumonia", "DISEASE", 0, 9], ["bronchiolitis", "DISEASE", 59, 72], ["bronchitis", "DISEASE", 100, 110], ["Pneumonia", "PROBLEM", 0, 9], ["bronchiolitis", "PROBLEM", 59, 72], ["bronchitis", "PROBLEM", 100, 110], ["bronchiolitis", "OBSERVATION", 59, 72], ["bronchitis", "OBSERVATION", 100, 110]]], ["An underlying condition was observed in 19.12% (74/387) cases and 48 children were diagnosed with severe disease.Virus Identification and Epidemiological Characteristics ::: RESULTSAt least one potential viral pathogen was detected in 366 (94.57%) of the study children.", [["children", "ORGANISM", 69, 77], ["children", "ORGANISM", 261, 269], ["children", "SPECIES", 69, 77], ["children", "SPECIES", 261, 269], ["An underlying condition", "PROBLEM", 0, 23], ["severe disease", "PROBLEM", 98, 112], ["Virus Identification", "TEST", 113, 133], ["viral pathogen", "PROBLEM", 204, 218], ["the study", "TEST", 251, 260], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["disease", "OBSERVATION", 105, 112], ["viral", "OBSERVATION_MODIFIER", 204, 209], ["pathogen", "OBSERVATION", 210, 218]]], ["Most virus positive cases were children aged less than 3 years and the detection rate was significantly higher than children older than 3 years old (P = 0.000).", [["children", "ORGANISM", 31, 39], ["children", "ORGANISM", 116, 124], ["children", "SPECIES", 31, 39], ["children", "SPECIES", 116, 124], ["Most virus positive cases", "PROBLEM", 0, 25], ["the detection rate", "TEST", 67, 85]]], ["Two hundred and five children (52.97%) were positive for RSV and 47 children (12.14%) were positive for HMPV.", [["children", "ORGANISM", 21, 29], ["RSV", "ORGANISM", 57, 60], ["children", "ORGANISM", 68, 76], ["HMPV", "ORGANISM", 104, 108], ["children", "SPECIES", 21, 29], ["children", "SPECIES", 68, 76], ["RSV", "SPECIES", 57, 60], ["HMPV", "SPECIES", 104, 108], ["RSV", "PROBLEM", 57, 60], ["HMPV", "PROBLEM", 104, 108], ["HMPV", "OBSERVATION", 104, 108]]], ["Furthermore, 24.55% is positive for HRV, 16.80% for AdV, 14.57% for PIV3, 10.08% for HBoV, 8.27% for NL63, 4.65% for IFVA, 4.65% for IFVB, 3.36% for PIV4, 2.84% for PIV1, 2.58% for EV, 1.55% for PIV2, and 0.26% for HKU1.", [["HBoV", "DISEASE", 85, 89], ["IFVB", "CHEMICAL", 133, 137], ["AdV", "ORGANISM", 52, 55], ["PIV3", "GENE_OR_GENE_PRODUCT", 68, 72], ["HBoV", "ORGANISM", 85, 89], ["HKU1", "GENE_OR_GENE_PRODUCT", 215, 219], ["HKU1", "PROTEIN", 215, 219], ["AdV", "SPECIES", 52, 55], ["HBoV", "SPECIES", 85, 89], ["EV", "SPECIES", 181, 183], ["HRV", "TEST", 36, 39], ["AdV", "TEST", 52, 55], ["PIV3", "TEST", 68, 72], ["HBoV", "TEST", 85, 89], ["NL63", "TEST", 101, 105], ["IFVA", "TEST", 117, 121], ["IFVB", "TEST", 133, 137], ["PIV4", "TEST", 149, 153], ["PIV1", "TEST", 165, 169], ["EV", "TEST", 181, 183], ["PIV2", "TEST", 195, 199], ["HKU1", "TREATMENT", 215, 219]]], ["There was no difference in the detection rate for RSV and HMPV and gender (RSV: 51.53% vs. 56.00%, P = 0.410; HMPV: 12.60% vs. 11.20%, P = 0.694).Virus Identification and Epidemiological Characteristics ::: RESULTSRSV was detected throughout the year, although the detection rate was highest in the winter months (February, November, and January), followed by spring, autumn, and summer (P = 0.000).", [["RSV", "ORGANISM", 50, 53], ["HMPV", "ORGANISM", 58, 62], ["RSV", "SPECIES", 50, 53], ["HMPV", "SPECIES", 58, 62], ["RSV", "SPECIES", 75, 78], ["the detection rate", "TEST", 27, 45], ["RSV", "PROBLEM", 50, 53], ["HMPV", "PROBLEM", 58, 62], ["RSV", "TEST", 75, 78], ["P", "TEST", 99, 100], ["HMPV", "TEST", 110, 114], ["P", "TEST", 135, 136], ["Virus Identification", "TEST", 146, 166], ["RESULTSRSV", "TEST", 207, 217], ["the detection rate", "TEST", 261, 279], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["HMPV was detected every month except for October; the detection rate was highest in June and July, but there was no significant difference between four seasons (P = 0.843; Fig. 1).Virus Identification and Epidemiological Characteristics ::: RESULTSPatients who tested positive for RSV ranged in age from 8 days to 12 years, the median age was 9 months.", [["HMPV", "ORGANISM", 0, 4], ["RSV", "ORGANISM", 281, 284], ["HMPV", "SPECIES", 0, 4], ["RSV", "SPECIES", 281, 284], ["HMPV", "PROBLEM", 0, 4], ["the detection rate", "TEST", 50, 68], ["P", "TEST", 161, 162], ["RSV", "PROBLEM", 281, 284], ["no", "UNCERTAINTY", 113, 115], ["significant", "OBSERVATION_MODIFIER", 116, 127]]], ["The HMPV positive patients ranged in age from 1 month to 5 years, with the median age 12 months.", [["HMPV", "ORGANISM", 4, 8], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["HMPV", "SPECIES", 4, 8]]], ["Patients were devided into 5 age groups (\u22646 m, \u223c12 m, \u223c36 m, \u223c60 m, >60 m).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["We found different distribution in RSV positive patients and HMPV positive ones.", [["RSV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 48, 56], ["HMPV", "ORGANISM", 61, 65], ["patients", "SPECIES", 48, 56], ["RSV", "SPECIES", 35, 38], ["HMPV", "SPECIES", 61, 65], ["RSV positive patients", "PROBLEM", 35, 56], ["HMPV positive ones", "PROBLEM", 61, 79], ["different", "OBSERVATION_MODIFIER", 9, 18], ["distribution", "OBSERVATION_MODIFIER", 19, 31], ["RSV positive patients", "OBSERVATION", 35, 56]]], ["RSV was detected in all age groups although 93.66% (192/205) of positive cases were children aged less than 3 years.", [["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["The highest RSV positive rate was observed in age group under 6 months, followed by age group 7\u201312 months and 13\u201336 months.", [["RSV", "ORGANISM", 12, 15], ["RSV", "SPECIES", 12, 15], ["The highest RSV positive rate", "PROBLEM", 0, 29], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["RSV", "OBSERVATION", 12, 15]]], ["Children aged <6 months were particularly vulnerable (P = 0.000).", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["HMPV was not detected in children older than 5 years.", [["HMPV", "ORGANISM", 0, 4], ["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4]]], ["The highest HMPV rate was detected in age group 3\u20135years old.", [["HMPV", "ORGANISM", 12, 16], ["HMPV", "SPECIES", 12, 16], ["The highest HMPV rate", "TEST", 0, 21], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["HMPV", "OBSERVATION", 12, 16]]], ["(P = 0.045; Fig. 2).Clinical Characteristics of RSV and HMPV Positive Patients ::: RESULTSThe viral detection rate was highest in bronchiolitis patients (98.75%, 158/160), followed by bronchitis (92.11%, 35/38) and pneumonia (91.53%, 173/189) patients; significant differences were observed in viral etiologies associated with each diagnoses (P = 0.010).", [["bronchiolitis", "DISEASE", 130, 143], ["bronchitis", "DISEASE", 184, 194], ["pneumonia", "DISEASE", 215, 224], ["RSV", "ORGANISM", 48, 51], ["HMPV", "ORGANISM", 56, 60], ["Patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 243, 251], ["Patients", "SPECIES", 70, 78], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 243, 251], ["RSV", "SPECIES", 48, 51], ["HMPV", "SPECIES", 56, 60], ["RSV", "PROBLEM", 48, 51], ["RESULTSThe viral detection rate", "TEST", 83, 114], ["bronchiolitis", "PROBLEM", 130, 143], ["bronchitis", "PROBLEM", 184, 194], ["pneumonia", "PROBLEM", 215, 224], ["significant differences", "PROBLEM", 253, 276], ["viral etiologies", "PROBLEM", 294, 310], ["RSV", "OBSERVATION", 48, 51], ["bronchiolitis", "OBSERVATION", 130, 143], ["bronchitis", "OBSERVATION", 184, 194], ["pneumonia", "OBSERVATION", 215, 224]]], ["HRV, ADV, and PIV3 were the most common viruses in children with bronchitis.", [["bronchitis", "DISEASE", 65, 75], ["PIV3", "GENE_OR_GENE_PRODUCT", 14, 18], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["HRV", "SPECIES", 0, 3], ["ADV", "SPECIES", 5, 8], ["HRV", "TEST", 0, 3], ["PIV3", "TREATMENT", 14, 18], ["bronchitis", "PROBLEM", 65, 75], ["bronchitis", "OBSERVATION", 65, 75]]], ["For children with pneumonia, RSV was the most common virus followed by HRV, ADV, PIV3, and HMPV.", [["pneumonia", "DISEASE", 18, 27], ["RSV", "DISEASE", 29, 32], ["children", "ORGANISM", 4, 12], ["RSV", "ORGANISM", 29, 32], ["PIV3", "GENE_OR_GENE_PRODUCT", 81, 85], ["HMPV", "ORGANISM", 91, 95], ["children", "SPECIES", 4, 12], ["RSV", "SPECIES", 29, 32], ["HRV", "SPECIES", 71, 74], ["ADV", "SPECIES", 76, 79], ["HMPV", "SPECIES", 91, 95], ["pneumonia", "PROBLEM", 18, 27], ["RSV", "PROBLEM", 29, 32], ["HRV", "TEST", 71, 74], ["ADV, PIV3", "TREATMENT", 76, 85], ["HMPV", "TREATMENT", 91, 95], ["pneumonia", "OBSERVATION", 18, 27], ["RSV", "OBSERVATION", 29, 32], ["HMPV", "OBSERVATION", 91, 95]]], ["For children with bronchiolitis, the most common virus was RSV, followed by HRV, ADV, HMPV, and HBoV.", [["bronchiolitis", "DISEASE", 18, 31], ["children", "ORGANISM", 4, 12], ["RSV", "ORGANISM", 59, 62], ["HMPV", "ORGANISM", 86, 90], ["HBoV", "ORGANISM", 96, 100], ["children", "SPECIES", 4, 12], ["RSV", "SPECIES", 59, 62], ["HRV", "SPECIES", 76, 79], ["ADV", "SPECIES", 81, 84], ["HMPV", "SPECIES", 86, 90], ["HBoV", "SPECIES", 96, 100], ["bronchiolitis", "PROBLEM", 18, 31], ["RSV", "PROBLEM", 59, 62], ["HRV", "TEST", 76, 79], ["ADV", "TREATMENT", 81, 84], ["HMPV", "TREATMENT", 86, 90], ["HBoV", "PROBLEM", 96, 100], ["bronchiolitis", "OBSERVATION", 18, 31], ["HBoV", "OBSERVATION", 96, 100]]], ["Bronchiolitis was the leading diagnoses in RSV and HMPV positive patients, followed by pneumonia and bronchitis.", [["Bronchiolitis", "DISEASE", 0, 13], ["RSV and HMPV positive", "DISEASE", 43, 64], ["pneumonia", "DISEASE", 87, 96], ["bronchitis", "DISEASE", 101, 111], ["RSV", "ORGANISM", 43, 46], ["HMPV", "ORGANISM", 51, 55], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["RSV", "SPECIES", 43, 46], ["HMPV", "SPECIES", 51, 55], ["Bronchiolitis", "PROBLEM", 0, 13], ["RSV", "PROBLEM", 43, 46], ["HMPV positive patients", "PROBLEM", 51, 73], ["pneumonia", "PROBLEM", 87, 96], ["bronchitis", "PROBLEM", 101, 111], ["RSV", "ANATOMY", 43, 46], ["HMPV positive", "OBSERVATION", 51, 64], ["pneumonia", "OBSERVATION", 87, 96], ["bronchitis", "OBSERVATION", 101, 111]]], ["Patients were divided into two groups: those with RSV or HMPV infection and those without RSV or HMPV infection (Table I).", [["HMPV infection", "DISEASE", 57, 71], ["HMPV infection", "DISEASE", 97, 111], ["Patients", "ORGANISM", 0, 8], ["RSV", "ORGANISM", 50, 53], ["HMPV", "ORGANISM", 57, 61], ["RSV", "ORGANISM", 90, 93], ["HMPV", "ORGANISM", 97, 101], ["Patients", "SPECIES", 0, 8], ["RSV", "SPECIES", 50, 53], ["HMPV", "SPECIES", 57, 61], ["RSV", "SPECIES", 90, 93], ["HMPV", "SPECIES", 97, 101], ["RSV", "PROBLEM", 50, 53], ["HMPV infection", "PROBLEM", 57, 71], ["RSV", "PROBLEM", 90, 93], ["HMPV infection", "PROBLEM", 97, 111], ["RSV", "OBSERVATION", 50, 53], ["HMPV infection", "OBSERVATION", 57, 71], ["without", "UNCERTAINTY", 82, 89], ["HMPV", "OBSERVATION", 97, 101]]], ["For RSV and HMPV positive patients, the most common symptoms were cough, wheezing, and fever.", [["RSV and HMPV positive", "DISEASE", 4, 25], ["cough", "DISEASE", 66, 71], ["wheezing", "DISEASE", 73, 81], ["fever", "DISEASE", 87, 92], ["RSV", "ORGANISM", 4, 7], ["HMPV", "ORGANISM", 12, 16], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["RSV", "SPECIES", 4, 7], ["HMPV", "SPECIES", 12, 16], ["RSV", "PROBLEM", 4, 7], ["HMPV positive patients", "PROBLEM", 12, 34], ["the most common symptoms", "PROBLEM", 36, 60], ["cough", "PROBLEM", 66, 71], ["wheezing", "PROBLEM", 73, 81], ["fever", "PROBLEM", 87, 92], ["cough", "OBSERVATION", 66, 71], ["wheezing", "OBSERVATION", 73, 81], ["fever", "OBSERVATION", 87, 92]]], ["A high frequency of wheezing (52% vs. 33.52%, P = 0.000) was noted as significant in RSV positive patients in comparison with RSV negative patients.", [["wheezing", "DISEASE", 20, 28], ["RSV", "ORGANISM", 85, 88], ["patients", "ORGANISM", 98, 106], ["RSV", "ORGANISM", 126, 129], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 139, 147], ["RSV", "SPECIES", 85, 88], ["RSV", "SPECIES", 126, 129], ["wheezing", "PROBLEM", 20, 28], ["P", "TEST", 46, 47], ["high", "OBSERVATION_MODIFIER", 2, 6], ["significant", "OBSERVATION_MODIFIER", 70, 81]]], ["However there was no significant difference with respect to clinical features between HMPV positive and HMPV negative patients.Viral Load and Clinical Features ::: RESULTSAmong the 205 RSV positive samples, the log copies of RSV\u2010RNA per ml ranged from 3.03 to 11.32; the median viral load value was 8.07, the mean viral load (mean \u00b1 SD) was 7.40 \u00b1 2.02.", [["samples", "ANATOMY", 198, 205], ["HMPV", "ORGANISM", 86, 90], ["HMPV", "ORGANISM", 104, 108], ["patients", "ORGANISM", 118, 126], ["RSV", "ORGANISM", 185, 188], ["samples", "CANCER", 198, 205], ["RSV", "ORGANISM", 225, 228], ["RSV\u2010RNA", "RNA", 225, 232], ["patients", "SPECIES", 118, 126], ["HMPV", "SPECIES", 86, 90], ["HMPV", "SPECIES", 104, 108], ["RSV", "SPECIES", 185, 188], ["RSV", "SPECIES", 225, 228], ["significant difference", "PROBLEM", 21, 43], ["HMPV", "TEST", 86, 90], ["HMPV", "TEST", 104, 108], ["Viral Load", "TEST", 127, 137], ["RSV", "TEST", 225, 228], ["RNA", "TEST", 229, 232], ["the median viral load value", "TEST", 267, 294], ["the mean viral load", "TEST", 305, 324], ["no", "UNCERTAINTY", 18, 20], ["significant", "OBSERVATION_MODIFIER", 21, 32]]], ["For the 47 children that were HMPV positive, the log copies of HMPV\u2010RNA per ml ranged from 3.10 to 9.24, with the median viral load of 7.24 and the mean viral load of 6.36 \u00b1 2.13.Viral Load and Clinical Features ::: RESULTSThe relationship between viral load and clinical characteristics including age, gender, respiratory rate, temperature, wheezing, cyanosis, diagnosis, hospitalization, days of illness, white blood cells (WBC), and C reactive protein (CRP) were evaluated (Table II).", [["respiratory", "ANATOMY", 311, 322], ["white blood cells", "ANATOMY", 407, 424], ["WBC", "ANATOMY", 426, 429], ["wheezing", "DISEASE", 342, 350], ["cyanosis", "DISEASE", 352, 360], ["children", "ORGANISM", 11, 19], ["HMPV", "ORGANISM", 30, 34], ["HMPV", "ORGANISM", 63, 67], ["white blood cells", "CELL", 407, 424], ["WBC", "CELL", 426, 429], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 436, 454], ["CRP", "GENE_OR_GENE_PRODUCT", 456, 459], ["HMPV\u2010RNA", "RNA", 63, 71], ["white blood cells", "CELL_TYPE", 407, 424], ["WBC", "CELL_TYPE", 426, 429], ["C reactive protein", "PROTEIN", 436, 454], ["CRP", "PROTEIN", 456, 459], ["children", "SPECIES", 11, 19], ["HMPV", "SPECIES", 30, 34], ["HMPV", "SPECIES", 63, 67], ["HMPV", "TEST", 30, 34], ["HMPV", "TEST", 63, 67], ["the median viral load", "TEST", 110, 131], ["the mean viral load", "TEST", 144, 163], ["Viral Load", "TEST", 179, 189], ["viral load", "TEST", 248, 258], ["respiratory rate", "TEST", 311, 327], ["wheezing", "PROBLEM", 342, 350], ["cyanosis", "PROBLEM", 352, 360], ["illness", "PROBLEM", 398, 405], ["white blood cells", "TEST", 407, 424], ["WBC", "TEST", 426, 429], ["C reactive protein (", "PROBLEM", 436, 456], ["CRP", "TEST", 456, 459], ["viral load", "OBSERVATION", 248, 258], ["reactive protein", "OBSERVATION", 438, 454]]], ["For RSV, the viral load was significantly higher among children aged <1 year.", [["RSV", "ORGANISM", 4, 7], ["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["RSV", "SPECIES", 4, 7], ["RSV", "PROBLEM", 4, 7], ["the viral load", "TEST", 9, 23], ["viral load", "OBSERVATION", 13, 23]]], ["Without fever and wheezing were associated with a significantly higher RSV viral load.", [["fever", "DISEASE", 8, 13], ["wheezing", "DISEASE", 18, 26], ["RSV", "ORGANISM", 71, 74], ["RSV", "SPECIES", 71, 74], ["fever", "PROBLEM", 8, 13], ["wheezing", "PROBLEM", 18, 26], ["a significantly higher RSV viral load", "PROBLEM", 48, 85], ["fever", "OBSERVATION", 8, 13], ["wheezing", "OBSERVATION", 18, 26], ["RSV viral load", "OBSERVATION", 71, 85]]], ["The RSV viral load was significantly different between three diagnostic groups; children with bronchiolitis had higher RSV viral loads than those with pneumonia, however most other clinical characteristics had no significant correlation with the RSV load.", [["bronchiolitis", "DISEASE", 94, 107], ["pneumonia", "DISEASE", 151, 160], ["RSV", "ORGANISM", 4, 7], ["children", "ORGANISM", 80, 88], ["RSV", "ORGANISM", 119, 122], ["RSV", "ORGANISM", 246, 249], ["children", "SPECIES", 80, 88], ["RSV", "SPECIES", 4, 7], ["RSV", "SPECIES", 119, 122], ["RSV", "SPECIES", 246, 249], ["The RSV viral load", "TEST", 0, 18], ["bronchiolitis", "PROBLEM", 94, 107], ["higher RSV viral loads", "PROBLEM", 112, 134], ["pneumonia", "PROBLEM", 151, 160], ["the RSV load", "PROBLEM", 242, 254], ["RSV", "OBSERVATION", 4, 7], ["viral load", "OBSERVATION", 8, 18], ["bronchiolitis", "OBSERVATION", 94, 107], ["RSV viral loads", "OBSERVATION", 119, 134], ["pneumonia", "OBSERVATION", 151, 160], ["RSV load", "OBSERVATION", 246, 254]]], ["There was no correlation between HMPV viral load and any clinical characteristic (Table II and Fig. 3).", [["HMPV", "ORGANISM", 33, 37], ["HMPV", "SPECIES", 33, 37], ["HMPV viral load", "TEST", 33, 48], ["no", "UNCERTAINTY", 10, 12]]], ["Thirty of 205 RSV positive children and 9 of 47 HMPV positive children had an underlying chronic illness; there was no significant difference between children with or without underlying illness and viral load (RSV: P = 0.070; HMPV: P = 0.634).Viral Load and Clinical Features ::: RESULTSCorrelation between viral load and severity of disease was also estimated.", [["chronic illness", "DISEASE", 89, 104], ["RSV", "ORGANISM", 14, 17], ["children", "ORGANISM", 27, 35], ["HMPV", "ORGANISM", 48, 52], ["children", "ORGANISM", 62, 70], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 62, 70], ["children", "SPECIES", 150, 158], ["RSV", "SPECIES", 14, 17], ["HMPV", "SPECIES", 48, 52], ["RSV", "SPECIES", 210, 213], ["an underlying chronic illness", "PROBLEM", 75, 104], ["underlying illness", "PROBLEM", 175, 193], ["viral load", "PROBLEM", 198, 208], ["HMPV", "TEST", 226, 230], ["Viral Load", "TEST", 243, 253], ["viral load", "TEST", 307, 317], ["disease", "PROBLEM", 334, 341], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["illness", "OBSERVATION", 97, 104], ["no", "UNCERTAINTY", 116, 118], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["viral load", "OBSERVATION", 307, 317], ["disease", "OBSERVATION", 334, 341]]], ["To refer to previously publications, we consider age, sex, and underlying diseases may be the confounding factors of the disease severity and viral load.", [["underlying diseases", "PROBLEM", 63, 82], ["the disease severity", "PROBLEM", 117, 137], ["viral load", "PROBLEM", 142, 152], ["diseases", "OBSERVATION", 74, 82], ["viral load", "OBSERVATION", 142, 152]]], ["We conducted a Binary logistic to analyze the association between disease severity and viral load.", [["disease severity", "PROBLEM", 66, 82], ["viral load", "PROBLEM", 87, 97], ["viral load", "OBSERVATION", 87, 97]]], ["For RSV and HMPV, there has no statistical significance between severity and viral load when excluding these three factors (P = 0.166 and 0.721).Co\u2010Infection With Other Viruses ::: RESULTSOf the 205 RSV positive specimens, at least one additional virus was detected in 117 (57.07%); the most common viruses observed in co\u2010infections with RSV were HRV (n = 37), AdV (n = 26), HMPV (n = 20) and PIV3 (n = 19).", [["specimens", "ANATOMY", 212, 221], ["Co\u2010Infection", "DISEASE", 145, 157], ["co\u2010infections", "DISEASE", 319, 332], ["RSV", "DISEASE", 338, 341], ["RSV", "ORGANISM", 4, 7], ["HMPV", "ORGANISM", 12, 16], ["RSV", "ORGANISM", 199, 202], ["RSV", "ORGANISM", 338, 341], ["AdV", "ORGANISM", 361, 364], ["HMPV", "ORGANISM", 375, 379], ["RSV", "SPECIES", 4, 7], ["HMPV", "SPECIES", 12, 16], ["RSV", "SPECIES", 199, 202], ["RSV", "SPECIES", 338, 341], ["HRV", "SPECIES", 347, 350], ["AdV", "SPECIES", 361, 364], ["HMPV", "SPECIES", 375, 379], ["RSV", "PROBLEM", 4, 7], ["HMPV", "PROBLEM", 12, 16], ["statistical significance between severity and viral load", "PROBLEM", 31, 87], ["P", "TEST", 124, 125], ["additional virus", "PROBLEM", 236, 252], ["the most common viruses", "PROBLEM", 283, 306], ["RSV", "PROBLEM", 338, 341], ["HRV", "TEST", 347, 350], ["AdV", "TEST", 361, 364], ["HMPV", "TEST", 375, 379], ["PIV3", "TEST", 393, 397], ["HMPV", "OBSERVATION", 12, 16], ["no", "UNCERTAINTY", 28, 30], ["viral load", "OBSERVATION", 77, 87], ["most common", "OBSERVATION_MODIFIER", 287, 298], ["viruses", "OBSERVATION", 299, 306]]], ["For HMPV, the co\u2010infection rate was even higher (77.47%; 35/47); the most common viruses associated with HMPV detection were RSV (n = 20), AdV (n = 13), HRV (n = 10), and HBoV (n = 7).", [["HBoV", "DISEASE", 171, 175], ["HMPV", "ORGANISM", 4, 8], ["HMPV", "ORGANISM", 105, 109], ["RSV", "ORGANISM", 125, 128], ["AdV", "ORGANISM", 139, 142], ["HBoV", "ORGANISM", 171, 175], ["HMPV", "SPECIES", 4, 8], ["HMPV", "SPECIES", 105, 109], ["RSV", "SPECIES", 125, 128], ["AdV", "SPECIES", 139, 142], ["HRV", "SPECIES", 153, 156], ["HBoV", "SPECIES", 171, 175], ["HMPV", "PROBLEM", 4, 8], ["the co\u2010infection rate", "TEST", 10, 31], ["the most common viruses", "PROBLEM", 65, 88], ["HMPV detection", "TEST", 105, 119], ["RSV", "TEST", 125, 128], ["AdV (n", "TEST", 139, 145], ["HRV", "TEST", 153, 156], ["HBoV", "TEST", 171, 175]]], ["Children positive for RSV alone had a higher viral load than children who were co\u2010infected with other viruses (mean \u00b1 SD: 8.18 \u00b11.35 vs. 6.81 \u00b12.23, P = 0.000).", [["Children", "ORGANISM", 0, 8], ["RSV", "ORGANISM", 22, 25], ["children", "ORGANISM", 61, 69], ["Children", "SPECIES", 0, 8], ["children", "SPECIES", 61, 69], ["RSV", "SPECIES", 22, 25], ["RSV", "PROBLEM", 22, 25], ["P", "TEST", 149, 150], ["RSV", "OBSERVATION", 22, 25]]], ["However, the viral load was not significantly different between HMPV alone and HMPV associated with other viruses (mean \u00b1 SD: 6.75 \u00b11.99 vs. 6.22 \u00b12.18, P = 0.465) (Fig. 4).", [["HMPV", "ORGANISM", 64, 68], ["HMPV", "ORGANISM", 79, 83], ["HMPV", "SPECIES", 64, 68], ["HMPV", "SPECIES", 79, 83], ["the viral load", "TEST", 9, 23], ["HMPV", "PROBLEM", 64, 68], ["HMPV", "PROBLEM", 79, 83], ["other viruses", "PROBLEM", 100, 113], ["SD", "TEST", 122, 124], ["P", "TEST", 153, 154], ["viral load", "OBSERVATION", 13, 23]]], ["The severe lower respiratory tract infection rates were 17.05% (15/88) in RSV single infections and 11.11% (13/117) in RSV associated with other viruses.", [["lower respiratory tract", "ANATOMY", 11, 34], ["lower respiratory tract infection", "DISEASE", 11, 44], ["RSV single infections", "DISEASE", 74, 95], ["RSV", "DISEASE", 119, 122], ["lower respiratory", "ORGANISM_SUBDIVISION", 11, 28], ["tract", "ORGANISM_SUBDIVISION", 29, 34], ["RSV", "ORGANISM", 74, 77], ["RSV", "ORGANISM", 119, 122], ["RSV", "SPECIES", 74, 77], ["RSV", "SPECIES", 119, 122], ["The severe lower respiratory tract infection rates", "PROBLEM", 0, 50], ["RSV single infections", "PROBLEM", 74, 95], ["RSV", "PROBLEM", 119, 122], ["other viruses", "PROBLEM", 139, 152], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["lower", "ANATOMY_MODIFIER", 11, 16], ["respiratory tract", "ANATOMY", 17, 34], ["infection", "OBSERVATION", 35, 44], ["infections", "OBSERVATION", 85, 95], ["viruses", "OBSERVATION", 145, 152]]], ["The incidence of severe disease was not significantly different between these two groups (P = 0.221); the same result was observed with HMPV (8.33% vs. 11.43%, P = 0.764).DISCUSSIONIn this study, real\u2010time PCR was used to explore the disease etiology and examine correlation between viral load and clinical features of pediatric RSV and HMPV infections in Lanzhou, China.", [["HMPV", "DISEASE", 136, 140], ["RSV", "DISEASE", 329, 332], ["HMPV infections", "DISEASE", 337, 352], ["RSV", "ORGANISM", 329, 332], ["HMPV", "ORGANISM", 337, 341], ["HMPV", "SPECIES", 136, 140], ["RSV", "SPECIES", 329, 332], ["HMPV", "SPECIES", 337, 341], ["severe disease", "PROBLEM", 17, 31], ["P", "TEST", 90, 91], ["HMPV", "TEST", 136, 140], ["P", "TEST", 160, 161], ["this study", "TEST", 184, 194], ["real\u2010time PCR", "TEST", 196, 209], ["the disease etiology", "PROBLEM", 230, 250], ["viral load", "TEST", 283, 293], ["pediatric RSV", "PROBLEM", 319, 332], ["HMPV infections", "PROBLEM", 337, 352], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["disease", "OBSERVATION", 24, 31], ["significantly different", "OBSERVATION_MODIFIER", 40, 63], ["pediatric RSV", "OBSERVATION", 319, 332], ["HMPV infections", "OBSERVATION", 337, 352]]], ["This study found that 94.57% patient samples had at least one detectable potential viral pathogen; this detection rate was significantly higher than previous studies (48.1\u201390%) that used traditional PCR or direct immunofluorescence [Singleton et al., 2010; Ahmed et al., 2012; Bicer et al., 2013; Bukhari and Elhazmi 2013] and was higher than a German study that used real\u2010time PCR (detecting 14 viruses with a result of 78% positive) [Franz et al., 2010].", [["samples", "ANATOMY", 37, 44], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["This study", "TEST", 0, 10], ["potential viral pathogen", "PROBLEM", 73, 97], ["this detection rate", "TEST", 99, 118], ["previous studies", "TEST", 149, 165], ["traditional PCR", "TEST", 187, 202], ["direct immunofluorescence", "TEST", 206, 231], ["a German study", "TEST", 343, 357], ["real\u2010time PCR", "TEST", 368, 381], ["viral pathogen", "OBSERVATION", 83, 97]]], ["It is possible that the detection rate in this study could be due to the increased sensitivity of real\u2010time PCR compared to conventional PCR and viral culture methods.", [["the detection rate", "TEST", 20, 38], ["this study", "TEST", 42, 52], ["the increased sensitivity of real\u2010time PCR", "PROBLEM", 69, 111], ["conventional PCR", "TEST", 124, 140], ["viral culture methods", "TEST", 145, 166]]], ["This study also detected 14 different viruses, the viral pathogen spectrum was more comprehensive than many previous studies (7\u201312 viruses) [Singleton et al., 2010; Ahmed et al., 2012; Bicer et al., 2013; Bukhari and Elhazmi, 2013].", [["This study", "TEST", 0, 10], ["14 different viruses", "PROBLEM", 25, 45], ["the viral pathogen spectrum", "TEST", 47, 74], ["many previous studies", "TEST", 103, 124], ["14 different", "OBSERVATION_MODIFIER", 25, 37], ["viruses", "OBSERVATION", 38, 45]]], ["Additionally patients in this study all were diagnosed with ALRTI, and in many instances, the patients were suffering from severe disease.", [["ALRTI", "DISEASE", 60, 65], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 94, 102], ["this study", "TEST", 25, 35], ["severe disease", "PROBLEM", 123, 137], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 130, 137]]], ["Meerhoff et al. [2010] indicated that using NPA resulted in a higher detection rate than using a nasal swab as a sample, it is possible that the use of NPA might also be associated with the higher rate of detection seen in this study.", [["nasal swab", "ANATOMY", 97, 107], ["NPA", "CHEMICAL", 44, 47], ["NPA", "CHEMICAL", 152, 155], ["NPA", "CHEMICAL", 44, 47], ["NPA", "CHEMICAL", 152, 155], ["NPA", "SIMPLE_CHEMICAL", 44, 47], ["NPA", "SIMPLE_CHEMICAL", 152, 155], ["NPA", "TREATMENT", 44, 47], ["a nasal swab", "TREATMENT", 95, 107], ["NPA", "TREATMENT", 152, 155], ["this study", "TEST", 223, 233]]], ["Finally, other factors such as race and geographical conditions may have some influence on the viral burden in the population, and thus the detection rate.DISCUSSIONRSV was detected in 52.79% of the children and it was the most common virus among the 14 viruses detected as part of this study.", [["children", "ORGANISM", 199, 207], ["children", "SPECIES", 199, 207], ["race and geographical conditions", "PROBLEM", 31, 63], ["the viral burden", "PROBLEM", 91, 107], ["the detection rate", "TEST", 136, 154], ["this study", "TEST", 282, 292]]], ["The detection rate was similar to that reported by Franz et al. [2010] who also used a real\u2010time PCR approach.", [["The detection rate", "TEST", 0, 18], ["a real\u2010time PCR approach", "TREATMENT", 85, 109]]], ["Only 12.14% of children were found HMPV positive, although this detection rate was higher than other studies that used the same detection method such as in Italy (2.9%), Germany (less than 9%), and the United States (9%) [Bosis et al., 2008; Martin et al., 2008; Franz et al., 2010].", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["HMPV", "SPECIES", 35, 39], ["HMPV positive", "PROBLEM", 35, 48], ["this detection rate", "TEST", 59, 78], ["other studies", "TEST", 95, 108], ["HMPV", "OBSERVATION", 35, 39]]], ["Similar to other studies [Franz et al., 2010; Singleton et al., 2010; Bicer et al., 2013; Bukhari and Elhazmi, 2013], RSV was the most common virus in children with ALRTI [Franz et al., 2010; Singleton et al., 2010; Bicer et al., 2013; Bukhari and Elhazmi, 2013].", [["ALRTI", "DISEASE", 165, 170], ["RSV", "ORGANISM", 118, 121], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["RSV", "SPECIES", 118, 121], ["other studies", "TEST", 11, 24], ["RSV", "PROBLEM", 118, 121]]], ["RSV and HMPV were associated with more severe illness [Singleton et al., 2010].", [["illness", "DISEASE", 46, 53], ["RSV", "ORGANISM", 0, 3], ["HMPV", "ORGANISM", 8, 12], ["RSV", "SPECIES", 0, 3], ["HMPV", "SPECIES", 8, 12], ["RSV", "PROBLEM", 0, 3], ["HMPV", "PROBLEM", 8, 12], ["more severe illness", "PROBLEM", 34, 53], ["HMPV", "OBSERVATION", 8, 12]]], ["It is apparent that RSV and HMPV play an important role in children with ALRTI in different regions globally.DISCUSSIONMany respiratory viruses have significant seasonality.", [["ALRTI", "DISEASE", 73, 78], ["RSV", "ORGANISM", 20, 23], ["HMPV", "ORGANISM", 28, 32], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["RSV", "SPECIES", 20, 23], ["HMPV", "SPECIES", 28, 32], ["RSV", "PROBLEM", 20, 23], ["respiratory viruses", "PROBLEM", 124, 143], ["RSV", "OBSERVATION", 20, 23], ["HMPV", "OBSERVATION", 28, 32], ["respiratory", "ANATOMY", 124, 135], ["viruses", "OBSERVATION", 136, 143], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["seasonality", "OBSERVATION", 161, 172]]], ["Previous studies have demonstrated that cold exposure may increase the possibility of bronchoconstriction, airway congestion, secretion, and decrease innate immune mechanisms such as mucocialiary clearance [Giesbrecht, 1995].", [["airway", "ANATOMY", 107, 113], ["mucocialiary", "ANATOMY", 183, 195], ["airway", "MULTI-TISSUE_STRUCTURE", 107, 113], ["Previous studies", "TEST", 0, 16], ["cold exposure", "PROBLEM", 40, 53], ["bronchoconstriction", "PROBLEM", 86, 105], ["airway congestion", "PROBLEM", 107, 124], ["secretion", "PROBLEM", 126, 135], ["decrease innate immune mechanisms", "PROBLEM", 141, 174], ["possibility of", "UNCERTAINTY", 71, 85], ["bronchoconstriction", "OBSERVATION", 86, 105], ["airway", "ANATOMY", 107, 113], ["congestion", "OBSERVATION", 114, 124]]], ["This indicates that cold seasons may increase the risk of respiratory infections.", [["respiratory", "ANATOMY", 58, 69], ["respiratory infections", "DISEASE", 58, 80], ["cold seasons", "PROBLEM", 20, 32], ["respiratory infections", "PROBLEM", 58, 80], ["respiratory", "ANATOMY", 58, 69], ["infections", "OBSERVATION", 70, 80]]], ["In this study, RSV showed a clear seasonal distribution in winter\u2010spring.", [["RSV", "ORGANISM", 15, 18], ["RSV", "SPECIES", 15, 18], ["this study", "TEST", 3, 13], ["RSV", "PROBLEM", 15, 18], ["clear", "OBSERVATION_MODIFIER", 28, 33], ["seasonal distribution", "OBSERVATION", 34, 55]]], ["In contrast, the maximum prevalence was observed in March to August in Singapore and Brazil, but in September to November in Malaysia which also located in tropical zone [Chew et al., 1998; Pecchini et al., 2008; Khor et al., 2012].", [["tropical", "ANATOMY_MODIFIER", 156, 164], ["zone", "ANATOMY_MODIFIER", 165, 169]]], ["There was no significant seasonality of HMPV observed in this study, but in studies performed in Korea and Turkey, the peak season was winter\u2010spring [Kim et al., 2010; Bicer et al., 2013].", [["HMPV", "ORGANISM", 40, 44], ["HMPV", "SPECIES", 40, 44], ["HMPV", "PROBLEM", 40, 44], ["this study", "TEST", 57, 67], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["seasonality", "OBSERVATION_MODIFIER", 25, 36], ["HMPV", "OBSERVATION", 40, 44]]], ["These observations suggest that not all respiratory virus infection is common in cold seasons.", [["respiratory virus infection", "DISEASE", 40, 67], ["respiratory virus", "ORGANISM", 40, 57], ["all respiratory virus infection", "PROBLEM", 36, 67], ["respiratory virus", "OBSERVATION", 40, 57]]], ["The seasonality of viruses was different in different regions; this may correlate with local geographical and climatic features.DISCUSSIONPathogens associated with respiratory tract infections can be very complex and there is no specific symptom to distinguish one infection from another.", [["respiratory tract", "ANATOMY", 164, 181], ["respiratory tract infections", "DISEASE", 164, 192], ["infection", "DISEASE", 265, 274], ["tract", "ORGANISM_SUBDIVISION", 176, 181], ["viruses", "PROBLEM", 19, 26], ["local geographical and climatic features", "PROBLEM", 87, 127], ["respiratory tract infections", "PROBLEM", 164, 192], ["specific symptom", "PROBLEM", 229, 245], ["one infection", "PROBLEM", 261, 274], ["seasonality", "OBSERVATION_MODIFIER", 4, 15], ["viruses", "OBSERVATION", 19, 26], ["different", "OBSERVATION_MODIFIER", 31, 40], ["may correlate with", "UNCERTAINTY", 68, 86], ["local", "OBSERVATION_MODIFIER", 87, 92], ["geographical", "OBSERVATION_MODIFIER", 93, 105], ["climatic features", "OBSERVATION", 110, 127], ["respiratory tract", "ANATOMY", 164, 181], ["no", "UNCERTAINTY", 226, 228], ["infection", "OBSERVATION", 265, 274]]], ["Research about the viral etiology of bronchiolitis among children in northern Taiwan indicated that RSV and HMPV were the main virus for children with bronchiolitis, with RSV observed as the most common cause [Chen et al., 2012].", [["bronchiolitis", "DISEASE", 37, 50], ["bronchiolitis", "DISEASE", 151, 164], ["RSV", "DISEASE", 171, 174], ["children", "ORGANISM", 57, 65], ["RSV", "ORGANISM", 100, 103], ["HMPV", "ORGANISM", 108, 112], ["children", "ORGANISM", 137, 145], ["RSV", "ORGANISM", 171, 174], ["children", "SPECIES", 57, 65], ["children", "SPECIES", 137, 145], ["RSV", "SPECIES", 100, 103], ["HMPV", "SPECIES", 108, 112], ["RSV", "SPECIES", 171, 174], ["bronchiolitis", "PROBLEM", 37, 50], ["RSV", "PROBLEM", 100, 103], ["HMPV", "PROBLEM", 108, 112], ["bronchiolitis", "PROBLEM", 151, 164], ["RSV", "PROBLEM", 171, 174], ["bronchiolitis", "OBSERVATION", 37, 50], ["RSV", "OBSERVATION", 100, 103], ["bronchiolitis", "OBSERVATION", 151, 164]]], ["In this study, bronchiolitis patients were most likely to result in the identification of a potential viral pathogen among the three diagnoses; bronchiolitis was most often associated with RSV and HMPV positive patients.", [["bronchiolitis", "DISEASE", 15, 28], ["bronchiolitis", "DISEASE", 144, 157], ["patients", "ORGANISM", 29, 37], ["RSV", "ORGANISM", 189, 192], ["HMPV", "ORGANISM", 197, 201], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 211, 219], ["RSV", "SPECIES", 189, 192], ["HMPV", "SPECIES", 197, 201], ["this study", "TEST", 3, 13], ["bronchiolitis", "PROBLEM", 15, 28], ["a potential viral pathogen", "PROBLEM", 90, 116], ["bronchiolitis", "PROBLEM", 144, 157], ["RSV", "PROBLEM", 189, 192], ["HMPV positive patients", "PROBLEM", 197, 219], ["bronchiolitis", "OBSERVATION", 15, 28], ["most likely", "UNCERTAINTY", 43, 54], ["viral", "OBSERVATION_MODIFIER", 102, 107], ["pathogen", "OBSERVATION", 108, 116], ["bronchiolitis", "OBSERVATION", 144, 157]]], ["The main symptoms in RSV and HMPV positive patients were cough, wheezing, and fever.DISCUSSIONScagnolari et al. [2012] indicated that RSV viral load was positively associated with the clinical severity of bronchiolitis hospitalization.", [["RSV and HMPV positive", "DISEASE", 21, 42], ["cough", "DISEASE", 57, 62], ["wheezing", "DISEASE", 64, 72], ["fever", "DISEASE", 78, 83], ["bronchiolitis", "DISEASE", 205, 218], ["RSV", "ORGANISM", 21, 24], ["HMPV", "ORGANISM", 29, 33], ["patients", "ORGANISM", 43, 51], ["RSV", "ORGANISM", 134, 137], ["RSV", "SPECIES", 21, 24], ["HMPV", "SPECIES", 29, 33], ["patients", "SPECIES", 43, 51], ["RSV", "SPECIES", 21, 24], ["HMPV", "SPECIES", 29, 33], ["RSV", "SPECIES", 134, 137], ["The main symptoms", "PROBLEM", 0, 17], ["RSV", "PROBLEM", 21, 24], ["HMPV", "PROBLEM", 29, 33], ["cough", "PROBLEM", 57, 62], ["wheezing", "PROBLEM", 64, 72], ["fever", "PROBLEM", 78, 83], ["RSV viral load", "PROBLEM", 134, 148], ["bronchiolitis hospitalization", "PROBLEM", 205, 234], ["main", "OBSERVATION_MODIFIER", 4, 8], ["RSV", "ANATOMY", 21, 24], ["cough", "OBSERVATION", 57, 62], ["fever", "OBSERVATION", 78, 83], ["RSV", "OBSERVATION", 134, 137], ["viral load", "OBSERVATION", 138, 148], ["bronchiolitis", "OBSERVATION", 205, 218]]], ["Fodha et al. [2007] also found that nasopharyngeal RSV loads were higher in patients with severe disease.", [["nasopharyngeal", "ANATOMY", 36, 50], ["nasopharyngeal RSV", "ORGANISM", 36, 54], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["RSV", "SPECIES", 51, 54], ["nasopharyngeal RSV loads", "PROBLEM", 36, 60], ["severe disease", "PROBLEM", 90, 104], ["nasopharyngeal", "ANATOMY", 36, 50], ["RSV loads", "OBSERVATION", 51, 60], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["disease", "OBSERVATION", 97, 104]]], ["In contrast, clinical aspects observed in patients with serious LRTIs, like respiratory rate, cyanosis, and hospitalization were not associated with high viral loads.", [["respiratory", "ANATOMY", 76, 87], ["LRTIs", "DISEASE", 64, 69], ["cyanosis", "DISEASE", 94, 102], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["serious LRTIs", "PROBLEM", 56, 69], ["like respiratory rate", "PROBLEM", 71, 92], ["cyanosis", "PROBLEM", 94, 102], ["high viral loads", "PROBLEM", 149, 165], ["serious", "OBSERVATION_MODIFIER", 56, 63], ["LRTIs", "OBSERVATION", 64, 69], ["respiratory rate", "OBSERVATION", 76, 92], ["cyanosis", "OBSERVATION", 94, 102], ["viral loads", "OBSERVATION", 154, 165]]], ["We also analyzed the relationship between severity and viral load using multiple linear regression, the viral load showed no apparent significant difference between severe and not severe disease groups in this study.", [["viral load", "TEST", 55, 65], ["multiple linear regression", "PROBLEM", 72, 98], ["the viral load", "TEST", 100, 114], ["severe disease groups", "PROBLEM", 180, 201], ["this study", "TEST", 205, 215], ["viral load", "OBSERVATION", 55, 65], ["no apparent", "UNCERTAINTY", 122, 133], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["difference", "OBSERVATION", 146, 156], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["not", "UNCERTAINTY", 176, 179], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["disease", "OBSERVATION", 187, 194]]], ["These findings are in agreement with previous studies indicating that RSV viral load may have no correlation with the disease severity [Wright et al., 2002; Jansen et al., 2010].", [["RSV", "ORGANISM", 70, 73], ["RSV", "SPECIES", 70, 73], ["previous studies", "TEST", 37, 53], ["RSV viral load", "PROBLEM", 70, 84], ["the disease severity", "PROBLEM", 114, 134]]], ["However, in this study, RSV viral load was significantly different between three diagnostic groups and a high RSV viral load may be a risk factor of developing bronchiolitis.", [["bronchiolitis", "DISEASE", 160, 173], ["RSV", "ORGANISM", 24, 27], ["RSV", "ORGANISM", 110, 113], ["RSV", "SPECIES", 24, 27], ["RSV", "SPECIES", 110, 113], ["this study", "TEST", 12, 22], ["RSV viral load", "TEST", 24, 38], ["a high RSV viral load", "PROBLEM", 103, 124], ["developing bronchiolitis", "PROBLEM", 149, 173], ["viral load", "OBSERVATION", 28, 38], ["high RSV", "OBSERVATION", 105, 113], ["viral load", "OBSERVATION", 114, 124], ["developing", "OBSERVATION_MODIFIER", 149, 159], ["bronchiolitis", "OBSERVATION", 160, 173]]], ["Excluding severity and underlying diseases, Children aged <1 year had a higher viral load than other children.", [["children", "ORGANISM", 101, 109], ["Children", "SPECIES", 44, 52], ["children", "SPECIES", 101, 109], ["severity", "PROBLEM", 10, 18], ["underlying diseases", "PROBLEM", 23, 42], ["diseases", "OBSERVATION", 34, 42]]], ["It is possible that this is due to the children aged <1 year having an immature immune system resulting in an inappropriate shift toward a Th2 immune response to RSV infection [Gerna et al., 2008].", [["immune system", "ANATOMY", 80, 93], ["RSV infection", "DISEASE", 162, 175], ["children", "ORGANISM", 39, 47], ["immune system", "ANATOMICAL_SYSTEM", 80, 93], ["RSV", "ORGANISM", 162, 165], ["children", "SPECIES", 39, 47], ["RSV", "SPECIES", 162, 165], ["an immature immune system", "PROBLEM", 68, 93], ["an inappropriate shift", "PROBLEM", 107, 129], ["RSV infection", "PROBLEM", 162, 175]]], ["In our study, days of illness <14 days had a higher viral load compared with \u226514 days for RSV, this was because the long days of illness may associated with co\u2010infecting, this also consistent with the result in our study that children positive for RSV alone had a higher viral load than co\u2010infected with other viruses.DISCUSSIONSome previous studies have showed that high HMPV viral load may be associated with an increase in the presence of fever, bronchodilator use, obtaining chest radiograph, and hospitalization; viral load was significantly higher in children with LRTI and hospitalized children [Bosis et al., 2008; Martin et al., 2008].", [["chest", "ANATOMY", 479, 484], ["illness", "DISEASE", 22, 29], ["illness", "DISEASE", 129, 136], ["RSV", "DISEASE", 248, 251], ["fever", "DISEASE", 442, 447], ["LRTI", "DISEASE", 571, 575], ["RSV", "ORGANISM", 90, 93], ["children", "ORGANISM", 226, 234], ["RSV", "ORGANISM", 248, 251], ["HMPV", "ORGANISM", 372, 376], ["chest", "ORGANISM_SUBDIVISION", 479, 484], ["children", "ORGANISM", 557, 565], ["children", "ORGANISM", 593, 601], ["children", "SPECIES", 226, 234], ["children", "SPECIES", 557, 565], ["children", "SPECIES", 593, 601], ["RSV", "SPECIES", 90, 93], ["RSV", "SPECIES", 248, 251], ["HMPV", "SPECIES", 372, 376], ["a higher viral load", "PROBLEM", 43, 62], ["RSV", "PROBLEM", 90, 93], ["illness", "PROBLEM", 129, 136], ["our study", "TEST", 211, 220], ["RSV", "PROBLEM", 248, 251], ["a higher viral load", "PROBLEM", 262, 281], ["other viruses", "PROBLEM", 304, 317], ["previous studies", "TEST", 333, 349], ["high HMPV viral load", "PROBLEM", 367, 387], ["fever", "PROBLEM", 442, 447], ["bronchodilator use", "TREATMENT", 449, 467], ["chest radiograph", "TEST", 479, 495], ["viral load", "TEST", 518, 528], ["viral load", "OBSERVATION", 377, 387], ["increase", "OBSERVATION_MODIFIER", 414, 422], ["fever", "OBSERVATION", 442, 447], ["chest", "ANATOMY", 479, 484]]], ["These studies also showed a significant correlation between HMPV viral load and disease severity.", [["HMPV", "ORGANISM", 60, 64], ["HMPV", "SPECIES", 60, 64], ["These studies", "TEST", 0, 13], ["HMPV viral load", "PROBLEM", 60, 75], ["disease severity", "PROBLEM", 80, 96], ["HMPV viral load", "OBSERVATION", 60, 75]]], ["In contrast, our study showed no correlation between viral load and disease severity, this was consistent with a previous study conducted in Chongqing, China [Peng et al., 2010], which also indicated that HMPV viral load was significant correlated with the course of illness; high viral load occurred between 6 and 11 days post\u2010infection.DISCUSSIONCo\u2010infection of RSV was detected in 57.07% and HMPV was detected in 77.47% of the cases, these rates were higher than reported in previous studies [Franz et al., 2010; Martin et al., 2012].", [["HMPV", "ORGANISM", 205, 209], ["RSV", "ORGANISM", 364, 367], ["HMPV", "ORGANISM", 395, 399], ["HMPV", "SPECIES", 205, 209], ["RSV", "SPECIES", 364, 367], ["HMPV", "SPECIES", 395, 399], ["our study", "TEST", 13, 22], ["viral load and disease severity", "PROBLEM", 53, 84], ["a previous study", "TEST", 111, 127], ["HMPV viral load", "PROBLEM", 205, 220], ["illness", "PROBLEM", 267, 274], ["high viral load", "PROBLEM", 276, 291], ["RSV", "PROBLEM", 364, 367], ["HMPV", "TEST", 395, 399], ["these rates", "TEST", 437, 448], ["viral load", "OBSERVATION", 53, 63], ["consistent with", "UNCERTAINTY", 95, 110], ["viral load", "OBSERVATION", 210, 220], ["viral load", "OBSERVATION", 281, 291], ["RSV", "OBSERVATION", 364, 367]]], ["However, this is consistent with the overall higher detection rate in observed this study as mentioned above.", [["this study", "TEST", 79, 89], ["consistent with", "UNCERTAINTY", 17, 32], ["higher", "OBSERVATION_MODIFIER", 45, 51]]], ["In this study, children infected with RSV alone had a higher viral load than in RSV patients co\u2010infected with other viruses; this observation was not seen with HMPV and reflects in part an observation made by Franz et al. [2010].", [["children", "ORGANISM", 15, 23], ["RSV", "ORGANISM", 38, 41], ["RSV", "ORGANISM", 80, 83], ["patients", "ORGANISM", 84, 92], ["HMPV", "ORGANISM", 160, 164], ["children", "SPECIES", 15, 23], ["patients", "SPECIES", 84, 92], ["RSV", "SPECIES", 38, 41], ["RSV", "SPECIES", 80, 83], ["HMPV", "SPECIES", 160, 164], ["this study", "TEST", 3, 13], ["RSV", "PROBLEM", 38, 41], ["a higher viral load", "PROBLEM", 52, 71], ["other viruses", "PROBLEM", 110, 123], ["HMPV", "PROBLEM", 160, 164], ["viral load", "OBSERVATION", 61, 71]]], ["Martin et al. [2012] showed that the correlation between viral load and viral co\u2010infection was virus specific and in their study, both RSV and HMPV were present at consistently high viral loads regardless of whether the patient was co\u2010infected with another virus.", [["RSV", "ORGANISM", 135, 138], ["HMPV", "ORGANISM", 143, 147], ["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 220, 227], ["RSV", "SPECIES", 135, 138], ["HMPV", "SPECIES", 143, 147], ["viral load", "PROBLEM", 57, 67], ["viral co\u2010infection", "PROBLEM", 72, 90], ["virus", "PROBLEM", 95, 100], ["their study", "TEST", 117, 128], ["RSV", "PROBLEM", 135, 138], ["HMPV", "PROBLEM", 143, 147], ["another virus", "PROBLEM", 249, 262], ["viral co\u2010infection", "OBSERVATION", 72, 90], ["HMPV", "OBSERVATION", 143, 147]]], ["The effect of co\u2010infection on disease RSV or HMPV disease severity remains unclear and controversial.", [["RSV", "DISEASE", 38, 41], ["HMPV disease", "DISEASE", 45, 57], ["RSV", "ORGANISM", 38, 41], ["HMPV", "ORGANISM", 45, 49], ["RSV", "SPECIES", 38, 41], ["HMPV", "SPECIES", 45, 49], ["co\u2010infection", "PROBLEM", 14, 26], ["disease RSV", "PROBLEM", 30, 41], ["HMPV disease severity", "PROBLEM", 45, 66], ["HMPV disease", "OBSERVATION", 45, 57]]], ["Semple et al. [2005] found dual infection by HMPV and RSV was associated with severe bronchiolitis, while other studies have found no association of co\u2010infection with disease severity [Peng et al., 2009] or co\u2010infection was correlated with less severe disease [Martin et al., 2012].", [["infection", "DISEASE", 32, 41], ["RSV", "DISEASE", 54, 57], ["bronchiolitis", "DISEASE", 85, 98], ["co\u2010infection", "DISEASE", 149, 161], ["HMPV", "ORGANISM", 45, 49], ["RSV", "ORGANISM", 54, 57], ["HMPV", "SPECIES", 45, 49], ["RSV", "SPECIES", 54, 57], ["dual infection", "PROBLEM", 27, 41], ["HMPV", "PROBLEM", 45, 49], ["RSV", "PROBLEM", 54, 57], ["severe bronchiolitis", "PROBLEM", 78, 98], ["other studies", "TEST", 106, 119], ["co\u2010infection", "PROBLEM", 149, 161], ["disease severity", "PROBLEM", 167, 183], ["co\u2010infection", "PROBLEM", 207, 219], ["less severe disease", "PROBLEM", 240, 259], ["infection", "OBSERVATION", 32, 41], ["HMPV", "OBSERVATION", 45, 49], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["bronchiolitis", "OBSERVATION", 85, 98]]], ["In our study, the incidence of severe disease was similar between single infections and co\u2010infections, indicating that co\u2010infection was not associated with more severe disease.", [["infections", "DISEASE", 73, 83], ["co\u2010infections", "DISEASE", 88, 101], ["co\u2010infection", "DISEASE", 119, 131], ["our study", "TEST", 3, 12], ["severe disease", "PROBLEM", 31, 45], ["single infections and co\u2010infections", "PROBLEM", 66, 101], ["more severe disease", "PROBLEM", 156, 175], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 38, 45], ["infections", "OBSERVATION", 73, 83], ["not associated with", "UNCERTAINTY", 136, 155], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["disease", "OBSERVATION", 168, 175]]], ["An immune response to the first virus infection might alter the disease severity of a subsequently virus by the induction of interferon and other anti\u2010viral response modifiers [Martin et al., 2012].", [["infection", "DISEASE", 38, 47], ["interferon", "GENE_OR_GENE_PRODUCT", 125, 135], ["interferon", "PROTEIN", 125, 135], ["the first virus infection", "PROBLEM", 22, 47], ["the disease severity", "PROBLEM", 60, 80], ["a subsequently virus", "PROBLEM", 84, 104], ["interferon", "TREATMENT", 125, 135], ["other anti\u2010viral response modifiers", "TREATMENT", 140, 175]]], ["The impact of these immunomodulators could be to restrain colonization and pathogenicity of the co\u2010infecting virus.", [["co\u2010infecting virus", "ORGANISM", 96, 114], ["these immunomodulators", "TREATMENT", 14, 36], ["restrain colonization", "PROBLEM", 49, 70], ["the co\u2010infecting virus", "PROBLEM", 92, 114], ["immunomodulators", "OBSERVATION", 20, 36], ["co\u2010infecting virus", "OBSERVATION", 96, 114]]], ["However, more research is needed to determine what the relationship between co\u2010infecting viruses and disease development is.DISCUSSIONThere are some limitations in our study.", [["co\u2010infecting viruses and disease development", "PROBLEM", 76, 120], ["our study", "TEST", 164, 173], ["viruses", "OBSERVATION", 89, 96]]], ["It was difficult to determine at which stage of disease development patients are when they received the diagnosis of ALRTI.", [["ALRTI", "DISEASE", 117, 122], ["patients", "ORGANISM", 68, 76], ["ALRTI", "CANCER", 117, 122], ["patients", "SPECIES", 68, 76], ["disease", "OBSERVATION", 48, 55]]], ["NPAs were not able to be collected at the same time point, although they were collected within 3 days of diagnosis of ALRTI; this may have influenced viral detection rate and viral load results.", [["ALRTI", "DISEASE", 118, 123], ["NPAs", "SIMPLE_CHEMICAL", 0, 4], ["NPAs", "TREATMENT", 0, 4], ["viral detection rate", "TEST", 150, 170], ["viral load results", "TEST", 175, 193]]], ["Furthermore, viral loads of many viruses in healthy children remain unknown; a control group of healthy children should be established in order to determine the basal viral load level to help determine loads associated with increased disease risk.", [["children", "ORGANISM", 52, 60], ["children", "ORGANISM", 104, 112], ["children", "SPECIES", 52, 60], ["children", "SPECIES", 104, 112], ["the basal viral load level", "TEST", 157, 183], ["increased disease risk", "PROBLEM", 224, 246], ["viral loads", "OBSERVATION", 13, 24], ["many", "OBSERVATION_MODIFIER", 28, 32], ["viruses", "OBSERVATION", 33, 40], ["increased", "OBSERVATION_MODIFIER", 224, 233], ["disease", "OBSERVATION", 234, 241]]], ["In addition, follow\u2010up examinations should be performed, to more accurately reflect the correlation between viral load and changing disease progression and severity.DISCUSSIONIn conclusion, the findings of the present study indicated that RSV and HMPV are very important viral pathogens in children with ALRTI in China.", [["ALRTI", "DISEASE", 304, 309], ["RSV", "ORGANISM", 239, 242], ["HMPV", "ORGANISM", 247, 251], ["children", "ORGANISM", 290, 298], ["children", "SPECIES", 290, 298], ["RSV", "SPECIES", 239, 242], ["HMPV", "SPECIES", 247, 251], ["follow\u2010up examinations", "TEST", 13, 35], ["viral load", "PROBLEM", 108, 118], ["changing disease progression and severity", "PROBLEM", 123, 164], ["the present study", "TEST", 206, 223], ["RSV", "PROBLEM", 239, 242], ["HMPV", "PROBLEM", 247, 251], ["viral load", "OBSERVATION", 108, 118], ["severity", "OBSERVATION_MODIFIER", 156, 164], ["RSV", "OBSERVATION", 239, 242], ["HMPV", "OBSERVATION", 247, 251]]], ["Bronchiolitis is the most common disease associated with RSV and HMPV detection.", [["Bronchiolitis", "DISEASE", 0, 13], ["RSV", "ORGANISM", 57, 60], ["HMPV", "ORGANISM", 65, 69], ["RSV", "SPECIES", 57, 60], ["HMPV", "SPECIES", 65, 69], ["Bronchiolitis", "PROBLEM", 0, 13], ["the most common disease", "PROBLEM", 17, 40], ["RSV", "PROBLEM", 57, 60], ["HMPV detection", "TEST", 65, 79], ["most common", "OBSERVATION_MODIFIER", 21, 32], ["RSV", "OBSERVATION", 57, 60], ["HMPV", "OBSERVATION", 65, 69]]], ["High viral loads or co\u2010infection with other respiratory viruses may be associate with some symptoms but do not appear to have a significant impact on disease severity.", [["respiratory viruses", "DISEASE", 44, 63], ["High viral loads", "PROBLEM", 0, 16], ["co\u2010infection", "PROBLEM", 20, 32], ["other respiratory viruses", "PROBLEM", 38, 63], ["some symptoms", "PROBLEM", 86, 99], ["disease severity", "PROBLEM", 150, 166], ["viral loads", "OBSERVATION", 5, 16], ["respiratory", "ANATOMY", 44, 55], ["viruses", "OBSERVATION", 56, 63], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["impact", "OBSERVATION", 140, 146], ["disease", "OBSERVATION", 150, 157]]], ["We believe a series of global, multi\u2010center, standard case\u2013control studies are necessary to further clarify the correlation between viral infections and the clinical course of them in ALRTI.ETHICAL APPROVALThe process obtained families informed consent and the study protocol was approved by the Ethics Committee of the First Hospital of Lanzhou University.", [["viral infections", "DISEASE", 132, 148], ["ALRTI", "DISEASE", 184, 189], ["standard case\u2013control studies", "TEST", 45, 74], ["viral infections", "PROBLEM", 132, 148], ["the study protocol", "TEST", 257, 275], ["infections", "OBSERVATION", 138, 148]]]], "6a7451e99b49989553a6d69e92a75134211e7bf5": [["Historical BackgroundEllipsometry was used already 1932 for studies of organic monolayers by Tronsted et al. [1] , but Vroman [2] , Rothen and Mathot [3] and Stromberg et al. [4] were most likely among the first to report measurements on protein layers.", [["Historical BackgroundEllipsometry", "TEST", 0, 33], ["organic monolayers", "TEST", 71, 89], ["Vroman", "TEST", 119, 125], ["Rothen", "TEST", 132, 138], ["Mathot", "TEST", 143, 149], ["Stromberg et al.", "TEST", 158, 174]]], ["Azzam et al. [5] demonstrated similar results in studies of immunological reactions and also provided a theoretical framework.", [["immunological reactions", "PROBLEM", 60, 83]]], ["Their pioneering work included studies of kinetics of protein adsorption at solid/liquid interfaces.", [["protein adsorption at solid/liquid interfaces", "PROBLEM", 54, 99], ["liquid interfaces", "OBSERVATION", 82, 99]]], ["These early investigators found ellipsometry to be a suitable tool for non-destructive analysis of thin films, both ex situ as well as in situ at a solid/liquid interface, but surprisingly the use of the technique for protein adsorption studies during the last 40 years has been limited to a few laboratories.", [["non-destructive analysis", "TEST", 71, 95], ["thin films", "TEST", 99, 109], ["a solid/liquid interface", "TREATMENT", 146, 170], ["the technique", "TREATMENT", 200, 213], ["protein adsorption studies", "TEST", 218, 244]]], ["1 In addition, with a few exceptions, the types of applications are generally very simple and often limited to single wavelength measurements.", [["single wavelength measurements", "TEST", 111, 141], ["few", "OBSERVATION_MODIFIER", 22, 25]]], ["This may be due to that most users in the field have a background in biochemistry or medicine and not are sufficiently trained in optics and physics to make full use of the technique.", [["the technique", "TREATMENT", 169, 182], ["may be due to", "UNCERTAINTY", 5, 18]]], ["The development in the field during this period has been reviewed several times [6] [7] [8] [9] [10] [11] [12] [13] .Historical BackgroundHowever, one also finds that about one third of the reports are from the last five years and new research groups have started to use ellipsometry and more advanced methodology is employed.", [["[6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 80, 115], ["ellipsometry", "TREATMENT", 271, 283]]], ["The applications of the technique on protein adsorption have now expanded to include imaging ellipsometry [14] , total internal reflection ellipsometry [15] [16] [17] , infrared ellipsometry [18, 19] , in combination with quartz micro balance [20, 21] and more.", [["quartz", "CHEMICAL", 222, 228], ["the technique on protein adsorption", "TREATMENT", 20, 55], ["imaging ellipsometry", "TEST", 85, 105], ["total internal reflection ellipsometry", "TEST", 113, 151], ["infrared ellipsometry", "TEST", 169, 190], ["quartz micro balance", "TEST", 222, 242]]], ["Fortunately spectroscopy becomes more and more common and attempts are made to address scientific issues beyond semi-quantitative analysis of layer thickness and simple determination of surface mass density.Opportunities and ChallengesEllipsometry offers possibilities for true quantitative measurement of thin layers with sub-nm sensitivity and has the in situ advantage to allow monitoring of dynamic processes.", [["surface", "ANATOMY", 186, 193], ["layers", "TISSUE", 311, 317], ["Fortunately spectroscopy", "TEST", 0, 24], ["layer thickness", "PROBLEM", 142, 157], ["surface mass density", "PROBLEM", 186, 206], ["thin layers", "PROBLEM", 306, 317], ["sub-nm sensitivity", "PROBLEM", 323, 341], ["layer thickness", "OBSERVATION_MODIFIER", 142, 157], ["surface", "OBSERVATION_MODIFIER", 186, 193], ["mass", "OBSERVATION", 194, 198]]], ["It is based on photons-in photons-out and is thus nondestructive and can be applied even at a solid/liquid interface.Opportunities and ChallengesThe in situ advantage should not be underestimated for protein adsorption studies because: (1) protein layers can to be studied on model surfaces very similar to those in the normal environment for proteins; (2) protein layer surface dynamics can be studied directly; and (3) no labeling of protein molecules is required.", [["surface", "ANATOMY", 371, 378], ["protein molecules", "PROTEIN", 436, 453], ["a solid/liquid interface", "TREATMENT", 92, 116], ["protein adsorption studies", "TEST", 200, 226], ["protein layers", "PROBLEM", 240, 254], ["protein layer surface dynamics", "TEST", 357, 387], ["labeling of protein molecules", "PROBLEM", 424, 453], ["nondestructive", "OBSERVATION_MODIFIER", 50, 64]]], ["These three characteristics facilitate studies of central phenomena in protein adsorption research including competitive adsorption of proteins, protein layer structure and dynamics, protein interaction on surfaces and protein exchange reactions and more.", [["central phenomena in protein adsorption research", "PROBLEM", 50, 98], ["competitive adsorption of proteins", "TREATMENT", 109, 143], ["protein layer structure", "PROBLEM", 145, 168], ["protein exchange reactions", "TREATMENT", 219, 245], ["central phenomena", "OBSERVATION", 50, 67]]], ["Studies under flow is an example on an additional possibility.", [["flow", "OBSERVATION", 14, 18]]], ["It is no doubt that ellipsometry is a convenient and excellent tool to study surface dynamics in biological systems.", [["surface", "ANATOMY", 77, 84], ["no doubt", "UNCERTAINTY", 6, 14]]], ["We may distinguish between basic research on protein adsorption performed in research laboratories and biosensor applications with goal to get established in clinical laboratories and even in the doctors office.", [["protein adsorption", "TREATMENT", 45, 63], ["biosensor applications", "TREATMENT", 103, 125]]], ["For the research applications, the available ellipsometers on the market have precision, speed and general performance to match the requirements for high-precision bioadsorption studies.", [["high-precision bioadsorption studies", "TEST", 149, 185]]], ["It is fair to say that the instrument problem is solved in this context.", [["the instrument problem", "PROBLEM", 23, 45]]], ["Of course, depending on the actual scientific question addressed, there are always technical challenges related to how to expose proteins to a surface: in situ or ex situ adsorption; flowing or static adsorption conditions; solution stirring or not; temperature control; etc.Opportunities and ChallengesWith the instrument problem solved, the two most important scientific challenges are the data evaluation and to select the most appropriate surface for the problem addressed.", [["surface", "ANATOMY", 143, 150], ["surface", "ANATOMY", 443, 450], ["surface", "CELLULAR_COMPONENT", 143, 150], ["static adsorption conditions", "TREATMENT", 194, 222], ["solution stirring", "TREATMENT", 224, 241], ["the data evaluation", "TEST", 388, 407]]], ["In in vitro studies of protein adsorption one may always question if the model surface used is relevant.", [["surface", "ANATOMY", 79, 86], ["protein adsorption", "TREATMENT", 23, 41]]], ["Ellipsometry has this problem in common with many other techniques but a special limitation for ellipsometry is that a relatively flat surface at least a few square mm 2 large is required.", [["surface", "ANATOMY", 135, 142], ["surface", "CELLULAR_COMPONENT", 135, 142], ["Ellipsometry", "TEST", 0, 12]]], ["Adsorption studies on curved surfaces or small particles are not possible.", [["Adsorption studies", "TEST", 0, 18], ["small particles", "PROBLEM", 41, 56], ["small", "OBSERVATION_MODIFIER", 41, 46], ["particles", "OBSERVATION", 47, 56], ["not possible", "UNCERTAINTY", 61, 73]]], ["Many ellipsometric protein adsorption studies are traditionally performed on silicon wafers 2 which are extremely flat and lend themselves to surface modification by silanization to change their surface chemistry, physics and energy.", [["surface", "ANATOMY", 142, 149], ["surface", "ANATOMY", 195, 202], ["silicon", "CHEMICAL", 77, 84], ["Many ellipsometric protein adsorption studies", "TEST", 0, 45], ["silicon wafers", "TREATMENT", 77, 91], ["protein adsorption", "OBSERVATION", 19, 37]]], ["Another commonly used material is gold which can be modified using thiol chemistry.", [["thiol", "CHEMICAL", 67, 72], ["thiol", "CHEMICAL", 67, 72], ["gold", "SIMPLE_CHEMICAL", 34, 38], ["thiol chemistry", "TEST", 67, 82]]], ["From an optical point of view, these two types of surfaces are excellent and provide high optical contrast to protein layers and are readily available.", [["surfaces", "OBSERVATION_MODIFIER", 50, 58]]], ["The second challenge, evaluation of the primary data \u03a8 and , is a central problem in ellipsometry.", [["The second challenge", "TEST", 0, 20], ["evaluation", "TEST", 22, 32]]], ["For protein layers the main issue is how to simultaneously determine layer thickness and layer refractive index.", [["protein layers", "PROBLEM", 4, 18], ["layer refractive index", "TEST", 89, 111], ["layers", "OBSERVATION_MODIFIER", 12, 18], ["main", "OBSERVATION_MODIFIER", 23, 27], ["layer", "OBSERVATION_MODIFIER", 89, 94], ["refractive index", "OBSERVATION", 95, 111]]], ["This will be discussed in some detail in the following sections.Opportunities and ChallengesFor biosensor applications of ellipsometry, one may say that the challenges are the opposite.", [["sections", "ANATOMY", 55, 63], ["biosensor applications of ellipsometry", "TREATMENT", 96, 134]]], ["The evaluation problem is solved in the sense that sufficient sensitivity is obtainable to detect small amounts of adsorbed protein on a surface.", [["surface", "ANATOMY", 137, 144], ["surface", "CELLULAR_COMPONENT", 137, 144], ["adsorbed protein", "PROTEIN", 115, 131], ["The evaluation problem", "TEST", 0, 22], ["small amounts of adsorbed protein", "PROBLEM", 98, 131], ["small", "OBSERVATION_MODIFIER", 98, 103], ["amounts", "OBSERVATION_MODIFIER", 104, 111], ["adsorbed protein", "OBSERVATION", 115, 131]]], ["However, ellipsometry is not a method for chemical identification, so chemical and biological specificity must be achieved through biorecognition.", [["chemical identification", "TEST", 42, 65]]], ["This is a central challenge but is rather a biochemical issue than an ellipsometric.", [["central", "OBSERVATION_MODIFIER", 10, 17], ["challenge", "OBSERVATION", 18, 27], ["ellipsometric", "OBSERVATION", 70, 83]]], ["The main ellipsometric challenge is on the instrumental side.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["ellipsometric", "OBSERVATION_MODIFIER", 9, 22], ["challenge", "OBSERVATION", 23, 32]]], ["There are several concepts proposed but systems suitable for clinical tests are not readily available.", [["clinical tests", "TEST", 61, 75]]], ["This review is limited to presentation of a few approaches to realize biosensor concepts.Objectives and OutlineThe objective of this chapter is to provide an overview of the use of ellipsometry in the life science area with limitation to protein layers.", [["ellipsometry", "TREATMENT", 181, 193]]], ["In the methodology sections, hardware configurations will be described very briefly as there are numerous variants found in the literature.", [["sections", "ANATOMY", 19, 27], ["hardware configurations", "TREATMENT", 29, 52], ["hardware", "OBSERVATION", 29, 37], ["numerous", "OBSERVATION_MODIFIER", 97, 105], ["variants", "OBSERVATION", 106, 114]]], ["Focus will instead be on strategies for evaluation of ellipsometric data.", [["evaluation of ellipsometric data", "TEST", 40, 72]]], ["For applications, the more simple applications based on singlewavelength ellipsometry for thickness and surface mass determination will only be summarized as there are several reviews available on this subject.", [["surface", "ANATOMY", 104, 111], ["applications", "TREATMENT", 4, 16], ["the more simple applications", "TREATMENT", 18, 46], ["singlewavelength ellipsometry for thickness and surface mass determination", "TEST", 56, 130], ["surface", "OBSERVATION_MODIFIER", 104, 111], ["mass", "OBSERVATION", 112, 116]]], ["Instead, recent development including more advanced approaches like imaging and spectroscopy employed for studies of surface dynamics, structural analysis and biosensing will be addressed.Methodology-Experimental AspectsEx situ experiments with ellipsometry on protein layers do not differ from other types of ellipsometric thin film studies and various types of instruments are described elsewhere.", [["surface", "ANATOMY", 117, 124], ["imaging", "TEST", 68, 75], ["spectroscopy", "TEST", 80, 92], ["studies of surface dynamics", "TEST", 106, 133], ["structural analysis", "TEST", 135, 154], ["Methodology", "TEST", 188, 199], ["Experimental AspectsEx situ experiments", "TREATMENT", 200, 239], ["ellipsometry on protein layers", "PROBLEM", 245, 275], ["ellipsometric thin film studies", "TEST", 310, 341], ["instruments", "OBSERVATION", 363, 374]]], ["Here we discuss some configurations used in in situ applications, i.e. at solid/liquid interfaces.Methodology-Experimental AspectsNull ellipsometry in a PCSA (polarizer-compensator-sample-analyzer) configuration is the traditional ellipsometer used for protein adsorption studies.", [["PCSA", "CHEMICAL", 153, 157], ["Methodology", "TEST", 98, 109], ["protein adsorption studies", "TEST", 253, 279]]], ["A PCSA instrument is robust, easy to operate, has high resolution and simple data collection.", [["A PCSA instrument", "TEST", 0, 17], ["high resolution and simple data collection", "PROBLEM", 50, 92]]], ["Among drawbacks are limitations to single-wavelength operation and low speed.", [["single-wavelength operation", "TREATMENT", 35, 62], ["low speed", "OBSERVATION_MODIFIER", 67, 76]]], ["If fast dynamics are studied a possibility is to operate a PCSA instrument in offnull mode [22] .", [["a PCSA instrument", "TEST", 57, 74]]], ["This configuration is also convenient for imaging ellipsometry [14] .", [["imaging ellipsometry", "TEST", 42, 62]]], ["In more advanced applications involving spectroscopy, photometric instruments like the rotating analyzer configuration are normally employed.Methodology-Experimental AspectsVery important for in situ measurements in liquids is design and features of the cell required to hold the liquid.", [["cell", "ANATOMY", 254, 258], ["cell", "CELL", 254, 258], ["spectroscopy", "TEST", 40, 52], ["photometric instruments", "TREATMENT", 54, 77], ["Experimental AspectsVery", "TREATMENT", 153, 177], ["the cell", "PROBLEM", 250, 258], ["the liquid", "TREATMENT", 276, 286]]], ["Most cells are home made and adapted to the particular needs of the experiments conducted.", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10]]], ["Among the most important factors is how liquids are mixed in the cell.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69]]], ["In some designs a flow system is included but it is very hard to avoid dead (unstirred) volumes and there is always an unstirred layer close to the surface under test.", [["surface", "ANATOMY", 148, 155], ["surface", "CELLULAR_COMPONENT", 148, 155], ["a flow system", "TEST", 16, 29], ["dead (unstirred) volumes", "PROBLEM", 71, 95], ["an unstirred layer", "PROBLEM", 116, 134], ["flow system", "OBSERVATION", 18, 29], ["unstirred", "OBSERVATION_MODIFIER", 119, 128], ["layer", "OBSERVATION_MODIFIER", 129, 134]]], ["Molecules always must diffuse over this layer.", [["diffuse", "OBSERVATION_MODIFIER", 22, 29]]], ["Magnetic stirring is often used and has the advantage that the same liquid is in the cell all the time compared to a in flow system.", [["cell", "ANATOMY", 85, 89], ["cell", "CELL", 85, 89], ["Magnetic stirring", "TREATMENT", 0, 17]]], ["Cells also have windows and proper windows characterization must be performed and included in the data evaluation in a similar manner as for windows in vacuum systems.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["proper windows characterization", "TEST", 28, 59], ["the data evaluation", "TEST", 94, 113], ["vacuum", "OBSERVATION", 152, 158]]], ["Additional complications in cell design is if temperature control is required for the surface or molecular interactions studied.Methodology-Experimental AspectsA major difference form measurements performed in air or vacuum is that the ambient, i.e. the liquid, has a refractive index larger than one and, more important, has a dispersion [23] .", [["cell", "ANATOMY", 28, 32], ["surface", "ANATOMY", 86, 93], ["cell", "CELL", 28, 32], ["surface", "CELLULAR_COMPONENT", 86, 93], ["Additional complications in cell design", "PROBLEM", 0, 39], ["temperature control", "TREATMENT", 46, 65], ["a refractive index", "TEST", 266, 284], ["complications", "OBSERVATION", 11, 24], ["cell design", "OBSERVATION", 28, 39], ["refractive", "OBSERVATION", 268, 278]]], ["Furthermore, addition of molecules to the liquid may change its refractive index which in most cases is seen as a change in \u03a8 which can be mistaken for an adsorption process.", [["\u03a8", "SIMPLE_CHEMICAL", 124, 125], ["molecules to the liquid", "TREATMENT", 25, 48], ["its refractive index", "PROBLEM", 60, 80], ["an adsorption process", "PROBLEM", 152, 173], ["refractive index", "OBSERVATION", 64, 80]]], ["However, this change is very fast and occurs as soon as mixing is complete (within seconds), whereas a change due to molecular adsorption on the surface occurs slower (tens of seconds or slower) due to diffusion over the unstirred layer at the interface.", [["surface", "ANATOMY", 145, 152], ["surface", "CELLULAR_COMPONENT", 145, 152], ["molecular adsorption", "PROBLEM", 117, 137], ["very", "OBSERVATION_MODIFIER", 24, 28], ["fast", "OBSERVATION_MODIFIER", 29, 33], ["molecular adsorption", "OBSERVATION", 117, 137], ["surface", "OBSERVATION_MODIFIER", 145, 152], ["slower", "OBSERVATION_MODIFIER", 160, 166], ["unstirred layer", "OBSERVATION", 221, 236], ["interface", "ANATOMY_MODIFIER", 244, 253]]], ["To consider in the evaluation of data is also that molecules do not only adsorb on the surface-molecules also desorb at the same time, i.e there is a replacement.", [["surface", "ANATOMY", 87, 94], ["the evaluation", "TEST", 15, 29], ["a replacement", "TREATMENT", 148, 161], ["replacement", "OBSERVATION", 150, 161]]], ["Often the biomolecules replace water molecules and contact adsorbed ions.Methodology-Modeling AspectsA data set of (\u03a8, )-pairs is obtained in an ellipsometric experiment.", [["water molecules", "SIMPLE_CHEMICAL", 31, 46], ["ellipsometric experiment", "OBSERVATION", 145, 169]]], ["In ex situ mode it is possible to perform spectroscopic, variable angle, dynamic and imaging ellipsometry, whereby, wavelength \u03bb, incidence angle \u03b8 , time t and lateral position, respectively, are independent parameters.", [["imaging ellipsometry", "TEST", 85, 105]]], ["In a traditional in situ protein adsorption experiment, the time evolution of \u03a8 and at single \u03bb is monitored which in a modern methodological perspective is very rudimentary as there is much to gain by using spectroscopic ellipsometry.Methodology-Modeling AspectsThe basic model for evaluation is that we have a surface with known properties on which there is a layer with thickness d and refractive index N = n + ik, where n and k (the extinction coefficient) are the real and imaginary parts of N .", [["surface", "ANATOMY", 312, 319], ["N", "CHEMICAL", 497, 498], ["\u03a8", "PROTEIN", 78, 79], ["spectroscopic ellipsometry", "TEST", 208, 234], ["evaluation", "TEST", 283, 293], ["refractive index", "TEST", 389, 405], ["ik", "PROBLEM", 414, 416]]], ["In addition the fill factor f of the layer may be of interest if density effects are addressed.", [["may be of", "UNCERTAINTY", 43, 52], ["density", "OBSERVATION", 65, 72]]], ["If spectroscopy is employed, it is also helpful to introduce dispersion models to describe the \u03bb-variation of N .", [["N", "CHEMICAL", 110, 111], ["spectroscopy", "TEST", 3, 15]]], ["A complementary parameter traditionally used is the surface mass density \u0393 which represents the amount of protein on a surface in units of e.g. ng/mm 2 .", [["surface", "ANATOMY", 52, 59], ["surface", "ANATOMY", 119, 126], ["surface", "CELLULAR_COMPONENT", 119, 126], ["A complementary parameter", "TREATMENT", 0, 25], ["the surface mass density", "PROBLEM", 48, 72], ["a surface in units", "TREATMENT", 117, 135], ["surface", "OBSERVATION_MODIFIER", 52, 59], ["mass", "OBSERVATION", 60, 64], ["amount", "OBSERVATION_MODIFIER", 96, 102]]], ["Figure 2 .1 shows a few schematic examples of protein layer structures and also presents the two most common models used for evaluation.", [["Figure", "TEST", 0, 6], ["evaluation", "TEST", 125, 135], ["protein layer", "OBSERVATION", 46, 59]]], ["The model to the bottom left most closely represents reality in the sense that d is the physical extension of the layer into the ambient and N is its effective refractive index.", [["N", "CHEMICAL", 141, 142], ["bottom", "ANATOMY_MODIFIER", 17, 23], ["left", "ANATOMY_MODIFIER", 24, 28], ["effective", "OBSERVATION_MODIFIER", 150, 159], ["refractive index", "OBSERVATION", 160, 176]]], ["The model to the bottom right represents a \"collapsed\" layer with d eq and N p corresponding to thickness and intrinsic index of a dense protein layer.", [["a \"collapsed\" layer", "PROBLEM", 41, 60], ["thickness", "TEST", 96, 105], ["a dense protein layer", "PROBLEM", 129, 150], ["bottom", "ANATOMY_MODIFIER", 17, 23], ["right", "ANATOMY_MODIFIER", 24, 29], ["collapsed", "OBSERVATION", 44, 53], ["layer", "OBSERVATION_MODIFIER", 55, 60], ["d eq", "OBSERVATION_MODIFIER", 66, 70], ["intrinsic", "OBSERVATION_MODIFIER", 110, 119], ["index", "OBSERVATION_MODIFIER", 120, 125], ["dense", "OBSERVATION_MODIFIER", 131, 136], ["protein layer", "OBSERVATION", 137, 150]]], ["They also pointed out that steady-state irreversible adsorption of HSA and fibrinogen on hydrophobic polymers strongly depends on the dynamics.Methodology-Modeling AspectsThe examples of layers illustrated in Fig. 2 .1 should, to be more precise, be described in an anisotropic model due to form birefringence.", [["HSA", "SIMPLE_CHEMICAL", 67, 70], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 75, 85], ["HSA", "PROTEIN", 67, 70], ["fibrinogen", "PROTEIN", 75, 85], ["HSA", "TEST", 67, 70], ["fibrinogen on hydrophobic polymers", "TREATMENT", 75, 109], ["an anisotropic model", "TREATMENT", 263, 283], ["layers", "OBSERVATION_MODIFIER", 187, 193]]], ["However, the out-ofplane (normal to the surface) sensitivity is low in an ellipsometric experiment at oblique incidence on a thin layer so the anisotropy can normally not be resolved.", [["surface", "ANATOMY", 40, 47], ["a thin layer", "TREATMENT", 123, 135], ["low", "OBSERVATION_MODIFIER", 64, 67], ["ellipsometric experiment", "OBSERVATION", 74, 98], ["normally not be", "UNCERTAINTY", 158, 173], ["resolved", "OBSERVATION", 174, 182]]], ["One has to simplify and use isotropic models as shown in Fig. 2 .1.Methodology-Modeling AspectsHere we will first discuss strategies to determine d and N followed by presentation of model dispersion functions for protein layers.", [["isotropic models", "TREATMENT", 28, 44], ["protein layers", "PROBLEM", 213, 227]]], ["A short introduction to alternatives to determine \u0393 is also included.Strategies to Determine Both Thickness and Refractive IndexIt is often stated that it is impossible, or at least very hard, to resolve both d and N for a thin film in an ellipsometric experiment.", [["\u0393", "DNA", 50, 51], ["a thin film", "TEST", 221, 232], ["Refractive", "OBSERVATION", 112, 122]]], ["The argument is that the product Nd enters into the film phase thickness \u03b2 in the reflection coefficients in the three-phase model.", [["Nd", "CHEMICAL", 33, 35], ["Nd", "PROBLEM", 33, 35], ["the film phase thickness", "TEST", 48, 72]]], ["From this product it is not possible to determine both d and N .", [["not possible", "UNCERTAINTY", 24, 36]]], ["However,Fig. 2.1The schematic sketches on top show four different protein configurations including irregular shaped, spherical and ellipsoidal (end-on and side-on) molecules.", [["end-on and side-on) molecules", "PROTEIN", 144, 173], ["Fig.", "TEST", 8, 12], ["four different protein configurations", "PROBLEM", 51, 88], ["irregular shaped, spherical and ellipsoidal (end", "PROBLEM", 99, 147], ["four different", "OBSERVATION_MODIFIER", 51, 65], ["protein configurations", "OBSERVATION", 66, 88], ["irregular", "OBSERVATION_MODIFIER", 99, 108], ["shaped", "OBSERVATION_MODIFIER", 109, 115], ["spherical", "OBSERVATION_MODIFIER", 117, 126], ["ellipsoidal", "OBSERVATION_MODIFIER", 131, 142]]], ["Below is shown two simplified models for evaluation: (left) a layer with thickness d and index N representing the layer extension (true thickness) and effective index, respectively; (right) a layer with thickness d eq and index N p representing the equivalent thickness for a dense layer and intrinsic protein index, respectively N enters weakly but independent of d into the reflection expressions through the Fresnel interface coefficients which allows a separation of d and N if the accuracy of the data is sufficiently high.Fig.", [["evaluation", "TEST", 41, 51], ["thickness d and index N", "PROBLEM", 73, 96], ["thickness d eq", "TEST", 203, 217], ["a dense layer and intrinsic protein index", "PROBLEM", 274, 315], ["the data", "TEST", 498, 506], ["left", "ANATOMY_MODIFIER", 54, 58], ["layer", "OBSERVATION_MODIFIER", 114, 119], ["right", "ANATOMY_MODIFIER", 183, 188], ["dense", "OBSERVATION_MODIFIER", 276, 281], ["layer", "OBSERVATION_MODIFIER", 282, 287], ["protein index", "OBSERVATION", 302, 315]]], ["2.1The bottom line is that it all depends on the character of the sample, the measurement conditions and earlier also on the performance of the instrument used.", [["The bottom line", "TREATMENT", 3, 18], ["the measurement conditions", "TEST", 74, 100], ["bottom line", "OBSERVATION", 7, 18]]], ["Modern instruments are very precise and are not limiting.", [["Modern instruments", "TREATMENT", 0, 18]]], ["The traditionally used silicon surfaces have the disadvantage that mainly changes upon adsorption of a protein layer due to that silicon is near-dielectric.", [["silicon", "CHEMICAL", 129, 136], ["silicon", "CHEMICAL", 23, 30], ["silicon", "CHEMICAL", 129, 136], ["The traditionally used silicon surfaces", "TREATMENT", 0, 39], ["a protein layer", "TREATMENT", 101, 116]]], ["The change in can be very large providing very high detection sensitivity but the change in \u03a8 is often small and in most cases smaller than systematic errors in the system.", [["very high detection sensitivity", "PROBLEM", 42, 73], ["systematic errors in the system", "PROBLEM", 140, 171], ["very", "OBSERVATION_MODIFIER", 21, 25], ["large", "OBSERVATION", 26, 31], ["change", "OBSERVATION_MODIFIER", 82, 88], ["often", "OBSERVATION_MODIFIER", 97, 102], ["small", "OBSERVATION_MODIFIER", 103, 108], ["most cases", "OBSERVATION_MODIFIER", 116, 126], ["smaller", "OBSERVATION_MODIFIER", 127, 134], ["system", "ANATOMY", 165, 171]]], ["Effectively there is therefore only one experimental parameter available and two (d and n) or three (d, n and k) model parameters cannot be determined in a single experiment.", [["two (d and n) or three (d, n and k) model parameters", "TREATMENT", 77, 129]]], ["2.1However, there is no principle hindrance to determine both d and N for a protein layer.", [["principle hindrance", "PROBLEM", 24, 43], ["a protein layer", "TREATMENT", 74, 89], ["no", "UNCERTAINTY", 21, 23], ["principle", "OBSERVATION_MODIFIER", 24, 33], ["hindrance", "OBSERVATION", 34, 43]]], ["This was proven already in the 80's for a 2.4 nm thick layer of bovine serum albumin (BSA) adsorbed on a HgCdTe substrate [25] .", [["serum", "ANATOMY", 71, 76], ["HgCdTe", "CHEMICAL", 105, 111], ["HgCdTe", "CHEMICAL", 105, 111], ["bovine", "ORGANISM", 64, 70], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["albumin", "SIMPLE_CHEMICAL", 77, 84], ["BSA", "SIMPLE_CHEMICAL", 86, 89], ["HgCdTe", "SIMPLE_CHEMICAL", 105, 111], ["bovine", "SPECIES", 64, 70], ["a 2.4 nm thick layer of bovine serum albumin", "TREATMENT", 40, 84], ["a HgCdTe substrate", "TREATMENT", 103, 121]]], ["Later similar in situ experiments were performed and the spectral dependence of N of a 4.1 nm thick layer of lactoperoxidase on gold was determined as shown in Fig. 2.2 [26] .Fig.", [["lactoperoxidase", "SIMPLE_CHEMICAL", 109, 124], ["gold", "SIMPLE_CHEMICAL", 128, 132], ["lactoperoxidase", "PROTEIN", 109, 124], ["a 4.1 nm thick layer of lactoperoxidase", "TREATMENT", 85, 124]]], ["2.1The strategy used in the two examples above is based on spectroscopic ellipsometric data and uses that d and n can be determined in a spectral region where k = 0.", [["spectroscopic ellipsometric data", "TEST", 59, 91]]], ["The thickness determined in this way should be considered as a representation of the extension of the layer and the index is the average layer index as illustrated in Fig. 2.1 .", [["thickness", "OBSERVATION_MODIFIER", 4, 13], ["layer", "OBSERVATION_MODIFIER", 102, 107], ["index", "OBSERVATION_MODIFIER", 116, 121], ["average", "OBSERVATION_MODIFIER", 129, 136], ["layer", "OBSERVATION_MODIFIER", 137, 142], ["index", "OBSERVATION_MODIFIER", 143, 148], ["Fig", "OBSERVATION_MODIFIER", 167, 170]]], ["The latter would correspond to the intrinsic refractive index of the protein itself only if the layer is 100 % dense which rarely is the case for a non-crystalline layer.Fig.", [["a non-crystalline layer", "TREATMENT", 146, 169], ["refractive index", "OBSERVATION", 45, 61], ["layer", "OBSERVATION_MODIFIER", 96, 101], ["100 %", "OBSERVATION_MODIFIER", 105, 110], ["dense", "OBSERVATION", 111, 116]]], ["2.1Kramers-Kronig counterpart to the \u03b1-band around 3 eV is not seen in n at the scales used.", [["2.1Kramers", "PROTEIN", 0, 10]]], ["2.1Arwin-Aspnes method - [28] Analytical inversion k = 0 [ 31] Dispersion models Cauchy, Gauss, Lorentz etc. [32, 33] Malmsten [27] used interference enhancement to study protein adsorption on silicon with 30 nm thermal oxide and could thereby reduce the disadvantage with silicon.", [["silicon", "CHEMICAL", 193, 200], ["silicon", "CHEMICAL", 273, 280], ["silicon", "CHEMICAL", 193, 200], ["oxide", "CHEMICAL", 220, 225], ["silicon", "CHEMICAL", 273, 280], ["[32, 33] Malmsten [27]", "SIMPLE_CHEMICAL", 109, 131], ["oxide", "SIMPLE_CHEMICAL", 220, 225], ["Arwin", "TEST", 3, 8], ["method", "TEST", 16, 22], ["Analytical inversion k", "TEST", 30, 52], ["interference enhancement", "PROBLEM", 137, 161], ["study protein adsorption on silicon", "TREATMENT", 165, 200], ["30 nm thermal oxide", "TREATMENT", 206, 225]]], ["He successfully used accurate single wavelength null ellipsometry data recorded in situ to resolve dynamics in d and n (assuming k = 0) for human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen and lysozym.", [["serum", "ANATOMY", 146, 151], ["human", "ORGANISM", 140, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["albumin", "GENE_OR_GENE_PRODUCT", 152, 159], ["HSA", "GENE_OR_GENE_PRODUCT", 161, 164], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 167, 183], ["IgG", "GENE_OR_GENE_PRODUCT", 185, 188], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 191, 201], ["lysozym", "GENE_OR_GENE_PRODUCT", 206, 213], ["human serum albumin", "PROTEIN", 140, 159], ["HSA", "PROTEIN", 161, 164], ["immunoglobulin G", "PROTEIN", 167, 183], ["IgG", "PROTEIN", 185, 188], ["fibrinogen", "PROTEIN", 191, 201], ["lysozym", "PROTEIN", 206, 213], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["accurate single wavelength null ellipsometry data", "TREATMENT", 21, 70], ["k", "TEST", 129, 130], ["human serum albumin", "TEST", 140, 159], ["HSA", "TEST", 161, 164], ["immunoglobulin G (IgG", "TEST", 167, 188], ["fibrinogen", "TEST", 191, 201], ["lysozym", "TEST", 206, 213]]], ["2.1If the interface between the protein layer and the substrate is sufficiently sharp, the Arwin-Aspnes method [28] can be used to find d, whereafter the protein layer index can be determined on a wavelength-by-wavelength basis as shown by [29, 30] .", [["layer", "OBSERVATION_MODIFIER", 40, 45], ["sharp", "OBSERVATION_MODIFIER", 80, 85]]], ["The above methods use numerical inversion to find N at fixed d.", [["numerical inversion", "TREATMENT", 22, 41]]], ["However, if k = 0 is assumed, one can use analytic inversion.", [["k", "TEST", 12, 13], ["analytic inversion", "TREATMENT", 42, 60]]], ["A fifth degree polynomial equation is then obtained.", [["A fifth degree polynomial equation", "TEST", 0, 34], ["fifth degree", "OBSERVATION_MODIFIER", 2, 14], ["polynomial equation", "OBSERVATION", 15, 34]]], ["It can be readily solved and was applied at the air/water interface to layers of arachidic acid and valine gramicidin A with thickness in the range of 2 to 3 nm [31] .", [["arachidic acid", "CHEMICAL", 81, 95], ["valine gramicidin", "CHEMICAL", 100, 117], ["arachidic acid", "CHEMICAL", 81, 95], ["valine", "CHEMICAL", 100, 106], ["arachidic acid", "SIMPLE_CHEMICAL", 81, 95], ["valine gramicidin A", "SIMPLE_CHEMICAL", 100, 119], ["the air/water interface", "TREATMENT", 44, 67], ["arachidic acid", "TREATMENT", 81, 95], ["valine gramicidin", "TREATMENT", 100, 117]]], ["An alternative to wavelength-by-wavelength analysis is to include dispersion models for N as shown by Berlind et al. [32] who used a Cauchy dispersion in the visible part of the spectrum and Arwin et al. [33] who used a more complex model dielectric function in the infrared.", [["N", "CHEMICAL", 88, 89], ["a Cauchy dispersion", "TREATMENT", 131, 150], ["a more complex model dielectric function", "TREATMENT", 218, 258]]], ["2.1One can also combine ellipsometry with other methods to determine both thickness and porosity of thin organic films.", [["other methods", "TREATMENT", 42, 55], ["thin organic films", "TEST", 100, 118]]], ["Rodenhausen et al. [20] combined in situ ellipsometry with quartz crystal microbalance measurements to address the ultrathin film limit 2\u03c0nd/\u03bb 1.", [["quartz", "CHEMICAL", 59, 65], ["quartz crystal microbalance measurements", "TEST", 59, 99], ["the ultrathin film limit", "TEST", 111, 135]]], ["11 in this book.Spectral Representations of Protein LayersAs discussed above, a majority of the early ellipsometric protein adsorption studies were performed with single wavelength methodology and only a single value of N was obtained, often at \u03bb = 546 nm or \u03bb = 633 nm.", [["Protein Layers", "PROTEIN", 44, 58], ["Protein Layers", "PROBLEM", 44, 58], ["the early ellipsometric protein adsorption studies", "TEST", 92, 142], ["Protein Layers", "OBSERVATION", 44, 58]]], ["However, spectroscopic ellipsometry comes more an more in use for protein adsorption studies and with spectroscopic data available it is possible to model N for a protein layer using dispersion models.", [["spectroscopic ellipsometry", "TEST", 9, 35], ["protein adsorption studies", "TEST", 66, 92], ["spectroscopic data", "TEST", 102, 120], ["a protein layer using dispersion models", "TREATMENT", 161, 200]]], ["Most protein molecules are non-absorbing in the visible spectral range and thus a protein layer can be assumed to be transparent.", [["protein molecules", "PROTEIN", 5, 22], ["Most protein molecules", "PROBLEM", 0, 22], ["a protein layer", "PROBLEM", 80, 95], ["molecules", "OBSERVATION", 13, 22], ["transparent", "OBSERVATION_MODIFIER", 117, 128]]], ["A Cauchy model is the basic model and is defined bySpectral Representations of Protein Layerswhere A, B and C are parameters determined by fitting Eq.", [["C", "SIMPLE_CHEMICAL", 108, 109], ["Protein Layerswhere A, B and C", "PROTEIN", 79, 109], ["Protein Layerswhere", "OBSERVATION", 79, 98]]], ["Sometimes it is sufficient to fit only A and B. Protein molecules have a background adsorption in the ultraviolet (UV) spectral range due to the peptide chain which is seen in the lactoperoxidase-spectrum in Fig. 2 In the infrared (IR) region, proteins have characteristic but complex absorption bands which carry information about protein secondary structure and other structural details.", [["lactoperoxidase", "SIMPLE_CHEMICAL", 180, 195], ["lactoperoxidase", "PROTEIN", 180, 195], ["infrared (IR) region", "DNA", 222, 242], ["A and B. Protein molecules", "PROBLEM", 39, 65], ["the peptide chain", "PROBLEM", 141, 158], ["the lactoperoxidase", "TREATMENT", 176, 195], ["complex absorption bands", "PROBLEM", 277, 301], ["complex", "OBSERVATION_MODIFIER", 277, 284], ["absorption bands", "OBSERVATION", 285, 301]]], ["The analysis of these optical features allows for example to determine the amount of \u03b1-helix or \u03b2-sheet structure in proteins [34] .", [["\u03b1-helix", "SIMPLE_CHEMICAL", 85, 92], ["\u03b1-helix", "PROTEIN", 85, 92], ["\u03b2-sheet structure", "PROTEIN", 96, 113], ["these optical features", "TEST", 16, 38]]], ["These vibrational resonances can also be modeled with Lorentzian or Gaussian dispersion models.", [["Lorentzian or Gaussian dispersion models", "TREATMENT", 54, 94]]], ["A suitable overall model dielectric function (MDF) for = N 2 versus photon energy E isSpectral Representations of Protein Layerswhere \u221e is a constant accounting for resonances at energies larger than the spectral range studied, A j , \u0393 j and E j are amplitude, broadening and energy, respectively, of j UV-VIS resonances, and A k , \u0393 k and\u03bd k are amplitude, broadening and energy, respectively, of k IR resonances.", [["photon energy", "TEST", 68, 81], ["resonances at energies", "PROBLEM", 165, 187], ["A k", "TEST", 326, 329], ["Protein Layerswhere", "OBSERVATION", 114, 133]]], ["(2.2) is given later in this chapter.Determination of Surface Mass DensityIf the correlation between N and d cannot be resolved one can present results in terms of the derived parameter \u0393 , the surface mass density.", [["surface", "ANATOMY", 194, 201], ["Surface Mass Density", "PROBLEM", 54, 74], ["the surface mass density", "PROBLEM", 190, 214], ["Surface", "OBSERVATION_MODIFIER", 54, 61], ["Mass", "OBSERVATION", 62, 66], ["Density", "OBSERVATION_MODIFIER", 67, 74], ["surface", "OBSERVATION_MODIFIER", 194, 201], ["mass", "OBSERVATION", 202, 206]]], ["As an example, Cuypers et al. [35] found that the time evolution of d and n (k = 0 was assumed) was very noise for adsorption of protrombin on chromium, whereas if \u0393 was derived, a considerable reduction in noise occurs.", [["protrombin", "CHEMICAL", 129, 139], ["chromium", "CHEMICAL", 143, 151], ["protrombin", "CHEMICAL", 129, 139], ["chromium", "CHEMICAL", 143, 151], ["protrombin", "SIMPLE_CHEMICAL", 129, 139], ["chromium", "SIMPLE_CHEMICAL", 143, 151], ["\u0393", "PROTEIN", 164, 165], ["d and n (k = 0", "TEST", 68, 82], ["very noise", "PROBLEM", 100, 110], ["protrombin on chromium", "PROBLEM", 129, 151], ["a considerable reduction in noise", "PROBLEM", 179, 212]]], ["Some advantages with using \u0393 is that it is easy to understand and also directly can be compared with results from radio immunoassays [36, 37] and gravimetric methods.", [["radio immunoassays", "TEST", 114, 132], ["gravimetric methods", "TEST", 146, 165]]], ["In addition one need the molecular weight, molar refractivity and partial specific volume of the molecules in the layer.", [["the molecular weight", "TEST", 21, 41], ["molar refractivity", "PROBLEM", 43, 61], ["partial", "OBSERVATION_MODIFIER", 66, 73], ["specific", "OBSERVATION_MODIFIER", 74, 82], ["volume", "OBSERVATION_MODIFIER", 83, 89], ["molecules", "OBSERVATION", 97, 106], ["layer", "ANATOMY_MODIFIER", 114, 119]]], ["The model is derived assuming a Lorentz-Lorenz effective medium for a mixed layer (ambient and biomolecules).Determination of Surface Mass DensityA more frequently used and recommended model for \u0393 was developed by de Feijter et al. [38] .", [["a Lorentz-Lorenz effective medium", "TREATMENT", 30, 63], ["a mixed layer (ambient and biomolecules", "TREATMENT", 68, 107], ["Surface Mass DensityA", "PROBLEM", 126, 147], ["Surface", "OBSERVATION_MODIFIER", 126, 133], ["Mass", "OBSERVATION", 134, 138]]], ["They derived the expression 3Determination of Surface Mass Densitywhere n amb is the refractive index of the ambient (in general a liquid) and dn/dc is the refractive index increment of the protein.", [["Surface Mass", "PROBLEM", 46, 58], ["Surface", "OBSERVATION_MODIFIER", 46, 53], ["Mass", "OBSERVATION", 54, 58]]], ["The value on dn/dc can be determined with an Abbe refractometer or with prism deviation measurements on protein solutions [23] .", [["dn", "DNA", 13, 15], ["The value", "TEST", 0, 9], ["an Abbe refractometer", "TREATMENT", 42, 63], ["prism deviation measurements", "TEST", 72, 100], ["protein solutions", "TREATMENT", 104, 121]]], ["Further possibilities to determine \u0393 and also a comparison among the methods can be found elsewhere [10] .Protein Adsorption and Dynamics on Model SurfacesDetermination of thickness and/or surface mass density is one of the most common applications of ellipsometry in the area of protein adsorption.", [["surface", "ANATOMY", 189, 196], ["Protein Adsorption", "TREATMENT", 106, 124], ["thickness and/or surface mass density", "PROBLEM", 172, 209], ["Adsorption", "OBSERVATION_MODIFIER", 114, 124], ["Surfaces", "OBSERVATION_MODIFIER", 147, 155], ["thickness", "OBSERVATION_MODIFIER", 172, 181], ["surface", "OBSERVATION_MODIFIER", 189, 196], ["mass", "OBSERVATION", 197, 201], ["density", "OBSERVATION", 202, 209], ["most common", "OBSERVATION_MODIFIER", 224, 235], ["ellipsometry", "OBSERVATION", 252, 264], ["protein adsorption", "OBSERVATION", 280, 298]]], ["It is often performed in situ to monitor surface dynamics.", [["surface", "ANATOMY", 41, 48], ["surface", "CELLULAR_COMPONENT", 41, 48]]], ["[6] [7] [8] [9] [10] [11] [12] [13] .Studies of Protein Layer StructureAbove we discussed the basic challenge to quantify and monitor the dynamics of protein adsorption.", [["[6] [7] [8] [9", "CHEMICAL", 0, 14], ["[6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 0, 35], ["the basic challenge", "TEST", 90, 109], ["protein adsorption", "TREATMENT", 150, 168]]], ["In this section we will address some structural aspects including layer density, layer structure from dynamics of n and d, molecular ordering from anisotropy and from analysis of infrared chemical signatures.", [["layer density", "PROBLEM", 66, 79], ["infrared chemical signatures", "PROBLEM", 179, 207], ["layer", "OBSERVATION_MODIFIER", 66, 71], ["density", "OBSERVATION", 72, 79], ["layer", "OBSERVATION_MODIFIER", 81, 86]]], ["Layer Density A very basic structural parameter of a protein layer is its density.Studies of Protein Layer StructureFor an adsorbed layer of a rigid protein, there will certainly be density deficiencies.", [["Protein Layer Structure", "PROTEIN", 93, 116], ["Layer Density", "PROBLEM", 0, 13], ["a rigid protein", "PROBLEM", 141, 156], ["density deficiencies", "PROBLEM", 182, 202], ["Density", "OBSERVATION", 6, 13], ["very", "OBSERVATION_MODIFIER", 16, 20], ["basic structural", "OBSERVATION_MODIFIER", 21, 37], ["parameter", "OBSERVATION_MODIFIER", 38, 47], ["protein layer", "OBSERVATION", 53, 66], ["density", "OBSERVATION", 74, 81], ["Layer Structure", "OBSERVATION", 101, 116], ["rigid protein", "OBSERVATION", 143, 156], ["density deficiencies", "OBSERVATION", 182, 202]]], ["For a more flexible protein, conformation changes may occur upon adsorption but still one cannot expect an ideal homogeneous layer with flat parallel boundaries.", [["a more flexible protein", "PROBLEM", 4, 27]]], ["Density is strongly related to n and various effective medium approximations (EMA) are used.", [["strongly related to", "UNCERTAINTY", 11, 30], ["effective", "OBSERVATION_MODIFIER", 45, 54], ["medium approximations", "OBSERVATION", 55, 76]]], ["A very simple density modeling can be done if n for a (more) dense protein layer is known as examplified by determination of a density deficiency of 30 % of a BSA layer on platinum [6] compared to a nominally dense BSA layer on HgCdTe.", [["platinum", "CHEMICAL", 172, 180], ["HgCdTe", "CHEMICAL", 228, 234], ["platinum", "CHEMICAL", 172, 180], ["HgCdTe", "CHEMICAL", 228, 234], ["BSA", "SIMPLE_CHEMICAL", 159, 162], ["platinum [6]", "SIMPLE_CHEMICAL", 172, 184], ["BSA layer", "SIMPLE_CHEMICAL", 215, 224], ["HgCdTe", "SIMPLE_CHEMICAL", 228, 234], ["A very simple density modeling", "PROBLEM", 0, 30], ["a (more) dense protein layer", "PROBLEM", 52, 80], ["a density deficiency", "PROBLEM", 125, 145], ["a BSA layer on platinum", "TREATMENT", 157, 180], ["a nominally dense BSA layer on HgCdTe", "PROBLEM", 197, 234], ["very", "OBSERVATION_MODIFIER", 2, 6], ["simple", "OBSERVATION_MODIFIER", 7, 13], ["density", "OBSERVATION", 14, 21], ["density deficiency", "OBSERVATION", 127, 145], ["dense", "OBSERVATION_MODIFIER", 209, 214], ["BSA", "OBSERVATION_MODIFIER", 215, 218], ["layer", "OBSERVATION_MODIFIER", 219, 224]]], ["Ellipsometry can in principle provide n for thin layers as discussed above but it has not been proven yet to have sensitivity to resolve in-depth density profiles for protein monolayers as can be done with neutron reflectometry [39, 40] .", [["monolayers", "CELL", 175, 185], ["Ellipsometry", "TEST", 0, 12], ["thin layers", "PROBLEM", 44, 55], ["sensitivity", "PROBLEM", 114, 125], ["protein monolayers", "TEST", 167, 185], ["neutron reflectometry", "TEST", 206, 227]]], ["However, for thicker protein layers, density depth-profiling is possible as shown by Kozma et al. [41] .", [["thicker protein layers", "PROBLEM", 13, 35], ["density depth-profiling", "PROBLEM", 37, 60], ["density", "OBSERVATION", 37, 44]]], ["They studied several hundred nm thick flagellar filament protein layers on surface activated Ta 2 O 3 .", [["surface", "ANATOMY", 75, 82], ["Ta 2 O 3", "CHEMICAL", 93, 101], ["Ta 2 O 3", "GENE_OR_GENE_PRODUCT", 93, 101], ["surface activated Ta 2 O 3", "PROTEIN", 75, 101]]], ["The protein layers were described by five EMA sublayers.", [["EMA sublayers", "PROTEIN", 42, 55], ["protein layers", "OBSERVATION", 4, 18]]], ["By fitting this model to spectroscopic ellipsometry data, they determined the in-depth variation in surface mass density.", [["surface", "ANATOMY", 100, 107], ["spectroscopic ellipsometry data", "TEST", 25, 56], ["surface mass density", "PROBLEM", 100, 120], ["surface", "OBSERVATION_MODIFIER", 100, 107], ["mass density", "OBSERVATION", 108, 120]]], ["Malmsten [27] made pioneering work and used single-wavelength ellipsometry to resolve structural details and film formation mechanisms for layers of fibrinogen, \u03b3 -globulin and more proteins on silicon with 30 nm thermal oxide.", [["\u03b3 -globulin", "CHEMICAL", 161, 172], ["silicon", "CHEMICAL", 194, 201], ["silicon", "CHEMICAL", 194, 201], ["oxide", "CHEMICAL", 221, 226], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 149, 159], ["\u03b3 -globulin", "SIMPLE_CHEMICAL", 161, 172], ["thermal oxide", "SIMPLE_CHEMICAL", 213, 226], ["fibrinogen", "PROTEIN", 149, 159], ["\u03b3", "PROTEIN", 161, 162], ["globulin", "PROTEIN", 164, 172], ["single-wavelength ellipsometry", "TREATMENT", 44, 74], ["fibrinogen", "TEST", 149, 159], ["globulin", "TREATMENT", 164, 172], ["silicon", "TREATMENT", 194, 201], ["30 nm thermal oxide", "TREATMENT", 207, 226]]], ["3 shows that IgG adsorbing on an oxidized silicon surface made hydrophobic by methylization, proceeds with n linearly increasing from the value of the ambient medium to a final value of around 1.37 corresponding to \u0393 = 3 mg/m 2 .", [["silicon", "CHEMICAL", 42, 49], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "PROTEIN", 13, 16], ["IgG adsorbing", "PROBLEM", 13, 26], ["an oxidized silicon surface", "TREATMENT", 30, 57]]], ["During the whole adsorption process, d is more or less constant except for low \u0393 where noise is seen.", [["low \u0393 where noise", "PROBLEM", 75, 92]]], ["The dimensions of IgG are 23.5\u00d74.5\u00d74.5 nm and Malmsten concluded that IgG has a near end-on orientation.", [["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgG", "PROTEIN", 18, 21], ["IgG", "PROTEIN", 70, 73], ["IgG", "TEST", 18, 21], ["Malmsten", "TEST", 46, 54], ["IgG", "TEST", 70, 73], ["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["IgG", "OBSERVATION_MODIFIER", 18, 21], ["IgG", "OBSERVATION", 70, 73]]], ["The relatively low n and \u0393 show in addition that the layer has low packing density.", [["low packing density", "PROBLEM", 63, 82], ["layer", "OBSERVATION_MODIFIER", 53, 58], ["low packing", "OBSERVATION_MODIFIER", 63, 74], ["density", "OBSERVATION", 75, 82]]], ["Fibrinogen showed a more complex dynamics with a near-linear change in both n and d [27] .", [["Fibrinogen", "GENE_OR_GENE_PRODUCT", 0, 10], ["Fibrinogen", "PROTEIN", 0, 10], ["Fibrinogen", "TEST", 0, 10], ["a more complex dynamics", "PROBLEM", 18, 41], ["more complex", "OBSERVATION_MODIFIER", 20, 32], ["linear", "OBSERVATION_MODIFIER", 54, 60], ["change", "OBSERVATION", 61, 67]]], ["Further structural studies with ellipsometry along these lines but also including multilayer adsorption were performed by Berlind et al. [32] who studied fibrinogen covalently bonded on functionalized silicon surfaces using affinity ligand coupling chemistry.", [["silicon", "CHEMICAL", 201, 208], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 154, 164], ["silicon surfaces", "SIMPLE_CHEMICAL", 201, 217], ["fibrinogen", "PROTEIN", 154, 164], ["Further structural studies", "TEST", 0, 26], ["ellipsometry", "TEST", 32, 44], ["functionalized silicon surfaces", "TREATMENT", 186, 217], ["affinity ligand coupling chemistry", "TREATMENT", 224, 258]]], ["Adsorption of fibrinogen was monitored in situ with ellipsometry at \u03bb = 500 nm and ellipsometric spectra were measured at steady-state in the range 350-1050 nm.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 14, 24], ["fibrinogen", "PROTEIN", 14, 24], ["fibrinogen", "TEST", 14, 24], ["ellipsometry", "TEST", 52, 64], ["ellipsometric spectra", "TEST", 83, 104], ["fibrinogen", "OBSERVATION", 14, 24]]], ["Fibrinogen matrices with thickness up to 58 nm and with surface mass density \u0393 of 1.6 \u00b5g/cm 2 were prepared in this way.", [["surface", "ANATOMY", 56, 63], ["Fibrinogen", "GENE_OR_GENE_PRODUCT", 0, 10], ["Fibrinogen matrices", "TEST", 0, 19], ["thickness", "TEST", 25, 34], ["surface mass density", "TEST", 56, 76], ["thickness", "OBSERVATION_MODIFIER", 25, 34], ["58 nm", "OBSERVATION_MODIFIER", 41, 46], ["surface", "OBSERVATION_MODIFIER", 56, 63], ["mass", "OBSERVATION", 64, 68], ["density", "OBSERVATION_MODIFIER", 69, 76]]], ["The first adsorption step results in a fibrinogen layer with \u0393 = 1 \u00b5g/cm 2 .", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 39, 49], ["a fibrinogen layer", "TEST", 37, 55], ["\u0393", "TEST", 61, 62]]], ["A chemical activation using ethyl-3-dimethyl-aminopropyl-carbodiimide and N-hydroxy-succinimide (EDC/NHS) methodology was then performed with intention to promote binding of the next fibrinogen layer.", [["ethyl-3-dimethyl-aminopropyl-carbodiimide", "CHEMICAL", 28, 69], ["N-hydroxy-succinimide", "CHEMICAL", 74, 95], ["EDC", "CHEMICAL", 97, 100], ["ethyl-3-dimethyl-aminopropyl-carbodiimide", "CHEMICAL", 28, 69], ["N-hydroxy-succinimide", "CHEMICAL", 74, 95], ["EDC", "CHEMICAL", 97, 100], ["ethyl-3-dimethyl-aminopropyl-carbodiimide", "SIMPLE_CHEMICAL", 28, 69], ["N-hydroxy-succinimide", "SIMPLE_CHEMICAL", 74, 95], ["EDC", "SIMPLE_CHEMICAL", 97, 100], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 183, 193], ["ethyl", "TREATMENT", 28, 33], ["dimethyl", "TREATMENT", 36, 44], ["aminopropyl-carbodiimide", "TREATMENT", 45, 69], ["hydroxy-succinimide (EDC/NHS", "TREATMENT", 76, 104]]], ["However, only a small thickness increase was observed upon a second fibrinogen adsorption step.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 68, 78], ["fibrinogen", "PROTEIN", 68, 78], ["a small thickness increase", "PROBLEM", 14, 40], ["a second fibrinogen adsorption step", "TREATMENT", 59, 94], ["small", "OBSERVATION_MODIFIER", 16, 21], ["thickness", "OBSERVATION_MODIFIER", 22, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["Furthermore \u0393 increases monotonically during the whole experiment and when n or d decreases, \u0393 remains constant, i.e. no desorption occurs.", [["increases", "OBSERVATION_MODIFIER", 14, 23], ["monotonically", "OBSERVATION_MODIFIER", 24, 37]]], ["This thickness decrease is accompanied with an index increase supporting a densification of the fibrinogen layer.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 96, 106], ["This thickness decrease", "PROBLEM", 0, 23], ["an index increase", "PROBLEM", 44, 61], ["a densification of the fibrinogen layer", "PROBLEM", 73, 112], ["thickness", "OBSERVATION_MODIFIER", 5, 14], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["accompanied with", "UNCERTAINTY", 27, 43], ["index", "OBSERVATION_MODIFIER", 47, 52], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["densification", "OBSERVATION_MODIFIER", 75, 88], ["fibrinogen layer", "OBSERVATION", 96, 112]]], ["A proposed structural model for the fibrinogen layer is shown in Fig. 2 .5 and is further discussed in [32] .", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 36, 46], ["the fibrinogen layer", "TEST", 32, 52], ["structural model", "OBSERVATION", 11, 27], ["fibrinogen layer", "OBSERVATION", 36, 52], ["Fig", "OBSERVATION_MODIFIER", 65, 68]]], ["Earlier single-\u03bb ellipsometry experiments with ex situ activation and incubation showed very different results [42] with a considerable increase in \u0393 after each incubation step more or less proportional to the number of incubation/activation steps performed.", [["incubation/activation steps", "TREATMENT", 220, 247]]], ["These differences are most probably due to the drying steps in the ex situ case.Molecular Ordering from AnisotropyProtein molecules in a layer are normally assumed to be randomly oriented and very few protein layers are crystalline.", [["AnisotropyProtein molecules", "PROTEIN", 104, 131], ["most probably due to", "UNCERTAINTY", 22, 42], ["drying", "OBSERVATION", 47, 53]]], ["However, there are some indications that protein molecules can be uniaxial.", [["protein molecules", "PROTEIN", 41, 58], ["protein molecules", "PROBLEM", 41, 58]]], ["Sano [43] showed that structural anisotropy in BSA leads to uniaxial In addition there may be form induced birefringence in protein layers as briefly discussed in the methodology section above.", [["BSA", "SIMPLE_CHEMICAL", 47, 50], ["structural anisotropy", "PROBLEM", 22, 43], ["induced birefringence in protein layers", "PROBLEM", 99, 138], ["may be form", "UNCERTAINTY", 87, 98], ["induced birefringence", "OBSERVATION", 99, 120], ["protein layers", "OBSERVATION", 124, 138]]], ["Of course, the resolving power of ellipsometry on protein films may be insufficient to resolve their anisotropy regardless of being intrinsic or form induced.", [["protein films", "TEST", 50, 63], ["resolving", "OBSERVATION_MODIFIER", 15, 24], ["power", "OBSERVATION_MODIFIER", 25, 30]]], ["In highly ordered, but thin films of fatty acids prepared by Langmuir-Blodgett techniques, Engelsen [44] demonstrated that anisotropic modeling is relevant.", [["fatty acids", "CHEMICAL", 37, 48], ["Langmuir-Blodgett", "CHEMICAL", 61, 78], ["fatty acids", "CHEMICAL", 37, 48], ["fatty acids", "SIMPLE_CHEMICAL", 37, 48], ["thin films of fatty acids", "TEST", 23, 48]]], ["Future refinement of ellipsometric methodology will tell if anisotropy of protein films will add to further understanding of their properties and structure.Molecular Ordering from AnisotropyChemical Structure Infrared spectroscopy is well established for studies of protein structure.", [["ellipsometric methodology", "TEST", 21, 46], ["anisotropy of protein films", "TEST", 60, 87], ["Infrared spectroscopy", "TEST", 209, 230], ["protein structure", "PROBLEM", 266, 283]]], ["The advantage is that vibrational signatures can be correlated to the secondary structures in protein molecules [34] .", [["protein molecules", "PROTEIN", 94, 111]]], ["However, surprisingly few reports on application of infrared spectroscopic ellipsometry (IRSE) for studies of protein layers are found in the literature in spite of that IRSE has the advantage to provide a quantification of the amount of protein on a surface, i.e. to determine the layer thickness in addition to the IR spectral features.", [["surface", "ANATOMY", 251, 258], ["IRSE", "SIMPLE_CHEMICAL", 170, 174], ["surface", "CELLULAR_COMPONENT", 251, 258], ["infrared spectroscopic ellipsometry", "TEST", 52, 87], ["protein layers", "PROBLEM", 110, 124], ["few", "OBSERVATION_MODIFIER", 22, 25]]], ["The limited use of IRSE may be due to that the instrumentation is rather expensive and slow.", [["IRSE", "TREATMENT", 19, 23], ["the instrumentation", "TREATMENT", 43, 62], ["instrumentation", "OBSERVATION", 47, 62]]], ["With a pyroelectric DTGS detector, a typical measurement on a protein monolayer may take 12 h or more but using other types of detectors can shorten the measurement time.", [["monolayer", "CELL", 70, 79], ["a pyroelectric DTGS detector", "TEST", 5, 33], ["a protein monolayer", "TREATMENT", 60, 79]]], ["A rather large sample area of several mm 2 is also required.", [["A rather large sample area", "PROBLEM", 0, 26], ["large", "OBSERVATION_MODIFIER", 9, 14], ["sample", "OBSERVATION_MODIFIER", 15, 21], ["area", "OBSERVATION_MODIFIER", 22, 26], ["several mm", "OBSERVATION_MODIFIER", 30, 40]]], ["The speed and sample size can be reduced by employing synchrotron infrared spectroscopic ellipsometry as shown by Hinrichs et al. [45] .", [["synchrotron infrared spectroscopic ellipsometry", "TREATMENT", 54, 101]]], ["They studied peptides, proteins and their antibodies and could in particular identify the so called amide bands [19] .Molecular Ordering from AnisotropyIRSE has been applied to determine N of bovine carbonic anhydrase (BCA) adsorbed in a 500 nm thick porous silicon layer [18] .", [["amide", "CHEMICAL", 100, 105], ["silicon", "CHEMICAL", 258, 265], ["bovine", "ORGANISM", 192, 198], ["carbonic anhydrase", "GENE_OR_GENE_PRODUCT", 199, 217], ["BCA", "SIMPLE_CHEMICAL", 219, 222], ["antibodies", "PROTEIN", 42, 52], ["AnisotropyIRSE", "PROTEIN", 142, 156], ["bovine carbonic anhydrase", "PROTEIN", 192, 217], ["bovine", "SPECIES", 192, 198], ["AnisotropyIRSE", "TREATMENT", 142, 156], ["bovine carbonic anhydrase", "PROBLEM", 192, 217], ["a 500 nm thick porous silicon layer", "TREATMENT", 236, 271]]], ["Using Lorentzian resonances, as those in Eq.", [["Lorentzian resonances", "TREATMENT", 6, 27]]], ["(2.2), five absorption bands, including the amide I, II and A, could be resolved and parameterized.", [["amide", "CHEMICAL", 44, 49], ["amide I, II and A", "PROTEIN", 44, 61], ["five absorption bands", "TEST", 7, 28]]], ["In addition it was found that more BCA per surface area was adsorbed near the surface.", [["surface area", "ANATOMY", 43, 55], ["surface", "ANATOMY", 78, 85], ["BCA", "CHEMICAL", 35, 38], ["BCA", "CHEMICAL", 35, 38], ["BCA", "SIMPLE_CHEMICAL", 35, 38], ["surface", "CELLULAR_COMPONENT", 78, 85], ["more", "OBSERVATION_MODIFIER", 30, 34], ["BCA", "OBSERVATION", 35, 38], ["surface", "OBSERVATION_MODIFIER", 43, 50], ["surface", "OBSERVATION_MODIFIER", 78, 85]]], ["Protein monolayers and multilayers have also Real part n (left) and extinction coefficient k (right) for a fibrinogen monolayer on gold measured at room temperature (RT) before and after heating to 120 \u2022 C. Reprinted from [33] been studied by IRSE on flat model surfaces [33] .", [["monolayers", "ANATOMY", 8, 18], ["monolayers", "CELL", 8, 18], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 107, 117], ["IRSE", "SIMPLE_CHEMICAL", 243, 247], ["Protein monolayers", "TEST", 0, 18], ["multilayers", "TEST", 23, 34], ["a fibrinogen monolayer", "TEST", 105, 127], ["left", "ANATOMY_MODIFIER", 58, 62]]], ["In particular the effect of heating on the secondary structure (the amide bands) were observed.", [["amide", "CHEMICAL", 68, 73], ["the amide bands", "TREATMENT", 64, 79], ["effect", "OBSERVATION_MODIFIER", 18, 24]]], ["For a multilayer with ten alternating HSA and anti-HSA layers with a total thickness of 40.2 nm, it was found that heating to 120 \u2022 C reduced the thickness around 1 nm and that mainly the amide A band was affected as observed in N .", [["amide A", "CHEMICAL", 188, 195], ["HSA", "SIMPLE_CHEMICAL", 38, 41], ["ten alternating HSA", "TREATMENT", 22, 41], ["anti-HSA layers", "TREATMENT", 46, 61], ["a total thickness", "TEST", 67, 84], ["40.2 nm", "OBSERVATION_MODIFIER", 88, 95]]], ["Upon heating to 200 \u2022 C, major changes in all amide bands occurred.", [["amide", "CHEMICAL", 46, 51], ["all amide bands", "TREATMENT", 42, 57]]], ["Also effects of heating a 4.1 nm monolayer of fibrinogen on gold was studied [33] .", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 46, 56], ["gold", "SIMPLE_CHEMICAL", 60, 64], ["fibrinogen", "PROTEIN", 46, 56], ["heating a 4.1 nm monolayer of fibrinogen", "TREATMENT", 16, 56]]], ["Figure 2 .6 shows that heating of a fibrinogen to 120 \u2022 C increases both n and k.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 36, 46], ["fibrinogen", "PROTEIN", 36, 46], ["Figure", "TEST", 0, 6], ["a fibrinogen", "TEST", 34, 46]]], ["The thickness decreases to 3.5 nm so effectively a densification of the layer has occurred.", [["a densification of the layer", "PROBLEM", 49, 77], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["decreases", "OBSERVATION_MODIFIER", 14, 23], ["3.5 nm", "OBSERVATION_MODIFIER", 27, 33], ["densification", "OBSERVATION_MODIFIER", 51, 64], ["layer", "OBSERVATION_MODIFIER", 72, 77]]], ["A possible explanation is that water has desorbed.", [["water", "SIMPLE_CHEMICAL", 31, 36], ["possible explanation is", "UNCERTAINTY", 2, 25]]], ["Very small changes, except for increase in amplitudes, very found upon heating.Protein Layer Based BiosensingIt was early shown that ellipsometry could be used for detection of biomolecules (see e.g. Ref.", [["Very small changes", "PROBLEM", 0, 18], ["increase in amplitudes", "PROBLEM", 31, 53], ["ellipsometry", "TEST", 133, 145], ["biomolecules", "PROBLEM", 177, 189], ["small", "OBSERVATION_MODIFIER", 5, 10], ["changes", "OBSERVATION", 11, 18], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["The Isoscope or comparison ellipsometer [47] and the fixed polarizer ellipsometer [48] are two examples of suggested point-of-care systems.", [["the fixed polarizer ellipsometer", "TREATMENT", 49, 81]]], ["Also imaging ellipsometry were suggested many years ago as a high through-put system for biosensing [14, 49] .", [["imaging ellipsometry", "TEST", 5, 25]]], ["It seems that ellipsometry as a biosensor principle not finds its way from research to clinical laboratories.", [["a biosensor principle", "PROBLEM", 30, 51]]], ["No user-friendly and costefficient instruments suitable for clinical use are commercially available.", [["costefficient instruments", "TREATMENT", 21, 46]]], ["In spite of this, suggestions for biosensing applications continues to be published which indicates that researches are believers in its potential.", [["biosensing applications", "TREATMENT", 34, 57]]], ["The review will here be limited to presentation of some studies addressing two of the most important aspects in this context: (1) imaging ellipsometry readout for achieving high through-put and (2) bioaffinity for achieving specificity.Protein Layer Based BiosensingImaging ellipsometry provides a means to map the lateral thickness or surface mass density variations on a surface.", [["surface", "ANATOMY", 336, 343], ["surface", "ANATOMY", 373, 380], ["surface", "CELLULAR_COMPONENT", 373, 380], ["some studies", "TEST", 51, 63], ["imaging ellipsometry readout", "TEST", 130, 158], ["Imaging ellipsometry", "TEST", 266, 286], ["surface mass density variations", "PROBLEM", 336, 367], ["lateral", "OBSERVATION_MODIFIER", 315, 322], ["thickness", "OBSERVATION_MODIFIER", 323, 332], ["surface", "OBSERVATION_MODIFIER", 336, 343], ["mass", "OBSERVATION", 344, 348], ["density variations", "OBSERVATION", 349, 367]]], ["By using a beam with a large diameter, it is possible to image a large area, e.g. 15 \u00d7 30 mm 2 [14] .", [["a large diameter", "TREATMENT", 21, 37], ["large diameter", "OBSERVATION_MODIFIER", 23, 37], ["large", "OBSERVATION_MODIFIER", 65, 70], ["area", "OBSERVATION_MODIFIER", 71, 75]]], ["An example of imaging of 4 mm diameter spots of three different proteins is shown in Fig. 2.7 .", [["imaging", "TEST", 14, 21], ["4 mm diameter spots of three different proteins", "PROBLEM", 25, 72], ["4 mm", "OBSERVATION_MODIFIER", 25, 29], ["three different", "OBSERVATION_MODIFIER", 48, 63], ["proteins", "OBSERVATION", 64, 72], ["Fig", "OBSERVATION_MODIFIER", 85, 88]]], ["With a focusing lens, small area, e.g. 60 \u00d7 200 \u00b5m 2 can be imaged [50] .", [["small area", "PROBLEM", 22, 32], ["small", "OBSERVATION_MODIFIER", 22, 27], ["area", "OBSERVATION_MODIFIER", 28, 32]]], ["Recently Gunnarsson et al. [51] demonstrated time-resolved imaging with a sensitivity in surface mass density of 1 ng/mm 2 and pixel size less than 0.5 \u00b5m.", [["surface", "ANATOMY", 89, 96], ["imaging", "TEST", 59, 66], ["a sensitivity in surface mass density", "TEST", 72, 109], ["pixel size", "TEST", 127, 137], ["surface", "OBSERVATION_MODIFIER", 89, 96], ["mass", "OBSERVATION", 97, 101], ["size", "OBSERVATION_MODIFIER", 133, 137]]], ["Development of affinity biochips with 900 targets and ellipsometric readout has also been reported [52] .Protein Layer Based BiosensingThe development of imaging ellipsometry for biosensing based on protein layers and as well as other layers has been pioneered by Jin and coworkers [53, 54] .", [["900 targets", "DNA", 38, 49], ["affinity biochips", "PROBLEM", 15, 32], ["ellipsometric readout", "TEST", 54, 75], ["imaging ellipsometry", "TEST", 154, 174], ["protein layers", "TREATMENT", 199, 213], ["affinity biochips", "OBSERVATION", 15, 32]]], ["Their applications include detection of monoclonal antibodies from SARS (severe acute respiratory syndrome) using virus, immobilized on silicon substrates, as antigen [55] , detection of the protein hormone human somatropin down to 0.0004 IU/ml [56] , detection of Riemerella anatipestifier (bacteria causing septicemia in birds) down to 5.2 \u00d7 10 3 CFU/ml using immunoglobulin as sensing layer [57] , detection of tumor markers for cancer diagnostics down to 10 U/ml [58, 59] , biological amplification for detection of alpha-fetoprotein in cancer diagnostics down to 5 ng/ml [60] , detection of duck hepatitis virus down to 8 \u00d7 10 \u22129.5 LD 50 /ml using polyclonal antibodies on silicon [61] , detection of hepatitis B virus markers down to 1 mg/ml [62] , and more.Protein Layer Based BiosensingProof of concept of using imaging ellipsometry for immunosensors have also been given by Bae and coworkers.", [["tumor", "ANATOMY", 414, 419], ["cancer", "ANATOMY", 432, 438], ["cancer", "ANATOMY", 541, 547], ["SARS", "DISEASE", 67, 71], ["acute respiratory syndrome", "DISEASE", 80, 106], ["septicemia", "DISEASE", 309, 319], ["tumor", "DISEASE", 414, 419], ["cancer", "DISEASE", 432, 438], ["cancer", "DISEASE", 541, 547], ["duck hepatitis virus", "DISEASE", 596, 616], ["silicon", "CHEMICAL", 678, 685], ["hepatitis B", "DISEASE", 706, 717], ["silicon", "CHEMICAL", 136, 143], ["silicon", "CHEMICAL", 678, 685], ["human", "ORGANISM", 207, 212], ["somatropin", "GENE_OR_GENE_PRODUCT", 213, 223], ["Riemerella anatipestifier", "ORGANISM", 265, 290], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 362, 376], ["tumor", "CANCER", 414, 419], ["cancer", "CANCER", 432, 438], ["alpha-fetoprotein", "GENE_OR_GENE_PRODUCT", 520, 537], ["cancer", "CANCER", 541, 547], ["duck hepatitis virus", "ORGANISM", 596, 616], ["hepatitis B virus", "ORGANISM", 706, 723], ["monoclonal antibodies", "PROTEIN", 40, 61], ["protein hormone human somatropin", "PROTEIN", 191, 223], ["immunoglobulin", "PROTEIN", 362, 376], ["tumor markers", "PROTEIN", 414, 427], ["alpha-fetoprotein", "PROTEIN", 520, 537], ["polyclonal antibodies", "PROTEIN", 653, 674], ["hepatitis B virus markers", "PROTEIN", 706, 731], ["human", "SPECIES", 207, 212], ["duck hepatitis virus", "SPECIES", 596, 616], ["hepatitis B virus", "SPECIES", 706, 723], ["human", "SPECIES", 207, 212], ["Riemerella anatipestifier", "SPECIES", 265, 290], ["duck hepatitis virus", "SPECIES", 596, 616], ["hepatitis B virus", "SPECIES", 706, 723], ["monoclonal antibodies", "PROBLEM", 40, 61], ["SARS (severe acute respiratory syndrome", "PROBLEM", 67, 106], ["virus", "PROBLEM", 114, 119], ["silicon substrates", "TREATMENT", 136, 154], ["the protein hormone", "TEST", 187, 206], ["somatropin", "TEST", 213, 223], ["Riemerella anatipestifier (bacteria", "PROBLEM", 265, 300], ["septicemia", "PROBLEM", 309, 319], ["immunoglobulin", "TREATMENT", 362, 376], ["tumor markers", "TEST", 414, 427], ["cancer diagnostics", "TEST", 432, 450], ["biological amplification", "TEST", 478, 502], ["alpha-fetoprotein in cancer", "PROBLEM", 520, 547], ["diagnostics", "TEST", 548, 559], ["duck hepatitis virus", "TEST", 596, 616], ["polyclonal antibodies on silicon", "TREATMENT", 653, 685], ["hepatitis B virus markers", "TREATMENT", 706, 731], ["imaging ellipsometry", "TEST", 820, 840], ["immunosensors", "TREATMENT", 845, 858], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106], ["septicemia", "OBSERVATION", 309, 319]]], ["They showed a detection limit of 10 ng/ml for insulin [63] , detection of the bacteria Legionella pneumophila down to 10 3 CFU/ml [64] and the bacteria Yersinia enterocolitica also with detection limit 10 3 CFU/ml [65] .Protein Layer Based BiosensingIn most cases, the sensitivity of ellipsometry for detection of adsorbing molecules is sufficient for immunoassays.", [["Yersinia enterocolitica", "DISEASE", 152, 175], ["insulin", "GENE_OR_GENE_PRODUCT", 46, 53], ["Legionella pneumophila", "ORGANISM", 87, 109], ["Yersinia enterocolitica", "ORGANISM", 152, 175], ["adsorbing molecules", "PROTEIN", 314, 333], ["Legionella pneumophila", "SPECIES", 87, 109], ["Yersinia enterocolitica", "SPECIES", 152, 175], ["Legionella pneumophila", "SPECIES", 87, 109], ["Yersinia enterocolitica", "SPECIES", 152, 175], ["insulin", "TREATMENT", 46, 53], ["the bacteria Legionella pneumophila", "TEST", 74, 109], ["CFU/ml", "TEST", 123, 129], ["the bacteria Yersinia enterocolitica", "PROBLEM", 139, 175], ["ellipsometry", "TEST", 284, 296], ["adsorbing molecules", "PROBLEM", 314, 333], ["immunoassays", "TEST", 352, 364], ["bacteria", "OBSERVATION_MODIFIER", 143, 151], ["Yersinia enterocolitica", "OBSERVATION", 152, 175]]], ["However, if increased sensitivity is required, one can employ SPP-enhancement as discussed in Chap.", [["SPP", "PROTEIN", 62, 65], ["Chap", "PROTEIN", 94, 98], ["increased sensitivity", "PROBLEM", 12, 33]]], ["An example of such an application, of relevance for diagnosis of Alzheimer's decease, is a label-free direct immunoassay for detection of \u03b2-amyloid peptide (1-16) using monoclonal antibodies immobilized on a gold surface [66] .Protein Layer Based BiosensingA complement or alternative to use biochemical specificity is to use optical specificity, e.g. fluorescence or chemiluminescence.", [["Alzheimer's decease", "DISEASE", 65, 84], ["\u03b2-amyloid peptide (1-16", "CHEMICAL", 138, 161], ["\u03b2-amyloid peptide", "SIMPLE_CHEMICAL", 138, 155], ["monoclonal antibodies", "PROTEIN", 169, 190], ["Protein Layer Based BiosensingA complement", "PROTEIN", 227, 269], ["Alzheimer's decease", "PROBLEM", 65, 84], ["\u03b2-amyloid peptide", "PROBLEM", 138, 155], ["monoclonal antibodies", "TEST", 169, 190], ["biochemical specificity", "TEST", 292, 315], ["optical specificity", "TEST", 326, 345], ["chemiluminescence", "PROBLEM", 368, 385]]], ["Hinrichs et al. [45] suggest the use of infrared spectroscopic mapping ellipsometry.", [["infrared spectroscopic mapping ellipsometry", "TREATMENT", 40, 83]]], ["Areas of 6 \u00d7 6 mm 2 with a resolution of 300 \u00d7 300 \u00b5m 2 were mapped and protein amide bands were identified.", [["amide", "CHEMICAL", 80, 85], ["protein amide bands", "PROTEIN", 72, 91], ["protein amide bands", "TEST", 72, 91], ["6 \u00d7 6 mm", "OBSERVATION_MODIFIER", 9, 17], ["resolution", "OBSERVATION_MODIFIER", 27, 37]]], ["The drawback is that currently infrared radiation from a synchroton beam line is required.Protein Layer Based BiosensingIn conclusion we find that affinity-based biosensing with ellipsometry can provide sufficiently low detection limits for many important clinical applications and compares well with alternative methods.", [["synchroton beam line", "CELL_LINE", 57, 77], ["infrared radiation", "TREATMENT", 31, 49], ["a synchroton beam line", "TREATMENT", 55, 77], ["alternative methods", "TREATMENT", 301, 320]]], ["In addition it is a label-free technique.Other ApplicationsProtein Adsorption as a Surface and Thin Film Probe Protein adsorption has been used as a probe for testing the biocompatibility and other functionalities of surfaces and thin film materials.", [["Other ApplicationsProtein Adsorption", "TREATMENT", 41, 77], ["a Surface and Thin Film Probe Protein adsorption", "TREATMENT", 81, 129], ["a probe", "TREATMENT", 147, 154], ["testing the biocompatibility", "TREATMENT", 159, 187], ["thin film materials", "TEST", 230, 249]]], ["Gyulai et al. studied biodegradable polyesters for drug carrier systems and used adsorption of BSA to determine how protein repellent the polyester surface is [67] .", [["polyester", "CHEMICAL", 138, 147], ["BSA", "SIMPLE_CHEMICAL", 95, 98], ["studied biodegradable polyesters", "TREATMENT", 14, 46], ["drug carrier systems", "TREATMENT", 51, 71], ["adsorption of BSA", "TREATMENT", 81, 98]]], ["Mikhaylova et al. used lysozyme and HSA as model proteins with different charge to probe complex adsorption responses on hydroxyl-terminated hyperbranched aromatic polyester thin films [68] .", [["hydroxyl", "CHEMICAL", 121, 129], ["hydroxyl", "CHEMICAL", 121, 129], ["hyperbranched aromatic polyester", "CHEMICAL", 141, 173], ["lysozyme", "GENE_OR_GENE_PRODUCT", 23, 31], ["HSA", "SIMPLE_CHEMICAL", 36, 39], ["hydroxyl", "SIMPLE_CHEMICAL", 121, 129], ["lysozyme", "PROTEIN", 23, 31], ["HSA", "PROTEIN", 36, 39], ["lysozyme", "TREATMENT", 23, 31], ["HSA", "TREATMENT", 36, 39], ["model proteins", "PROBLEM", 43, 57], ["hydroxyl-terminated hyperbranched aromatic polyester thin films", "TREATMENT", 121, 184]]], ["They found that a thicker polyester film resulted in a lower BSA adsorption probably coupled to a higher hydrophilicity.", [["BSA", "CHEMICAL", 61, 64], ["polyester", "CHEMICAL", 26, 35], ["BSA", "SIMPLE_CHEMICAL", 61, 64], ["a thicker polyester film", "TEST", 16, 40], ["a lower BSA adsorption", "PROBLEM", 53, 75], ["a higher hydrophilicity", "PROBLEM", 96, 119], ["higher hydrophilicity", "OBSERVATION", 98, 119]]], ["Warenda et al. [69] studied HSA interaction with oligosaccharide-modified hyperbranched poly(ethylene imine) films and found that HSA adsorption was below 50 ng/cm 2 under certain conditions.", [["poly(ethylene imine", "CHEMICAL", 88, 107], ["poly(ethylene imine)", "CHEMICAL", 88, 108], ["HSA", "SIMPLE_CHEMICAL", 28, 31], ["oligosaccharide-modified hyperbranched poly(ethylene imine) films", "SIMPLE_CHEMICAL", 49, 114], ["HSA", "SIMPLE_CHEMICAL", 130, 133], ["oligosaccharide", "TREATMENT", 49, 64], ["modified hyperbranched poly(ethylene imine) films", "TREATMENT", 65, 114], ["HSA adsorption", "TREATMENT", 130, 144]]], ["A low protein adsorption is crucial for the use of these films in biosensors.", [["A low protein adsorption", "PROBLEM", 0, 24], ["these films in biosensors", "TREATMENT", 51, 76], ["low protein", "OBSERVATION_MODIFIER", 2, 13]]], ["BSA has also been used to test biocompatibility of thin films of tantalum, niobium, zirconium and titanium oxides [70] and HSA to test biocompatibility of thin polymer brushes [71] (see also Chap.", [["BSA", "CHEMICAL", 0, 3], ["tantalum", "CHEMICAL", 65, 73], ["niobium", "CHEMICAL", 75, 82], ["zirconium", "CHEMICAL", 84, 93], ["titanium oxides", "CHEMICAL", 98, 113], ["tantalum", "CHEMICAL", 65, 73], ["niobium", "CHEMICAL", 75, 82], ["zirconium", "CHEMICAL", 84, 93], ["titanium oxides", "CHEMICAL", 98, 113], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["tantalum", "SIMPLE_CHEMICAL", 65, 73], ["niobium", "SIMPLE_CHEMICAL", 75, 82], ["zirconium", "SIMPLE_CHEMICAL", 84, 93], ["titanium oxides [70]", "SIMPLE_CHEMICAL", 98, 118], ["HSA", "SIMPLE_CHEMICAL", 123, 126], ["thin films of tantalum, niobium, zirconium and titanium oxides", "TREATMENT", 51, 113], ["HSA to test biocompatibility of thin polymer brushes", "TREATMENT", 123, 175]]], ["5).OutlookIt is no doubt that ellipsometry, especially in spectroscopic and imaging modes, is among the most valuable tools for studying protein adsorption on solid surfaces including possibilities to follow dynamics of a thin film structure.", [["spectroscopic and imaging modes", "TEST", 58, 89], ["studying protein adsorption on solid surfaces", "PROBLEM", 128, 173], ["a thin film structure", "PROBLEM", 220, 241], ["no doubt", "UNCERTAINTY", 16, 24], ["ellipsometry", "OBSERVATION", 30, 42]]], ["Among the new developments now being mature are spatial imaging ellipsometry with potential applications in high-through put screening of bioadsorption but also in surface mapping in general.", [["surface", "ANATOMY", 164, 171], ["spatial imaging ellipsometry", "TEST", 48, 76], ["potential applications", "TREATMENT", 82, 104], ["bioadsorption", "TREATMENT", 138, 151], ["new", "OBSERVATION_MODIFIER", 10, 13]]], ["A representative example is the investigation of light-activated affinity micropatterning of proteins using imaging ellipsometry [72] .", [["imaging ellipsometry", "TEST", 108, 128]]], ["Such spatially resolved immobilization of proteins may find applications in surface control of biomaterials and tissue engineering, multi-analyte biosensors, clinical assays and genomic arrays.OutlookTime-resolved spectroscopic ellipsometry and time-resolved imaging ellipsometry have so far only a few applications.", [["surface", "ANATOMY", 76, 83], ["tissue", "ANATOMY", 112, 118], ["tissue", "TISSUE", 112, 118], ["immobilization of proteins", "TREATMENT", 24, 50], ["surface control of biomaterials", "TREATMENT", 76, 107], ["tissue engineering", "TREATMENT", 112, 130], ["multi-analyte biosensors", "TEST", 132, 156], ["clinical assays", "TEST", 158, 173], ["genomic arrays", "TREATMENT", 178, 192], ["spectroscopic ellipsometry", "TEST", 214, 240], ["imaging ellipsometry", "TEST", 259, 279]]], ["Internal reflection ellipsometry is also mature and holds great promises due to its extreme sensitivity if the SPP phenomenon is utilized as is discussed in Chap.", [["Internal reflection ellipsometry", "TEST", 0, 32], ["its extreme sensitivity", "PROBLEM", 80, 103], ["the SPP phenomenon", "PROBLEM", 107, 125]]], ["Infrared spectroscopic ellipsometry is a technique with large promises in the life science area in general and in particular for protein adsorption studies.", [["Infrared spectroscopic ellipsometry", "TEST", 0, 35], ["protein adsorption studies", "TEST", 129, 155], ["large", "OBSERVATION_MODIFIER", 56, 61]]], ["IRSE allows describing composition, structure and layer thickness in the same measurements.", [["IRSE", "PROTEIN", 0, 4], ["layer", "OBSERVATION_MODIFIER", 50, 55], ["thickness", "OBSERVATION_MODIFIER", 56, 65]]], ["Ellipsometry is sometimes combined with other in situ techniques including potentiometry, impedance spectroscopy and quartz-micro balance (see also Chap.", [["impedance spectroscopy", "TEST", 90, 112]]], ["The latter has recently been proven to be a powerful combination in structural analysis of thin protein films [20, 21] .OutlookA major problem is technology transfer from the scientific community to colleagues in industrial and clinical laboratories, especially for biosensor applications.", [["thin protein films", "TEST", 91, 109], ["biosensor applications", "TREATMENT", 266, 288]]], ["Perhaps we have to wait for an ellipsometer on a chip.", [["a chip", "TREATMENT", 47, 53]]]], "6dab259f3cac146d0cadf07d4085a8ecc4069bed": [["The supportive information is presented in the order as it is discussed in the main manuscript.Table of ContentsIn chapter 1 we explained in detail how numbers of contacts and the effects of covariates were analysed.", [["Contents", "OBSERVATION", 104, 112]]], ["In chapter 2 we investigated the influence of participants' characteristics on the size of a recruitment tree.", [["participants", "SPECIES", 46, 58], ["a recruitment tree", "TREATMENT", 91, 109], ["size", "OBSERVATION_MODIFIER", 83, 87], ["recruitment tree", "OBSERVATION", 93, 109]]], ["Here we also provided the absolute number of self-reported symptoms and a visualisation of the mixing patterns by degree.", [["self-reported symptoms", "PROBLEM", 45, 67]]], ["In chapter 4 we analysed the distance between recruiters and their recruits, and quantified the extent to which a recruiter who lives in a certain region in the Netherlands invited contact persons that live in the same municipality as the recruiter is working and/or studying.Numbers of contact persons and the effect of covariatesIn the questionnaire participants were asked for number of contact persons during one full day ('yesterday'), this number was defined to be a participant's 'degree'.", [["persons", "ORGANISM", 189, 196], ["persons", "ORGANISM", 398, 405], ["persons", "SPECIES", 189, 196], ["persons", "SPECIES", 295, 302], ["participants", "SPECIES", 352, 364], ["persons", "SPECIES", 398, 405], ["contact persons", "OBSERVATION", 287, 302]]], ["First, we looked at the distribution of degree, stratified by days of week and the locations that were predefined in the questionnaire ( Figure A1 ).", [["degree", "OBSERVATION_MODIFIER", 40, 46]]], ["For at home and at other places the distributions of degree were fairly similar.", [["fairly", "OBSERVATION_MODIFIER", 65, 71], ["similar", "OBSERVATION_MODIFIER", 72, 79]]], ["During weekdays participants reported more contact persons at work or university, then during the weekend.", [["participants", "SPECIES", 16, 28], ["persons", "SPECIES", 51, 58]]], ["There were no large differences in the total degree distributions (see 'at all locations') between weekdays and weekends.", [["large differences in the total degree distributions", "PROBLEM", 14, 65], ["no", "UNCERTAINTY", 11, 13], ["large", "OBSERVATION_MODIFIER", 14, 19], ["differences", "OBSERVATION_MODIFIER", 20, 31], ["total degree", "OBSERVATION_MODIFIER", 39, 51]]], ["We investigated which covariates influence degree using a regression model.", [["a regression model", "TREATMENT", 56, 74]]], ["Firstly, we investigated which theoretical distribution best fitted the empirical distribution using the R package 'GAMLSS'.Numbers of contact persons and the effect of covariatesThe degree distribution showed strong over-dispersion, with a mean degree of 19.6 per participant (median: 11.0; SD: 35.3).", [["persons", "SPECIES", 143, 150], ["participant", "SPECIES", 265, 276], ["the R package 'GAMLSS'", "TREATMENT", 101, 123], ["a mean degree", "TEST", 239, 252], ["SD", "TEST", 292, 294], ["contact persons", "OBSERVATION", 135, 150], ["degree", "OBSERVATION_MODIFIER", 183, 189], ["distribution", "OBSERVATION_MODIFIER", 190, 202], ["strong", "OBSERVATION_MODIFIER", 210, 216]]], ["Table A1 displays the parameter estimates and AIC's of the various fitted distributions.", [["A1", "PROTEIN", 6, 8], ["the parameter estimates", "TEST", 18, 41]]], ["Note that the power-law was fitted with the GAMLSS function \"PARETO2\".", [["PARETO2", "PROTEIN", 61, 68]]], ["Figure A2 displays the various distributions in a reverse cumulative probability distribution plot (Log10 transformed).", [["A2", "PROTEIN", 7, 9], ["various", "OBSERVATION_MODIFIER", 23, 30], ["distributions", "OBSERVATION_MODIFIER", 31, 44]]], ["Based on the AIC's, the continuous distributions Log-normal and Power-law best fitted the empirical degree distribution [2] .", [["the AIC's", "TEST", 9, 18]]], ["However, these are continuous distributions fitted to a discrete distribution.Numbers of contact persons and the effect of covariatesTherefore, we chose the first best fitted discrete distribution: the Poisson-inverse Gaussian (PIG).Numbers of contact persons and the effect of covariatesThe PIG distribution, an alternative to negative binomial, has the potential for modelling highly dispersed count data due to the flexibility of Inverse Gaussian distribution [3, 4] .", [["persons", "SPECIES", 97, 104], ["persons", "SPECIES", 252, 259], ["modelling highly dispersed count data", "PROBLEM", 369, 406], ["continuous", "OBSERVATION_MODIFIER", 19, 29], ["distributions", "OBSERVATION_MODIFIER", 30, 43], ["discrete", "OBSERVATION_MODIFIER", 56, 64], ["distribution", "OBSERVATION_MODIFIER", 65, 77], ["contact persons", "OBSERVATION", 89, 104], ["contact persons", "OBSERVATION", 244, 259], ["PIG distribution", "OBSERVATION", 292, 308]]], ["We applied the PIG distribution in the regression analysis.Numbers of contact persons and the effect of covariatesWe used a PIG regression model to investigate the effect of the following covariates on degree: age, sex, household size and ILI, and days of the week.", [["persons", "SPECIES", 78, 85], ["the PIG distribution", "TREATMENT", 11, 31], ["the regression analysis", "TEST", 35, 58], ["a PIG regression model", "TREATMENT", 122, 144], ["PIG distribution", "OBSERVATION_MODIFIER", 15, 31], ["contact persons", "OBSERVATION", 70, 85]]], ["The reference categories were the 0 \u0336 39 age group, females, one-person households, no self-reported ILI, and Sunday.", [["ILI", "DISEASE", 101, 104], ["person", "SPECIES", 65, 71]]], ["Table A2 shows the output of the regression model.", [["A2", "PROTEIN", 6, 8]]], ["IRR stands for incidence rate ratio that are standard provided when conducting a PIG regression analysis.Descriptive analysis of recruitment treesWe conducted a descriptive analysis to investigate which characteristics of individuals in a recruitment tree influence the total size of a tree.", [["incidence rate ratio", "TREATMENT", 15, 35], ["a PIG regression analysis", "TEST", 79, 104], ["recruitment trees", "TREATMENT", 129, 146], ["a descriptive analysis", "TEST", 159, 181], ["a recruitment tree", "TREATMENT", 237, 255], ["recruitment trees", "OBSERVATION", 129, 146], ["recruitment tree", "OBSERVATION", 239, 255], ["total", "OBSERVATION_MODIFIER", 270, 275], ["size", "OBSERVATION_MODIFIER", 276, 280], ["tree", "OBSERVATION_MODIFIER", 286, 290]]], ["Firstly, we plotted the number of nodes, i.e., participants who completed the questionnaire, stratified by characteristics of seeds ( Figure A3 ).Descriptive analysis of recruitment treesThe characteristics of seeds did not appear to influence the number of nodes in a recruitment tree.", [["nodes", "ANATOMY", 34, 39], ["nodes", "ANATOMY", 258, 263], ["nodes", "MULTI-TISSUE_STRUCTURE", 34, 39], ["participants", "SPECIES", 47, 59], ["recruitment trees", "TREATMENT", 170, 187], ["number", "OBSERVATION_MODIFIER", 24, 30], ["nodes", "OBSERVATION", 34, 39], ["recruitment trees", "OBSERVATION", 170, 187], ["seeds", "OBSERVATION", 210, 215], ["nodes", "OBSERVATION", 258, 263], ["recruitment tree", "OBSERVATION", 269, 285]]], ["Figure A3 -B did show a slight increase in tree size for a larger proportion of trees with a female seed, e.g., of all trees with a node size of 4 more than 75% had a female seed.", [["node", "ANATOMY", 132, 136], ["A3 -B", "GENE_OR_GENE_PRODUCT", 7, 12], ["node", "MULTI-TISSUE_STRUCTURE", 132, 136], ["Figure A3", "TEST", 0, 9], ["a slight increase in tree size", "PROBLEM", 22, 52], ["a node size", "TEST", 130, 141], ["slight", "OBSERVATION_MODIFIER", 24, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["tree", "OBSERVATION_MODIFIER", 43, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["larger", "OBSERVATION_MODIFIER", 59, 65], ["female seed", "OBSERVATION", 93, 104], ["all", "ANATOMY_MODIFIER", 115, 118], ["trees", "ANATOMY_MODIFIER", 119, 124], ["node", "OBSERVATION", 132, 136], ["size", "OBSERVATION_MODIFIER", 137, 141]]], ["This effect of female seeds was not shown for trees with a size of 5 or more nodes, which is probably due to the lower number of trees with those sizes.Descriptive analysis of recruitment treesIn Figure A4 we investigated the relationship between tree size and the composition of the entire recruitment tree.", [["nodes", "ANATOMY", 77, 82], ["female seeds", "PROBLEM", 15, 27], ["size", "OBSERVATION_MODIFIER", 59, 63], ["more", "OBSERVATION_MODIFIER", 72, 76], ["nodes", "OBSERVATION", 77, 82], ["probably due to", "UNCERTAINTY", 93, 108], ["lower", "OBSERVATION_MODIFIER", 113, 118], ["number", "OBSERVATION_MODIFIER", 119, 125], ["trees", "OBSERVATION", 129, 134], ["sizes", "OBSERVATION_MODIFIER", 146, 151], ["tree", "OBSERVATION_MODIFIER", 247, 251], ["size", "OBSERVATION_MODIFIER", 252, 256], ["recruitment tree", "OBSERVATION", 291, 307]]], ["Overall, the larger the proportion of women or individuals with a bachelor's degree or higher in a recruitment tree, the larger the tree size was on average (see FiguresMixing by age and comparison with POLYMODWe compared the recruiter-recruit matrix stratified by age with the participant-contact matrix by age collected during the Dutch POLYMOD study (see Figure A5 ) [5, 6] .", [["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43], ["participant", "SPECIES", 278, 289], ["the Dutch POLYMOD study", "TEST", 329, 352], ["larger", "OBSERVATION_MODIFIER", 13, 19], ["proportion", "OBSERVATION_MODIFIER", 24, 34], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["recruitment tree", "OBSERVATION", 99, 115], ["larger", "OBSERVATION_MODIFIER", 121, 127], ["tree", "OBSERVATION_MODIFIER", 132, 136], ["size", "OBSERVATION_MODIFIER", 137, 141]]], ["We used the Dutch POLYMOD data that was corrected for digit preference by participants for the age of contact persons, details on this correction can be found in Van de Kassteele, J., et al. [6] .Mixing by age and comparison with POLYMODStrong assortative mixing patterns by age were observed in both matrices.", [["POLYMOD", "DNA", 18, 25], ["participants", "SPECIES", 74, 86], ["persons", "SPECIES", 110, 117]]], ["However, in our sampled recruiter-recruit matrix the younger age groups (below 20 years of age) were not represented.", [["matrix", "CELLULAR_COMPONENT", 42, 48]]], ["In the Dutch POLYMOD study these younger age groups were purposely oversampled to be able to analyse their contact patterns, as the hypothesis is that children play a central role in the transmission dynamics of influenza pandemics [6] .", [["influenza pandemics", "DISEASE", 212, 231], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["influenza pandemics", "PROBLEM", 212, 231]]], ["Children have frequent contact within their own groups and they have a wide range of contacts, therewith connecting all age groups [7] .", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Comparison with the Dutch POLYMOD study.", [["the Dutch POLYMOD study", "TEST", 16, 39]]], ["We compared the recruiter-recruit matrix stratified by age with the participant-contact matrix by age collected during the Dutch POLYMOD study [6] .", [["matrix", "CELLULAR_COMPONENT", 34, 40], ["participant", "SPECIES", 68, 79], ["the Dutch POLYMOD study", "TEST", 119, 142]]], ["In Figure 2D (see main manuscript) we compared the number of contact persons reported at different locations by our participants, with the contacts reported at different locations in the Dutch POLYMOD study [6] .", [["persons", "ORGANISM", 69, 76], ["persons", "SPECIES", 69, 76], ["participants", "SPECIES", 116, 128]]], ["For this comparison the sample was weighted for the size of age groups in the POLYMOD study.", [["the POLYMOD study", "TEST", 74, 91]]], ["The applied weights can be found in Table A3 .Mixing by degreeWe plotted the recruiter-recruit matrix by degree (see Figure A6 ).", [["matrix", "CELLULAR_COMPONENT", 95, 101], ["The applied weights", "TREATMENT", 0, 19]]], ["We observed random recruitment by degree between a recruiter and a recruit, which corresponds to the correlation coefficients for degree displayed in Table 3 in the main manuscript.", [["random", "OBSERVATION_MODIFIER", 12, 18], ["recruitment", "OBSERVATION_MODIFIER", 19, 30]]], ["As the dots clustered in the left corner, we looked more closely at the distribution up till an individual degree of 50.", [["left corner", "ANATOMY", 29, 40], ["left", "ANATOMY_MODIFIER", 29, 33]]], ["Furthermore, we plotted the distribution on a log10 scale, which also illustrated random mixing.Distance between recruiter-recruit pairsWe investigated the distance between recruiters and recruits based on the provided 4-digit postal codes.", [["a log10 scale", "TREATMENT", 44, 57], ["distribution", "OBSERVATION_MODIFIER", 28, 40]]], ["The distribution of the distance between recruiter-recruit pairs was right-skewed ( Figure A7 ).Distance between recruiter-recruit pairsBased on the distribution in Figure A7 , we categorised for Table 4 (see main manuscript) distance into three groups: same postal code, 1 \u0336 10 km and > 10km.", [["recruiter-recruit pairs", "DNA", 41, 64], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["right", "ANATOMY_MODIFIER", 69, 74]]], ["Histograms of distances between recruiter-recruit pairs in kilometres (km).The mean distance between seeds (wave 0) and their recruits in wave 1 was higher than the mean distance between recruiter-recruit pairs in consequent waves.", [["recruiter-recruit pairs", "PROTEIN", 187, 210], ["mean", "OBSERVATION_MODIFIER", 79, 83], ["recruit pairs", "OBSERVATION", 197, 210], ["waves", "OBSERVATION_MODIFIER", 225, 230]]], ["Age distributions of recruiters and recruits stratified by distance.", [["recruiters", "OBSERVATION", 21, 31]]], ["Pink colour: recruiters; blue colour: recruits.", [["blue colour", "OBSERVATION", 25, 36]]], ["Thus, link step '1' indicates the link between seeds and recruits-inwave-1; link step 2 the link between recruiters-in-wave-1 and recruits-in-wave-2, and so on.A logistic regression analysisThe Netherlands counts 12 provinces that represent the administrative layers between the national government and the local municipalities (i.e. subdivisions of a province).", [["inwave-1", "GENE_OR_GENE_PRODUCT", 66, 74], ["A logistic regression analysis", "TEST", 160, 190], ["The Netherlands counts", "TEST", 190, 212]]], ["Therefore, we investigated for Dutch participants the relationship between the geographical locations where a recruiter works and/or studies, and the location where their recruited contact person lives.", [["participants", "SPECIES", 37, 49], ["person", "SPECIES", 189, 195]]], ["We excluded participants living in Belgium.", [["participants", "SPECIES", 12, 24]]], ["The work location was defined by the city or village that was provided in the questionnaire.A logistic regression analysisOur goal was to quantify the extent to which a recruiter who lives in a certain region (four regions defined, see above) invites contact persons that live in the same municipality as the recruiter is working/studying.A logistic regression analysisWe used a mixed effect logistic regression model to estimate the binary outcome:A logistic regression analysis-recruiter did not invite a recruit who lives in the same municipality as the recruiter is working or studying (0) -recruiter invited a recruit who lives in the same municipality as the recruiter is working or studying (1) This outcome variable was created through recoding:A logistic regression analysis-\"municipality where recruiter works/studies\" \u2260 \"municipality where his/her recruit lives\" [1] -\"municipality where recruiter works/studies\" = \"municipality where his/her recruit lives\" [2] The log odds of the binary outcome was modelled as a linear combination of the variables \"region of residence recruiter\" (four regions) and \"recruiter lives and works in same municipality\" (binary:A logistic regression analysisyes/no), with the region West-Netherlands and 'recruiter not working in the same municipality as he/she is living' as a reference group.", [["persons", "ORGANISM", 259, 266], ["persons", "SPECIES", 259, 266], ["A logistic regression analysis", "TEST", 92, 122], ["A logistic regression analysisWe", "TREATMENT", 339, 371], ["a mixed effect logistic regression model", "TREATMENT", 377, 417], ["A logistic regression analysis", "TEST", 449, 479]]], ["The random intercept was provided by recruiter ID, to correct for differences between recruiters, e.g., in numbers of contact persons invited per recruiter and type of recruited contact persons. -indicated that they lived in the Netherlands -provided a work or study location in the questionnaire.", [["persons", "ORGANISM", 186, 193], ["persons", "SPECIES", 186, 193]]], ["We used the fitted logistic regression model to estimate probabilities of the outcome (2) for the four regions in the Netherlands (i.e., predictions based on not knowing what recruiter ID is being predicted).", [["the fitted logistic regression model", "TREATMENT", 8, 44]]], ["Confidence intervals (95%) were calculated by both using fixed-effects uncertainty only, as well as by using fixed effects uncertainty + random effect variance.", [["Confidence intervals", "TEST", 0, 20], ["random effect variance", "PROBLEM", 137, 159]]], ["Table A6 shows the output of the mixed effect logistic regression.", [["the output", "TEST", 15, 25]]], ["The variable working and living in same municipality significantly influenced the outcome.", [["variable", "OBSERVATION_MODIFIER", 4, 12]]]], "fc29a4720833f473ce7717aa5c48cdc038c375c8": [["IntroductionThe World Health Organization declared the COVID-19 pandemic on the 11 th of March, 2020.", [["the COVID", "TEST", 51, 60]]], ["Previously, on the 14 th of February, the first COVID-19 autopsy in Spain had been performed in the Hospital Arnau de Vilanova-Lliria, Valencia; however, the virological diagnosis had been made subsequent to the post-mortem examination (1).", [["the first COVID", "TEST", 38, 53], ["the post-mortem examination", "TEST", 208, 235]]], ["On March 13 th a state of emergency was declared in Spain and the Ministry of Health recommended that autopsies should only be performed under conditions that fulfilled security measures and that appropriate personal protective equipment (PPE) should be obligatory.", [["autopsies", "TREATMENT", 102, 111], ["appropriate personal protective equipment (PPE)", "TREATMENT", 196, 243]]], ["Due to the initial difficult situation in the majority of hospitals, no autopsies of COVID-19 patients were carried out during March or the beginning of April.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["COVID", "TEST", 85, 90]]], ["However, the situation improved and by mid-April clinicians began requesting autopsy studies.", [["autopsy studies", "TEST", 77, 92]]], ["We describe the implementation of a COVID-19 Autopsy program in the Ram\u00f3n y Cajal University Hospital in Madrid and the results of the first autopsy.", [["the first autopsy", "TEST", 131, 148]]], ["As the main target organ in severe COVID-19 disease is the lung, we also reviewed the reports published to date of lung pathology in these patients.Logistic aspectsSeveral measures were taken in order to implement a COVID-19 autopsy programme in the University Hospital Ram\u00f3n y Cajal in Madrid.", [["organ", "ANATOMY", 19, 24], ["lung", "ANATOMY", 59, 63], ["lung", "ANATOMY", 115, 119], ["COVID", "DISEASE", 35, 40], ["organ", "ORGAN", 19, 24], ["COVID-19", "CANCER", 35, 43], ["lung", "ORGAN", 59, 63], ["lung", "ORGAN", 115, 119], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["severe COVID-19 disease", "PROBLEM", 28, 51], ["lung pathology", "PROBLEM", 115, 129], ["main", "OBSERVATION_MODIFIER", 7, 11], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["19 disease", "OBSERVATION", 41, 51], ["lung", "ANATOMY", 59, 63], ["lung", "ANATOMY", 115, 119], ["pathology", "OBSERVATION", 120, 129]]], ["The autopsy room ventilation was adapted ( Fig. 1 A and B) in order to guarantee more than 12 air changes per hour and confirm negative pressure in the room.", [["The autopsy room ventilation", "TREATMENT", 0, 28], ["negative pressure", "OBSERVATION", 127, 144]]], ["In addition, the aspiration system of the autopsy table was checked.", [["the aspiration system", "TEST", 13, 34], ["the autopsy table", "TEST", 38, 55]]], ["Air was expelled from the autopsy room to the exterior through a High Efficiency Particulate Air filter.", [["a High Efficiency Particulate Air filter", "TREATMENT", 63, 103], ["High Efficiency", "OBSERVATION", 65, 80], ["Air filter", "OBSERVATION", 93, 103]]], ["The personnel involved in the autopsy procedure attended a special two-hour course given by the Preventive Medicine Service.Clinical dataThe deceased was a 54 year-old-man with hypertension, gout, migraine and obstructive sleep apnea treated with continuous positive airway pressure oxygenotherapy.", [["airway", "ANATOMY", 267, 273], ["hypertension", "DISEASE", 177, 189], ["gout", "DISEASE", 191, 195], ["migraine", "DISEASE", 197, 205], ["obstructive sleep apnea", "DISEASE", 210, 233], ["man", "ORGANISM", 168, 171], ["airway", "MULTI-TISSUE_STRUCTURE", 267, 273], ["man", "SPECIES", 168, 171], ["the autopsy procedure", "TREATMENT", 26, 47], ["Clinical data", "TEST", 124, 137], ["hypertension", "PROBLEM", 177, 189], ["gout", "PROBLEM", 191, 195], ["migraine", "PROBLEM", 197, 205], ["obstructive sleep apnea", "PROBLEM", 210, 233], ["continuous positive airway pressure oxygenotherapy", "TREATMENT", 247, 297], ["hypertension", "OBSERVATION", 177, 189], ["gout", "OBSERVATION", 191, 195], ["obstructive", "OBSERVATION_MODIFIER", 210, 221], ["sleep apnea", "OBSERVATION", 222, 233], ["airway pressure", "OBSERVATION", 267, 282]]], ["His body index mass was 30.9.", [["body", "ANATOMY", 4, 8], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["His body index mass", "TEST", 0, 19], ["mass", "OBSERVATION", 15, 19]]], ["He attended the casualty department complaining of dyspnoea and an eight-day history of chills, fever and cough.", [["dyspnoea", "DISEASE", 51, 59], ["chills", "DISEASE", 88, 94], ["fever", "DISEASE", 96, 101], ["cough", "DISEASE", 106, 111], ["dyspnoea", "PROBLEM", 51, 59], ["chills", "PROBLEM", 88, 94], ["fever", "PROBLEM", 96, 101], ["cough", "PROBLEM", 106, 111], ["chills", "OBSERVATION", 88, 94], ["fever", "OBSERVATION", 96, 101], ["cough", "OBSERVATION", 106, 111]]], ["On admission, a nasopharyngeal swab PCR was positive for SARS-CoV-2 and an X-ray showed bilateral lung opacities; he had an 88% O2 saturation.", [["nasopharyngeal swab", "ANATOMY", 16, 35], ["lung", "ANATOMY", 98, 102], ["lung opacities", "DISEASE", 98, 112], ["O2", "CHEMICAL", 128, 130], ["O2", "CHEMICAL", 128, 130], ["lung", "ORGAN", 98, 102], ["O2", "SIMPLE_CHEMICAL", 128, 130], ["SARS-CoV", "SPECIES", 57, 65], ["a nasopharyngeal swab PCR", "TEST", 14, 39], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["an X-ray", "TEST", 72, 80], ["bilateral lung opacities", "PROBLEM", 88, 112], ["O2 saturation", "TEST", 128, 141], ["nasopharyngeal", "ANATOMY", 16, 30], ["bilateral", "ANATOMY_MODIFIER", 88, 97], ["lung", "ANATOMY", 98, 102], ["opacities", "OBSERVATION", 103, 112]]], ["The patient was found to have elevated D-Dimer, lymphopenia and raised levels of lactate dehydrogenase, interleukin-6, ferritin and Creactive protein.Clinical dataAfter 3 days of steroid treatment and bed rest, his condition worsened and he was transferred to the Intensive Care Unit where mechanical ventilation and posterior orotracheal intubation was implemented.", [["orotracheal", "ANATOMY", 327, 338], ["lymphopenia", "DISEASE", 48, 59], ["lactate", "CHEMICAL", 81, 88], ["steroid", "CHEMICAL", 179, 186], ["lactate", "CHEMICAL", 81, 88], ["steroid", "CHEMICAL", 179, 186], ["patient", "ORGANISM", 4, 11], ["D-Dimer", "SIMPLE_CHEMICAL", 39, 46], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 81, 102], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 104, 117], ["ferritin", "GENE_OR_GENE_PRODUCT", 119, 127], ["Creactive", "GENE_OR_GENE_PRODUCT", 132, 141], ["lactate dehydrogenase", "PROTEIN", 81, 102], ["interleukin-6", "PROTEIN", 104, 117], ["ferritin", "PROTEIN", 119, 127], ["Creactive protein", "PROTEIN", 132, 149], ["patient", "SPECIES", 4, 11], ["elevated D-Dimer", "PROBLEM", 30, 46], ["lymphopenia", "PROBLEM", 48, 59], ["lactate dehydrogenase", "PROBLEM", 81, 102], ["interleukin", "TEST", 104, 115], ["ferritin", "TEST", 119, 127], ["Creactive protein", "TEST", 132, 149], ["steroid treatment", "TREATMENT", 179, 196], ["bed rest", "TREATMENT", 201, 209], ["mechanical ventilation", "TREATMENT", 290, 312], ["posterior orotracheal intubation", "TREATMENT", 317, 349], ["elevated", "OBSERVATION", 30, 38], ["lymphopenia", "OBSERVATION", 48, 59], ["lactate dehydrogenase", "OBSERVATION", 81, 102], ["mechanical ventilation", "OBSERVATION", 290, 312], ["posterior", "ANATOMY_MODIFIER", 317, 326], ["orotracheal intubation", "OBSERVATION", 327, 349]]], ["He was treated with lopinavir/ritonavir, dolquine, azitromicine, metilprednisone, tocilizumab and enoxaparine.", [["lopinavir/ritonavir", "CHEMICAL", 20, 39], ["dolquine", "CHEMICAL", 41, 49], ["azitromicine", "CHEMICAL", 51, 63], ["metilprednisone", "CHEMICAL", 65, 80], ["tocilizumab", "CHEMICAL", 82, 93], ["enoxaparine", "CHEMICAL", 98, 109], ["lopinavir", "CHEMICAL", 20, 29], ["ritonavir", "CHEMICAL", 30, 39], ["dolquine", "CHEMICAL", 41, 49], ["azitromicine", "CHEMICAL", 51, 63], ["metilprednisone", "CHEMICAL", 65, 80], ["tocilizumab", "CHEMICAL", 82, 93], ["enoxaparine", "CHEMICAL", 98, 109], ["He", "ORGANISM", 0, 2], ["lopinavir", "SIMPLE_CHEMICAL", 20, 29], ["ritonavir", "SIMPLE_CHEMICAL", 30, 39], ["dolquine", "SIMPLE_CHEMICAL", 41, 49], ["azitromicine", "SIMPLE_CHEMICAL", 51, 63], ["metilprednisone", "SIMPLE_CHEMICAL", 65, 80], ["tocilizumab", "SIMPLE_CHEMICAL", 82, 93], ["enoxaparine", "SIMPLE_CHEMICAL", 98, 109], ["lopinavir", "TREATMENT", 20, 29], ["ritonavir", "TREATMENT", 30, 39], ["dolquine", "TREATMENT", 41, 49], ["azitromicine", "TREATMENT", 51, 63], ["metilprednisone", "TREATMENT", 65, 80], ["tocilizumab", "TREATMENT", 82, 93], ["enoxaparine", "TREATMENT", 98, 109]]], ["However, the patient's condition progressively deteriorated and he developed renal failure and sudden desaturations, making tracheostomy and haemodialysis necessary.", [["renal", "ANATOMY", 77, 82], ["renal failure", "DISEASE", 77, 90], ["sudden desaturations", "DISEASE", 95, 115], ["patient", "ORGANISM", 13, 20], ["renal", "ORGAN", 77, 82], ["patient", "SPECIES", 13, 20], ["renal failure", "PROBLEM", 77, 90], ["sudden desaturations", "PROBLEM", 95, 115], ["tracheostomy", "TREATMENT", 124, 136], ["haemodialysis", "TREATMENT", 141, 154], ["renal", "ANATOMY", 77, 82], ["failure", "OBSERVATION", 83, 90], ["sudden", "OBSERVATION_MODIFIER", 95, 101], ["desaturations", "OBSERVATION", 102, 115], ["tracheostomy", "OBSERVATION", 124, 136]]], ["He suffered a pulmonary thromboembolism and died after 25 days in Intensive Care.", [["pulmonary", "ANATOMY", 14, 23], ["pulmonary thromboembolism", "DISEASE", 14, 39], ["pulmonary", "ORGAN", 14, 23], ["a pulmonary thromboembolism", "PROBLEM", 12, 39], ["pulmonary", "ANATOMY", 14, 23], ["thromboembolism", "OBSERVATION", 24, 39]]], ["Autopsy procedure workflow Two clear areas were delimited inside the autopsy room, a dirty area containing the dissection table and a clean area ( Figure 1A ).", [["Autopsy procedure", "TREATMENT", 0, 17], ["a dirty area", "PROBLEM", 83, 95], ["clear", "OBSERVATION_MODIFIER", 31, 36], ["areas", "OBSERVATION_MODIFIER", 37, 42], ["dirty", "OBSERVATION_MODIFIER", 85, 90], ["dissection", "OBSERVATION", 111, 121], ["clean", "OBSERVATION", 134, 139]]], ["Personnel entered via the clean area and left via the dirty area.", [["clean", "OBSERVATION", 26, 31], ["left", "ANATOMY_MODIFIER", 41, 45], ["dirty", "OBSERVATION", 54, 59]]], ["The corpse was brought in through the dirty area.", [["dirty", "OBSERVATION", 38, 43]]], ["All personnel dressed in an adjacent room and entered the autopsy room fully clad in PPE (figure 1B).", [["clad", "OBSERVATION", 77, 81]]], ["The autopsy was performed by two pathologists with the assistance of one technician.", [["The autopsy", "TEST", 0, 11]]], ["A pathology resident, working in the clean area, was in charge of collecting samples and also helped to disrobe participating personnel after the procedure.Clinical dataFollowing inspection of the cadaver, the thoraco-abdominal cavities were opened and carefully explored.", [["cadaver", "ANATOMY", 197, 204], ["thoraco-abdominal cavities", "ANATOMY", 210, 236], ["cadaver", "ORGAN", 197, 204], ["thoraco-abdominal cavities", "MULTI-TISSUE_STRUCTURE", 210, 236], ["the procedure", "TREATMENT", 142, 155], ["the cadaver", "TREATMENT", 193, 204], ["abdominal cavities", "ANATOMY", 218, 236]]], ["In order to reduce aerosol spreading, samples were taken in situ, without removing organs from body.", [["samples", "ANATOMY", 38, 45], ["organs", "ANATOMY", 83, 89], ["body", "ANATOMY", 95, 99], ["organs", "ORGAN", 83, 89], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["aerosol spreading", "TREATMENT", 19, 36], ["samples", "TEST", 38, 45], ["body", "ANATOMY", 95, 99]]], ["Samples from all lobes of both lungs, heart, liver, spleen, kidneys, costal bone marrow and skin were taken and immediately immersed in 4% formaldehyde.", [["Samples", "ANATOMY", 0, 7], ["lobes", "ANATOMY", 17, 22], ["lungs", "ANATOMY", 31, 36], ["heart", "ANATOMY", 38, 43], ["liver", "ANATOMY", 45, 50], ["spleen", "ANATOMY", 52, 58], ["kidneys", "ANATOMY", 60, 67], ["costal bone marrow", "ANATOMY", 69, 87], ["skin", "ANATOMY", 92, 96], ["formaldehyde", "CHEMICAL", 139, 151], ["formaldehyde", "CHEMICAL", 139, 151], ["lobes", "MULTI-TISSUE_STRUCTURE", 17, 22], ["lungs", "ORGAN", 31, 36], ["heart", "ORGAN", 38, 43], ["liver", "ORGAN", 45, 50], ["spleen", "ORGAN", 52, 58], ["kidneys", "ORGAN", 60, 67], ["costal bone marrow", "MULTI-TISSUE_STRUCTURE", 69, 87], ["skin", "ORGAN", 92, 96], ["formaldehyde", "SIMPLE_CHEMICAL", 139, 151], ["Samples from all lobes of both lungs", "TEST", 0, 36], ["all lobes", "ANATOMY_MODIFIER", 13, 22], ["both", "ANATOMY_MODIFIER", 26, 30], ["lungs", "ANATOMY", 31, 36], ["heart", "ANATOMY", 38, 43], ["liver", "ANATOMY", 45, 50], ["spleen", "ANATOMY", 52, 58], ["kidneys", "ANATOMY", 60, 67], ["costal", "ANATOMY_MODIFIER", 69, 75], ["bone marrow", "ANATOMY", 76, 87], ["skin", "ANATOMY", 92, 96]]], ["No frozen material was bio-banked.", [["frozen material", "PROBLEM", 3, 18], ["frozen material", "OBSERVATION", 3, 18]]], ["Following safety guidelines, after body closure, the autopsy table was cleaned with bleach and the participating personnel removed their PPE in a specially reserved area at the exit door.", [["body", "ANATOMY", 35, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["body closure", "TREATMENT", 35, 47], ["bleach", "TREATMENT", 84, 90]]], ["Immediately after leaving, they washed and changed their surgical scrub in a bathroom adjacent to the autopsy room, independent from the disrobing area previously described.Tissue ProcessingConventional histological and histochemical (PAS, Grocott, von-Kossa) processing were performed.", [["Tissue", "ANATOMY", 173, 179], ["Tissue", "TISSUE", 173, 179], ["histochemical (PAS", "TEST", 220, 238]]], ["Immunohistochemistry using pancytokeratin (Agilent; clone AE1/AE3), macrophage (CD68, clone PG-M1), lymphoid (CD4, clone 4B12; CD8, clone C8/144B), platelet lineage (CD61, clone 2f2) and viral (herpes1, clone 10A3; Herpes2, clone DBM 15.69; cytomegalovirus, clone CCH2) antibodies was requested after H&E evaluation.Pathological ResultsThe most striking lesions were observed in both lungs.", [["macrophage", "ANATOMY", 68, 78], ["clone PG-M1", "ANATOMY", 86, 97], ["lymphoid", "ANATOMY", 100, 108], ["CD4", "ANATOMY", 110, 113], ["clone 4B12", "ANATOMY", 115, 125], ["CD8", "ANATOMY", 127, 130], ["144B", "ANATOMY", 141, 145], ["platelet lineage", "ANATOMY", 148, 164], ["CD61", "ANATOMY", 166, 170], ["lesions", "ANATOMY", 354, 361], ["lungs", "ANATOMY", 384, 389], ["pancytokeratin", "GENE_OR_GENE_PRODUCT", 27, 41], ["AE1", "GENE_OR_GENE_PRODUCT", 58, 61], ["AE3", "GENE_OR_GENE_PRODUCT", 62, 65], ["macrophage", "CELL", 68, 78], ["CD68", "GENE_OR_GENE_PRODUCT", 80, 84], ["clone PG-M1", "GENE_OR_GENE_PRODUCT", 86, 97], ["lymphoid", "CELL", 100, 108], ["CD4", "GENE_OR_GENE_PRODUCT", 110, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 127, 130], ["platelet lineage", "CELL", 148, 164], ["CD61", "GENE_OR_GENE_PRODUCT", 166, 170], ["clone 2f2", "GENE_OR_GENE_PRODUCT", 172, 181], ["herpes1", "GENE_OR_GENE_PRODUCT", 194, 201], ["Herpes2", "GENE_OR_GENE_PRODUCT", 215, 222], ["cytomegalovirus", "ORGANISM", 241, 256], ["clone CCH2", "GENE_OR_GENE_PRODUCT", 258, 268], ["lesions", "PATHOLOGICAL_FORMATION", 354, 361], ["lungs", "ORGAN", 384, 389], ["pancytokeratin", "PROTEIN", 27, 41], ["AE1", "PROTEIN", 58, 61], ["AE3", "PROTEIN", 62, 65], ["CD68", "PROTEIN", 80, 84], ["M1", "CELL_LINE", 95, 97], ["CD4", "PROTEIN", 110, 113], ["clone 4B12", "CELL_LINE", 115, 125], ["CD8", "PROTEIN", 127, 130], ["clone C8", "CELL_LINE", 132, 140], ["144B", "CELL_LINE", 141, 145], ["platelet lineage", "CELL_TYPE", 148, 164], ["CD61", "CELL_LINE", 166, 170], ["clone 2f2", "CELL_LINE", 172, 181], ["herpes1", "PROTEIN", 194, 201], ["clone 10A3", "CELL_LINE", 203, 213], ["Herpes2", "PROTEIN", 215, 222], ["clone DBM 15.69; cytomegalovirus, clone CCH2) antibodies", "PROTEIN", 224, 280], ["Immunohistochemistry", "TEST", 0, 20], ["pancytokeratin", "TEST", 27, 41], ["clone AE1", "TEST", 52, 61], ["AE3", "TEST", 62, 65], ["macrophage", "TEST", 68, 78], ["CD68", "TEST", 80, 84], ["clone PG", "TEST", 86, 94], ["CD4", "TEST", 110, 113], ["clone", "TEST", 115, 120], ["CD8", "TEST", 127, 130], ["clone C8", "TEST", 132, 140], ["platelet lineage", "TEST", 148, 164], ["CD61", "TEST", 166, 170], ["clone", "TEST", 172, 177], ["viral", "TEST", 187, 192], ["herpes1", "TEST", 194, 201], ["clone", "TEST", 203, 208], ["Herpes2", "TEST", 215, 222], ["clone DBM", "TEST", 224, 233], ["cytomegalovirus", "PROBLEM", 241, 256], ["H&E evaluation", "TEST", 301, 315], ["striking lesions", "PROBLEM", 345, 361], ["macrophage", "ANATOMY", 68, 78], ["lymphoid", "ANATOMY", 100, 108], ["most striking", "OBSERVATION_MODIFIER", 340, 353], ["lesions", "OBSERVATION", 354, 361], ["both", "ANATOMY_MODIFIER", 379, 383], ["lungs", "ANATOMY", 384, 389]]], ["Macroscopically, they were heavy, firm and condensed.", [["heavy", "OBSERVATION_MODIFIER", 27, 32], ["firm", "OBSERVATION", 34, 38]]], ["The cut surface was red and rubbery.", [["surface", "ANATOMY", 8, 15], ["cut", "OBSERVATION_MODIFIER", 4, 7], ["surface", "OBSERVATION_MODIFIER", 8, 15], ["red", "OBSERVATION", 20, 23], ["rubbery", "OBSERVATION_MODIFIER", 28, 35]]], ["Microscopically, samples from two different areas of each lobe were studied.", [["samples", "ANATOMY", 17, 24], ["lobe", "ANATOMY", 58, 62], ["lobe", "MULTI-TISSUE_STRUCTURE", 58, 62], ["samples", "TEST", 17, 24], ["each lobe", "ANATOMY", 53, 62]]], ["Airspaces were reduced due to an increase in the interstitial connective tissue.", [["interstitial connective tissue", "ANATOMY", 49, 79], ["interstitial connective tissue", "TISSUE", 49, 79], ["Airspaces", "PROBLEM", 0, 9], ["an increase in the interstitial connective tissue", "PROBLEM", 30, 79], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["interstitial", "ANATOMY_MODIFIER", 49, 61], ["connective tissue", "OBSERVATION", 62, 79]]], ["Histological changes varied, in the best-preserved areas, which represented about 10% of the parenchyma studied, there was minimal septal thickening with capillary congestion, occasional mononuclear inflammatory infiltration and evident alveolar cell desquamation.", [["parenchyma", "ANATOMY", 93, 103], ["septal", "ANATOMY", 131, 137], ["capillary", "ANATOMY", 154, 163], ["mononuclear", "ANATOMY", 187, 198], ["alveolar cell", "ANATOMY", 237, 250], ["parenchyma", "TISSUE", 93, 103], ["septal", "PATHOLOGICAL_FORMATION", 131, 137], ["capillary", "TISSUE", 154, 163], ["mononuclear", "CELL", 187, 198], ["alveolar cell", "CELL", 237, 250], ["Histological changes", "PROBLEM", 0, 20], ["minimal septal thickening", "PROBLEM", 123, 148], ["capillary congestion", "PROBLEM", 154, 174], ["occasional mononuclear inflammatory infiltration", "PROBLEM", 176, 224], ["alveolar cell desquamation", "PROBLEM", 237, 263], ["varied", "OBSERVATION_MODIFIER", 21, 27], ["preserved", "OBSERVATION_MODIFIER", 41, 50], ["areas", "OBSERVATION", 51, 56], ["parenchyma", "ANATOMY_MODIFIER", 93, 103], ["minimal", "OBSERVATION_MODIFIER", 123, 130], ["septal", "ANATOMY_MODIFIER", 131, 137], ["thickening", "OBSERVATION", 138, 148], ["capillary congestion", "OBSERVATION", 154, 174], ["occasional", "OBSERVATION_MODIFIER", 176, 186], ["mononuclear", "OBSERVATION_MODIFIER", 187, 198], ["inflammatory infiltration", "OBSERVATION", 199, 224], ["alveolar cell desquamation", "OBSERVATION", 237, 263]]], ["AE1/AE3 and CD68 immunostaining demonstrated that most desquamated cells were epithelial, although some macrophages were also present.", [["cells", "ANATOMY", 67, 72], ["epithelial", "ANATOMY", 78, 88], ["macrophages", "ANATOMY", 104, 115], ["AE1", "GENE_OR_GENE_PRODUCT", 0, 3], ["AE3", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD68", "GENE_OR_GENE_PRODUCT", 12, 16], ["cells", "CELL", 67, 72], ["epithelial", "CELL", 78, 88], ["macrophages", "CELL", 104, 115], ["AE1", "PROTEIN", 0, 3], ["AE3", "PROTEIN", 4, 7], ["CD68", "PROTEIN", 12, 16], ["desquamated cells", "CELL_TYPE", 55, 72], ["macrophages", "CELL_TYPE", 104, 115], ["AE1/AE3", "TEST", 0, 7], ["CD68 immunostaining", "TEST", 12, 31], ["most desquamated cells", "PROBLEM", 50, 72], ["some macrophages", "PROBLEM", 99, 115], ["some", "OBSERVATION_MODIFIER", 99, 103], ["macrophages", "OBSERVATION", 104, 115]]], ["Pneumocytes were hyperplastic and showed cytopathic-like changes, such as multinucleation, prominent nucleolus and granular cytoplasm ( Fig. 2A) .", [["Pneumocytes", "ANATOMY", 0, 11], ["nucleolus", "ANATOMY", 101, 110], ["granular cytoplasm", "ANATOMY", 115, 133], ["Pneumocytes", "CELL", 0, 11], ["nucleolus", "CELLULAR_COMPONENT", 101, 110], ["granular", "ORGANISM_SUBSTANCE", 115, 123], ["cytoplasm", "ORGANISM_SUBSTANCE", 124, 133], ["Pneumocytes", "PROBLEM", 0, 11], ["hyperplastic", "PROBLEM", 17, 29], ["cytopathic-like changes", "PROBLEM", 41, 64], ["multinucleation", "PROBLEM", 74, 89], ["prominent nucleolus and granular cytoplasm", "PROBLEM", 91, 133], ["hyperplastic", "OBSERVATION", 17, 29], ["cytopathic", "OBSERVATION_MODIFIER", 41, 51], ["multinucleation", "OBSERVATION_MODIFIER", 74, 89], ["prominent", "OBSERVATION_MODIFIER", 91, 100], ["nucleolus", "OBSERVATION_MODIFIER", 101, 110], ["granular cytoplasm", "OBSERVATION", 115, 133]]], ["In addition to previous described changes, approximately 10% of the lung parenchyma analysed showed hyaline membranes, indicating the exudative stage of diffuse alveolar damage (DAD) (Fig. 2A) .", [["lung parenchyma", "ANATOMY", 68, 83], ["hyaline membranes", "ANATOMY", 100, 117], ["alveolar", "ANATOMY", 161, 169], ["alveolar damage", "DISEASE", 161, 176], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 68, 83], ["hyaline membranes", "CELLULAR_COMPONENT", 100, 117], ["alveolar", "TISSUE", 161, 169], ["previous described changes", "PROBLEM", 15, 41], ["hyaline membranes", "PROBLEM", 100, 117], ["diffuse alveolar damage", "PROBLEM", 153, 176], ["lung", "ANATOMY", 68, 72], ["parenchyma", "ANATOMY_MODIFIER", 73, 83], ["hyaline membranes", "OBSERVATION", 100, 117], ["exudative", "OBSERVATION_MODIFIER", 134, 143], ["diffuse", "OBSERVATION_MODIFIER", 153, 160], ["alveolar damage", "OBSERVATION", 161, 176]]], ["The most extensive pattern of lung lesions was consistent with DAD in proliferative (organizing) (70%) and fibrotic (10%) stages.", [["lung lesions", "ANATOMY", 30, 42], ["DAD", "DISEASE", 63, 66], ["lung lesions", "CANCER", 30, 42], ["lung lesions", "PROBLEM", 30, 42], ["DAD", "PROBLEM", 63, 66], ["fibrotic (10%) stages", "PROBLEM", 107, 128], ["most", "OBSERVATION_MODIFIER", 4, 8], ["extensive", "OBSERVATION_MODIFIER", 9, 18], ["pattern", "OBSERVATION_MODIFIER", 19, 26], ["lung", "ANATOMY", 30, 34], ["lesions", "OBSERVATION", 35, 42], ["consistent with", "UNCERTAINTY", 47, 62], ["proliferative", "OBSERVATION_MODIFIER", 70, 83], ["fibrotic", "OBSERVATION_MODIFIER", 107, 115]]], ["There was intense septal thickening with abundant reactive fibroblasts (Fig 2B and C) .", [["septal", "ANATOMY", 18, 24], ["fibroblasts", "ANATOMY", 59, 70], ["septal", "TISSUE", 18, 24], ["fibroblasts", "CELL", 59, 70], ["reactive fibroblasts", "CELL_TYPE", 50, 70], ["intense septal thickening", "PROBLEM", 10, 35], ["abundant reactive fibroblasts", "PROBLEM", 41, 70], ["intense", "OBSERVATION_MODIFIER", 10, 17], ["septal", "ANATOMY_MODIFIER", 18, 24], ["thickening", "OBSERVATION", 25, 35], ["abundant", "OBSERVATION_MODIFIER", 41, 49], ["reactive fibroblasts", "OBSERVATION", 50, 70]]], ["Interstitial inflammatory infiltrates were scarce and mainly composed of CD8+ lymphocytes with inconspicuous neutrophils.", [["Interstitial inflammatory infiltrates", "ANATOMY", 0, 37], ["CD8+ lymphocytes", "ANATOMY", 73, 89], ["neutrophils", "ANATOMY", 109, 120], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["neutrophils", "CELL", 109, 120], ["CD8+ lymphocytes", "CELL_TYPE", 73, 89], ["neutrophils", "CELL_TYPE", 109, 120], ["Interstitial inflammatory infiltrates", "PROBLEM", 0, 37], ["CD8+ lymphocytes", "PROBLEM", 73, 89], ["inconspicuous neutrophils", "PROBLEM", 95, 120], ["inflammatory", "OBSERVATION_MODIFIER", 13, 25], ["infiltrates", "OBSERVATION", 26, 37], ["CD8+ lymphocytes", "OBSERVATION", 73, 89], ["inconspicuous", "OBSERVATION_MODIFIER", 95, 108], ["neutrophils", "OBSERVATION", 109, 120]]], ["There were abundant thrombi in both medium-and small-sized blood vessels, which were observed in all 10 histological sections analysed.", [["thrombi", "ANATOMY", 20, 27], ["blood vessels", "ANATOMY", 59, 72], ["sections", "ANATOMY", 117, 125], ["thrombi", "DISEASE", 20, 27], ["thrombi", "PATHOLOGICAL_FORMATION", 20, 27], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 59, 72], ["abundant thrombi", "PROBLEM", 11, 27], ["abundant", "OBSERVATION_MODIFIER", 11, 19], ["thrombi", "OBSERVATION", 20, 27], ["both", "ANATOMY_MODIFIER", 31, 35], ["medium", "ANATOMY_MODIFIER", 36, 42], ["small", "OBSERVATION_MODIFIER", 47, 52], ["sized", "OBSERVATION_MODIFIER", 53, 58], ["blood vessels", "ANATOMY", 59, 72]]], ["Thrombi in all locations showed CD61 expression indicating their platelet composition (Fig. 2D) .", [["platelet", "ANATOMY", 65, 73], ["CD61", "GENE_OR_GENE_PRODUCT", 32, 36], ["platelet", "CELL", 65, 73], ["CD61", "PROTEIN", 32, 36], ["Thrombi", "PROBLEM", 0, 7], ["CD61 expression", "TEST", 32, 47], ["their platelet composition", "PROBLEM", 59, 85], ["CD61 expression", "OBSERVATION", 32, 47], ["platelet composition", "OBSERVATION", 65, 85]]], ["Histochemical and immunohistochemical studies did not reveal the presence of any further infectious pathogen.", [["immunohistochemical studies", "TEST", 18, 45], ["any further infectious pathogen", "PROBLEM", 77, 108], ["infectious", "OBSERVATION", 89, 99]]], ["Some Von Kossa positive calcium deposits were found in both alveolar spaces and septum.Pathological ResultsThe kidneys showed cortical necrosis and oxalate calcium crystalluria.", [["alveolar spaces", "ANATOMY", 60, 75], ["septum", "ANATOMY", 80, 86], ["kidneys", "ANATOMY", 111, 118], ["cortical", "ANATOMY", 126, 134], ["calcium", "CHEMICAL", 24, 31], ["necrosis", "DISEASE", 135, 143], ["calcium", "CHEMICAL", 156, 163], ["calcium", "CHEMICAL", 24, 31], ["oxalate calcium", "CHEMICAL", 148, 163], ["Von Kossa", "GENE_OR_GENE_PRODUCT", 5, 14], ["alveolar", "MULTI-TISSUE_STRUCTURE", 60, 68], ["septum", "MULTI-TISSUE_STRUCTURE", 80, 86], ["kidneys", "ORGAN", 111, 118], ["cortical", "MULTI-TISSUE_STRUCTURE", 126, 134], ["oxalate calcium crystalluria", "SIMPLE_CHEMICAL", 148, 176], ["Some Von Kossa", "TEST", 0, 14], ["calcium deposits", "PROBLEM", 24, 40], ["cortical necrosis", "PROBLEM", 126, 143], ["oxalate calcium crystalluria", "PROBLEM", 148, 176], ["Von Kossa", "OBSERVATION", 5, 14], ["calcium deposits", "OBSERVATION", 24, 40], ["both", "ANATOMY_MODIFIER", 55, 59], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["septum", "ANATOMY_MODIFIER", 80, 86], ["kidneys", "ANATOMY", 111, 118], ["cortical", "ANATOMY_MODIFIER", 126, 134], ["necrosis", "OBSERVATION", 135, 143], ["oxalate calcium crystalluria", "OBSERVATION", 148, 176]]], ["No other relevant histological alterations were noted.DiscussionThe COVID-19 pandemic had an enormous impact on the Spanish Health System during March and the two first weeks of April, especially in areas such as Madrid.", [["other relevant histological alterations", "PROBLEM", 3, 42], ["April", "TREATMENT", 178, 183], ["relevant", "OBSERVATION_MODIFIER", 9, 17], ["histological", "OBSERVATION_MODIFIER", 18, 30], ["alterations", "OBSERVATION", 31, 42], ["enormous", "OBSERVATION_MODIFIER", 93, 101], ["impact", "OBSERVATION", 102, 108]]], ["In most hospitals, more than 90% of the hospital beds were occupied by COVID-19 patients, the number of patients attending the emergency department was two to three times higher than usual, there was a marked shortage of PPE and more than 20% of hospital staff were infected by COVID-19.", [["COVID-19", "CHEMICAL", 278, 286], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 104, 112], ["a marked shortage of PPE", "PROBLEM", 200, 224], ["COVID", "TEST", 278, 283], ["marked", "OBSERVATION_MODIFIER", 202, 208]]], ["In such an urgent situation, autopsies were not considered a priority, at least in our centre.DiscussionThe Ministry of Health, advised by the SEAP-IAP, and in agreement with most international scientific institutions, recommended performing autopsies only if all security issues regarding the autopsy rooms and PPEs were taken into account.", [["SEAP", "PROTEIN", 143, 147], ["PPEs", "TEST", 312, 316]]], ["In our experience, appointing a single physician to be in charge of requesting all post mortems facilitated administrative issues and was a positive factor in the implementation of the autopsy programme.DiscussionIn the autopsy reported here, the main pathological findings were observed, as expected, in the lung.", [["lung", "ANATOMY", 309, 313], ["lung", "ORGAN", 309, 313], ["lung", "ANATOMY", 309, 313]]], ["There were extensive lesions of DAD, in addition to cytopathiclike changes in the pneumocytes, probably attributed to COVID-19.", [["lesions", "ANATOMY", 21, 28], ["pneumocytes", "ANATOMY", 82, 93], ["DAD", "DISEASE", 32, 35], ["lesions", "PATHOLOGICAL_FORMATION", 21, 28], ["pneumocytes", "CELL", 82, 93], ["pneumocytes", "CELL_TYPE", 82, 93], ["COVID-19", "DNA", 118, 126], ["extensive lesions of DAD", "PROBLEM", 11, 35], ["cytopathiclike changes in the pneumocytes", "PROBLEM", 52, 93], ["COVID", "TEST", 118, 123], ["extensive", "OBSERVATION_MODIFIER", 11, 20], ["lesions", "OBSERVATION", 21, 28], ["pneumocytes", "OBSERVATION", 82, 93], ["probably attributed to", "UNCERTAINTY", 95, 117]]], ["Although there were some areas of exudative DAD, the most generalized pattern was consistent with an organizing/proliferative phase.DiscussionTo date, there are few reports regarding the pathological lesions produced by COVID-19 in the lung (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .", [["lesions", "ANATOMY", 200, 207], ["lung", "ANATOMY", 236, 240], ["DAD", "DISEASE", 44, 47], ["COVID-19", "CHEMICAL", 220, 228], ["COVID-19", "CHEMICAL", 220, 228], ["lesions", "PATHOLOGICAL_FORMATION", 200, 207], ["lung", "ORGAN", 236, 240], ["3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15)", "SIMPLE_CHEMICAL", 246, 302], ["exudative DAD", "PROBLEM", 34, 47], ["an organizing/proliferative phase", "PROBLEM", 98, 131], ["the pathological lesions", "PROBLEM", 183, 207], ["COVID", "TEST", 220, 225], ["some", "OBSERVATION_MODIFIER", 20, 24], ["areas", "OBSERVATION_MODIFIER", 25, 30], ["exudative", "OBSERVATION_MODIFIER", 34, 43], ["DAD", "OBSERVATION", 44, 47], ["consistent with", "UNCERTAINTY", 82, 97], ["proliferative phase", "OBSERVATION", 112, 131], ["lesions", "OBSERVATION", 200, 207], ["lung", "ANATOMY", 236, 240]]], ["In some cases, the authors describe pneumonic changes similar to those we observed in less affected areas of the lung in our patient.", [["lung", "ANATOMY", 113, 117], ["lung", "ORGAN", 113, 117], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["pneumonic changes", "PROBLEM", 36, 53], ["pneumonic", "OBSERVATION", 36, 45], ["lung", "ANATOMY", 113, 117]]], ["In this phase, the presence of cells with cytopathic changes was evident.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["cytopathic changes", "PROBLEM", 42, 60], ["cells", "OBSERVATION", 31, 36], ["cytopathic", "OBSERVATION", 42, 52]]], ["In most previously reported cases, the lesions were consistent with DAD in the exudative and, less frequently, the proliferative/organizing phase.", [["lesions", "ANATOMY", 39, 46], ["DAD", "DISEASE", 68, 71], ["exudative", "DISEASE", 79, 88], ["lesions", "PATHOLOGICAL_FORMATION", 39, 46], ["the lesions", "PROBLEM", 35, 46], ["DAD", "PROBLEM", 68, 71], ["lesions", "OBSERVATION", 39, 46], ["consistent with", "UNCERTAINTY", 52, 67], ["exudative", "OBSERVATION", 79, 88]]], ["Our case showed all the spectrum of DAD from the early exudative phase to extensive fibrosis, suggesting a continuous viral effect on the lung throughout the clinical course of the disease.", [["lung", "ANATOMY", 138, 142], ["DAD", "DISEASE", 36, 39], ["fibrosis", "DISEASE", 84, 92], ["lung", "ORGAN", 138, 142], ["extensive fibrosis", "PROBLEM", 74, 92], ["a continuous viral effect on the lung", "PROBLEM", 105, 142], ["the disease", "PROBLEM", 177, 188], ["exudative", "OBSERVATION_MODIFIER", 55, 64], ["extensive", "OBSERVATION_MODIFIER", 74, 83], ["fibrosis", "OBSERVATION", 84, 92], ["continuous", "OBSERVATION_MODIFIER", 107, 117], ["viral effect", "OBSERVATION", 118, 130], ["lung", "ANATOMY", 138, 142], ["disease", "OBSERVATION", 181, 188]]], ["One previous, brief report found acute fibrinous organizing pneumonia as the main feature in four out of five biopsies.", [["biopsies", "ANATOMY", 110, 118], ["pneumonia", "DISEASE", 60, 69], ["biopsies", "CANCER", 110, 118], ["acute fibrinous organizing pneumonia", "PROBLEM", 33, 69], ["five biopsies", "TEST", 105, 118], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["fibrinous", "OBSERVATION_MODIFIER", 39, 48], ["organizing", "OBSERVATION_MODIFIER", 49, 59], ["pneumonia", "OBSERVATION", 60, 69], ["main", "OBSERVATION_MODIFIER", 77, 81], ["biopsies", "OBSERVATION", 110, 118]]], ["In a preliminary analysis of 10 autopsies performed in our hospital (in preparation), two patients showed this type of lesion, which had been previously reported in 30% of autopsies from patients with severe acute respiratory syndrome due to SARS-CoV infection (18, 19) .", [["lesion", "ANATOMY", 119, 125], ["acute respiratory syndrome", "DISEASE", 208, 234], ["SARS-CoV infection", "DISEASE", 242, 260], ["patients", "ORGANISM", 90, 98], ["lesion", "CANCER", 119, 125], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 242, 250], ["a preliminary analysis", "TEST", 3, 25], ["this type of lesion", "PROBLEM", 106, 125], ["severe acute respiratory syndrome", "PROBLEM", 201, 234], ["SARS", "PROBLEM", 242, 246], ["CoV infection", "PROBLEM", 247, 260], ["lesion", "OBSERVATION", 119, 125], ["severe", "OBSERVATION_MODIFIER", 201, 207], ["acute", "OBSERVATION_MODIFIER", 208, 213], ["respiratory syndrome", "OBSERVATION", 214, 234], ["CoV", "OBSERVATION_MODIFIER", 247, 250], ["infection", "OBSERVATION", 251, 260]]], ["Whether or not this is a specific lesion of a pattern of tissue organization in the context of DAD, or its possible clinical relevance, remain to be seen.", [["tissue", "ANATOMY", 57, 63], ["DAD", "DISEASE", 95, 98], ["tissue", "TISSUE", 57, 63], ["a specific lesion", "PROBLEM", 23, 40], ["specific", "OBSERVATION_MODIFIER", 25, 33], ["lesion", "OBSERVATION", 34, 40], ["tissue", "OBSERVATION", 57, 63]]], ["Another frequent finding in previous reports was the presence of vascular thrombi in blood vessels of different size.", [["vascular thrombi", "ANATOMY", 65, 81], ["blood vessels", "ANATOMY", 85, 98], ["vascular thrombi", "DISEASE", 65, 81], ["vascular thrombi", "MULTI-TISSUE_STRUCTURE", 65, 81], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 85, 98], ["vascular thrombi in blood vessels of different size", "PROBLEM", 65, 116], ["frequent", "OBSERVATION_MODIFIER", 8, 16], ["vascular", "ANATOMY", 65, 73], ["thrombi", "OBSERVATION", 74, 81], ["blood vessels", "OBSERVATION", 85, 98], ["different", "OBSERVATION_MODIFIER", 102, 111], ["size", "OBSERVATION_MODIFIER", 112, 116]]], ["The only reports in which this finding is not observed were those based on the study of biopsies, where sampling is more limited.", [["biopsies", "CANCER", 88, 96], ["the study", "TEST", 75, 84], ["biopsies", "TEST", 88, 96], ["sampling", "TEST", 104, 112]]], ["It is controversial whether COVID-19 patients present a higher hypercoagulability status than other critical conditions, which could explain these findings.", [["hypercoagulability", "DISEASE", 63, 81], ["COVID-19", "ORGANISM", 28, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["COVID", "TEST", 28, 33], ["a higher hypercoagulability status", "PROBLEM", 54, 88], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["hypercoagulability", "OBSERVATION", 63, 81]]], ["However, it should be noted that vascular thrombosis is an integral component of DAD and we did not observe vascular thrombosis elsewhere.DiscussionIn conclusion, we present the process of implementation of a COVID-19 Autopsy Program in our Hospital, report the main findings from the first autopsy performed and briefly review the lung pathology reported in these patients.", [["vascular", "ANATOMY", 33, 41], ["vascular", "ANATOMY", 108, 116], ["lung", "ANATOMY", 332, 336], ["vascular thrombosis", "DISEASE", 33, 52], ["DAD", "DISEASE", 81, 84], ["vascular thrombosis", "DISEASE", 108, 127], ["vascular", "MULTI-TISSUE_STRUCTURE", 33, 41], ["vascular", "MULTI-TISSUE_STRUCTURE", 108, 116], ["lung", "ORGAN", 332, 336], ["patients", "ORGANISM", 365, 373], ["patients", "SPECIES", 365, 373], ["vascular thrombosis", "PROBLEM", 33, 52], ["vascular thrombosis", "PROBLEM", 108, 127], ["the first autopsy", "TEST", 281, 298], ["the lung pathology", "TEST", 328, 346], ["vascular", "ANATOMY", 33, 41], ["thrombosis", "OBSERVATION", 42, 52], ["vascular", "ANATOMY", 108, 116], ["thrombosis", "OBSERVATION", 117, 127], ["lung", "ANATOMY", 332, 336], ["pathology", "OBSERVATION", 337, 346]]]], "c15355525d295d310619059556c9d2ea6b625617": [["COVID-19 Resuscitation guidelines: a blanket rule for everyone?Thorne CJ 1 , Ainsworth M 1Severn deanery, United KingdomTo the Editor,Severn deanery, United KingdomThe COVID-19 pandemic has had a profound impact on the management of both in-hospital and out of hospital cardiac arrest.", [["cardiac", "ANATOMY", 270, 277], ["cardiac arrest", "DISEASE", 270, 284], ["a blanket rule", "TREATMENT", 35, 49], ["the management", "TREATMENT", 215, 229], ["cardiac arrest", "PROBLEM", 270, 284], ["cardiac", "ANATOMY", 270, 277], ["arrest", "OBSERVATION", 278, 284]]], ["Both the European Resuscitation Council (ERC) and the Resuscitation Council UK 1 have published guidelines for cardiac arrest management in confirmed or suspected COVID-19 cases which differs substantially from the 2015 ALS guidelines 2 .", [["cardiac", "ANATOMY", 111, 118], ["cardiac arrest", "DISEASE", 111, 125], ["ALS", "DISEASE", 220, 223], ["cardiac arrest management", "TREATMENT", 111, 136], ["COVID", "TEST", 163, 168]]], ["This is primarily due to the need for personal protective equipment (PPE) donning prior to any aerosol generating procedure (AGP).", [["personal protective equipment (PPE)", "TREATMENT", 38, 73], ["any aerosol generating procedure", "TREATMENT", 91, 123]]], ["The ILCOR consensus on science highlights the paucity of evidence as to which resuscitation interventions are considered AGPs and supports defibrillation before PPE, but recommends PPE donning before cardiopulmonary resuscitation (CPR) 3, 4 .", [["cardiopulmonary", "ANATOMY", 200, 215], ["resuscitation interventions", "TREATMENT", 78, 105], ["AGPs", "PROBLEM", 121, 125], ["defibrillation", "TREATMENT", 139, 153], ["PPE", "TREATMENT", 161, 164], ["PPE", "TREATMENT", 181, 184], ["cardiopulmonary resuscitation", "TREATMENT", 200, 229]]], ["This is contradicted by Public Health England guidance which deems CPR not to be an AGP 5 .", [["CPR", "TREATMENT", 67, 70]]], ["Anecdotally, there has been varied implementation of the guidelines across the UK, with many hospitals adapting the guidelines to develop their own specific algorithms.", [["varied", "OBSERVATION_MODIFIER", 28, 34]]], ["Some hospitals have extrapolated, such that all inpatients are considered COVID-19 suspected and the COVID-19 ALS algorithm 1 is applied as a blanket rule irrespective of the probability of COVID-19 infection.", [["ALS", "DISEASE", 110, 113], ["infection", "DISEASE", 199, 208], ["COVID", "TEST", 74, 79], ["the COVID-19 ALS algorithm", "TREATMENT", 97, 123], ["a blanket rule", "TREATMENT", 140, 154], ["COVID-19 infection", "PROBLEM", 190, 208], ["infection", "OBSERVATION", 199, 208]]], ["Other hospitals use the 2015 ALS algorithm for 'clean' wards and the COVID-19 algorithm for infected wards, with PPE for clean wards being personal preference.", [["ALS", "DISEASE", 29, 32], ["the 2015 ALS algorithm", "TREATMENT", 20, 42], ["the COVID", "TREATMENT", 65, 74], ["PPE", "TREATMENT", 113, 116]]], ["This non-standardised approach has created uncertainty which is not in keeping with ALS principles.Severn deanery, United KingdomAs members of hospital cardiac arrest teams, we wish to share our experience of the implementation of COVID-19 resuscitation guidelines.", [["cardiac", "ANATOMY", 152, 159], ["ALS", "DISEASE", 84, 87], ["cardiac arrest", "DISEASE", 152, 166], ["This non-standardised approach", "TREATMENT", 0, 30], ["ALS principles", "PROBLEM", 84, 98], ["COVID-19 resuscitation guidelines", "TREATMENT", 231, 264]]], ["We have witnessed an overall decrease in the number of cardiac arrests outside of intensive care, primarily due to better treatment escalation plans.", [["cardiac", "ANATOMY", 55, 62], ["cardiac arrests", "DISEASE", 55, 70], ["cardiac", "ORGAN", 55, 62], ["cardiac arrests", "PROBLEM", 55, 70], ["overall", "OBSERVATION_MODIFIER", 21, 28], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["cardiac", "ANATOMY", 55, 62], ["arrests", "OBSERVATION", 63, 70]]], ["All resuscitation attempts are treated as potential COVID-19 and are generally terminated sooner than pre-COVID.", [["All resuscitation attempts", "TREATMENT", 0, 26], ["COVID", "TEST", 52, 57]]], ["The variable availability of PPE and rapid donning has added additional stress to a time-critical and already fraught situation.", [["PPE", "PROBLEM", 29, 32], ["variable", "OBSERVATION_MODIFIER", 4, 12]]], ["There is considerable uncertainty about what first responders should do, often meaning that basic life support is not initiated until the resuscitation team arrives.Severn deanery, United KingdomWe have experienced some unintended consequences of COVID-19 resuscitation guidance amongst patients without COVID-19.", [["COVID-19", "CHEMICAL", 304, 312], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["basic life support", "TREATMENT", 92, 110], ["COVID-19 resuscitation guidance", "TREATMENT", 247, 278], ["COVID", "TEST", 304, 309], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["uncertainty", "OBSERVATION", 22, 33]]], ["A recent witnessed arrest with an initially shockable rhythm converted to pulseless electrical activity after a single shock by ward staff.", [["shock", "DISEASE", 119, 124], ["A recent witnessed arrest", "PROBLEM", 0, 25], ["an initially shockable rhythm", "PROBLEM", 31, 60], ["pulseless electrical activity", "PROBLEM", 74, 103], ["arrest", "OBSERVATION", 19, 25]]], ["Resuscitation was then withheld until the hospital resuscitation team arrived, donned PPE some 5-8 minutes later.", [["Resuscitation", "TREATMENT", 0, 13]]], ["Whilst in this particular case the patient had a good outcome, there is a risk of harm in future cases from the delayed initiation of resuscitation related to COVID-19 guidelines being applied outside of the context for which they were intended.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["resuscitation", "TREATMENT", 134, 147], ["COVID-19 guidelines", "TREATMENT", 159, 178]]], ["Resuscitation attempts in the current climate require a dynamic risk assessment incorporating the risk to the patient of delaying CPR verses the risk of staff exposure to COVID-19.Severn deanery, United KingdomOur experiences highlight two salient questions: Should all hospital inpatients be treated as COVID-19 suspected?", [["COVID-19", "CHEMICAL", 171, 179], ["COVID-19", "CHEMICAL", 304, 312], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["Resuscitation", "TREATMENT", 0, 13], ["a dynamic risk assessment", "TEST", 54, 79], ["CPR", "TREATMENT", 130, 133], ["COVID", "TEST", 171, 176], ["COVID", "TEST", 304, 309]]], ["Secondly; how and when will standard ALS treatment for non-COVID patients be resumed?", [["ALS", "DISEASE", 37, 40], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["ALS treatment", "TREATMENT", 37, 50], ["non-COVID patients", "TREATMENT", 55, 73]]], ["This is pertinent as we pass the initial COVID-19 peak, with hospitals testing patients on admission and cohorting accordingly.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["the initial COVID", "TEST", 29, 46], ["hospitals testing", "TEST", 61, 78]]], ["There is an urgent need for national guidelines that address these questions to re-standardise ALS management nationwide.", [["ALS", "DISEASE", 95, 98], ["national guidelines", "TREATMENT", 28, 47], ["re-standardise ALS management", "TREATMENT", 80, 109]]]], "678db6009cc521e45085bee8f185da75b5b5a859": [["IntroductionThe novel coronavirus disease continues to spread rapidly at a global scale.", [["coronavirus disease", "DISEASE", 22, 41], ["coronavirus", "ORGANISM", 22, 33], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["coronavirus disease", "OBSERVATION", 22, 41]]], ["On January 30, 2020, the World Health Organization (WHO) identified the emergence of the novel coronavirus as a pandemic and a health emergency of global concern (PHEIC) (Eurosurveillance Editorial Team, 2020).", [["coronavirus", "DISEASE", 95, 106], ["coronavirus", "ORGANISM", 95, 106], ["the novel coronavirus", "PROBLEM", 85, 106]]], ["On Feb 11, 2020, this novel coronavirus was officially named as Corona Virus Disease 2019 (COVID-19) by WHO.", [["coronavirus", "ORGANISM", 28, 39], ["Corona Virus", "ORGANISM", 64, 76], ["Corona Virus Disease 2019 (COVID-19", "SPECIES", 64, 99], ["this novel coronavirus", "PROBLEM", 17, 39], ["Corona Virus Disease", "PROBLEM", 64, 84], ["COVID", "TEST", 91, 96]]], ["As of August 25, 2020, more than 23 million confirmed cases with 800,000 deaths had been reported worldwide (World Health Organization, 2020a) .", [["deaths", "DISEASE", 73, 79]]], ["While the global virus has sparked an unprecedented response among the scholarly community, the large majority of recent topics of inquiry have been concerning emergency care, viral pathogenesis, and so forth.", [["the global virus", "PROBLEM", 6, 22], ["emergency care", "TREATMENT", 160, 174], ["viral pathogenesis", "PROBLEM", 176, 194], ["global", "OBSERVATION_MODIFIER", 10, 16], ["virus", "OBSERVATION", 17, 22], ["unprecedented", "OBSERVATION_MODIFIER", 38, 51], ["response", "OBSERVATION_MODIFIER", 52, 60], ["large", "OBSERVATION_MODIFIER", 96, 101], ["majority", "OBSERVATION_MODIFIER", 102, 110]]], ["In contrast, attention to the impact of COVID-19 on people's mental health, particularly for the younger population, have been scant (Tran, Ha, et al., 2020) .IntroductionCOVID-19 not only endangers people's health and lives but is also likely to yield short and long-term negative psychological consequences for human societies.", [["COVID-19", "CHEMICAL", 40, 48], ["COVID-19", "CHEMICAL", 40, 48], ["COVID-19", "GENE_OR_GENE_PRODUCT", 40, 48], ["people", "ORGANISM", 52, 58], ["people", "ORGANISM", 199, 205], ["human", "ORGANISM", 313, 318], ["people", "SPECIES", 52, 58], ["people", "SPECIES", 199, 205], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["COVID", "TEST", 40, 45]]], ["Several early studies on the psychological effects of COVID-19 showed notable prevalence of anxiety, depression, stress (Wang et al., 2020a) , insomnia , and post-traumatic stress disorder Wang et al., 2020b) among those affected.", [["COVID-19", "CHEMICAL", 54, 62], ["anxiety", "DISEASE", 92, 99], ["depression", "DISEASE", 101, 111], ["insomnia", "DISEASE", 143, 151], ["post-traumatic stress disorder", "DISEASE", 158, 188], ["COVID-19", "CHEMICAL", 54, 62], ["COVID", "TEST", 54, 59], ["anxiety", "PROBLEM", 92, 99], ["depression", "PROBLEM", 101, 111], ["stress", "PROBLEM", 113, 119], ["insomnia", "PROBLEM", 143, 151], ["post-traumatic stress disorder", "PROBLEM", 158, 188]]], ["In particular, those who experienced physical symptoms of COVID-19 were also 2-3 times more likely to report having the aforementioned negative psychological symptoms .", [["physical symptoms", "PROBLEM", 37, 54], ["COVID", "TEST", 58, 63], ["the aforementioned negative psychological symptoms", "PROBLEM", 116, 166]]], ["The prolonged prevalence of COVID-19 remains a source of great psychological pressure, both for the general public (Wang et al., 2020a) and specific sectors of society Hao et al., 2020; Tan, Hao, et al., 2020) .IntroductionWith the salience of the increasing number of COVID-19 infections, widespread dissemination of misinformation (dubbed the COVID-19 infodemic; World Health Organization, 2020b), and unavailability of epidemic prevention resources in the marketplace, those residing in close proximity of epicenters of COVID-19 may be highly susceptible to the negative outcomes of acute and chronic stress (Liu et al., 2020) .", [["infections", "DISEASE", 278, 288], ["COVID", "TEST", 28, 33], ["COVID-19 infections", "PROBLEM", 269, 288], ["the COVID", "TEST", 341, 350], ["COVID", "TEST", 523, 528], ["acute and chronic stress", "PROBLEM", 586, 610], ["increasing", "OBSERVATION_MODIFIER", 248, 258], ["number", "OBSERVATION_MODIFIER", 259, 265], ["widespread", "OBSERVATION_MODIFIER", 290, 300], ["dissemination", "OBSERVATION_MODIFIER", 301, 314], ["acute", "OBSERVATION_MODIFIER", 586, 591], ["chronic", "OBSERVATION_MODIFIER", 596, 603]]], ["Indeed, stressors have long been documented to be strong risk factors of several mental health consequences, such as depression, anxiety, and insomnia (Pappa et al., 2020; Vedhara et al., 2000; Wahab et al., 2013) .", [["depression", "DISEASE", 117, 127], ["anxiety", "DISEASE", 129, 136], ["insomnia", "DISEASE", 142, 150], ["several mental health consequences", "PROBLEM", 73, 107], ["depression", "PROBLEM", 117, 127], ["anxiety", "PROBLEM", 129, 136], ["insomnia", "PROBLEM", 142, 150]]], ["However, not everyone under these stressors will exhibit negative outcomes; those who are well-equipped to adequately cope with the stressors may be able to appropriate their psychological and cognitive resources to manage impending or concurrent issues (Lazarus, 1993) .IntroductionBecause one's overall well-being is largely contingent on their mental health (Prince et al., 2007) , it remains important to examine the psychological consequences of stressors stemming from COVID-19 related issues.", [["stressors stemming", "PROBLEM", 451, 469]]], ["Heretofore, we refer to these stress-induced consequences stemming from the COVID-19 pandemic as simply stress consequences.", [["the COVID", "TEST", 72, 81], ["stress consequences", "PROBLEM", 104, 123]]], ["Given the novelty of COVID-19, however, it is unclear how the specific stressors associated with the disease may have impacted Chinese college students early in the pandemic.", [["COVID", "TEST", 21, 26], ["the disease", "PROBLEM", 97, 108]]], ["Thus, the aim of the present study is to investigate whether the stressors of COVID-19 experienced by college students is significantly associated with stress consequences and examine the potential mediating and moderating mechanisms in this association.The mediating role of ruminationIn examining the consequences of sudden stressors, it is important to consider the possible mediators that may play a role in increasing stress consequences.", [["the present study", "TEST", 17, 34], ["COVID", "TEST", 78, 83], ["stress consequences", "PROBLEM", 152, 171], ["sudden stressors", "PROBLEM", 319, 335], ["increasing stress consequences", "PROBLEM", 412, 442]]], ["In particular, rumination may be a subsequent consequence of sudden stressors as well as being an antecedent of stress consequences.", [["rumination", "DISEASE", 15, 25], ["sudden stressors", "PROBLEM", 61, 77], ["stress consequences", "PROBLEM", 112, 131]]], ["Rumination is a maladaptive form of cognitive self-reflection, characterized by repeated thoughts and recollection of feelings associated with negative events (Nolen-Hoeksema, Wisco, & Lyubomirsky, 2008; Robinson & Alloy, 2003) .", [["Rumination", "DISEASE", 0, 10], ["cognitive self-reflection", "DISEASE", 36, 61]]], ["The perseverative cognition hypothesis posits that rumination is a common response to stress and reasons that such perseverative cognition exacerbates stress consequences as stressors are prolonged under a ruminative state (Brosschot, Gerin, & Thayer, 2006) .", [["rumination", "DISEASE", 51, 61], ["perseverative cognition", "DISEASE", 115, 138], ["such perseverative cognition exacerbates stress consequences", "PROBLEM", 110, 170]]], ["Rumination is commonly regarded as a poor coping strategy, characterized by its passive nature and tendency to hinder individual social problem solving.", [["Rumination", "DISEASE", 0, 10], ["a poor coping strategy", "PROBLEM", 35, 57]]], ["Indeed, prior research has shown that individuals exhibiting high levels of rumination are often coupled with facing their problems more negatively and divorced from adaptive problem-solving behaviors that otherwise serve to address the source of the issue (Hasegawa et al., 2015) .", [["rumination", "DISEASE", 76, 86], ["high levels of rumination", "PROBLEM", 61, 86], ["adaptive problem", "PROBLEM", 166, 182]]], ["As rumination is associated with increased negative emotions and decreased suppression of negative information, this unique cognitive mechanism serves as a catalyst in the cycle of negative emotions and cognitions (Liu & Tian, 2013) .", [["increased negative emotions", "PROBLEM", 33, 60], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["negative emotions", "OBSERVATION", 43, 60]]], ["This sustained negative patterns of emotion and cognition has been documented to result in a plethora of adverse health consequences, such as impaired sleep (Allen, 2007) , sleep disorders (Butz & Stahlberg, 2018; Guastella & Moulds, 2007; Takano, Iijima, & Tanno, 2012) , depression and anxiety (Aldao, Nolen-Hoeksema, & Schweizer, 2010) , and decreased health levels (Joormann & Gotlib, 2010) .The mediating role of ruminationWhile past studies have evidenced that rumination predicts a diverse range of stress consequences, no studies to date have directly investigated the mediating role of rumination in the association between COVID-19 related stressors and stress consequences in college students.", [["impaired sleep", "DISEASE", 142, 156], ["sleep disorders", "DISEASE", 173, 188], ["depression", "DISEASE", 273, 283], ["anxiety", "DISEASE", 288, 295], ["rumination", "DISEASE", 467, 477], ["sleep disorders", "PROBLEM", 173, 188], ["Takano", "TREATMENT", 240, 246], ["depression", "PROBLEM", 273, 283], ["anxiety", "PROBLEM", 288, 295], ["stress consequences", "PROBLEM", 506, 525], ["negative", "OBSERVATION", 15, 23]]], ["Many scholars have conceptualized rumination as a risk or protective factor (i.e., it buffers or exacerbates the effects of stress).", [["rumination", "DISEASE", 34, 44]]], ["However, the unique and unusual social ecology brought about by COVID-19 warrant examining rumination as a consequence of COVID-19 stressors.", [["rumination", "DISEASE", 91, 101], ["COVID", "TEST", 122, 127]]], ["Rumination has been documented to be influenced by perceived stress (Chen & Huang, 2019; Wang et al., 2019) and because attention increases under high levels of vigilance (Qi & Gao, 2020) , the cognitive behavior presents itself as a natural, but potentially dangerous, variable in models of stress consequences (Nolen-Hoeksema et al., 2008) for adolescents (Skitch & Abela, 2008) .", [["Rumination", "DISEASE", 0, 10], ["cognitive behavior", "DISEASE", 194, 212], ["adolescents", "SPECIES", 346, 357], ["stress consequences", "PROBLEM", 292, 311]]], ["Specifically, rumination has been evidenced to be a mutable variable in response to stressful life events (e.g., Li et al., 2019; Liu & Wang, 2017; Michl, McLaughlin, Shepherd, & Nolen-Hoeksema, 2013 ) and can play a mediating role between changing stressors and their respective consequences, such as work stressors and impaired sleep (Berset, Elfering, L\u00fcthy, L\u00fcthi, & Semmer, 2011) and perceived stress and depression (Wang et al., 2019) .", [["impaired sleep", "DISEASE", 321, 335], ["depression", "DISEASE", 410, 420], ["depression", "PROBLEM", 410, 420]]], ["As COVID-19 brought about sudden changes to our social ecology, as well as great uncertainty regarding the impending future, rumination tendencies may increase in those who may not have otherwise be susceptible in response to more routine stressors.", [["COVID-19", "DNA", 3, 11], ["rumination tendencies", "PROBLEM", 125, 146]]], ["Given the uncertainty associated with the course of COVID-19, it stands to reason that students may engage in more rumination as their stressors increase, which in turn may increase their risk for developing several negative psychological outcomes.The moderating role of psychological supportCOVID-19 stressors may increase college students' stress consequences through the mediating role of rumination, but there is a diverse range of sensitivity among individuals with regard to how they respond to stressors.", [["COVID", "TEST", 52, 57], ["psychological supportCOVID", "TREATMENT", 271, 297]]], ["In other words, not all college students with high COVID-19 stressors may engage in a high level of rumination or experience the detriments of COVID-19 stressors or rumination.", [["rumination", "DISEASE", 100, 110], ["rumination", "DISEASE", 165, 175], ["COVID", "TEST", 143, 148], ["rumination", "PROBLEM", 165, 175]]], ["One key buffering mechanism may be psychological support.", [["psychological support", "TREATMENT", 35, 56]]], ["Psychological support is defined as the capacity to use internal and external resources to establish an environmental and individual support system in an effort to maintain and promote one's mental health (Zhou & Zhang, 2017) .", [["Psychological support", "TREATMENT", 0, 21], ["internal and external resources", "TREATMENT", 56, 87], ["individual support system", "TREATMENT", 122, 147]]], ["Because stress consequences result from a dynamic interplay between risk and protective factors (Masten, 2001) , psychological support may serve as a protective factor against psychological risk factors specific to .", [["stress consequences", "PROBLEM", 8, 27], ["psychological support", "TREATMENT", 113, 134], ["psychological risk factors", "PROBLEM", 176, 202]]], ["In other words, psychological support may weaken the negative association between COVID-19 stressors and its subsequent stress consequences.", [["psychological support", "TREATMENT", 16, 37], ["COVID", "TEST", 82, 87], ["its subsequent stress consequences", "PROBLEM", 105, 139]]], ["Findings from several studies allude to supporting this notion.", [["several studies", "TEST", 14, 29]]], ["For instance, social support has been documented to yield favorable sleep outcomes (Kent de Grey, Uchino, Trettevik, Cronan, & Hogan, 2018), such as lower levels of insomnia severity (Kim & Suh, 2019) .", [["insomnia", "DISEASE", 165, 173], ["insomnia severity", "PROBLEM", 165, 182]]], ["Further, social support has been evidenced to buffer the adverse impact of negative life events on wellbeing (Nezlek & Allen, 2006 ) as well as perfectionism on depression and anxiety (Zhou, Zhu, Zhang, & Cai, 2013) .", [["depression", "DISEASE", 161, 171], ["anxiety", "DISEASE", 176, 183], ["perfectionism", "PROBLEM", 144, 157], ["depression", "PROBLEM", 161, 171], ["anxiety", "PROBLEM", 176, 183]]], ["That is, social support plays a critical role in reducing depression (Bouteyre, Maurel, & Bernaud, 2007; Costa et al., 2017) .The moderating role of psychological supportPsychological support may be particularly prevalent and effective during times of pandemics.", [["depression", "DISEASE", 58, 68], ["psychological support", "TREATMENT", 149, 170], ["Psychological support", "TREATMENT", 170, 191], ["pandemics", "PROBLEM", 252, 261]]], ["The history of epidemics has generally observed the public utilizing more psychological coping strategies, such as problem-focused coping as well as seeking social support as negative stress consequences also rise (Chew, Wei, Vasoo, Chua, & Sim, 2020) .", [["epidemics", "PROBLEM", 15, 24], ["psychological coping strategies", "TREATMENT", 74, 105]]], ["During the SARS epidemic, individuals reported receiving more social support from family and friends compared to before the epidemic (Lau, Yang, Tsui, Pang, & Wing, 2006) .", [["SARS", "DISEASE", 11, 15]]], ["While the efficacy of psychological support in combatting the stress consequences specific to COVID-19 requires more investigation, an early report yielded promising results showing that social support was negatively associated with the degree of anxiety and stress (Xiao, Zhang, Kong, Li, & Yang, 2020) .", [["anxiety", "DISEASE", 247, 254], ["psychological support", "TREATMENT", 22, 43], ["the stress consequences", "PROBLEM", 58, 81], ["social support", "TREATMENT", 187, 201], ["anxiety", "PROBLEM", 247, 254], ["stress", "PROBLEM", 259, 265]]], ["However, further examination of this buffering effect is warranted given the ubiquity of COVID-19 related stressors in recent times and the accessibility of psychological stressors as a possible protective mechanism.", [["further examination", "TEST", 9, 28], ["this buffering effect", "PROBLEM", 32, 53], ["psychological stressors", "PROBLEM", 157, 180]]], ["To date, no previous studies examined whether psychological support as a protective factor that buffers the adverse impact of stressors of COVID-19 on stress consequences and a moderator in the indirect relation between stressors of COVID-19 and stress consequence via rumination. rumination would mediate the relation between stressors of COVID-19 and stress consequences in college students, and (b) to test whether the direct and indirect relations between stressors of COVID-19 and stress consequences via rumination were moderated by psychological support.", [["COVID-19", "CHEMICAL", 139, 147], ["rumination", "DISEASE", 281, 291], ["COVID-19", "CHEMICAL", 139, 147], ["previous studies", "TEST", 12, 28], ["psychological support", "TREATMENT", 46, 67], ["COVID", "TEST", 139, 144], ["stress consequences", "PROBLEM", 151, 170], ["COVID", "TEST", 233, 238], ["stress consequence via rumination", "PROBLEM", 246, 279], ["COVID", "TEST", 340, 345], ["COVID", "TEST", 473, 478], ["stress consequences", "PROBLEM", 486, 505], ["psychological support", "TREATMENT", 539, 560]]], ["The proposed model is illustrated in Fig. 1 .", [["illustrated", "OBSERVATION", 22, 33], ["Fig", "OBSERVATION_MODIFIER", 37, 40]]], ["Rumination will mediate the relation between stressors of COVID-19 and stress consequences.The moderating role of psychological supportHypothesis 2.", [["Rumination", "DISEASE", 0, 10], ["COVID", "TEST", 58, 63], ["stress consequences", "PROBLEM", 71, 90]]], ["Psychological support will moderate the direct and indirect relations between stressors of COVID-19 and stress consequences via rumination.ParticipantsA total of 841 college students in China (M age = 19.50, SD = 1.580, range = 18-25, 61.0% Female) participated in this study from February 17 to March 15, 2020.", [["Psychological support", "TREATMENT", 0, 21], ["COVID", "TEST", 91, 96], ["stress consequences via rumination", "PROBLEM", 104, 138]]], ["Participation in this study was entirely voluntary and no compensation was given to participants for their participation.", [["participants", "SPECIES", 84, 96], ["this study", "TEST", 17, 27]]], ["To abide by local government policies, the study questionnaire was distributed to potential participants electronically via SurveyStar (Changsha Ranxing Science and Technology, Shanghai, China) and no face-to-face contact was made.", [["participants", "SPECIES", 92, 104], ["the study questionnaire", "TEST", 39, 62]]], ["All participants consented to participation and data were anonymized.", [["participants", "SPECIES", 4, 16]]], ["Furthermore, 68.6% of these participants were 1st year standing, 16.5% were 2nd year standing, 10.0% were 3rd year standing, and 4.9% were 4th year standing.", [["participants", "ORGANISM", 28, 40], ["participants", "SPECIES", 28, 40]]], ["As the Ministry of Education in China extended Winter recess from February 2020 to April 2020, universities were not in active session when data were collected.Stressors of COVID-19We compiled the COVID-19 stressors scale, comprised of 19 items, \u03b1 = 0.942 (see Supplemental Materials for the scale).", [["COVID", "TEST", 173, 178], ["the COVID", "TEST", 193, 202], ["stressors scale", "TEST", 206, 221]]], ["The scale included four dimensions: (1) disease stressors of COVID-19 (7 items; e.g., \"I am worried that I will be infected by COVID-19\"), (2) information stressors of COVID-19 (4 items; e.g., \"I heard some negative news about COVID-19\"), (3) measures stressors of COVID-19 (4 items; e.g., \"Academic schedule was disrupted\"), and (4) environmental stressors of COVID-19 (4 items; e.g., \"I am separated and alienated from my classmates and friends\").", [["COVID", "TEST", 61, 66], ["COVID", "TEST", 168, 173], ["COVID", "TEST", 265, 270], ["COVID", "TEST", 361, 366]]], ["Participants rated each item on a five-point scale ranging from 1 (No Stress) to 5 (Great Stress).", [["Participants", "SPECIES", 0, 12]]], ["Greater mean scores indicated higher levels of COVID-19 related stress.RuminationThe Chinese Version (Han & Yang, 2009 ) of the Ruminative Responses Scale (RRS) (Nolen-Hoeksema & Morrow, 1991) was administered to measure participants' level of rumination, \u03b1 = 0.950.", [["Rumination", "DISEASE", 71, 81], ["participants", "SPECIES", 221, 233], ["Greater mean scores", "TEST", 0, 19], ["COVID", "TEST", 47, 52], ["RRS", "TEST", 156, 159], ["rumination", "TEST", 244, 254], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["The scale consisted of 22 items (e.g., \"I go away by myself and think about why I feel this way\" and \"I think back to other times I have been depressed\") and included three dimensions: (1) brooding (5 items), (2) reflective pondering (5 items), and (3) symptom rumination (12 items).", [["depressed", "DISEASE", 142, 151], ["reflective pondering (5 items)", "PROBLEM", 213, 243], ["symptom rumination", "PROBLEM", 253, 271]]], ["Participants rated each item on a four-point scale ranging from 1 (never) to 4 (always), with higher mean scores indicating higher levels of rumination.", [["rumination", "DISEASE", 141, 151], ["Participants", "SPECIES", 0, 12], ["higher mean scores", "PROBLEM", 94, 112]]], ["This scale has been used in the Chinese population (e.g., Chen et al., 2018; Cui et al., 2017; Li et al., 2019; Wang et al., 2020b) and shown good reliability and validity.Stress consequencesStress consequences were assessed by the Pressure Effect Scale (Liu, 2014) which comprised 17 items (e.g., \"Difficulty concentrating,\" \"Poor appetite, loss of appetite,\" \"Easy to lose temper and feel irritable\"; see Supplemental Materials for scale).", [["loss of appetite", "DISEASE", 342, 358], ["This scale", "TREATMENT", 0, 10], ["Stress consequences", "PROBLEM", 172, 191], ["Stress consequences", "PROBLEM", 191, 210], ["Poor appetite", "PROBLEM", 327, 340], ["loss of appetite", "PROBLEM", 342, 358], ["irritable", "PROBLEM", 391, 400], ["good reliability", "OBSERVATION", 142, 158]]], ["The scale included three dimensions:Stress consequences(1) behavioral symptoms (6 items), (2) psychological symptoms (7 items), (3) physical symptoms (4 items), with good reliability and validity in Chinese samples, \u03b1 = 0.869.", [["Stress consequences", "PROBLEM", 36, 55], ["behavioral symptoms", "PROBLEM", 59, 78], ["psychological symptoms", "PROBLEM", 94, 116], ["physical symptoms", "PROBLEM", 132, 149], ["Chinese samples", "TEST", 199, 214]]], ["Participants rated each item on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree) with higher scores showing higher levels of stress consequences.Psychological supportPsychological support was measured by the College Students Psychological Support Scale (Zhou & Zhang, 2017) , with good reliability and validity in Chinese samples, \u03b1 = 0.851.", [["Participants", "SPECIES", 0, 12], ["stress consequences", "PROBLEM", 149, 168], ["Psychological supportPsychological support", "TREATMENT", 169, 211], ["Chinese samples", "TEST", 338, 353]]], ["Participants rated each item on a 5-point scale ranging from 1 (never) to 5 (always), with higher mean scores indicating higher levels of psychological support.ProcedureThis study was approved by the Research Ethics Committee of the first author's institution.", [["Participants", "SPECIES", 0, 12], ["psychological support", "TREATMENT", 138, 159]]], ["Participants were given the survey questionnaire where they provided demographic information and completed the measurements listed above.Data analysisThe purpose of this study was to explore whether rumination played a mediating role between the stressors of COVID-19 and the stress consequences of college students, and whether psychological support played a moderating role in the indirect path between the stressors of COVID-19 and the direct path between stressors of COVID-19 and stress consequences.", [["rumination", "DISEASE", 199, 209], ["Participants", "SPECIES", 0, 12], ["Data analysis", "TEST", 137, 150], ["this study", "TEST", 165, 175], ["COVID", "TEST", 259, 264], ["psychological support", "TREATMENT", 329, 350], ["COVID", "TEST", 422, 427], ["COVID", "TEST", 472, 477], ["stress consequences", "PROBLEM", 485, 504]]], ["Second, the mediating effect of rumination was examined by using PROCESS macro for SPSS (Model 4) (Hayes, 2017) .", [["rumination", "PROBLEM", 32, 42], ["effect", "OBSERVATION_MODIFIER", 22, 28]]], ["Third, the analyses of the moderating effect of psychological support on the direct and indirect links between stressors of COVID-19 and stress consequences were constructed applying the PROCESS macro (Model 59).", [["psychological support", "TREATMENT", 48, 69], ["COVID", "TEST", 124, 129], ["stress consequences", "PROBLEM", 137, 156]]], ["All study continuous variables were standardized, and the models utilized 5000 resamples through bootstrapping confidence intervals (CIs) to determine whether the effects in PROCESS Model 4 and Model 59 were significant (Hayes, 2017) .", [["All study", "TEST", 0, 9], ["PROCESS Model", "TEST", 174, 187], ["significant", "OBSERVATION_MODIFIER", 208, 219]]], ["Table 1 lists the means, standard deviations, skewness, kurtosis, bivariate correlations, and Cronbach's \u03b1 for the study variables.", [["bivariate correlations", "TEST", 66, 88], ["the study variables", "TEST", 111, 130]]], ["The data were examined for normality of distribution by skewness and kurtosis (Kline, 2015) .", [["The data", "TEST", 0, 8], ["kurtosis", "TEST", 69, 77]]], ["The skewness and kurtosis of all variables were within the acceptable ranges (|skewness| < 3 and |kurtosis| < 10).", [["skewness", "OBSERVATION_MODIFIER", 4, 12]]], ["As expected, stressors of COVID-19 were positively correlated with rumination and stress consequences, but negatively correlated with psychological support.", [["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["COVID", "TEST", 26, 31], ["stress consequences", "PROBLEM", 82, 101], ["psychological support", "TREATMENT", 134, 155]]], ["Rumination was positively and negatively correlated with stress consequences and psychological support, respectively.", [["Rumination", "TEST", 0, 10], ["stress consequences", "PROBLEM", 57, 76], ["psychological support", "TREATMENT", 81, 102]]], ["Additionally, stress consequence was negatively correlated with psychological support.Testing for mediation effectHypothesis 1 assumed that rumination mediates the relation between stressors of COVID-19 and stress consequence.", [["psychological support", "TREATMENT", 64, 85], ["mediation effectHypothesis", "PROBLEM", 98, 124], ["COVID", "TEST", 194, 199], ["stress consequence", "PROBLEM", 207, 225]]], ["The regression results for testing mediation are reported in Table 2 .", [["testing mediation", "TEST", 27, 44]]], ["Results indicated that stressors of COVID-19 were positively related to rumination, which was, in turn, positively associated with stress consequences.", [["rumination", "DISEASE", 72, 82], ["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "GENE_OR_GENE_PRODUCT", 36, 44], ["COVID", "TEST", 36, 41], ["stress consequences", "PROBLEM", 131, 150]]], ["The residual direct effect of stressors of COVID-19 on stress consequences remained positive.", [["COVID-19", "CHEMICAL", 43, 51], ["COVID-19", "CHEMICAL", 43, 51], ["COVID", "TEST", 43, 48], ["stress consequences", "TEST", 55, 74], ["positive", "PROBLEM", 84, 92], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["direct", "OBSERVATION_MODIFIER", 13, 19], ["effect", "OBSERVATION_MODIFIER", 20, 26], ["positive", "OBSERVATION", 84, 92]]], ["These results show that rumination partially mediated the association between stressors of COVID-19 and stress consequences (indirect effect = 0.280, SE = 0.022, 95% CI = [0.238, 0.326]), and the mediation effect accounted for 60.87% of the total effect of stressors of COVID-19 on stress consequences.", [["COVID-19", "CHEMICAL", 270, 278], ["COVID-19", "CHEMICAL", 270, 278], ["rumination", "PROBLEM", 24, 34], ["COVID", "TEST", 91, 96], ["stress consequences", "PROBLEM", 104, 123], ["SE", "TEST", 150, 152], ["CI", "TEST", 166, 168], ["COVID", "TEST", 270, 275], ["stress consequences", "PROBLEM", 282, 301]]], ["Therefore, Hypothesis 1 was supported.Moderated mediation effect analysisHypothesis 2 proposed that the direct and indirect relationships between stressors of COVID-19 and stress consequences via rumination would be moderated by psychological support.", [["COVID", "TEST", 159, 164], ["stress consequences", "PROBLEM", 172, 191], ["psychological support", "TREATMENT", 229, 250]]], ["The results of parameters for three regression models are shown in Table 3 .", [["three regression models", "TEST", 30, 53]]], ["Model 1 of Table 3 shows that the product (interaction term) of stressors of COVID-19 and psychological support had a significant negative association with rumination.Moderated mediation effect analysisFollowing the methodology from a previous study , we plotted predicted rumination against stressors of COVID-19, separately for low and high levels of psychological support (one SD below the mean and one SD above the mean, respectively) (Fig. 2) .", [["rumination", "DISEASE", 156, 166], ["COVID", "TEST", 77, 82], ["psychological support", "TREATMENT", 90, 111], ["Moderated mediation effect analysis", "PROBLEM", 167, 202], ["a previous study", "TEST", 233, 249], ["COVID", "TEST", 305, 310], ["psychological support", "TREATMENT", 353, 374]]], ["Simple slope test demonstrated that for college students with high levels of psychological support, stressors of COVID-19 were positively associated with rumination, b simple = 0.25, p < 0.001.", [["Simple slope test", "TEST", 0, 17], ["psychological support", "TREATMENT", 77, 98], ["COVID", "TEST", 113, 118], ["rumination", "TEST", 154, 164]]], ["For college students with low psychological support, stressors of COVID-19 yielded a stronger positive association with rumination, b simple = 0.50, p < 0.001.", [["low psychological support", "TREATMENT", 26, 51], ["COVID", "TEST", 66, 71], ["rumination", "TEST", 120, 130]]], ["Simple slope tests demonstrated that the higher the level of psychological support, the weaker the association between stressors of COVID-19 and rumination.Moderated mediation effect analysisMoreover, as Model 2 of Table 3 illustrates, the effect of stressors of COVID-19 on stress consequences was significant, but this effect was not moderated by psychological support (p = 0.057).", [["rumination", "DISEASE", 145, 155], ["COVID-19", "CHEMICAL", 263, 271], ["COVID-19", "CHEMICAL", 263, 271], ["Simple slope tests", "TEST", 0, 18], ["psychological support", "TREATMENT", 61, 82], ["COVID", "TEST", 132, 137], ["Moderated mediation effect analysisMoreover", "PROBLEM", 156, 199], ["COVID", "TEST", 263, 268], ["stress consequences", "PROBLEM", 275, 294]]], ["In addition, Model 2 of Table 3 also indicated that there was a significant main effect of rumination on stress consequences, and the product (interaction term) of rumination and psychological support had a significant negative association with stress consequence (p = 0.008), which suggests the effect of rumination on stress consequences was moderated by psychological support.Moderated mediation effect analysisFor a clear demonstration of the moderating role of psychological support, this study plotted the predicted stress consequences against rumination, separately for low and high levels of psychological support (one SD below and one SD above the mean, respectively; Fig. 2 ).", [["rumination", "DISEASE", 306, 316], ["rumination on stress consequences", "PROBLEM", 91, 124], ["rumination", "PROBLEM", 164, 174], ["psychological support", "TREATMENT", 179, 200], ["stress consequence", "PROBLEM", 245, 263], ["rumination on stress consequences", "PROBLEM", 306, 339], ["psychological support", "TREATMENT", 357, 378], ["Moderated mediation effect analysis", "PROBLEM", 379, 414], ["psychological support", "TREATMENT", 466, 487], ["this study", "TEST", 489, 499], ["psychological support", "TREATMENT", 600, 621], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["main", "OBSERVATION_MODIFIER", 76, 80]]], ["Simple slope tests revealed that in both high and low levels of psychological support, rumination significantly correlated with stress consequence.", [["Simple slope tests", "TEST", 0, 18], ["psychological support", "TREATMENT", 64, 85], ["rumination", "PROBLEM", 87, 97], ["stress consequence", "PROBLEM", 128, 146], ["low levels", "OBSERVATION_MODIFIER", 50, 60]]], ["However, the relation between rumination and stress consequences appeared to be stronger for those reporting low psychological support than those reporting high psychological support.Moderated mediation effect analysisThe bias-corrected percentile bootstrap analysis further indicated that the indirect effect of stressors of COVID-19 on stress consequences through rumination was moderated by psychological support.", [["rumination", "DISEASE", 30, 40], ["COVID-19", "CHEMICAL", 326, 334], ["COVID-19", "CHEMICAL", 326, 334], ["stress consequences", "PROBLEM", 45, 64], ["Moderated mediation effect analysis", "PROBLEM", 183, 218], ["The bias", "TEST", 218, 226], ["corrected percentile bootstrap analysis", "TEST", 227, 266], ["COVID", "TEST", 326, 331], ["stress consequences", "PROBLEM", 338, 357], ["psychological support", "TREATMENT", 394, 415]]], ["Particularly, for college students low in psychological support, the indirect effect of stressors of COVID-19 on stress consequences via rumination was significant, b = 0.28, SE = 0.03, 95% CI boot = [0.22, 0.34].", [["COVID-19", "CHEMICAL", 101, 109], ["COVID-19", "CHEMICAL", 101, 109], ["psychological support", "TREATMENT", 42, 63], ["COVID", "TEST", 101, 106], ["rumination", "TEST", 137, 147], ["SE", "TEST", 175, 177], ["CI boot", "TEST", 190, 197]]], ["The indirect effect was also significant for college students with high psychological support, but weaker, b = 0.10, SE = 0.02, 95%DiscussionWhile several empirical studies have shown the effect of stressors on stress consequences (Davey et al., 2016; Furuyashiki & Kitaoka, 2019; Gillespie et al., 2001; Lowe et al., 2017) , the underlying mediating and moderating mechanisms remain less clear.", [["high psychological support", "TREATMENT", 67, 93], ["several empirical studies", "TEST", 147, 172], ["stress consequences", "PROBLEM", 211, 230], ["less", "OBSERVATION_MODIFIER", 384, 388], ["clear", "OBSERVATION", 389, 394]]], ["Investigating the degree to which these underlying mechanisms of the stress consequences of college students under the pressure of COVID-19 is vitally important.", [["COVID-19", "CHEMICAL", 131, 139], ["COVID", "TEST", 131, 136]]], ["The present study examined and proposed a novel moderated mediation model to test how stressors of COVID-19 generated harmful stress consequences, whether this relation was mediated by rumination, and how psychological may buffer the negative effects of COVID-19 stressors and rumination.", [["COVID-19", "CHEMICAL", 99, 107], ["rumination", "DISEASE", 277, 287], ["COVID-19", "CHEMICAL", 99, 107], ["The present study", "TEST", 0, 17], ["COVID", "TEST", 99, 104], ["harmful stress consequences", "PROBLEM", 118, 145], ["COVID", "TEST", 254, 259], ["rumination", "PROBLEM", 277, 287]]], ["Our results indicated that the impact of stressors of COVID-19 on stress consequences was significant and positive among Chinese college students, and this relation can be partially explained by heightened rumination.", [["COVID-19", "CHEMICAL", 54, 62], ["COVID-19", "CHEMICAL", 54, 62], ["COVID-19", "GENE_OR_GENE_PRODUCT", 54, 62], ["COVID", "TEST", 54, 59], ["stress consequences", "PROBLEM", 66, 85], ["heightened rumination", "PROBLEM", 195, 216], ["heightened rumination", "OBSERVATION", 195, 216]]], ["That is, stressors of COVID-19 increased rumination, which in turn, also increased stress consequences.", [["rumination", "DISEASE", 41, 51], ["COVID-19", "CHEMICAL", 22, 30], ["COVID", "TEST", 22, 27], ["increased rumination", "PROBLEM", 31, 51], ["increased stress consequences", "PROBLEM", 73, 102], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["stress consequences", "OBSERVATION", 83, 102]]], ["Furthermore, the indirect relation was moderated by psychological support in the first and second stage of the mediation process.", [["psychological support", "TREATMENT", 52, 73], ["the mediation process", "PROBLEM", 107, 128]]], ["These two relations became weaker for college students with higher levels of psychological support.The mediating role of ruminationMediation results of this study suggested that rumination was not only an outcome of stressors of COVID-19 but also a partial catalyst for stress consequences.", [["COVID-19", "CHEMICAL", 229, 237], ["psychological support", "TREATMENT", 77, 98], ["this study", "TEST", 152, 162], ["COVID", "TEST", 229, 234], ["a partial catalyst", "TREATMENT", 247, 265], ["stress consequences", "PROBLEM", 270, 289]]], ["For the first stage of the mediation process (i.e., stressors of COVID-19 \u2192 rumination), this study indicated that stressors of COVID-19 promoted the activation of rumination mechanisms.", [["COVID-19", "CHEMICAL", 128, 136], ["COVID-19", "CHEMICAL", 128, 136], ["COVID-19", "GENE_OR_GENE_PRODUCT", 128, 136], ["COVID", "TEST", 65, 70], ["this study", "TEST", 89, 99], ["COVID", "TEST", 128, 133]]], ["This finding is in line with prior literature on rumination and stress consequences, whereby rumination tendencies are partly mutable in response to stressful life events Liu & Wang, 2017; Michl et al., 2013) .", [["rumination tendencies", "DISEASE", 93, 114], ["stress consequences", "PROBLEM", 64, 83], ["rumination tendencies", "PROBLEM", 93, 114]]], ["Uncontrollable factors and stressors may create a dissonance between the ideal goal state and the reality state, leading to rumination (Nolen-Hoeksema et al., 2008) .", [["rumination", "DISEASE", 124, 134], ["Uncontrollable factors", "PROBLEM", 0, 22]]], ["Indeed, those who have not learned proper emotion management strategies may be more sensitive to a perceived sudden lack of sense of control over their environment (Nolen-Hoeksema et al., 1995) given the impact that COVID-19 had on the current social ecology.The mediating role of ruminationFor the second stage of our mediation model (i.e., rumination \u2192 stress consequences), the present study found that rumination was associated with more stress consequences.", [["rumination", "DISEASE", 406, 416], ["the present study", "TEST", 377, 394], ["rumination", "PROBLEM", 406, 416], ["more stress consequences", "PROBLEM", 437, 461]]], ["Engaging in rumination may indeed lead college students to find themselves in a cycle of negative emotions and cognitions, thus making college students more susceptible to suffering stress consequences, such as anxiety (Liu & Wang, 2017) , poorer sleep quality , and depression (Michl et al., 2013) .", [["anxiety", "DISEASE", 211, 218], ["depression", "DISEASE", 267, 277], ["stress consequences", "PROBLEM", 182, 201], ["anxiety", "PROBLEM", 211, 218], ["poorer sleep quality", "PROBLEM", 240, 260], ["depression", "PROBLEM", 267, 277]]], ["One may argue that COVID-19 stressors are unique from typical stressors; that is, because of the novelty of COVID-19, uncertainty shrouds any discussion or coverage of the pandemic and may make rumination over possible \"what ifs\" an unfortunate natural response among those affected.", [["COVID", "TEST", 108, 113]]], ["As our model shows, this may be particularly problematic given the rudimentary nature of rumination in leading to stress consequences.The mediating role of ruminationIt is also worth noting, however, that rumination only partially mediated the association between stressors of COVID-19 and stress consequences.", [["rumination", "DISEASE", 89, 99], ["rumination", "DISEASE", 205, 215], ["rumination", "PROBLEM", 89, 99], ["stress consequences", "PROBLEM", 114, 133], ["COVID", "TEST", 277, 282], ["stress consequences", "PROBLEM", 290, 309]]], ["That is, stressors of COVID-19 remained a significant, direct predictor of stress consequences even upon controlling for rumination.", [["COVID-19", "CHEMICAL", 22, 30], ["COVID-19", "GENE_OR_GENE_PRODUCT", 22, 30], ["COVID", "TEST", 22, 27], ["stress consequences", "PROBLEM", 75, 94], ["rumination", "PROBLEM", 121, 131]]], ["The remaining direct and positive association between stressors of COVID-19 and stress consequences may suggest that COVID-19 related stressors are uniquely salient risk factors that could significantly increase the prevalence of stress consequences.", [["COVID", "TEST", 67, 72], ["stress consequences", "PROBLEM", 80, 99], ["stress consequences", "PROBLEM", 230, 249]]], ["Thus, each of the separate paths in the mediation model was noteworthy and social interventions may be necessary at various stages of managing one's COVID-19 stressors to mitigate susceptibility to stress consequences.The moderating role of psychological supportOur findings also suggest that psychological support could moderate the relation between stressors of COVID-19 and rumination as well as the path between rumination and stress consequences.", [["social interventions", "TREATMENT", 75, 95], ["stress consequences", "PROBLEM", 198, 217], ["psychological support", "TREATMENT", 241, 262], ["psychological support", "TREATMENT", 293, 314], ["COVID", "TEST", 364, 369], ["stress consequences", "PROBLEM", 431, 450]]], ["Both patterns were consistent with the risk buffer model (Masten, 2001) and showed that the adverse effects of stressors of COVID-19 on rumination and rumination on stress consequences were weaker in college students with high psychological support than in those with low psychological support.", [["COVID-19", "CHEMICAL", 124, 132], ["rumination", "DISEASE", 151, 161], ["COVID-19", "CHEMICAL", 124, 132], ["COVID", "TEST", 124, 129], ["stress consequences", "PROBLEM", 165, 184], ["high psychological support", "TREATMENT", 222, 248], ["low psychological support", "TREATMENT", 268, 293], ["consistent with", "UNCERTAINTY", 19, 34]]], ["Psychological support may serve as a protective factor that mitigates the adverse effects of stressors of COVID-19 on rumination and rumination on stress consequences.", [["COVID-19", "CHEMICAL", 106, 114], ["rumination", "DISEASE", 133, 143], ["COVID-19", "CHEMICAL", 106, 114], ["Psychological support", "TREATMENT", 0, 21], ["a protective factor", "TREATMENT", 35, 54], ["COVID", "TEST", 106, 111], ["stress consequences", "PROBLEM", 147, 166]]], ["There are two possible explanations for these findings.", [["these findings", "PROBLEM", 40, 54], ["possible explanations for", "UNCERTAINTY", 14, 39]]], ["Firstly, after experiencing the stressors of COVID-19, psychological support can help college students shift their attention to positive things and reduce ruminant thoughts about negative events, thus acting as a buffer against rumination and protecting college students from stressors of COVID-19.", [["rumination", "DISEASE", 228, 238], ["COVID", "TREATMENT", 45, 50], ["psychological support", "TREATMENT", 55, 76], ["COVID", "TEST", 289, 294]]], ["Techniques specific to psychological support may be incorporated into conventional psychotherapy (e.g., Cognitive Behavior Therapy [CBT], Dialectical Behavior Therapy [DBT]) to assist more psychologically vulnerable populations (e.g., younger individuals) build the necessary resources to manage their stressors.", [["psychological support", "TREATMENT", 23, 44], ["conventional psychotherapy", "TREATMENT", 70, 96], ["Cognitive Behavior Therapy", "TREATMENT", 104, 130], ["CBT]", "TREATMENT", 132, 136], ["Dialectical Behavior Therapy", "TREATMENT", 138, 166]]], ["Such interventions may be critical for reducing the psychological impact of COVID-19 (Ho, Chee, & Ho, 2020) .", [["COVID-19", "CHEMICAL", 76, 84]]], ["Secondly, college students with higher psychological support have more psychological resources.", [["higher psychological support", "TREATMENT", 32, 60]]], ["Even with a higher tendency of rumination, these students experienced fewer stressful consequences due to the protective nature of having psychological support.", [["rumination", "DISEASE", 31, 41], ["a higher tendency of rumination", "PROBLEM", 10, 41], ["psychological support", "TREATMENT", 138, 159]]], ["Given the novelty of B. Ye, et al. Children and Youth Services Review 118 (2020) 105466 COVID-19, however, it is difficult to make definitive claims without a broader range of studies.", [["Children", "ORGANISM", 35, 43], ["Children", "SPECIES", 35, 43], ["COVID", "TEST", 88, 93]]], ["Future studies may examine how proper provision of psychoeducation with accurate health information pertaining to COVID-19 for those who are psychologically impacted by the virus and its related outcomes (Tran, Dang, et al., 2020) .", [["Future studies", "TEST", 0, 14], ["the virus", "PROBLEM", 169, 178]]], ["Nonetheless, it is noteworthy that for college students with high-levels of psychological support, the relation between stressors of COVID-19 and rumination as well as rumination and stress consequences remained significant.", [["rumination", "DISEASE", 146, 156], ["rumination", "DISEASE", 168, 178], ["psychological support", "TREATMENT", 76, 97], ["COVID", "TEST", 133, 138], ["stress consequences", "PROBLEM", 183, 202]]], ["These suggest that despite the possible benefits of psychological support, college students may still be negatively impacted by the stressors stemming from COVID-19.", [["COVID-19", "CHEMICAL", 156, 164], ["psychological support", "TREATMENT", 52, 73], ["COVID", "TEST", 156, 161]]], ["Contrary to our expectations, the relation between stressors of COVID-19 and stress consequences was not moderated by psychological support.", [["COVID", "TEST", 64, 69], ["stress consequences", "PROBLEM", 77, 96], ["psychological support", "TREATMENT", 118, 139]]], ["This finding suggests that high stressors of COVID-19 are a salient risk factor for stress consequences among college students, and psychological support does not serve as a buffer against the adverse impact of high stressors of COVID-19.", [["COVID-19", "CHEMICAL", 229, 237], ["high stressors of COVID", "PROBLEM", 27, 50], ["psychological support", "TREATMENT", 132, 153], ["COVID", "TEST", 229, 234], ["high", "OBSERVATION_MODIFIER", 27, 31]]], ["One possible explanation utilizing the Transactional Stress Process Model (Lazarus & Folkman, 1984) is that the stressors associated with COVID-19 may overload an individual, overburdening and exceeding their personal resources available to cope (Gellis, Kim, & Hwang, 2004) .", [["COVID-19", "CHEMICAL", 138, 146], ["COVID-19", "CHEMICAL", 138, 146], ["COVID", "TEST", 138, 143], ["overload", "PROBLEM", 151, 159]]], ["Because the stressors of COVID-19 may run high on the surface and be a chronic, salient threat, any dispositional psychological support may not be enough to prevent the onset of negative outcomes.", [["surface", "ANATOMY", 54, 61], ["COVID-19", "CHEMICAL", 25, 33], ["surface", "CELLULAR_COMPONENT", 54, 61], ["COVID", "TEST", 25, 30], ["a chronic, salient threat", "PROBLEM", 69, 94], ["chronic", "OBSERVATION_MODIFIER", 71, 78], ["negative", "OBSERVATION", 178, 186]]], ["Thus, while our results are promising, psychological support is not a catch-all solution in addressing the clear association of COVID-19 stressors and rumination to stress consequences.", [["rumination", "DISEASE", 151, 161], ["psychological support", "TREATMENT", 39, 60], ["a catch-all solution", "TREATMENT", 68, 88], ["stress consequences", "PROBLEM", 165, 184]]], ["Rather, our results should be interpreted as indication of a possible starting area of social intervention during times of pandemics.ImplicationsIn order to help college students maintain proper mental health during the ongoing COVID-19 pandemic, government and health authorities may benefit from routine monitoring and measuring of student stress and related outcomes.", [["social intervention", "TREATMENT", 87, 106], ["pandemics", "PROBLEM", 123, 132], ["routine monitoring", "TEST", 298, 316]]], ["Given the rampant ubiquity of misinformation floating social media, government and health authorities may also prioritize disseminating accurate information about COVID-19 and educating its populace about relying on trusted sources to reduce media-related stressors and prevent unnecessary stressors.", [["media-related stressors", "PROBLEM", 242, 265], ["unnecessary stressors", "PROBLEM", 278, 299]]], ["As psychological support moderated the relation between stressors of COVID-19 and rumination as well as the path between rumination and stress consequences, future research may examine the efficacy of incorporating guided problem-solving strategies to help college students better understand and cope with their problems in an adaptive manner.", [["rumination", "DISEASE", 82, 92], ["psychological support", "TREATMENT", 3, 24], ["COVID", "TREATMENT", 69, 74], ["stress consequences", "PROBLEM", 136, 155], ["incorporating guided problem", "TREATMENT", 201, 229], ["solving strategies", "TREATMENT", 230, 248]]], ["Interventions that aim to improve students' mood and confidence, develop their ability for help-seeking, and build their psychological resiliency may also yield positive results.", [["Interventions", "TREATMENT", 0, 13]]], ["As many colleges and universities contemplate opening campuses, administrators should monitor the mental health of their students and identify at-risk groups that may require additional interventions as the academic year progresses.Limitations and future directionsInterpretation of the findings of this study must consider the following limitations.", [["additional interventions", "TREATMENT", 175, 199], ["this study", "TEST", 299, 309]]], ["Firstly, the fact that this study is a cross-sectional survey study does not allow inference of causality.", [["this study", "TEST", 23, 33], ["a cross-sectional survey study", "TEST", 37, 67]]], ["Future studies may examine longitudinal data as they become available to infer causality of the findings in this study.", [["Future studies", "TEST", 0, 14], ["longitudinal data", "TEST", 27, 44], ["this study", "TEST", 108, 118]]], ["Future studies may collect data from multiple informants (e.g., teacher, peer, or parent) across different cultures to further examine the robustness of our findings.", [["Future studies", "TEST", 0, 14], ["different cultures", "TEST", 97, 115]]], ["Additionally, the current study did not collect information regarding students' field of study nor socioeconomic status.", [["the current study", "TEST", 14, 31]]], ["Prior studies have identified both healthcare related fields of study and socioeconomic status to be relevant factors in COVID-19-related stress and behaviors and future studies may incorporate this to examine how repeated exposure to minute details regarding the physiology of the virus may influence their stressors.", [["Prior studies", "TEST", 0, 13], ["study", "TEST", 64, 69], ["socioeconomic status", "PROBLEM", 74, 94], ["relevant factors", "PROBLEM", 101, 117], ["COVID", "TEST", 121, 126], ["stress and behaviors", "PROBLEM", 138, 158], ["future studies", "TEST", 163, 177], ["the virus", "PROBLEM", 278, 287]]], ["Future studies may also examine the robustness of the model presented in this paper in other populations that may be exposed to qualitatively different COVID-19 stressors in both frequency and intensity (e.g., frontline healthcare workers).", [["Future studies", "TEST", 0, 14]]], ["Lastly, while rumination in this study was conceptualized as being mutable in response to the advent of COVID-19, future studies may benefit from also examining the role of rumination as a moderating factor as COVID-19 stressors become chronic concerns in the long-term compared to being sudden negative life events.ConclusionAlthough further replication and extensions are needed, this study is an important step in unpacking how stressors of COVID-19 relate to stress consequences of Chinese college students.", [["COVID-19", "CHEMICAL", 444, 452], ["this study", "TEST", 28, 38], ["COVID", "TEST", 104, 109], ["future studies", "TEST", 114, 128], ["COVID", "TEST", 210, 215], ["chronic concerns", "PROBLEM", 236, 252], ["sudden negative life events", "PROBLEM", 288, 315], ["this study", "TEST", 382, 392], ["COVID", "TEST", 444, 449], ["chronic", "OBSERVATION_MODIFIER", 236, 243]]], ["Because rumination served as one potential mechanism by which stressors of COVID-19 were associated with more stress consequences, it remains important to address rumination directly or intervene in a manner that reduces the impact of rumination on stress consequences.", [["COVID-19", "CHEMICAL", 75, 83], ["rumination", "PROBLEM", 8, 18], ["COVID", "TEST", 75, 80], ["stress consequences", "PROBLEM", 249, 268]]], ["Our results on psychological support provide a promising step forward in examining how non-clinical interventions may help to mitigate the negative outcomes of COVID-19 stressors during these unique and unusual times.", [["psychological support", "TREATMENT", 15, 36], ["non-clinical interventions", "TREATMENT", 87, 113], ["COVID", "TEST", 160, 165]]]]}